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Abstract 
 
Infections  due  to  Streptococcus  pneumoniae  (the  pneumococcus)  remain  a  substantial 
source of morbidity and mortality in both developing and developed countries despite a 
century of research and the development of effective therapeutic interventions (such as 
antibiotic therapy and vaccination). The ability of the pneumococcus to evade multiple 
classes of antibiotic through several genetically determined resistance mechanisms and its 
evasion  of  capsular  polysaccharide  based  vaccines  through  serotype  replacement  and 
capsular switching, all reflect the extensive diversity and plasticity of the genome of this 
naturally transformable  organism which can readily alter its  genome in response to its 
environment and the pressures placed upon it in order to survive. 
The  purpose  of  this  thesis  is  to  investigate  this  diversity  from  a  genome  sequence 
perspective and to relate these observations to pneumococcal molecular epidemiology in a 
region of high biodiversity, the pathogenesis of certain disease manifestations and assess 
for a possible bacterial genetic basis for the pneumococcal phenotypes of, “carriage” and, 
“invasion.”  
In order to do this, microarray comparative genomic hybridization (CGH) has been utilized 
to  compare  DNA  from  a  variety  of  pneumococcal  isolates  chosen  from  10  diverse 
serotypes  and  Multilocus  Sequence  Types  and  from  clinically  relevant  serotypes  and 
sequence types (particularly serotypes 3, 4 and 14 and sequence types ST9, ST246 and 
ST180))  against  a  reference,  sequenced  pneumococcal  genome  from  an  extensively 
investigated serotype 4 isolate – TIGR4.  
Microarray  comparison  of  the  transcriptional  profiles  of  several  isolates  has  also  been 
undertaken to compare gene expression from isolates of serotype 1 (ST227 and ST306) 
and serotype 3 (ST180) related to particular disease states and exposure of a multi-resistant 
pneumococcus to an antimicrobial (clarithromycin) commonly used to treat pneumococcal 
pneumonia. 
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1  Introduction 
Infections  due  to  Streptococcus  pneumoniae  (the  pneumococcus)  remain  a  substantial 
source of morbidity and mortality in both developing and developed countries despite a 
century  of  research  and  the  development  of  therapeutic  interventions  such  as  multiple 
classes of antibiotics and vaccination. The World Health Organisation estimates that in 
developing countries 814,000 children under the age of five die annually from invasive 
pneumococcal diseases (Scott, 2007) with an estimated 1.6 million deaths affecting all ages 
globally (WHO, 2007).  
The ability of some isolates of S. pneumoniae to evade many antibiotic classes through 
several distinct genetically determined resistance mechanisms and pneumococcal evasion 
of  capsular  polysaccharide  based  vaccines  through  serotype  replacement  and  capsular 
switching, along with the discovery of 91 distinct polysaccharide capsular types and over 
4000 Multi Locus Sequence Types (MLST) all reflect the extensive diversity and plasticity 
of the genome of this naturally transformable organism which can readily alter its genome 
to survive in response to its environment and the pressures placed upon it. 
The purpose of this thesis is to investigate this genomic diversity from a genomic sequence 
perspective using contemporary microarray and sequencing technology and to relate these 
findings to the epidemiology of invasive pneumococcal disease (IPD) and carriage with the 
intent of further understanding a genetic basis for pneumococcal disease pathogenesis and 
the response of pneumococci to specified currently available therapeutic options.  
1.1 Taxonomy of Streptococcus pneumoniae 
The  taxonomy  of  Streptococcus  pneumoniae  (the  pneumococcus)  has  undergone  a 
dynamic process since separate initial descriptions in saliva by Pasteur (Pasteur, 1881) and 
as  Micrococcus  lanceolatus  by  Sternberg  (Sternberg,  1881).  For  instance,  in  1903 
Schottmuller described Streptococcus mucosus (Schottmuller, 1903) but  within a couple 
of years (Park et al., 1905, Collins, 1905) it was reclassified as a pneumococcus (a term 
used  since  1886  (Fraenkel,  1886))  on  the  basis  of  its  biochemistry  and  specific 
agglutination  and  agglutinin  absorption  tests  despite  its  markedly  different  mucoid 
morphology on solid agar.  From 1926 the genus Diplococcus was used until 1974 when it 
changed to Streptococcus pneumoniae (Musher, 2005). More recently, it has become clear     Chapter 2, 19 
that the species boundaries between S. pneumoniae and particularly Streptococcus mitis 
and Streptococcus oralis are not easily defined (Whatmore et al., 2000). 
Such a catalogue of reclassifications and disputed identification reflects the remarkable 
phenotypic diversity of the pneumococcus, which in turn reflects the substantial genomic 
and  transcriptional  diversity  of  the  organism,  resulting  from  a  constellation  of  several 
interacting mechanisms – the investigation of which is the focus of this thesis. 
1.2 Phenotypic identification and characteristics of 
Streptococcus pneumoniae 
Streptococcus  pneumoniae  is  a  Gram  positive  coccus  which  can  be  identified  by  its 
production  of  a-haemolysis  on  blood  agar,  bile  solubility,  inhibition  by  ethyl 
hydrocupereine (optochin) and catalase negativity (Musher, 2005). It is noteworthy that the 
Gram  stain  itself  was  developed  by  Christian  Gram  as  a  means  to  distinguish  the 
pneumococcus  from  other  pathogens  in  specimens  taken  from  patients  with  lobar 
pneumonia (Gram, 1884).  One or more of these tests may be inconclusive and further 
phenotypic  tests  such  as  agglutination  with  anti-pneumococcal  polysaccharide  capsule 
antibodies or genotypic tests can be required to distinguish the isolate from closely related 
oral streptococci (Whatmore et al., 2000, Hanage et al., 2005) although even some of these 
tests may also be inconclusive in rare instances (Dowson, 2004).   
1.2.1.1  A History of Serotyping Streptococcus pneumoniae 
In 1909 Neufeld and Haendel raised antibodies to pneumococci in horses and donkeys, 
allowing serological identification (Neufeld and Handel, 1909). This was repeated with a 
second strain in 1910 (Neufeld and Handel, 1910). In 1913, A.R Dochez and L.J. Gillespie 
at the Rockefeller Institute in New York (Dochez and Gillespie, 1913) and Frederick Lister 
at  the  South  African  Institute  for  Medical  Research  in  Johannesburg  (Lister,  1913) 
published serologically based typing schemes for pneumococci. The Rockefeller Institute 
scheme  described  Types  I,  II,  III  and  IV  of  which  Types  I,  II  and  III  were  identified 
serologically and Type IV was a group for pneumococci found not to react with their three 
sera. There was overlap with Lister’s typing scheme as Type I corresponded to Lister’s 
Group  C,  Type  II  corresponded  with  Lister’s  Group  B  and  Type  III  corresponded  to 
Lister’s Group E (Urquhart, 1921). Consequently the Lister scheme fell into disuse.      Chapter 2, 20 
To complicate matters, the Rockefeller Institute Type II was found to be a heterogeneous 
group  (Urquhart,  1921)  and  probably  consisted  of  several  different  contemporary 
serotypes. It is likely that since Type 1 was homogeneous and since clinical descriptions of 
Type 1 associated disease patterns match those described for the contemporary serotype 1, 
that  the  Rockefeller  Type  1  pneumococcus  is  equivalent  to  the  modern  serotype  1 
pneumococcus. 
Avery et al in 1917 at the Rockefeller Institute, proposed that Pneumococcus mucosus, 
described as, “larger, rounder, and less lanceolate than other types of pneumococcus,” and 
possessing, “a large distinct capsule,” which grew on blood agar with colonies which were, 
“moist, mucoid, and confluent” should become known as their Type III pneumococcus 
(Avery  et  al.,  1917).  This  phenotypic  description  matches  that  seen  for  contemporary 
serotype 3 isolates although mucoid colonies can be seen in serotypes 1, 3, 6, 8, 18, 20, 23 
and 25 (Gransden et al., 1985). Avery et al addressed this in 1917 saying, 
 “For  these  reasons  the  identification  of  Type  III  pneumococcus  by 
morphologic  and  cultural  characteristics  is  not  always  absolute,  and  the 
diagnosis  should  be  established  by  immunologic  methods,  when  Type  III 
serum is available (Avery et al., 1917).”  
However, it was not until 1934 when type III could be distinguished serologically from the 
phenotypically similar Type VIII (Finland and Sutliff, 1934) so only after 1934 is it fair to 
conclude  that  descriptions  of  the  Type  III  pneumococcus  are  equivalent  to  the 
contemporary serotype 3 pneumococcus.  
Standardisation of the Rockefeller typing scheme in Great Britain is documented by Glynn 
and Digby (Glynn and Digby, 1923), who note that from 1920, diagnostic and treatment 
sera for use in Britain by the Medical Research Council was supplied by the Rockefeller 
Institute. Standardisation of antipneumococcal serum had been practiced at the Rockefeller 
Institute since 1917 (Cole and Moore, 1917).  
The Quellung technique for serotyping the pneumococcus became the preferred method for 
serotyping in 1932 (Neufeld and Etinger-Tulczynska, 1932) although  first described in 
1902 (Neufeld, 1902). Between the end of World War II and the early 1980s there was 
little international agreement regarding pneumococcal nomenclature based on serotyping 
and the reasons for this are reviewed by Henrichsen (Henrichsen, 1999). The most recent 
serotype to be discovered was 6C in 2007 (Park et al., 2007) bringing the current total of     Chapter 2, 21 
recognised serotypes to 91 and reinforcing observations by Waltman et al  (Waltman et al., 
1991) that there is often substantial diversity within serogroups.  
 
1.3 Genetic typing of Streptococcus pneumoniae  
Typing methodologies based on the pneumococcal genetic structure have been developed. 
These genetic typing schemes are reviewed below although it is worth noting that many 
early  methods  were  only  useful  for  examining  genetic  relatedness  in  temporally  and 
geographically restricted studies (Robinson et al., 1998).  
The  need  for  standardised  molecular  typing  schemes  has  been  due  in  part  to  the 
international spread of clones of multiply antibiotic resistant pneumococci (Hermans et al., 
1997b) and after the establishment of the Pneumococcal Molecular Epidemiology Network 
(PMEN) in 1997, guidelines for molecular typing surveillance were published (McGee et 
al., 2001a). It is becoming apparent though that, even with current technologies, 
 “the clearest picture of invasiveness and genetic relatedness can be viewed 
when typing methods are used collectively (Obert et al., 2007).”  
1.3.1.1   Pulsed Field Gel Electrophoresis (PFGE) 
PFGE was first described for the pneumococcus by Lefevre et al (Lefevre et al., 1993) and 
has  been  used  in  several  studies  to  establish  the  genetic  relatedness  of  pneumococcal 
isolates (Hermans et al., 1995, Obert et al., 2007, Porat et al., 2006, McGee et al., 2001b, 
Tsolia et al., 2002, Rossi et al., 1998, Watanabe et al., 2003, Hall et al., 1996). In general it 
consists of generating fragments of chromosomal DNA using the restriction enzyme SmaI 
and then separating them using gel electrophoresis. As experimental conditions are not 
always  identical  between  studies,  the  comparison  of  results  over  time  and  between 
different laboratories is fraught with difficulties. It is labour intensive and does not lend 
itself well to computerised interpretation (Hermans et al., 1995).   Maiden et al   also 
propose that PFGE is better suited to investigating outbreaks as it is discriminatory enough 
to  distinguish  between  strains  circulating  within  a  geographical  area  but  is  not 
discriminatory enough for long term epidemiological surveillance (Maiden et al., 1998).  
1.3.1.2   Restriction Fragment End Labelling (RFEL) 
RFEL was described by Van Steenbergen et al in 1995 (Van Steenbergen et al., 1995). 
Although  similar  to  PFGE,  smaller  DNA  fragments  are  produced  by  RFEL  and     Chapter 2, 22 
pneumococcus  specific  reference  bands  can  be  produced  which  aids  computer  assisted 
analysis of results (Hermans et al., 1995). It has been used to identify clones of antibiotic 
resistant  pneumococci  (Hermans  et  al.,  1997b)  as  well  as  clustering  within  penicillin 
susceptible strains (Overweg et al., 2000a).  
1.3.1.3   Restriction Fragment Length Polymorphisms (RFLP) 
RFLP was an uncommon method used mainly in the 1990s as a means of assessing clonal 
relationships between similar isolates of the same serotype (Swiatlo et al., 1996, Robinson 
et  al.,  1998).  Pneumococcal  genomic  DNA  was  digested  with  the  restriction  enzyme 
HindIII, separated by gel electrophoresis and pressure or vacuum transferred to a nylon 
membrane where hybridization of fragments with probes of a recognised pneumococcal 
gene (such as pspA) or an insertion sequence (such as IS1167) occurred. The resulting 
banding  patterns  are  used  to  denote  different  subtypes.  Often  RFLP  was  used  in 
combination with another method of investigating  genetic relationships such  as MLEE 
(Robinson et al., 1998) and penicillin binding protein gene fingerprinting (Hermans et al., 
1997b). 
1.3.1.4   Penicillin Binding Protein Gene Fingerprinting 
The discovery that alleles for penicillin binding proteins (pbps) in the pneumococcus were 
heterogenous  permitted  their  use  in  an  early  molecular  typing  scheme  for  the 
pneumococcus.  The genes for pbps 1A, 2B and 2X were amplified from genomic DNA by 
Polymerase Chain Reaction (PCR). The purified genes for pbps were then digested by 
restriction enzymes using methodologies similar to RFLP (Munoz et al., 1991, Hermans et 
al., 1997a, McGee et al., 2001b, Swiatlo et al., 1996, Kell et al., 1993, Coffey et al., 1991). 
Like  many  early  typing  schemes,  although  significant  genomic  diversity  could  be 
demonstrated, gel results were difficult to interpret, hard to standardise and therefore hard 
to reproduce by different laboratories. 
1.3.1.5   BOX fingerprinting 
BOX  fingerprinting  for  pneumococci  is  a  method  which  has  been  superseded  by 
contemporary techniques. Essentially genomic DNA was digested by a restriction enzyme 
and separated by gel electrophoresis and hybridized against an oligonucleotide probe (a 
section of or the entire BOX repeat – a repetitive mosaic sequence comprised of boxA, 
boxB or boxC subunits found in the pneumococcal genome (Koeuth et al., 1995, Van 
Belkum et al., 1996) ). This allowed clustering of strains sharing identical fingerprints or 
banding patterns. BOX fingerprint clusters often did not correspond to clustering based on     Chapter 2, 23 
serotyping (Hermans et al., 1995, Rodriquez-Barradas et al., 1997, McGee et al., 2001b, 
Mollerach et al., 2004) or RFLP results (Robinson et al., 1999). BOX fingerprinting has 
been used in combination with RFLP using the IS1167 sequence to determine IS1167-
boxA genotypes but it was concluded that,  
“markers such as IS1167 and boxA are not ideal for dealing with the large 
genotypic diversity seen in cross-sectional samples of pneumococci (Robinson 
et al., 2001).”  
It did have an  application in investigating pneumococcal outbreaks (Ertugrul et al., 1997). 
1.3.1.6   Multi Locus Enzyme Electrophoresis (MLEE) 
MLEE was developed in the mid 1980s  (Selander et al., 1986) and used extensively to 
investigate genetic diversity of the pneumococcus in the 1990s (Hall et al., 1996). This 
method detects variation within housekeeping enzymes and their differing electrophoretic 
mobilities (Feil et al., 2000a). It was used to demonstrate diversity of penicillin resistance 
genes (Kell et al., 1993), capsule (Sibold et al., 1992) and Immunoglobulin A1 protease 
(Lomholt, 1995) and often used in studies in combination with other methods such as 
RFLP (Robinson et al., 1998), PFGE (Hall et al., 1996) and penicillin binding protein gene 
fingerprinting (Coffey et al., 1991). However, MLEE can produce ambiguous results as it,  
“relies  on  the  indirect  assignment  of  alleles  based  on  the  electrophoretic 
mobility of enzymes, and indistinguishable mobility variants may be encoded 
by very different nucleotide sequences (Maiden et al., 1998).”   
It did, however, pave the way for Multi Locus Sequence Typing.  
1.3.1.7   Multi Locus Sequence Typing (MLST) 
The development of Multi Locus Sequence Typing (MLST) (Enright and Spratt, 1999b, 
Enright  and  Spratt,  1998)  generated  a  genotyping  method  which  sequences  seven 
conserved housekeeping genes (aroE, gdh, gki, recP, spi, xpt, ddl) assigning each unique 
allele  with  a  number,  allowing  relatedness  between  isolates  to  be  identified  with  a 
numerical code and overall sequence type which is easily reproducible and  comparable 
between  laboratories  thereby  providing  unambiguous  results  which  are  electronically 
portable and suitable for global surveillance studies via the internet (Obert et al., 2007). It 
has been successfully automated (Jefferies et al., 2003).       Chapter 2, 24 
The depositing of MLST sequence data in an internet based repository
1 greatly enhances a 
global understanding of bacterial epidemiology and the development of software such as 
eBURST  (electronic  Based  Upon  Related  Sequence  Types)  allows  the  construction  of 
identifiable  genetic  lineages  and  clusters  (Feil  et  al.,  2004).  The  contributions  of 
recombination and mutation to clonal divergence can also be assessed using this data (Feil 
et al., 2000b). 
MLST has a further advantage as it can be performed after PCR amplification of DNA  
extracted directly from clinical material or non-viable organisms and, unlike serotyping, 
can  be  performed  on  uncapsulated  organisms  (Hanage  et  al.,  2005)  which  can  both 
improve diagnostic yields and epidemiological surveillance (Maiden et al., 1998).  The 
advantages, disadvantages and clinical applications of MLST are reviewed by Sullivan et 
al (Sullivan et al., 2005). 
1.3.1.8   Multi Locus Variable Number of Tandem Repeat Analysis 
(MLVA) 
MLVA was proposed for use as a typing scheme for epidemiological studies by Koeck et 
al  (Koeck  et  al.,  2005).  They  used  a  set  of  16  polymorphic  tandem  repeat  sequences 
identified  from  published  fully  sequenced  pneumococcal  genomes  from  which  49 
genotypes of pneumococci were identified.  Although it was claimed to be cheaper and 
requiring less expertise than MLST, it has not competed well against the popularity of 
MLST.  
1.3.1.9   Multi Invasive Locus Sequence Typing (MILST) 
Multi Virulence Sequence Typing is a further development of the MLST scheme which 
adds virulence genes to the housekeeping genes used in the profiling of bacteria. It has 
been  used  for  typing  Listeria  monocytogenes  with  greater  discriminatory  power  than 
MLST alone (Zhang et al., 2004). This typing scheme has been adapted for pneumococci 
by Obert et al, to form a scheme which they termed MILST (Obert et al., 2007) and which 
they propose not as a replacement for MLST but as an expansion of the scheme. 
1.3.1.10  Microarray Comparative Genomic Hybridization (CGH) 
One of the most utilised applications of microarray technology is to allow comparison of 
bacterial  genomes  and  identify  conserved  regions  and  regions  of  diversity.  The  first 
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applications of this technology to examine the pneumococcal genome demonstrated that 
some  genes  such  as  hyaluronidase,  neuraminidase  A  or  neuraminidase  B,  autolysin  or 
pneumolysin were highly conserved while sequence variation could be demonstrated for 
cell  surface  proteins  such  as  pneumococcal  surface  protein  C,  other  choline  binding 
proteins and the trimethoprim resistance gene dihydrofolate  reductase (dhfr) (Hakenbeck 
et al., 2001). The absence of genes such as some capsular genes when comparing the R6 
and TIGR4 genomes resulted in an understanding that there were significant regions of 
diversity in the pneumococcal genome and attempts at identifying a set of “core” genes. 
This has also been possible for CGH studies of Enterococcus faecalis (Aakra et al., 2007) 
and Staphylococcus aureus (Lindsay et al., 2006). Cassone et al review examples of the 
application  of  CGH  to  the  study  of  intra-  and  inter-  species  genomic  diversity  for 
Mycobacteria, Salmonella and Yersinia species (Cassone et al., 2007). 
Hollingshead and Briles observe that,  
“there is also valuable information to be gleaned from knowing the sequence of 
more than one genome within the same species. Additional genome sequence 
data  for  well-chosen  strains  will  yield  important  clues  to  solving  certain 
puzzles about the biochemical diversity, the virulence and pathogenesis range 
and/or the evolution of bacterial species (Hollingshead and Briles, 2001).”   
The  CGH  studies  which  follow  in  subsequent  chapters  are  designed  to  enhance  such 
understanding  of  the  diversity  of  the  pneumococcal  genome  by  comparing  clinically 
relevant  pneumococcal  isolates  with  the  established  sequenced  pneumococcal  genomes 
TIGR4  and  R6  and  also  assess  diversity  in  more  recently  sequenced  pneumococcal 
genomes. 
1.3.1.11  Transcriptome Microarrays 
Rather  than  comparing  gene  sequences  from  genomic  DNA,  bacterial  transcriptome 
microarrays  assess  the  presence  or  absence  of  expression  of  genes  by  taking  total 
messenger RNA  expressed by the organism, under carefully controlled  conditions, and 
synthesizing cDNA from the RNA by reverse transcription. The cDNA is then hybridized 
against the DNA sequences of the microarray. As such, they are, 
“a powerful tool to dissect regulatory networks (Rimini et al., 2000).” 
The first transcriptome  microarrays were for partial or full genomes (Escherichia coli 
(Richmond et al., 1999, Chuang et al., 1993) and Saccharomyces cerevisiae (De Risi et al., 
1997, Wodicka et al., 1997)).      Chapter 2, 26 
De Saizieu et al, 1998 used the first pneumococcal transcript oligonucleotide microarray, 
which contained only 100 genes, to investigate gene expression during competence (De 
Saizieu et al., 1998). With regard to pneumococcal disease pathogenesis, microarrays have 
been employed in the investigation of the genetic basis of autolysis (Sublett et al., 2004), 
the genetic basis of capsule loss (Ogburn and Dowson, 2004), competence (Mascher et al., 
2003, De Saizieu et al., 1998, Peterson et al., 2004, Peterson et al., 2000, Rimini et al., 
2000), mechanisms of iron uptake (Ulijasz et al., 2004b), the vancomycin stress response 
(Sublett  et  al.,  2004)  and  the  transcriptional  adaptation  of  pneumococci  to  various 
environmental changes (Pandya et al., 2005, Novak et al., 1999, Hendriksen et al., 2004). 
One potential limitation of this approach though is that microarrays can only detect genes 
which are on the array so whole pathways may not be represented if they involve novel 
genes.  
1.3.1.12  Genome Sequencing 
The first published whole genome sequences for bacteria began to appear in the mid-1990s 
beginning with that of Haemophilus influenzae in 1995 (Fleischmann et al., 1995). As 
early as 1991, partial sequences of a pneumococcal genome (located on SmaI and ApaI 
fragments) were used to construct a map of the genome (Gasc et al., 1991). 
Initial sequencing of regions of a pneumococcal genome (R6) with the aim of identifying 
potential  drug  targets  (amino-acyl  tRNA  synthetase  and  ribosomal  protein  genes)  are 
described by  Baltz et al (Baltz et al., 1998). The first  comparative analysis of  a draft 
pneumococcal genome was published in 2001 where the draft genome of G54 (a serotype 
19F strain) was compared with the genome of Streptococcus pyogenes (Dopazo et al., 
2001).  Currently, according to the National Center for Biotechnology Information (NCBI) 
Genome  Project
2,  there  are  six  completely  sequenced  pneumococcal  genomes  with  a 
further 14 in progress and a further 16 at an assembly stage. The list of genomes, “in 
progress,”  includes  the  ATCC700669  serotype  23F  isolate  (used  in  Chapter  3)  at  the 
Wellcome Trust Sanger Institute but does not include the OXC141, INV104B or INV200 
isolates  (used  in  Chapter  3)  which  have  also  been  sequenced  by  conventional  Sanger 
sequencing (using dideoxynucleotide sequence termination and capillary electrophoresis 
with fluorescent marker excitation by laser (Ryan et al., 2007, Metzker, 2005)) and are 
available from the Wellcome Trust Sanger Institute website
3. Neither does it include the 
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sequencing of isolates 03-2672, 03-3038, 06-1370 (used in Chapter 10), nor 02-1198, 03-
4156, 03-4183, 07-2838, 99-4038 and 99-4039 (used in Chapters 6 and 10) which are 
being sequenced at the Wellcome Trust Sanger Institute using high-throughput 454 Life 
Sciences  Corporation  (Roche,  USA)  pyrosequencing  methodologies  (Margulies  et  al., 
2005) recently described in the sequencing of Salmonella typhi (Holt et al., 2008) and 
pneumococci (Hiller et al., 2007).   
Knowing the genome sequence of a pathogen doesn’t necessarily mean that knowledge 
regarding gene function is known although it can be inferred (Tang and Moxon, 2001). 
From these inferences, potential antimicrobial drug targets  (Brazas and Hancock, 2005) or 
vaccine candidate molecules (Wizemann et al., 2001) can be identified although sequence 
similarity should be combined with other evidence such as experimental data to assign 
function (Kaushik and Sehgal, 2008). Comparative genome analysis is useful for assigning 
function to unknown genes  as gene and protein homologs in different bacteria are likely to 
be functionally linked and have similar degrees of conservation within the same pathways 
(Martin et al., 2003b). 
Bacteria which show substantial diversity (even within the same serotype) have a gene 
repertoire which can be divided into a “core” genome comprising essential genes such as 
housekeeping genes, a “dispensable” genome and “strain specific genes” which may confer 
selective advantages such as adaptation to particular environments (Kaushik and Sehgal, 
2008, Fraser-Liggett, 2005). When an ST180 serotype 3 strain (0100993) was compared 
with  TIGR4,  a  variety  of  chromosomal  rearrangements  and  variations  due  to  mobile 
genetic  elements  were  discovered  along  with  17  novel  genes  not  present  in  TIGR4 
(Oggioni et al, 2001). The first full comparison of pneumococcal genomes was published 
by Bruckner et al in 2004, who compared the TIGR4 and R6 genomes. They noted that the 
two genomes differed in size (2 versus 2.16Mb) and in approximately 10% of their gene 
content (Bruckner et al., 2004). R6 was noted to contain 69kb of genetic material not seen 
in TIGR4 and TIGR4 has 157kb of genetic material not seen in R6 (Bruckner et al., 2004). 
This  is  similar  to  the  situation  in  non-typeable  Haemophilus  influenzae  isolates  where 
around 10% of the gene content of 10 isolates was identified as novel compared to the 
sequenced  H.  influenzae  Rd  KW20  genome  with  many  of  these  unique  genes  non-
uniformly distributed in the genome (Shen et al., 2005). Shen et al, were later to describe 
58 novel genes from 8 pneumococcal isolates (serotypes 3, 6A, 9F, 11, 14, 18C, 19F and 
23F) which were not present in either the TIGR4 or R6 genomes (Shen et al., 2006a). 
Consequently, attempts have been made to try to identify a core pneumococcal genome 
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single  pneumococcal  genome  (e.g.  TIGR4)  and  even  of  the  multiple  pneumococcal 
genomes becoming available (Hiller et al., 2007) may not adequately represent the full 
extent of genomic diversity of this bacteria. 
1.4 Pneumococcal Carriage 
Pneumococci predominantly colonise the human nasopharynx and in the vast majority of 
instances do not progress to cause invasive disease. In the first two years of life, 95% of 
children can be colonized with pneumococci  and 73% can carry at least two serotypes 
simultaneously (Obaro and Adegbola, 2002).  Nasopharyngeal colonization can begin as 
early as the day of birth. The duration of carriage for a particular serotype is commonly 2.5 
to 4.5 months and the duration of carriage decreases with each successive pneumococcal 
serotype. This duration of carriage is inversely correlated with age (Gray et al., 1980) as 
pneumococcal carriage declines as children grow older (Bogaert et al., 2004). 
Historical observations regarding the carrier state for Type I and Type III pneumococci are 
often  different  in  the  pre-antibiotic  era  when  compared  with  modern  times.  Modern 
accounts  tend  to  suggest  that  it  is  uncommon  to  find  serotype  1  being  carried  by 
individuals (Brueggemann and Spratt, 2003, Brueggemann et al., 2003) and it has been 
claimed that, 
 “serotype 1 is almost never carried (Brueggemann et al., 2004),”  
It is erroneous to conclude that such a state cannot occur. Several historical accounts from 
the pre-antibiotic era make it clear that a healthy carrier state of Type I did and can occur 
in individuals in close contact with cases and  for prolonged periods in those who had 
recovered from Type I associated lobar pneumonia without antibiotic therapy.  
Dochez and Avery in 1915 noted carriage of Type I pneumococci in 3 of 66 pneumococcal 
carriers  (4.5%)  who  were,  “normal  individuals.”  They  were  unable  to  assess  Type  III 
carriage rates due to a lack of Type III antisera (Dochez and Avery, 1915). Stillman in 
1917 noted that,  
“although  pneumococcus  is  present  in  the  mouths  of  about  fifty  percent  of 
normal individuals, it is extremely rare to find pneumococcus of Type I in the 
normal mouth except in individuals who have been in intimate association with 
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This was a conclusion based on his earlier observation in 1916 that only 4 of 172 (2.3%) 
pneumococcal orophayrngeal carriers carried Type 1 and 44 of the 172 (26%) carried Type 
III.  There  was  persistent  carriage  of  Type  III  for  over  3  months  in  some  instances 
(Stillman, 1916) and Type I carriage of up to 90 days after recovery from pneumococal 
pneumonia (Dochez and Avery, 1915).  Meyer in 1920  demonstrated higher Type  III 
carriage rates than for Type I which was not detected (Meyer, 1920). Strom in 1932 also 
documents a long period of Type I carriage for 73 days after recovery from pneumonia 
(Strom, 1932).  
Stillman in 1917 cultured 107 healthy household contacts of 28 patients admitted with 
Type I lobar pneumonia and found that 15% were Type I carriers (Stillman, 1917). Almost 
a third of cases gave rise to a carrier state in at least one of their immediate associates. For 
these healthy contacts, the average period of carriage was 25 days for Type I - undoubtedly 
providing a human reservoir for further infection. Avery et al, also in 1917, notes a Type I 
carriage  rate  of  13%  in  the  contacts  of  cases  of  lobar  pneumonia  and  only  0.33%  in 
controls who had no contact with cases of lobar pneumonia and noted that the Type I 
carriers harboured it for 3 to 4 weeks (Avery et al., 1917). Similar differences between 
contacts and controls with regard to Type I carriage are documented in Glasgow in 1932 
(Christie, 1932). 
In a carriage study in 1919, using specimen collection methodology remarkably similar to 
the current World Health Organisation (WHO) standard method (O'Brien and Nohynek, 
2003), Sailer et al in Georgia, USA performed nasopharyngeal swabbing on 700 soldiers 
and detected a pneumococcal carriage rate of 16%. Of the carriers, 5.4% were Type I and 
4.5% were Type III. They observed that their carriage rates were influenced by recent 
outbreaks of measles and influenza (Sailer et al., 1919). There is also an association with 
higher  pneumococcal  carriage  rates  during  times  of  epidemic  upper  respiratory  tract 
infection (Gordon, 1921). Strom in 1932 documents the decline in serotype 1 carriage rates 
after a serotype 1 outbreak in a Norwegian orphanage in 1931 finding serotype 1 carriage 
rates of 33% at the height of the outbreak dropping to 16.9% 3 months later but being 
undetectable at all times in neighbouring orphanages unaffected by the outbreak (Strom, 
1932).  The  serotype  1  pneumococcal  pneumonia  outbreak  at  the  State  Hospital  in 
Worcester, Massachusetts also noted a carriage rate of almost 10% (Smillie et al., 1938). 
Other  risk  factors  for  pneumococcal  carriage  are  well  recognised  and  include 
overcrowding (Hodges et al., 1946, DeMaria et al., 1980, Hoge et al., 1994), concurrent 
outbreaks of invasive pneumococcal disease and pneumonia (DeMaria et al., 1980, Dagan     Chapter 2, 30 
et al., 2000, Hoge et al., 1994) and adults in close contact with children (Hendley et al., 
1975), ethnicity,  family size, smoking  and  recent antibiotic use  (Bogaert et al., 2004). 
Children are thought to be the most important reservoir for pneumococci (Leiberman et al., 
1999, Kyaw et al., 2002),  
Pneumococcal  carriage  rates  vary  substantially  between  studies  and  populations  as 
demonstrated in the review by Bogaert et al (Bogaert et al., 2004). Hodges and MacLeod 
suggest that serotype 1  and serotype 3 carriage rates varied so much in early  carriage 
studies,  because  of  differences  in  the  methodology  for  specimen  processing.  They 
compared  several  methods  and  mouse  inoculation  (favoured  by  the  early  Rockefeller 
Institute studies in New York) yielded higher recovery rates of serotype 1 and serotype 3 
pneumococci than direct plating of throat swabs onto blood agar (Hodges et al., 1946).  
The demonstration that different cultural methods affect the observed carriage rates could 
readily account for why serotype 1 carriage rates were apparently higher at the start of the 
20
th century when mouse inoculation was common but which dropped in later years when 
most carriage study methodology involved variants of plating nasopharyngeal swabs onto 
blood agar (Hodges et al., 1946). Differences in the frequency of sampling and in the 
populations  studied  could  also  account  for  difference  in  carriage  rates  (Davies  and 
Lockley, 1987). It is reasonable to conclude though that serotype 1 carriage does still occur 
in communities, that it does increase when numbers of cases of pneumococcal pneumonia 
due to serotype 1 increase in the community but that it may not be as readily detected by 
current standard methods as other serotypes such as serotype 3.  
The distribution of serotypes identified in the nasopharynx is usually wider than those 
causing IPD in the same population but varies substantially between human populations.  
In Europe and the USA the commonly seen serotypes found in carriage studies are 6B, 14, 
19F and 23F (Bogaert et al., 2004, Kyaw et al., 2002). This has a direct impact on the 
coverage of serotypes included in conjugate vaccines which can also vary substantially 
(Bogaert et al., 2004).  The prevalence of nasopharyngeal carriage is considerably higher 
in  developing  countries  and  the  probability  of  exposure  to  a  non-vaccine  serotype 
considerably greater (Scott, 2007). 
The  mechanism  of  colonisation  is  reviewed  by  Bogaert  et  al  (Bogaert  et  al.,  2004). 
Extracellular neuraminidase decreases viscosity of mucous on epithelial cell surfaces and 
exposes  N-acetyl-glycosamine  receptors  which  interact  with  pneumococcal  surface-
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upregulation of platelet activating factor receptors. Pneumococcal cell wall phosphocholine 
attaches to these receptors. The choline binding protein CbpA binds to exposed sialic acid 
residues  and  lacto-N-neotreatose  on  the  epithelial  surface  binding  to  the  polymeric 
immunoglobulin  receptor  (pIgR)  which  facilitates  transcytosis.  Phase  variation  is  also 
involved with transparent phase variants showing greater adherence than opaque variants.  
It  is  significant  that  pneumococcal  conjugate  vaccination  but  not  pneumococcal 
polysaccharide  vaccination  has  been  shown  to  reduce  carriage  of  vaccine  included 
serotypes as well as IPD (O'Brien and Dagan, 2003). 
1.5 Manifestations of Pneumococcal Infection 
1.5.1.1.1 Acute Otitis Media 
Acute  otitis  media  (AOM)  is  the  commonest  pneumococcal  disease  manifestation 
(Hausdorff et al., 2002) and is felt to be a major driving force in the establishment of 
antimicrobial resistant pneumococci (Hausdorff et al., 2002). This possibly relates to the 
frequent development of biofilms at this site promoting persistent infection and facilitating 
horizontal gene transfer (McEllistrem et al., 2007). 
In a multinational study, including several countries from the Americas and Europe, it was 
determined  that  serotypes  19F  and  23F  each  comprised  13-25%  of  middle  ear  fluid 
isolates, 14 and 6B comprised 6-18% and 6A, 19A and 9V each comprised 5-10% despite 
differences in location. In children aged 6 months to 59 months, 60-70% of the causative 
serotypes are covered by the 7-valent pneumococcal conjugate vaccine (PCV-7) but in 
children less than 6 months old or over 5 years old this coverage drops to 40 to 50%. 
Serotypes 1, 3 and 5 are important causes of AOM in children under 6 months (Hausdorff 
et al., 2002).  In Southern Israel, serotypes 1, 3, 5, 18C, 19A and 19F were associated with 
the development of AOM (Shouval et al., 2006). Serotypes 6A, 6B, 15A and non-typeable 
pneumococci do not tend to cause AOM (Shouval et al., 2006). 
PCV-7  is  effective  at  preventing  acute  otitis  media  (Eskola  et  al.,  2001)  although  not 
recurrent otitis media (Veenhoven et al., 2003). 
1.5.1.1.2 Pneumonia 
The  pneumococcus  is  the  commonest  bacterial  pathogen  to  cause  community  acquired 
pneumonia (up to 35% of cases) in adults requiring hospitalisation (Moine et al., 1995). 
Predisposing factors for the development of pneumococcal pneumonia include advanced 
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failure,  alcohol  abuse,  liver  disease,  neurological  disease,  recent  hospitalisation  and 
previous pneumonia (Musher et al., 2000) 
Co-infection or recent infection with influenza has been recognised as an association with 
pneumococcal pneumonia since the 1918 influenza pandemic (McLelland, 1918) but has 
only  recently  been  clearly  demonstrated  to  result  in  12%-30%  of  excess  cases  of 
pneumococcal pneumonia (Grabowska et al., 2006). 
The introduction of penicillin reduced mortality from pneumococcal pneumonia from 60% 
to 9% (Flippin et al., 1951). 
1.5.1.1.3 Pneumococcal Bloodstream Infections 
The  importance  of  obtaining  blood  cultures  during  pneumococcal  infections  was 
recognised even in the early 20
th century (McLelland, 1918). In 1938 it was recognised that 
a  blood  culture  positivity  rate  of  20%  could  be  found  for  patients  hospitalised  with 
pneumococcal  pneumonia  (Musher  et  al.,  2000).  Blood  culture  positivity  rates  are 
influenced by the severity of infection and level of bacteraemia, the culture method used 
(with  closed  automated  systems  being  more  sensitive)  and  whether  there  was  prior 
administration of antibiotics or pneumococcal vaccination. The presence of pneumococci 
in the bloodstream can result from invasion at the site of colonisation (primary) or from 
invasion at the site of an established infection (secondary) (Musher, 2004).  Likewise, the 
detection of pneumococci in the bloodstream may be transient and inconsequential or form 
part of more significant and life-threatening manifestations of the systemic inflammatory 
response syndrome, severe sepsis or septic shock (Munford, 2005). 
1.5.1.1.4 Meningitis 
Meningitis, the infection of cerebrospinal fluid and the meningeal coverings of the brain, is 
one of the most serious manifestations of invasive pneumococcal disease. Pneumococci 
account for about 37% of all adult cases of acute bacterial meningitis (Durand et al., 1993). 
Even when treated appropriately with penicillin or a third generation cephalosporin (in 
penicillin  susceptible  cases)  or  vancomycin  or  chloramphenicol  (for  penicillin  non-
susceptible cases), the case fatality rates can vary from 11 - 60% (Stanek and Mufson, 
1999).  Of those who survive, up to 54% develop neurological sequelae which may persist 
for  a  lifetime  (Stanek  and  Mufson,  1999,  Bohr  et  al.,  1984).  Recently,  it  has  been 
determined that early co-administration of dexamethasone with antibiotics may reduce the 
severity of these neurological sequelae in adults (Van de Beek et al., 2004) as well as 
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In animal models, the infecting serotype appears to determine recognisable differences in 
cerebral histopathology with serotype 1 causing more cortical haemorrhage, serotype 3 
cortical necrosis and abscess formation and serotype 9V, subcortical abscess formation 
(Ostergaard et al., 2004). 
The  pathogenesis  of  pneumococcal  meningitis  was  reviewed  extensively  by  Weber 
(Weber,  2004)  and  Koedal  et  al  (Koedel  et  al.,  2002)  and  involves  the  co-ordinated 
activities  of  several  virulence  factors  including  neuramindase  A,  IgA  protease, 
hyaluronidase,  capsule,  pneumococcal  surface  protein  A  and  C,  pneumolysin,  choline 
binding protein A, phase variation and autolysin. 
1.5.1.1.5 Conjunctivitis 
Pneumococcal conjunctivitis tends to manifest as outbreaks (Leighton et al., 2003, Martin 
et al., 2003a, Medeiros et al., 1998) although sporadic cases are recognised (Porat et al., 
2006). Serotype 3 and non-typeable pneumococci are associated with the development of 
acute conjunctivitis (Berron et al., 2005, Shouval et al., 2006).  It is thought that non-
typeable pneumococci have a selective predisposition to cause acute conjunctivitis (Porat 
et al., 2006) in both outbreaks (Medeiros et al., 1998, Leighton et al., 2003, Martin et al., 
2003a) and sporadic cases (Shouval et al., 2006). It is therefore unfortunate that current 
vaccination strategies have no effect on non-typeable pneumococci (Porat et al., 2006, 
Martin et al., 2003a). 
1.5.1.1.6 Endocarditis 
Between  0.8-3.4%  of  patients  with  pneumococcal  bacteraemia  develop  endocarditis 
(Lindberg and Fangel, 1999). There is an association with alcoholism (Bruyn et al., 1990) 
and a predilection for the aortic valve (Lindberg and Fangel, 1999, Bruyn et al., 1990). 
Affected  valves  can  rapidly  ulcerate  and  fail  (Stewart  and  Flint,  1919).  Embolic 
phenomena are common (Finland and Barnes, 1970), as are paravalvular abscesses (Bruyn 
et al., 1990). Even with appropriate antibiotic therapy, there is a fatal outcome in as high as 
40-50% of cases (Finland and Barnes, 1970, Bruyn et al., 1990) 
1.5.1.1.7  Cerebral Abscess 
Pneumococcal  cerebral  abscesses  are  uncommon  but  are  associated  with  significant 
morbidity (40% of survivors are left with neurological deficits) and high mortality (a case 
fatality  rate  of  35%  in  one  series)  despite  appropriate  antibiotic  therapy  and  surgery 
(Grigoriadis and Gold, 1997). Serotype 3 pneumococci have historically been associated 
with cerebral abscesses (Fincher, 1946, Anonymous, 1970, Colman and Hallas, 1983).     Chapter 2, 34 
1.5.1.1.8  Pleural Empyema 
The epidemiology of pneumococcal pleural empyema was well documented by Glynn and 
Digby in 1923 for the Medical Research Council (Glynn and Digby, 1923). During the 
1920s serotype 1 related pneumococcal empyema was a common manifestation with a high 
mortality of up to 53% of serotype 1 related disease and 77% of all cases of pneumococcal 
empyema in one British series (Whittle, 1929). Serotype 3 related pneumococcal empyema 
was rare (6% of all cases of pneumococcal empyema) (Whittle, 1929). These observations 
suggest that the current increase in serotype 1 related paediatric pneumococcal empyema 
being experienced in the United Kingdom (Fletcher et al., 2006, Eastham et al., 2004) may 
not  necessarily  be  a  new  phenomenon  but  may  be  the  initial  signs  of  the  serotype  1 
pneumococcal population in this country reverting back to a previously high incidence. 
1.5.1.2   Genomic Diversity in Invasive Pneumococcal Disease  
It is unwise to make generalisations regarding the global epidemiology of IPD precisely 
because of the extent of genomic diversity and the fact that different geographical regions 
(Hausdorff et al., 2001) and different human host populations within a geographical region 
(Hausdorff et al., 2001, Flannery et al., 2004, Greenwood, 1999) can demonstrate vastly 
different  incidence  of  IPD,  with  different  pneumococcal  serotypes  and  sequence  types 
contributing. In addition,  IPD is the result of the interaction between a dynamic population 
of bacteria and a dynamic human host population with changes over time being evident, 
especially in response to the use of antibiotics and vaccination policies (Kristinsson, 2008).  
However, the informed use of antibiotics and vaccination programme planning depends on 
knowledge of regional pneumococcal epidemiology. For this reason, several global and 
regional networks currently exist which record pneumococcal epidemiology and antibiotic 
resistance patterns such as the WHO Streptococcus pneumoniae Global Disease Burden 
project,  the  Pneumococcal  Global  Serotype  Project,  Global  Alliance  for  Vaccines  and 
Immunizations  Pneumococcal Vaccines Accelerated Development and Introduction Plan 
(GAVI PneumoADIP), Pneumococcal Molecular Epidemiology Network (PMEN), South 
Asian Pneumococcal Alliance (SAPNA),  Asian Network for Surveillance of Resistant 
Pathogens (ANSORP), The Network for Surveillance of Pneumococcal Disease in the East 
Africa Region (NETSPEAR) or the Pan American Health Organisation (PAHO). Likewise 
there are also national surveillance programmes throughout the world such as the Centres 
for Disease Control and Prevention (CDC) Active Bacterial Core Surveillance/Emerging 
Infections Program Network in the USA and the Health Protection Agency (HPA) and 
Health Protection Scotland (HPS) in the United Kingdom.      Chapter 2, 35 
Different studies have associated different serotypes with IPD and the results of some of 
these studies are displayed below in Table 1-1. 
Serotype associated 
with IPD 
Country  Reference 
1, 4, 14, 18C  England  (Brueggemann et al., 2003) 
1, 5, 7  England, USA, Papua New Guinea, 
Kenya, Canada and Iceland 
(Brueggemann et al., 2004) 
1, 4, 7F, 9V, 12F, 18C  Sweden  (Sandgren et al., 2004) 
1, 5, 12F  Israel  (Shouval et al., 2006) 
Table 1-1 Common pneumococcal serotypes associated with IPD in various countries. 
 
Most recently, the Pneumococcal  Global Serotype Project identified the most common 
serotypes causing IPD in children under 5 years of age. This shows that 7 to 11 serotypes 
account for over 80% of disease in every region and that Asia and Africa share the top 8 
serotypes. Serotype 14 is most commonly isolated in all regions but in older children in 
Asia and Africa, serotype 1 was most common (O'Brien, 2008). This is compatible with 
earlier observations (Kyaw et al., 2002, Hausdorff et al., 2000a, Hausdorff et al., 2000b). 
In Scotland, at the start of the 21
st century, the serogroups most commonly associated with 
IPD were 14, 9, 6, 19, 23, 8 and 4 (Kyaw et al., 2003) although enhanced surveillance has 
shown that this has changed between 2003 and 2006 (Lamb et al., 2008). Again using 
Scotland as an example, it appears that the number of MLST clones associated with IPD 
which circulate in a particular geographical region are limited and generally stable (Clarke 
et al., 2004b, Clarke et al., 2005, Clarke et al., 2004a, Jefferies et al., 2008)). This appears 
also to be true of antibiotic resistant clones as the number of such clones to be found in any 
individual country tends to be few (McGee et al., 2001a, Smith et al., 2006).  
1.6 Studies of the Genomic Diversity of Streptococcus 
pneumoniae 
Different  species  of  bacteria  demonstrate  different  degrees  of  genomic  diversity.  For 
instance,  Helicobacter  pylori  (Alm  et  al.,  1999,  Bjorkholm  et  al.,  2001)  and 
Campylobacter  jejuni  show  extensive  genomic  diversity  (Dorrell  et  al.,  2001)  while 
Mycobacterium  tuberculosis  does  not  and  appears  to  show  a  high  level  of  genomic 
conservation  (Behr  et  al.,  1999).  S.  pneumoniae  is  an  organism  which  exhibits  a  high 
degree of genomic diversity and natural populations appear to maintain a fluid state of 
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of  the  historical  milestones  which  have  aided  understanding  of  this  diversity  of 
pneumococcal genomes, the mechanisms generating this diversity, the role of biofilms and 
regions of the pneumococcal genome which have been identified as being highly variable.   
1.6.1.1   Historical background 
In 1991 using restriction fragment digests of the pneumococcal strain R6 (an avirulent, 
serotype 2 unencapsulated strain derived from the strain D39 (Lanie et al., 2007)), Gasc et 
al estimated this pneumococcal genome to be between 2,240 and 2,270kbp (Gasc et al., 
1991). It wasn’t until 2001 that the fully sequenced genome for R6 was published (Hoskins 
et al., 2001). Also published in 2001, was the sequenced genome of an isolate termed 
TIGR4 (Tettelin et al., 2001), as it was a serotype 4 isolate being investigated by The 
Institute of Genomic Research (TIGR) which originated from the blood of a 30 year old 
man  in Kongsvinger, Norway during the 1990s (Mann et al., 2006, Orihuela et al., 2004b, 
Bruckner et al., 2004, Tettelin et al., 2001). Although investigation of natural variation of 
individual alleles was possible by PCR and sequencing (Whatmore and Dowson, 1999), 
comparison of entire  genomes was expedited by  the manufacture of  DNA microarrays 
based on the R6 and TIGR4 genomes allowing direct comparisons between these genomes 
and those of other clinical isolates by using comparative genomic hybridization (Bruckner 
et al., 2004, Hakenbeck et al., 2001). 
Comparing the R6 and TIGR4 genomes was a milestone in realising the potential extent of 
diversity of pneumococcal genomes. The two genomes differ in size (R6 being 2Mb and 
TIGR4 being 2.16Mb and more similar to the other draft genomic sequence at that time for 
serotype 19F strain G54 which was 2.1Mb (Dopazo et al., 2001)). R6 and TIGR4 differ in 
around 10% of their genes (Bruckner et al., 2004). The R6 genome contains 69kb in six 
regions which are absent from TIGR4 and TIGR4 contains 157kb in twelve clusters which 
are absent from R6 (Bruckner et al., 2004).  Analysis of further genomes has identified 
many more genes which are not present in either R6 or TIGR4 genomes (Shen et al., 
2006a).  As  further  isolates  have  been  compared  with  R6  and  TIGR4  genomes,  it  has 
become apparent that there are recognised regions of diversity within the pneumococcal 
genome (Bruckner et al., 2004, Embry et al., 2007, Obert et al., 2006, Shen et al., 2006a, 
Silva et al., 2006, Hakenbeck et al., 2001) and attempts have been made to try to elucidate 
whether there is a “core” genome required by the pneumococcus for either invasive disease 
or asymptomatic carriage (Obert et al., 2006). Often spurious conclusions are drawn since 
no  apparent  acknowledgement  that  host  factors  may  be  influencing  invasive  disease 
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however, compatible with a distributed genome hypothesis which states that pathogenic 
bacteria possess a “supragenome” or  gene pool which is much larger than that of any 
single isolate and that a large set of “non-core” genes is accessed to generate genomic 
diversity (Hiller et al., 2007). These studies have also demonstrated that, in addition to 
allelic  variation,  the  pneumococcal  genome  demonstrates  intra-species  genic  variation 
which refers to the absence or presence of certain genes (Hiller et al., 2007).  
1.6.1.2   Mechanisms of Natural Diversity of the Pneumococcus 
1.6.1.2.1  Horizontal gene transfer and competence 
“Horizontal gene transfer, or the acquisition of exogenous genetic material and 
its  subsequent  stable  incorporation  into  a  recipient  genome,  has  been,  and 
continues to be, a central force that drives bacterial evolution (Joyce et al., 
2002).”  
Joyce et al also note that,  
“Gene  transfer  events  have  been  revealed  through  analyses  of  genome 
sequences,  which  differ  in  guanine  and  cytosine  (G+C)  content  and  codon 
usage  at  chromosomal  locations  that  have  recently  acquired  foreign  DNA 
(Joyce et al., 2002).”  
This  acquisition  of  exogenous  DNA  by  the  pneumococcus  depends  on  competence 
(Claverys, 2000), a state whereby DNA can be acquired from the extracellular environment 
during a short period in the pneumococcal growth cycle which is carefully controlled by 
the  com  operon  of  three  genes  (comC,  comD  and  comE  )  which  encode  competence 
stimulating peptide (CSP), histidine kinase and a response regulator. CSP is exported into 
the  extracellular  environment  by  comA  and  comB  and  when  CSP  reaches  a  critical 
concentration, comD is activated, phosphorylating comE and resulting in the upregulation 
of several genes involved in permitting competence (Whatmore et al., 1999). ComC and 
comD themselves have multiple alleles (Whatmore et al., 1999, Pozzi et al., 1996). 
The earliest descriptions of horizontal gene transfer in the pneumococcus related to the 
acquisition of penicillin resistance. Dowson et al in 1989 hypothesised that altered pbp2X 
genes arose from interspecies recombinational events with other species of streptococci 
(Dowson  et  al.,  1989).    In  1991,  Laible  et  al,  demonstrated  that  pbp2X    had  highly 
divergent regions likely resulting from interspecies recombinational events (Laible, 1991). 
Also in 1991, isolates of serogroup 19 and serogroup 23 were studied which had identical 
genes for pbp1A, pbp2A and pbp2X and it was concluded that these penicillin binding 
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horizontal  exchange  of  capsular  genes  was  not  fully  dismissed  (Coffey  et  al.,  1991). 
(Capsular switching as an example of horizontal gene transfer will be discussed below and 
the allelic diversity of pneumococcal surface proteins and other virulence factors will also 
be reviewed.) Further work published in 1993 found evidence of pbp2B gene transfer from 
Streptococcus  mitis  to  the  pneumococcus  (Dowson  et  al.,  1993)  and  that  there  was 
horizontal transfer of pbp2B from the pneumococcus to Streptococcus oralis (Coffey et al., 
1993) showing that the horizontal transfer of genes in pneumococci was a bilateral process. 
Further evidence of the extent of horizontal gene transfer was later seen when isolates of S. 
mitis  were  discovered  which  harboured  pneumolysin  and  autolysin  –  virulence  factors 
which were thought, until that time, to be specific to the pneumococcus (Whatmore et al., 
2000, Neeleman et al., 2004a, Neeleman et al., 2004b). Bruckner et al conclude that the 
high  numbers  of  insertion  elements  evident  in  pneumococcal  genomes  and  the  high 
number of PTS systems suggests high flexibility in these genomes (Bruckner et al., 2004). 
This accumulated evidence demonstrates that several pneumococcal genes exhibit many 
polymorphic  alleles,  many  of  which  are  mosaic  genes  which  have  been  generated  by 
intragenic recombination (Maiden, 1998, Bruckner et al., 2004). Feil et al have estimated 
that in the pneumococcal genome, recombination generates new alleles at a frequency ten 
time higher than mutation and that a single nucleotide is fifty times more likely to change 
through recombination than mutation (Feil et al., 2000a). 
1.6.1.2.2  Capsular switching 
Capsular switching is a form of horizontal gene transfer whereby the capsular genes coding 
for one serotype are exchanged for those of a different serotype (Coffey et al., 1998a, 
Coffey et al., 1999, Ramirez and Tomasz, 1999, Coffey et al., 1991). It is thought that this 
occurs  relatively  frequently  in  mixed  pneumococcal  populations  (Coffey  et  al.,  1998a) 
which are often found in the nasopharynx. The capsular gene cassette, flanked by genes 
dexB and aliA, is found at the same chromosomal location for all pneumococcal serotypes 
except serotype 37 (Claverys, 2000). This cassette contains up to 19 genes, several of 
which are serotype specific (Claverys, 2000). The serotype 37 capsule is coded by a single 
gene, tts, located 820kb distant to the capsular gene locus (Llull et al., 1999, Llull et al., 
2000).  Recently it has been observed that not only can the capsular locus be transferred 
spontaneously  but  also  the  adjacent  pbps  (Figure  1-1)  can  also  be  involved  in  a 
spontaneous recombination event both in vitro (Trzcinski et al., 2004, Coffey et al., 1999) 
and in vivo (Brueggemann et al., 2007, Coffey et al., 1999).     Chapter 2, 39 
 
Figure   1-1Schematic diagram of the pneumococcal genome.  
Adapted from (Brueggemann et al., 2007) this identifies the location of the capsular locus 
and its flanking genes (aliA and dexB) in relation to pbps (pbp1A, pbp1B, pbp2A, pbp2B, 
pbp2X,  pbp3)  and  housekeeping  genes  used  for  determination  of  MLST sequence  types 
(aroE, gdh, gki, recP, spi, xpt, ddl). 
 
The net effect of this is that a pneumococcal isolate with a particular sequence type can 
exist as several different serotypes depending on which capsular  genes it contains and 
expresses (Jefferies et al., 2004, Coffey et al., 1998b). The relationship between serotype 
and genome is complex and switching capsules can increase or decrease virulence (Kelly 
et  al.,  1994).  Genetic  factors  other  than  just  capsule  influence  virulence  (Obert  et  al., 
2006). 
This is of significant concern as there is accumulating evidence that after the introduction 
of PCV-7 within a population, serotype switching allows pneumococcocal populations to 
gradually escape the effects of the limited valency vaccines by disposing of the capsular 
genes affected by vaccination and replacing them with serotypes which the vaccine does 
not cover (Brueggemann et al., 2007).  
1.6.1.2.3  Serotype replacement 
Serotype  replacement  is  also  driven  by  the  introduction  of  pneumococcal  conjugate 
vaccines. By targeting only a limited number of serotypes, it is observed that non-vaccine     Chapter 2, 40 
related serotypes can replace serotypes covered by vaccines in the nasopharynx, permitting 
increased  carriage  and  transmission  of  non-vaccine  serotypes  in  the  community  and 
subsequently, invasive disease from non-vaccine serotypes (Spratt and Greenwood, 2000, 
Brueggemann et al., 2007). Unlike capsular switching (Ramirez and Tomasz, 1999), the 
genotype of these replacement serotypes maintain a sequence type in a relationship which 
is the same  as that which was seen prior to vaccine introduction. Evidence  for this is 
particularly  dramatic  for  an  increased  incidence  of  serotype  1  related,  complicated 
pneumonia  in  Utah,  USA  (Byington  et  al.,  2005c),  serotype  3  related  otitis  media 
(McEllistrem et al., 2007, McEllistrem et al., 2005) and 19A invasive disease in Alaska, 
USA (Singleton et al., 2007) and New York, USA (Pichichero and Casey, 2007).  
One  beneficial  effect  of  serotype  replacement  however,  is  a  decreased  incidence  of 
penicillin resistance among pneumococci  after conjugate vaccine introduction due to their 
predominant  serotypes  being  included  in  such  vaccine  formulations  (Byington  et  al., 
2005c, Spratt and Greenwood, 2000).  Of greater concern though are manifestations of 
serotype  replacement  resulting  in  the  emergence  of  multiply  antibiotic  resistant 
pneumococci of non-vaccine serotypes (Pichichero and Casey, 2007).  
1.6.1.2.4  Phase variation 
The pneumococcus exhibits phase variation whereby one isolate of the same serotype and 
MLST can exist in two distinct phenotypes (Bruckner et al., 2004, Weiser et al., 1994). 
These two forms, opaque and transparent, are most distinct when grown on translucent 
solid media (Weiser et al., 1994). Ring et al found that the transparent phenotype of phase 
variation increased the ability of pneumococci to cross the blood brain barrier by as much 
as  six  fold  compared  to  the  opaque  phenotype  (Ring  et  al.,  1998).  The  transparent 
phenotype  has  more  cell  wall  phosphorylcholine,  less  capsular  polysaccharide  and  has 
different surface proteins than its opaque counterpart indicating diversity of associated cell 
surface components which may influence virulence (Ring et al., 1998, Weiser and Kapoor, 
1999). Higher rates of transformation occur in transparent variants compared to opaque so 
less capsular material (transparent) appears to enhance transformation (Weiser and Kapoor, 
1999). Opaque variants survive better than transparent in the bloodstream and appear more 
resistant to phagocytosis (Obaro and Adegbola, 2002).  Weiser et al conclude,  
“An isolate should be considered a mixed population of phenotypes which 
differ in amounts of capsular polysaccharide, teichoic acid and choline binding 
proteins (Weiser and Kapoor, 1999).”  
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1.6.1.2.5  Bacteriophages 
It is estimated that as many as 75% of clinical pneumococcal isolates contain temperate 
bacteriophages  (Ramirez  et  al.,  1999)  of  which  four  have  been  sequenced  (Lopez  and 
Garcia,  2004).    Bacteriophages  have  also  been  found  commonly  in  nasopharyngeal 
carriage  isolates  (Sa-Leao  et  al.,  2002).  Lytic  phages  appear  to  contribute  to  natural 
transformation  of  the  pneumococcus  by  expanding  the  reservoir  of  exogenous  DNA 
available for incorporation into the pneumococcal genome (Lopez et al., 2000, Ramirez et 
al.,  1999)  and  may  also  alter  virulence  by  creating  chimeric  enzymes  through 
recombination after excising DNA from genes (Lopez et al., 2000). 
1.6.1.2.6  Plasmids 
It is thought that plasmids are not a common means by which diversity is introduced into 
the  pneumococcal  genome  (Bruckner  et  al.,  2004).  The  role  of  conjugation  in 
pneumococcal diversity is also unclear (Bruckner et al., 2004). However, the acquisition 
and loss of plasmids by pneumococci has been demonstrated as comparison of the genome 
of R6 with its progenitor strain D39, shows loss of its pDP1 plasmid (Lanie et al., 2007).    
1.6.1.2.7  The role of biofilms in propagating pneumococcal genomic diversity 
It is established that pneumococci form biofilms and that these contribute to certain disease 
manifestations such as otitis media (McEllistrem et al., 2007, Hall-Stoodley et al., 2006). 
DNA release and transformation are a part of the biofilm-related life cycle and readily 
occurs in many bacteria with released DNA stabilising the biofilm structure (Molin and 
Tolker-Nielsen,  2003).    Phase  variation  is  also  a  feature  of  pneumococcal  biofilms 
(McEllistrem et al., 2007). It is likely that such an environment conducive to horizontal 
gene transfer has a role in generating genomic diversity in pneumococcal populations in 
order to aid survival in changing environmental conditions (Boles et al., 2004). 
1.6.1.2.8  Regions of diversity in the pneumococcal genome 
Several  groups  have  used  microarray  CGH  to  demonstrate  regions  of  diversity  in  the 
pneumococcal  genome  using  the  TIGR4  genome  as  reference.  Initial  reports  of  these 
regions were by Hakenbeck et al who detected 10 clusters where hybridization signals 
indicated no hybridization in 20 diverse pneumococcal isolates from different serotypes 
and different geographical regions when hybridized against a serotype 4 strain (KNR.7/87) 
using an Affymetrix oligonucleotide array (Hakenbeck et al., 2001). These regions varied 
in size from 9kb to 37kb each (Hakenbeck et al., 2001).      Chapter 2, 42 
In  studies  identifying  regions  of  diversity  in  the  TIGR4  genome  (Silva  et  al.,  2006, 
Bruckner et al., 2004, Embry et al., 2007), there has been no standardised definition of 
what should characterise such a region. This has resulted in some groups considering there 
to be 13 regions of diversity of 3.7kb to 40.3kb in size (Embry et al., 2007, Obert et al., 
2006) while others have considered regions of diversity to be as small as 1.7kb and so 
document 25 such regions (Silva et al., 2006). Several regions of diversity relate to genes 
which have an identified virulence function (Embry et al., 2007). 
Bruckner et al have also identified 6 regions of diversity within the R6 genome (Bruckner 
et al., 2004) and Shen et al, identified 58 novel sequences in clinical isolates not present in 
TIGR4 or R6, some of which were virulence associated (Shen et al., 2006a).     Chapter 2, 43 
 
Region of 
Diversity 
Location in 
TIGR4 
Genome 
Size 
(kb) 
Encoded Virulence 
Determinants 
References 
RD 1  SP0067-0074  9.0  Zinc Metalloproteinase 
(ZmpC) 
(Silva et al., 2006, Bruckner 
et al., 2004) 
RD 2  SP0109-0115  5.8    (Silva et al., 2006, Bruckner 
et al., 2004) 
RD 3  SP0163-0168  5.6    (Silva et al., 2006, Bruckner 
et al., 2004, Obert et al., 
2006) 
RD 4  SP0346-0360  14.2  Capsular Polysaccharide 
synthesis operon 
(Silva et al., 2006, Bruckner 
et al., 2004) 
RD 5  SP0378-0380  3.3    (Silva et al., 2006) 
RD 6  SP0394-0397  5.4    (Silva et al., 2006, Bruckner 
et al., 2004) 
RD 7  SP0460-0468  12.6    (Silva et al., 2006, Bruckner 
et al., 2004) 
RD 8  SP0473-0478  7.1    (Silva et al., 2006) 
RD 9  SP0531-0544  5.6    (Silva et al., 2006, Bruckner 
et al., 2004) 
RD 10  SP0643-0648  11.0  RlrA pathogenicity islet  (Silva et al., 2006) 
RD 11  SP0644-0666  8.0    (Silva et al., 2006) 
RD 12  SP0692-0700  4.4    (Silva et al., 2006, Obert et 
al., 2006) 
RD 13  SP0888-0891  1.7    (Silva et al., 2006, Bruckner 
et al., 2004) 
RD 14  SP0949-0954  7.9    (Silva et al., 2006) 
RD 15  SP1050-1065  11.9  Pneumococcal 
Pathogenicity Island 1 
(PPI1) 
(Silva et al., 2006, Bruckner 
et al., 2004, Obert et al., 
2006) 
RD 16  SP1129-1147  9.2    (Silva et al., 2006, Bruckner 
et al., 2004, Obert et al., 
2006) 
RD 17  SP1315-1352  33.7    (Silva et al., 2006, Bruckner 
et al., 2004, Obert et al., 
2006) 
RD 18  SP1433-1444  12.1    (Silva et al., 2006, Bruckner 
et al., 2004) 
RD 19  SP1612-1622  10.3    (Silva et al., 2006, Bruckner 
et al., 2004, Obert et al., 
2006) 
RD 20  SP1756-1773  34.8  PsrP-sec Y2A2 
pathogenicity island 
(Silva et al., 2006, Bruckner 
et al., 2004, Obert et al., 
2006) 
RD 21  SP1793-1799  5.3    (Silva et al., 2006, Bruckner 
et al., 2004) 
RD 22  SP1828-1830  3.2    (Silva et al., 2006) 
RD 23  SP1911-1918  3.2    (Silva et al., 2006) 
RD 24  SP1948-1955  9.4    (Silva et al., 2006, Bruckner 
et al., 2004) 
RD 25  SP2159-2166  5.3    (Silva et al., 2006, Bruckner 
et al., 2004, Obert et al., 
2006) 
Table 1-2 Regions of diversity in the TIGR4 genome, size and putative virulence functions as 
determined by CGH in previous studies. 
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Region of 
Diversity 
Location in R6 
Genome 
Size 
(kb) 
Function  Reference 
RD 1  spr0102 to spr0119  14.4  Arginine biosynthesis  (Bruckner et al., 
2004) 
RD 2  spr0311 to spr0323  9.4  Capsule biosynthesis 
(equivalent to SP0347-0360) 
(Bruckner et al., 
2004) 
RD 3  spr0955 to spr0971  17.1  Macrolide efflux mefE related 
(equivalent to SP1054-1064) 
(Bruckner et al., 
2004) 
RD 4  spr1184 to spr1198  14.3  ABC transporter 
(equivalent to SP1309-1337) 
(Bruckner et al., 
2004) 
RD 5  spr1403 to spr1404  9.6  Cell wall anchor protein  (Bruckner et al., 
2004) 
RD 6  spr1618 to spr1621  4.1  ABC transporter 
(equivalent to SP1796-1799) 
(Bruckner et al., 
2004) 
Table 1-3 Regions of Diversity in the R6 genome, size and putative virulence functions as 
determined by CGH. 
1.6.1.3   Genomic Diversity and Temporal Changes Illustrated by 
Emerging and Significant Serotype and MultiLocus 
Sequence Type Combinations 
It is clear that pneumococcal populations are dynamic and although there is much concern 
regarding how vaccination policies are altering these population structures, it is evident 
that noticeable changes in the population structures were occurring prior to the introduction 
of  conjugate  vaccines.  This  section  will  focus  on  a  selection  of  serotype  and  MLST 
combinations which illustrate this dynamic diversity and which feature in later chapters.   
1.6.1.3.1 Serotype 1 
Figure 1-2 demonstrates the burden of disease caused by serotype 1 (Type I) pneumococci 
respectively in Glasgow from the 1920s until the 1980s. There is a marked decline in 
serotype 1 disease over the 20
th century, even recognising that many of the original papers 
in the pre-antibiotic era include both patients who received anti-pneumococcal serum and 
those who did not in their datasets and that case definitions are not standardised. Figure 1-3 
illustrates declining numbers of reported cases of pneumonia in Glasgow during the 1950s  
and  1960s  (which  may  be  a  product  of  the  Clean  Air  Act  passed  in  1956,  the  use  of 
antibiotics after MRC trials demonstrated their utility in 1951, the associated decline in 
cases  of    pulmonary  tuberculosis  or  a  general  recovery  from  the  social  and  economic 
effects of World War II) which could be influencing the reported numbers of cases of 
serotype 1 associated lobar pneumonia from the 1950s but it is noteworthy that the same 
decline in serotype 1 reporting was seen in Edinburgh (Figure 1-4) and in Boston, USA 
(Figure  1-5)  suggesting  that  a  genuine  decline  in  serotype  1  associated  pneumococcal 
disease was occurring in the United Kingdom and the USA during the 1950s and 1960s.     Chapter 2, 45 
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Figure    1-2  Proportions  of  cases  of  hospitalised  pneumococcal  lobar  pneumonia  due  to 
serotypes 1 and 3 documented in Glasgow over the 20
th Century. 
Data taken from (Grant, 1922, Christie, 1932, Grist et al., 1952, Smart, 1987, Cowan et al., 
1932) 
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Figure   1-3  Annual number of cases of pneumonia (all types) reported in Glasgow (1920-
1972).  
Data taken from Reports of the Medical Officer of Health, City of Glasgow 1920 to 1971. It is 
noteworthy that 1922, 1930, 1952, 1957 and 1970 were documented as  years when there 
were recognised influenza epidemics in Glasgow.      Chapter 2, 46 
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Figure    1-4  Proportions  of  cases  of  hospitalised  pneumococcal  lobar  pneumonia  in 
Edinburgh due to serotypes 1 and 3 over the 20
th Century. 
Records from  Edinburgh reproduce the same dramatic fall in the proportion of cases of 
serotype 1 associated disease that was documented in Glasgow during the 1950s and 1960s 
(Figure  1-2)  and  Boston,  USA  (Figure  1-4)  and  concurrent  rise  in  the  proportion  due  to 
serotype 3.  
Data taken from (Morgan et al., 1983, Calder et al., 1970, Davidson, 1925, Alston and Stewart, 
1930) 
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Figure   1-5 Proportion of blood cultures growing pneumococci at Boston City Hospital due 
to serotype 1 and serotype 3 (1935-1974). 
This also shows a dramatic fall in cases of serotype 1 associated disease during the 1950s 
and 1960s similar to that seen in Scotland but without an associated rise in proportion of 
cases due to serotype 3 during the early 1970s. Data from (Finland and Barnes, 1977b).     Chapter 2, 47 
 
It is clear from contemporary reports of IPD in both Scotland (Kirkham et al., 2006, Lamb 
et al., 2008, Diggle and Edwards, 2006) and England and Wales (George et al., 2006) as 
well as other European countries (Hausdorff, 2008, Hanquet et al., 2008) that cases due to 
serotype 1 are now increasing in incidence. Figure 1-6 documents this increase in Scotland 
since 1993.  
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Figure   1-6 Number of episodes of invasive serotype 1 associated disease seen in Scotland.  
Data  relates  to  episodes  reported  to  the  Scottish  Meningococcal  and  Pneumococcal 
Reference Laboratory 1993-2006. 
 
Serotype 1 accounts for > 6% of IPD in many geographical regions, but it is not included 
in the PCV-7 (Hausdorff et al., 2000b) although it is included in a new 13 valent conjugate 
vaccine (Kieninger et al., 2008). Unlike Europe and the USA, it is one of the commonest 
serotypes causing IPD in children in selected studies from Africa and Asia (Hausdorff et 
al., 2000b) and Latin America (Coral et al., 2001). It is associated with very high odds 
ratios for invasiveness in children (Brueggemann et al., 2004). This serotype also has an 
association with causing outbreaks of IPD (Jefferies et al., 2007) and is more commonly 
cultured  from  blood  than  CSF  (Hausdorff  et  al.,  2000a).  Serotype  1  has  also  been 
determined to have a low case fatality rate in Sweden (Sandgren et al., 2005, Berg et al., 
2006) and a lower relative risk of death in Denmark (Martens et al., 2004). 
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Figure   1-7 MLST sequence types associated with serotype 1 capsule in Scotland causing 
invasive pneumococcal disease (2002-2006). 
1.6.1.3.1.1  ST227 
 
Within the serotype 1 related IPD cases in Scotland since 2002, there are several sequence 
types represented but predominantly ST227 and ST306 (Figure 1-7). The proportion due to 
ST227 has remained stable since 2002. It was the predominant, stable serotype 1 clone in 
the USA between 1993 and 2002 (Brueggemann and Spratt, 2003, Gonzalez et al., 2004). 
In the immediate period after PCV-7 introduction in Utah (pre 2003), ST227 accounted for 
all cases of serotype 1 related paediatric empyema (Byington et al., 2005c) but since 2003 
this has not been the case (Byington et al., 2008). ST 227 is associated with a low case 
fatality rate in Sweden (Sjostrom et al., 2006). 
1.6.1.3.1.2  ST306 
 
It  is  of  some  concern  that  the  proportion  of  serotype  1  related  IPD  due  to  ST306  is 
increasing  each  year  in  Scotland  (Lamb  et  al.,  2008).  This  phenomenon  was  also 
documented 10 years ago in Sweden (Hedlund et al., 2003, Henriques Normark et al., 
2001).  ST306  accounts  for  the  majority  of  the  current  increase  in  serotype  1  IPD  in 
Scotland (Lamb et al., 2008, Jefferies et al., 2008). It is possible that ST306 is a new clone 
which has entered the Scottish population but it is also possible that it is a clone that was     Chapter 2, 49 
prevalent  during  the  early  20
th  century,  was  lost  from  the  Scottish  pneumococcal 
population for whatever reason and is now returning, potentially because of a lack of herd 
immunity to it as people who may have been exposed to it and developed some immunity 
during the 1920s and 1930s come to the end of their lifespan. It is certainly clear that a 
proportion of elderly, non-vaccinated, patients in a Glasgow Geriatric Hospital had pre-
existing immunity to serotype 1 pneumococci (Thakker et al., 1998) presumably the result 
of exposure to it earlier in their lifetimes.  
ST306  has  also  recently  emerged  in  Utah,  USA  as  a  common  clone  associated  with 
paediatric  empyema  (Byington  et  al.,  2008)  although  it  is  not  clear  whether  this  is  a 
phenomenon associated with serotype replacement resulting from pressure produced by 
PCV-7 or whether it is solely a property of ST306 which allows it to expand rapidly in a 
population as it is known that ST306 harbours mutations in virulence factors which may 
alter its behaviour (Kirkham et al., 2006). ST306 is also the dominant serotype 1 clone 
found  in  some  South  Pacific  islands  and  has  been  responsible  for  invasive  disease 
outbreaks in 1999 and 2007 (Le Hello et al., 2008.). 
The association of ST306 with  greater survival has  also been documented in a mouse 
model of pneumonia and bacteraemia where ST306 was associated with  the production of 
less tumor necrosis factor when compared to other sequence types associated with invasive 
disease (Sandgren et al., 2005). ST 306 is also associated with a low case fatality rate in 
Sweden (Sjostrom et al., 2006) and,  unusually,  has been detected as a carriage associated 
isolate in Portugal (Nunes et al., 2007). 
1.6.1.3.2  Serotype 3 
Serotype  3  pneumococci  have  always  been  noted  to  have  a  distinctive  phenotypic 
appearance with substantial mucoid capsule (Schottmuller, 1903) (or “slime layer” (Wood 
and Smith, 1949)). More recently it has been determined that duplications in the cap3A 
gene in the type 3 capsule locus are associated with high frequency phase variation (Waite 
et al., 2001). Properties of this polysaccharide capsule allow it to interact with Dendritic 
cell-specific ICAM 3 grabbing non-integrin (DC-SIGN) while most other pneumococcal 
serotypes do not (Koppel et al., 2005). Likewise, only serotype 3 pneumococci appear to 
have  a  gene  called  gadA  which  encodes  a  protein  similar  to  human  glutamate 
decarboxylase (Garcia and Lopez, 1995).  
Serotype 3 is a common cause of AOM (Hausdorff et al., 2000a, McEllistrem et al., 2007, 
Shouval et al., 2006) where biofilm formation may be important in its pathogenesis. It also     Chapter 2, 50 
causes acute conjunctivitis and it is postulated that serotype 3 possesses virulence factors 
which predispose it to mucosal sites (Shouval et al., 2006).  
Serotype  3  is  rarely  carried  by  Israeli  children  (Shouval  et  al.,  2006)  although  it  is  a 
serotype  3  associated  MLST  (ST180)  which  is  most  strongly  associated  with 
pneumococcal carriage by children in Oxfordshire (Brueggemann et al., 2003).  
In Sweden, greater severity of  IPD and higher case fatality  rates from  IPD are due to 
serotype 3 disease when compared to all other serotypes (Sjostrom et al., 2006). Serotype 3 
associated  IPD also has the highest relative risk of death in Denmark  (Martens et al., 
2004). 
Globally,  serotype  3  consistently  comprises  only  1-2%  of  IPD  in  young  children 
(Hausdorff, 2007).  In a meta-analysis of serogroup specific odds ratios for invasiveness in 
children , serotype 3 was one of the least likely to cause IPD (Brueggemann et al., 2004). 
Paradoxically, it is often one of the commonest serotypes to cause IPD in adults and the 
elderly  where  it  is  associated  with  severe  clinical  manifestations  and  poor  outcomes 
(Inverarity et al., 2008, Gransden et al., 1985). Figure 1-2 demonstrates the burden of 
disease caused by serotype 3 (Type III) pneumococci in Glasgow and Figure 1-4 from 
Edinburgh from the 1920s until the 1980s. The serotype 3 population does not appear to be 
increasing  at  present  in  Scotland  (Lamb  et  al.,  2008).  There  are  many  sequence  types 
among serotype 3 isolates in Scotland but this serotype is predominantly comprised of 
ST180 as seen in Figure 1-8 and Figure 1-9. It is noteworthy that serotype 3 isolates of 
different genotypes may have different virulence in mice (Kelly et al., 1994, Ren et al., 
2003). Genes associated with virulence have been determined in serotype 3 pneumococci 
by means of signature-tagged mutagenesis (Lau et al., 2001).     Chapter 2, 51 
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Figure   1-8 MLST sequence types associated with serotype 3 capsule in Scotland causing 
invasive pneumococcal disease (2002-2006). 
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Figure   1-9 Relationships of MLST sequence types constructed using eBURST version 3
4 of 
all isolates in the MLST database which express serotype 3 capsule.  
Blue dots indicate STs which are founders of clones from which single locus variants are 
demonstrated in black. Yellow dots indicate STs which are subgroup founders. ST180 is the 
dominant founder clone of serotype 3. 
 
In countries where use of PCV-7 is more established, serotype 3 is increasing in incidence, 
which is likely to be a result of serotype replacement (Byington et al., 2008, Hicks et al., 
2007). 
1.6.1.3.2.1  ST180 
 
Serotype  3  ST180  has  emerged  since  2001  as  a  cause  of  paediatric  pneumococcal 
empyema in Utah, USA (Byington et al., 2008)  and in Spain (Obando et al., 2008) and has 
also emerged as a non vaccine serotype in Alaska, USA causing IPD in adults and children 
(Miernyk et al., 2008) as well as paediatric empyema (Singleton et al., 2008). In addition, 
ST180  is  a  common  sequence  type  associated  with  AOM  (McEllistrem  et  al.,  2005). 
ST180 is associated with the highest case fatality rate from IPD in Sweden (Sjostrom et al., 
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2006). It has also been determined in children from Oxfordshire that ST180 rarely caused 
IPD but was highly associated with nasopharyngeal carriage (Brueggemann et al., 2003).  
The neuraminidase gene nanB appears to be present in all ST180 isolates while nanC is 
absent from all ST180 isolates (Pettigrew et al., 2006). 
1.6.1.3.3  Serotype 4 
Serotype 4 pneumococci are an important cause of IPD and can cause severe invasive 
disease  in  animal  models  (Sandgren  et  al.,  2005)  although  in  humans  they  have  been 
associated with milder disease manifestations (Sjostrom et al., 2006). 
1.6.1.3.4  Serotype 14 
At the start of the 21
st century, serotype 14 was the commonest serotype to cause IPD in 
children in the USA, Europe (including Scotland (Kyaw et al., 2003, Clarke et al., 2004c)) 
and Latin America and was still among the top five serotypes associated with paediatric 
IPD in Africa and Asia (Hausdorff et al., 2000b). It is more commonly cultured from blood 
than CSF (Hausdorff et al., 2000a) and is associated with an intermediate level of mortality 
(Henriques  et  al.,  2000).  Serotype  14  pneumococci  also  interact  with  the  dendritic 
pathogen receptor DC-SIGN (Koppel et al., 2005). 
Serotype 14 has recently been identified by PCR as a cause of paediatric empyema in the 
United  Kingdom  from  culture  negative  pleural  fluid  samples  (Sheppard  et  al.,  2008). 
Overuse of macrolide antibiotics has been cited as contributing to the spread of multiply 
resistant clones of serotype 14 pneumococci (including ST9) in Europe (Dias and Canica, 
2004). 
1.6.1.3.4.1  ST9 
In children from Oxfordshire, ST9 was mostly associated with causing IPD (Brueggemann 
et al., 2003). ST9 is almost 5 times more common in blood than it is in non-invasive sites 
(Amezaga et al., 2002) and has been associated with meningitis (Urwin et al., 1996). It is 
also associated with increased expression of a variant form of  glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) which may relate to its virulence (Cash et al., 1999). The ST9 
clone is associated with the M phenotype for macrolide resistance which is associated with 
the  mefA  gene  but  with  a  sequence  more  commonly  associated  with  Streptococcus 
pyogenes (Amezaga et al., 2002). The PMEN clone, England 
14-9, is a serotype 14, ST9 
clone which can be found in Scotland but here often has lower antimicrobial minimum 
inhibitory concentrations compared to the original clone suggesting some diversity within 
the clone (Smith et al., 2006).      Chapter 2, 54 
1.6.1.3.5  Serotype 19A 
Serotype 19A is not prevented by PCV-7. In countries which introduced this vaccine into 
their  paediatric  schedule  around  the  year  2000,  such  as  the  USA,  there  was  later  a 
noticeable  increase  in  the  incidence  of  serotype  19A  related  IPD  (Kristinsson,  2008, 
Weatherholtz et al., 2008, Singleton et al., 2008, Carvalho et al., 2008, Pai et al., 2005, 
Hicks et al., 2007). To complicate matters there is evidence from countries which did not 
introduce the vaccine, such as Scotland and Germany, that serotype 19A was responsible 
for significant levels of IPD (Ruckinger et al., 2008, Lamb et al., 2008, Clarke et al., 
2004c) and that the incidence of serotype 19A IPD had also increased (Kristinsson, 2008, 
Hanquet et al., 2008, Byington et al., 2006). So it was not initially clear whether this had 
been an example of serotype replacement in response to the vaccine or the acquisition of a 
more virulent clone of serotype 19A. It is also apparent that serotype 19A can be found 
causing asymptomatic carriage (see Chapter 9). 
More perplexing was the discovery that the circulating serotype 19A population in the 
USA since the introduction of  PCV-7 was genetically diverse as shown in Figure 1-10 and 
Figure  1-11  (Pai  et  al.,  2005).  For  instance,  some  isolates  are  resistant  to  multiple 
antibiotics while others are not (Brueggemann et al., 2007, Kristinsson, 2008, Pichichero 
and Casey, 2007, Singleton et al., 2007). More strikingly, Brueggemann et al  demonstrate 
that although some serotype 19A isolates are genotypically identical to strains circulating 
in the USA since the 1990s (and likely to have been selected by serotype replacement), 
there are others which clearly have evidence of having been produced as the result of 
capsular switching  (Figure 1-11) whereby the capsule is that of 19A while the genotype is 
identical to that of a serotype 4 clone (Brueggemann et al., 2007). They postulate that at 
least two vaccine escape capsular switch events have occurred. The main event resulted in 
a  penicillin  nonsusceptible  serotype  19A  with  genotype  ST695  which  arose  from 
recombination between a recipient serotype 4 ST695 and a donor serotype 19A ST199. 
This likely occurred around 2003 and resulted in clonal expansion through the Northeast 
USA because of its antibiotic resistance (Hanage et al., 2008, Pai et al., 2005). A second 
recombination  event  occurred  between  a  donor  serotype  19A  ST2365  and  a  recipient 
serotype 4 ST247 (Brueggemann et al., 2007). There is also evidence from Utah that a 
serotype 19A of sequence type ST667 (which is more usually seen in serotypes 14 and 19) 
is causing IPD (Byington et al., 2008) and from Atlanta and Massachusetts that a serotype 
19A of sequence type ST320 (acquired from the serotype 19F multiply resistant PMEN 
clone Taiwan
19F-14 ) accounts for a multiply antibiotic resistant clone which is resistant to 
penicillins,  macrolides,  clindamycin,  tetracyclines,  co-trimoxazole,  cefuroxime  and 
meropenem (Chancey et al., 2008, Carvalho et al., 2008, Hanage et al., 2008). In Alaska     Chapter 2, 55 
though, the serotype 19A clone which has expanded is associated with ST 172 and has 
been associated with a fall in antibiotic resistance (Singleton et al., 2007). 
 
Figure   1-10 Relationships of MLST sequence types constructed using eBURST version 3
5 of 
all isolates in the MLST database which express serotype 19A capsule.  
Blue dots indicate STs which are founders of clones from which single locus variants are 
demonstrated in black. Yellow dots indicate STs which are subgroup founders. ST199 is the 
dominant founder clone of serotype 19A. There is substantially greater diversity within STs 
which express serotype 19A capsule than for serotype 1 or 3.  
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Figure   1-11 Pie charts demonstrating the diversity of MLST sequence types (clonal complex 
or  CC)  which  express  serotype  19A  capsule  before  and  after  pneumococcal  conjugate 
vaccine introduction.  
Figure  taken  from  Pai  et  al,  2005.  This  increase  in  diversity  post  conjugate  vaccine 
introduction has also been seen in other expanding non vaccine serotypes such as 3 and 7F 
(Byington,  2007).  R  indicates  resistance  to  multiple  antimicrobials  and  r  indicates 
intermediate resistance to penicillin using Clinical and Laboratory Standards Institute (CLSI) 
criteria.  
 
Serotype  19A  ST199  isolates  are  associated  with  pneumococcal  haemolytic  uraemic 
syndrome which is also increasing in incidence in the United Kingdom (Waters et al., 
2007).  
1.6.1.4   Genomic Diversity and Virulence Associated Genes 
1.6.1.4.1 Antibiotic Resistance Genes 
1.6.1.4.1.1  Penicillin binding proteins (PBP) 
 
The discovery of several allelic variants for pbp2X, pbp2B and pbp1A of the six penicillin 
binding proteins was pivotal in understanding the phenomenon of horizontal gene transfer     Chapter 2, 57 
between pneumococcal isolates and between the pneumococcus and other  streptococcal 
species (Hakenbeck  et  al., 1999).  It has also been noted that when capsular switching 
occurs,  that  penicillin  resistance  genes  may  also  be  transferred  at  the  same  time 
(Brueggemann et al., 2007).  Diversity in the pbp2B gene can also influence diversity in 
the ddl housekeeping  gene during interspecies  recombinational exchanges  (Enright and 
Spratt, 1999a). 
1.6.1.4.1.2  Macrolides 
 
Resistance  to  macrolide  antibiotics  such  as  clarithromycin  occurs  mainly  by  two 
mechanisms. The first is methylation by a 23s-rRNA dimethyltransferase which prevents 
macrolides from binding to the ribosome (Retsema and Fu, 2001), resulting in resistance to 
macrolides, lincosamides and streptogramins (the MLSB phenotype) (Jain and Danziger, 
2004). Several erythromycin ribosome methylase genes (erm genes) produce the MLSB 
phenotype (Jain and Danziger, 2004). The ermB gene predominates in pneumococci (Jain 
and Danziger, 2004) and is carried by transposons, allowing transmission of this gene to 
occur horizontally and clonally (Okitsu et al., 2005). The MLSB phenotype results in high 
levels of resistance to macrolides. 
The second mechanism is due to antibiotic efflux which can occur via two classes of pump 
–  the  ATP-binding-cassette  (ABC)  transporter  superfamily  and  the  major  facilitator 
superfamily (MFS). The macrolide efflux pump (mefA) predominates in pneumococci and 
results  in  low  to  moderate  resistance  (the  M  phenotype  with  Minimum  Inhibitory 
Concentrations of 1-64 mg/L) (Jain and Danziger, 2004, Hyde et al., 2001). The presence 
of the mefA gene in R6 and its absence in TIGR4 features in one region of diversity which 
is apparent when these sequenced genomes are compared (Bruckner et al., 2004). 
A  third  unique  mechanism  which  developed  rapidly  in  a  patient  with  serotype  3 
pneumococcal pneumonia and which contributed to a fatal outcome,  resulted from an 
insertion of an 18bp tandem repeat in the L22 ribosomal protein and was described by 
Musher et al  (Musher et al., 2002). 
Macrolide resistance predominantly affects serogroups 6, 9, 14, 19 and 23 (Jacobs, 2002). 
In serotype 14, macrolide resistance is particularly associated with ST9 in Scotland (Clarke 
et al., 2004b).  
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1.6.1.4.1.3  Tetracyclines 
 
Six  diverse  alleles  for  the  tet(M)  gene  which  confers  tetracycline  resistance  in  the 
pneumococcus have been identified (Doherty et al., 2000). 
1.6.1.4.1.4  Trimethoprim 
 
Two main groups of mutations in the dihydrofolate reductase gene have been identified in 
pneumococcal isolates (Adrian, 1997). One of these mutations (Ile100-Leu) confers a 50 
fold increase in the 50% inhibitory dose (ID50) of trimethoprim (Adrian, 1997). 
1.6.1.4.2  Capsular genes 
Diversity of capsular genes and their expression is discussed earlier in section 1.6.1.2.2. 
1.6.1.4.3  Surface Proteins 
1.6.1.4.3.1  Neuraminidase  
 
The nanA gene is thought to be universally present in all pneumococcal strains (Pettigrew 
et al., 2006) while nanB was present in 96% of a series of isolates and nanC was present in 
only 51% of the same series (Pettigrew et al., 2006). NanA itself has substantial sequence 
diversity with three large regions of diversity – mosaic blocks A, C and D – and regions of 
insertions. Indeed, when comparing the R6 and TIGR4 genomes, it was noticed that the 
nanA gene in TIGR4 was smaller than that in R6 (Bruckner et al., 2004). Point mutations 
and  frameshift  mutations  have  also  been  recognised  in  the  nanA  sequence  (Calum 
Johnston, University of Glasgow, personal communication). 
1.6.1.4.3.2  Choline Binding Proteins 
1.6.1.4.3.2.1 Pneumococcal Surface Protein A (PspA) 
 
PspA and PspC are choline binding proteins associated with virulence. There is particular 
interest in PspA as it is immunogenic and has potential use for a protein based vaccine 
(Mollerach  et  al.,  2004,  Heeg  et  al.,  2007).  The  PspA  genes  are  mosaic  genes 
(Hollingshead et al., 2000) and PspA sequences can be classified into three main families 
by the variability in their alpha helices (Roche et al., 2003) although over 95% of strains 
belong to family 1 or family 2 (Roche et al., 2003, Coral et al., 2001, Mollerach et al., 
2004). Families 1 and  2 of PspA are over 50% divergent by sequence analysis (Ren et al., 
2003). Each family can be further subdivided into six clades (Hollingshead et al., 2000, 
Heeg et al., 2007).      Chapter 2, 59 
1.6.1.4.3.2.2 Pneumococcal Surface Protein C (PspC) 
 
PspC is encoded by a heterogeneous group of mosaic genes (Brooks-Walter et al., 1999). 
It has a virulence role in adherence, invasion and evasion of complement (Kerr et al., 
2006) but as it is highly polymorphic (Iannelli et al., 2002), there is substantial strain to 
strain variation and this influences virulence (Kerr et al., 2006). Such sequence variation is 
noticeable when performing microarray DNA CGH experiments (Hakenbeck et al., 2001).    
1.6.1.4.3.2.3 Other Choline Binding Proteins (cbps) 
 
In their comparison of the R6 and TIGR4 genomes, Bruckner et al identified differences 
between the two for several other cbps (Bruckner et al., 2004). One of these, cpbG, has 
been noted to exist in a truncated form due to a TTTA repeat causing a frameshift and 
premature stop codon (Mann et al., 2006) although different clinical presentations can be 
associated with either form (Mann et al., 2006). 
1.6.1.4.4 Pneumolysin 
Genetic diversity in the structure of pneumolysin has recently been shown to be associated 
with different biological behaviour of the toxin (Jefferies et al., 2007,  Kirkham et al., 
2006) indicating that genetic differences in the bacterial virulence genes could account for 
different  disease  manifestations.  Sequence  diversity  in  the  pneumolysin  gene  has  been 
recognised since 2005 (Hanage et al., 2005). 
1.6.1.4.5  Zinc Metalloproteinases 
The pneumococcus exhibits large proteases on its surface which are predominantly zinc 
metalloproteinases and early sequenced genomes showed there to be up to four per isolate 
(Chiavolini  et  al.,  2003).    These  are  particularly  important  for  invasive  infections  and 
virulence in serotype 4 pneumococci, none appear important for virulence in serotype 3 
pneumococci and only two are required for virulence in serotype 19F (Chiavolini et al., 
2003). Two of these have been characterised and show substantial genomic diversity – 
IgA1 protease and ZmpC. 
1.6.1.4.5.1  Immunoglobulin A1 protease 
 
This class of proteases allow the pneumococcus to evade host mucosal immunoglobulin 
which  explains  its  substantial  diversity  as  it  is  required  to  cleave  structurally  diverse 
substrates  (Poulsen  et  al.,  1998).  Pneumococcal  strains  demonstrate  variation  in  the 
number and sequence of repeat regions to facilitate this (Poulsen et al., 1998). There are 
also  substantial  sequence  similarities  between  the  pneumococcus  and  other  species  of     Chapter 2, 60 
alpha haemolytic streptococci (Poulsen et al., 1998).  This high level of diversity can be 
seen in results of microarray DNA CGH experiments where failure to hybridize indicates 
substantial divergence from the probe on the microarray (Hakenbeck et al., 2001). 
1.6.1.4.5.2  Zinc metalloproteinase C (ZmpC)  
 
ZmpC specifically cleaves human matrix metalloproteinase 9 (MMP-9) (Oggioni et al., 
2003). It is absent from the R6 genome (Hoskins et al., 2001, Chiavolini et al., 2003). It 
has  been  determined  to  be  present  in  26%  of  isolates  and  has  an  association  with 
pneumococcal isolates from patients with pneumonia (Chiavolini et al., 2003) and was not 
found in isolates from nasal or conjunctival swab isolates (Oggioni et al., 2003). It has 
therefore  been  suggested  that  it  has  a  role  in  virulence  and  pathogenicity  in  the  lung 
(Oggioni et al., 2003).  
1.6.1.4.6  Two-component signal transduction systems (TCSs) 
Two component systems allow pneumococci to respond to changes in their environment 
(Paterson et al., 2006). The two components are two proteins – a membrane associated 
sensor histidine kinase which on receipt of a specific stimulus phosphorylates an aspartate 
residue in a cytoplasmic cognate response regulator which invariably results in alteration 
of levels of gene transcription (Paterson et al., 2006). There are thirteen TCSs and one 
orphan response regulator described in the pneumococcus (Paterson et al., 2006, Standish 
et al., 2007). Allelic variation in these TCSs is recognised (Reichmann and Hakenbeck, 
2000). All thirteen TCSs have been sequenced and several are homologous with genes of 
other Gram positive bacteria (Lange et al., 1999).  For at least one of the TCSs, regulation 
of gene expression is strain dependent (Hendriksen et al., 2007, Blue and Mitchell, 2003). 
1.6.1.4.7  Pneumococcal pilus 
A pneumococcal pilus is encoded by the rlrA islet (LeMieux et al., 2006), which includes 
genes for three pilus subunits (RrgA, RrgB and RrgC) and can be found in some but not all 
pneumococcal isolates (Paterson and Mitchell, 2006) where it has a role in adherence and 
may be involved in virulence (Barocchi et al., 2006, Gianfaldoni et al., 2007). Its presence 
is associated with serotypes 4, 6B, 9V and 14 while it has been documented as absent from 
serotypes 1, 7F, 8 and 12B and its presence appears to be a clonal property (Aguiar et al., 
2008, Moschioni et al., 2008, Basset et al., 2007) where it is particularly associated with 
ST156 and ST162 (Sjostrom et al., 2007). Sequencing of the rlrA islets has identified three 
clade types with homology of 88-92% (Moschioni et al., 2008). Diversity of sequence in 
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has been recently demonstrated (Sjostrom et al., 2007). A second pilus has also recently 
been described (Bagnoli et al., 2008). 
1.6.1.5   Why Sequence the Pneumococcal Genome? 
There  are  several  practical  applications  resulting  from  investigating  the  diversity  of 
pneumococcal genomes and their constituent genes, other than to merely catalogue species 
diversity. This can identify genes which may distinguish oral streptococci and so improve 
taxonomy (Hollingshead and Briles, 2001, Lan and Reeves, 2001). Additionally, highly 
variable genes may distinguish poor vaccine candidate genes from more conserved and 
useful ones (Hollingshead and Briles, 2001, Serruto et al., 2004) such as lytA (Whatmore 
and Dowson, 1999). The availability of genome sequence data facilitates the development 
of new technologies (Hinds et al., 2002b) which can be used to develop new diagnostic 
tests (Hinds et al., 2008) or improve antimicrobial drug discovery through the development 
of genomic expression profiling (Hollingshead and Briles, 2001) or the identification of 
novel virulence associated genes (Hollingshead and Briles, 2001, Fournier et al., 2007).  
1.6.1.6 Aims of the Work Described in this Thesis 
The aims of this work were to investigate: 
1.  The genomic diversity of defined populations of clinically relevant Streptococcus 
pneumoniae by means of a comparative genomic hybridization approach using a 
validated contemporary PCR product microarray, PCR and genomic sequencing.  
2.  Factors which may be causing genomic diversity such as heterogeneity of genes, 
gene deletions or insertion of genetic material.  
3.  The influence that genomic diversity may have on phenotype.  
This was approached by: 
·  Comparison  of  microarray  CGH  results  with  genome  sequence  data  for  4  fully 
sequenced pneumococcal isolates. 
·  Illustrating, using ten pneumococcal isolates of different serotypes and unrelated 
sequence types, where regions of the pneumococcal genome were variable.     Chapter 2, 62 
·  Illustrating differences in the extent of inter-serotype and intra-serotype genomic 
diversity  by  comparing  five  isolates  of  ST9  from  different  serotypes  with  five 
isolates of ST9 all of which were serotype 14. 
·  Illustrating  the  extent  of  diversity  within  two  clones  of  identical  serotype  and 
sequence type (serotype 3, ST180 and serotype 4, ST246.) 
·  Investigating  the  degree  of  diversity  which  could  be  demonstrated  in  isolates 
retrieved  from  nosocomial  outbreaks  where  isolates  of  the  same  serotype  and 
sequence type (serotype 4, ST206 and serotype 1 ST227) were known to be linked 
epidemiologically. 
·  Documenting  sequence  type  diversity  involved  in  pneumococcal  carriage  in  a 
paediatric population from a geographical region of high biodiversity.    
The influence of genomic diversity on phenotype through the demonstration of microarray 
transcriptional profiles was investigated by: 
·  Comparison  of  IPD  related  serotype  3,  ST180  isolates  with  serotype  3,  ST180 
isolates isolated from nasopharyngeal carriage to investigate whether there could be 
a genetic basis for the difference in “invasive” and “carriage” phenotype.  
·  Identification of transcriptional profiles from different clinical disease conditions: 
1.  serotype  1  (ST227  and  ST306)  isolates  associated  with  parapneumonic 
complications of pneumonia. 
2.  serotype 3 (ST180) isolates from cases of cerebral abscess and meningitis. 
·  Demonstration  of  the  transcriptional  effects  on  a  multiply  antibiotic  resistant 
pneumococcal isolate by a sub-therapeutic dose of clarithromycin. 
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2  Materials and Methods 
2.1 General Procedures 
2.1.1.1   Bacterial Strains and Growth Conditions 
Details of the strains used in microarray experiments are displayed in Appendix 1. These 
details include serotypes, Multilocus Sequence Types, antibiotic sensitivities, details of the 
body fluid from which isolates were identified and the age of the source patients. Isolates 
were obtained from the strain collections of the Scottish Meningococcal and Pneumococcal 
Reference Laboratory (SMPRL) and the University of Glasgow Pneumococcal Research 
Group. All strains were taken from frozen stocks and grown overnight at 37°C on 5% 
horse blood agar (Oxoid, United Kingdom) in preparation for the manufacture of fresh 
glycerol stocks.  
2.1.1.2   Glycerol Stock Manufacture and Culture Checks 
Single colonies of test isolates grown overnight on 5% horse blood agar were inoculated 
with  a  sterile  plastic  loop  into  10ml  of  Brain  Heart  Infusion  broth  (Oxoid,  United 
Kingdom)  and  grown  at  37°C  in  a  water  bath  to  an  optical  density  of  0.6  at  600nm 
determined on a WPA biowave C08000 Cell Density Meter (WPA, United Kingdom). 1.2 
ml of sterile glycerol (Riedel-de-Haen®, Germany) was added to the remaining 9ml of 
culture and mixed. 1ml aliquots were then pipetted into cryotubes (Sarstedt, Germany) and 
stored at -80°C. The purity of glycerol stocks was assessed by growth of 10ml plated onto 
5% horse blood agar and incubated overnight at 37°C. 
2.1.1.3   Antibiotic Susceptibility Testing 
Antibiotic  susceptibility  were  determined  using  disc  susceptibility  testing  applying  the 
Clinical  and  Laboratory  Standards  Institute  (CLSI)  methodology.  Susceptibility  to 
oxacillin, ampicillin, ciprofloxacin, clarithromycin and clindamycin were determined and 
these are documented in Appendix 1. 
Isolates which were collected as part of the paediatric pneumococcal carriage study in 
Bolivia (Chapter 9) and isolate South Africa 2507 (Chapter 12) had antibiotic Minimum 
Inhibitory Concentrations (MICs) determined using E-tests® (AB Biodisk, Sweden). MICs 
were determined for penicillin, erythromycin, vancomycin, chloramphenicol, tetracycline 
and co-trimoxazole and documented in Appendix 2.     Chapter 2, 64 
2.1.1.4   Serotyping  
All serotyping of strains was performed at SMPRL using a coagglutination method (Smart, 
1986) utilising sera from Statens Serum Institut, Denmark. 
2.1.1.5   Nucleic Acid Extraction 
2.1.1.5.1 DNA Extraction for Microarray Analysis and Polymerase Chain 
Reaction 
From a pure frozen glycerol stock of the test pneumococcal isolate, 100ml was inoculated 
into 20mL Brain Heart Infusion and incubated at 37°C overnight.  Purity of this broth 
culture  was  assessed  by  streaking  10ml  aseptically  onto  5%  horse  blood  agar  (Oxoid, 
United Kingdom) and incubating this overnight at 37°C.  
The  remaining  culture  was  centrifuged    at    4000  revolutions  per  minute  (rpm)  for  15 
minutes  (serotype  3  pneumococcal  cultures  required  30  minutes)  at  4°C  in  a  Sigma 
Laboratory  centrifuge  4K15  (Philip  Harris,  United  Kingdom).  After  decanting  the 
supernatant, the pellet was resuspended in 1ml lysis buffer (consisting of 10µl 1M Tris pH 
8.0 (Ambion/Applied Biosystems, United Kingdom); 200µl 0.5M EDTA (Ambion/Applied 
Biosystems,  United  Kingdom);  50µl  10%  Sodium  Dodecyl  Sulphate  (SDS) 
(Ambion/Applied  Biosystems,  United  Kingdom);  740µl  double  distilled  water).  The 
resulting solution was transferred to a sterile 1.5ml microcentrifuge tube (Greiner Bio One, 
Germany) and incubated at 37°C for 1 hour in a digital dry bath (Accublock™ Digital Dry 
Bath,  Labnet  International,  Inc.,  United  Kingdom).  Proteinase  K  (Invitrogen,  United 
Kingdom) was added to a final concentration of 100µg/ml (5µg per ml from a 20mg/ml 
frozen stock). The resulting solution was incubated in the digital dry bath at 50°C for 3 
hours. 
RNaseA (Sigma-Aldrich, United Kingdom) was added to a final concentration of 20µg/ml 
(i.e. 2µl per ml of a 10mg/ml stock which had been boiled to remove DNase activity) and 
incubated at 37°C for 30 minutes. An equal volume of phenol: chloroform: isoamylalcohol 
(25:24:1) (Sigma-Aldrich, United Kingdom) was added and mixed by inverting the tubes 
sharply several times then centrifuged at 13000 rpm for 3 minutes at room temperature 
(Eppendorf centrifuge 5417C, USA). The upper phase was removed without disturbing the 
lower phase and added to a fresh microcentrifuge tube. 0.2 volumes of 10M ammonium 
acetate (Fisher Scientific, United Kingdom) were added along with 600µl absolute ethanol 
(Fisher Scientific, United Kingdom). The tubes were then inverted gently then spun at 30 
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The supernatant was carefully decanted and the remaining DNA pellet was air dried for 15-
20 minutes upside down on a paper towel then re-suspended in TE buffer (200 µl). Once 
re-suspended, the DNA was stored at -20°C.  The DNA was quantified on a Nanodrop ND-
1000 spectrophotometer (Agilent Technologies, United Kingdom). 
2.1.1.5.2 RNA Extraction for Microarray Analysis 
From a pure frozen glycerol stock of the test pneumococcal isolate, 100ml was inoculated 
into 15mL Brain Heart Infusion and incubated at 37°C until an optical density at 600nm of 
0.6 was reached.  Purity of this broth culture was assessed by streaking 10ml aseptically 
onto 5% horse blood agar and incubating this overnight at 37°C.  
10ml of broth culture was centrifuged at 5000 rpm at room temperature for 5 minutes in 15 
ml  centrifuge  tubes  after  which  the  supernatant  was  discarded  and  the  pellet  frozen 
immediately  in  liquid  nitrogen.  Frozen  pellets  were  then  stored  at  -80°C  until  RNA 
extractions  for  all  the  hybridizations  in  a  particular  experiment  could  be  performed  in 
parallel.  
Due to the possible action of RNases, it was considered essential to include a step early in 
the  cell  harvest  and  RNA  extraction  protocol  which  inactivates  RNases  (Conway  and 
Schoolnik, 2003), thereby limiting bias in the transcript representation due to differential 
turnover rates of RNA. On comparing a liquid nitrogen freezing step with the addition of 
RNAprotect Bacteria Reagent (Qiagen, United Kingdom) freezing in liquid  nitrogen was 
not only more cost effective but  yielded higher concentrations of RNA which were of 
better quality. 
Fresh lysozyme TE buffer was made. For 1ml of lysozyme TE buffer, 10µl 1M Tris HCl 
pH8.0  (Ambion/Applied  Biosystems,  United  Kingdom),  2µl  of  0.5M  EDTA  pH8.0 
(Ambion/Applied Biosystems, United Kingdom) and 15mg of lysozyme  (Sigma-Aldrich, 
United Kingdom) were added to 1ml of nuclease free water (Ambion/Applied Biosystems, 
United Kingdom). 
To begin the extraction, 200µl of lysozyme TE Buffer (15 mg/ml) was added to the pellet, 
vortexed  for  10  seconds  using  a  rotamixer  (Hook  and  Tucker  Instruments,  United 
Kingdom) and incubated at room temperature for 15 minutes with vortexing for 10 seconds 
every 2 minutes. 700µl of RLT Buffer from a Qiagen RNeasy Mini Kit (Qiagen RNeasy 
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The resulting lysate was transferred to a sterile 1.5ml microcentrifuge tube (Greiner Bio 
One,  Germany)  containing  25-50mg  of  100µm  glass  beads  (Sigma-Aldrich,  United 
Kingdom). Using a Hybaid Ribolyser (Hybaid, United Kingdom) set at speed 4, three runs 
of  20  seconds  were  used  to  facilitate  the  disruption  of  cells.  The  solution  was  then 
centrifuged  at  13000  rpm  (Eppendorf  centrifuge  5417C,  USA)  for  10  seconds.  The 
supernatant (approximately 900µl) was recovered to a new 1.5ml microcentrifuge tube 
(Greiner Bio One, Germany). 500µl of Ethanol 100% (Fisher Scientific, United Kingdom) 
was added and mixed without vortexing. 
700µl of this solution was added to the RNeasy Mini column (Qiagen- RNeasy MINI KIT, 
Qiagen,  United  Kingdom)  and  centrifuged  at  13000  rpm  for  30  seconds  at  room 
temperature (Eppendorf centrifuge 5417C, USA). The flow-through was discarded and the 
remaining 700µl added to the same RNeasy Mini column and centrifuged at 13000 rpm for 
30  seconds.  350µl  of  RW1  Buffer  was  added  into  the  RNeasy  Mini  column  (Qiagen- 
RNeasy MINI KIT, Qiagen, United Kingdom) and centrifuged at 13000 rpm for 5 minutes 
at room temperature. 
10µl DNase I stock solution was added to 70µl Buffer RDD (Qiagen RNase-Free DNase 
Set, Qiagen, United Kingdom) and this 80µl was pipetted directly onto the RNeasy Mini 
column  silica-gel  membrane,  and  placed  on  the  benchtop  at  room  temperature  for  15 
minutes. 
350µl  of  Buffer  RW1  was  pipetted  into  the  RNeasy  column  then  centrifuged  for  30 
seconds at 13000 rpm at room temperature and the flow through was discarded. A further 
700µl of RW1 Buffer was added into the RNeasy Mini column and centrifuged at 13000 
rpm for a further 30 seconds. The flow-through was again discarded and 500µl of RPE 
Buffer added into the RNeasy Mini column and centrifuged at 13000 rpm for 30 seconds. 
After discarding the flow through, an additional 500µl of RPE Buffer was added to the 
RNeasy Mini column and centrifuged at 13000 rpm for 2 minutes to dry the silica-gel 
membrane. 
To elute, the RNeasy Mini column was transferred to a new 1.5 ml collection tube. 50µl of 
nuclease free water (Ambion/Applied Biosystems, United Kingdom), was pipetted directly 
onto the silica-gel membrane  (30µl was added for serotype 3 pneumococcal RNA as the 
RNA yield was generally much lower than other serotypes). The tube was left to stand for 
3 minutes and then centrifuged for 1 minute at 13000 rpm. A 5µl aliquot was removed for 
quality  assessment  on  an  Agilent  2100  bioanalyser  (Agilent  Technologies,  United     Chapter 2, 67 
Kingdom) where an RNA integrity number above 9 was considered high enough quality 
for further use and quantification on a Nanodrop ND-1000 spectrophotometer (Agilent 
Technologies, United Kingdom) while the remaining stock of RNA was stored at -80°C 
until required.  
2.1.1.5.3 RNA Extraction for Quantitative Real Time Polymerase Chain Reaction 
(qRT-PCR) 
In addition to the steps above,  a second treatment to remove DNA was performed by 
adding    1ml  Ambion  TURBO  DNA-free™  (Ambion/Applied  Biosystems,  United 
Kingdom)  after  elution  into  nuclease  free  water  (Ambion/Applied  Biosystems,  United 
Kingdom) prior to assessing the RNA quality. 
2.1.1.6   Polymerase Chain Reaction (PCR) 
PCR of genes to confirm their presence or absence in test genomes was performed on a 
Techegene thermal cycler (Bibby Scientific, United Kingdom). This was set to 2 minutes 
of denaturation at 94°C followed by 35 cycles of 94°C for 30 seconds, X°C for 30 seconds 
(where X was 2°C lower than the primer melting temperature) and 40 seconds at 72°C. 
The final extension was set for 2 minutes at 72°C and then the reaction was held at 4°C. 
The reaction volume was 25ml consisting of 0.15ml Go Taq® DNA polymerase (Promega, 
USA), 5ml of 5xBuffer (Promega, USA), 2ml of Magnesium Chloride (Promega, USA), 
0.5ml of 10mM dNTPs (Invitrogen, United Kingdom), 0.5ml forward primer, 0.5ml reverse 
primer, 1ml genomic DNA and 15.35ml PCR grade water. 
2.1.1.7   Gel Electrophoresis 
Prior to use in microarray experiments, the quality of genomic DNA was also assessed by 
gel electrophoresis using a 0.7% agarose gel (Agarose MP, Roche Diagnostics, Germany). 
PCR products were run on a 2% agarose gel to assess the product size using a 100 bp DNA 
ladder  (Promega,  USA).  SYBR®  safe  (Invitrogen,  United  Kingdom)  was  used  to 
demonstrate bands of DNA. 
2.2 Microarray Protocols 
2.2.1.1   DNA Comparative Genomic Hybridization (CGH) 
DNA CGH experiments were all performed using a common reference design with TIGR4 
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of  DNA  with  a  dye  swap  step  so  that  for  each  test  isolate  of  pneumococcal  DNA 
(biological replicate), two microarrays were hybridized (technical replicates) – one with 
the test DNA labelled with fluorochrome Cy3 (GE Healthcare, United Kingdom) and one 
labelled with Cy5 (GE Healthcare, United Kingdom) (Churchill, 2002) as shown in Figure 
2-1. 
    
Figure   2-1 Results of microarray CGH dye swap experiments for isolate 06-1805 (ST227).  
In both microarrays illustrated above, DNA from the test clinical isolate 06-1805 (used in 
Chapter  10)  is  competitively  hybridized  with  DNA  from  the  laboratory  reference  strain, 
TIGR4. On the left, the  TIGR 4 genes  are labelled with the fluorophore  Cy3  and 06-1805 
genes are labelled with the fluorophore Cy5. This labelling is reversed on the microarray on 
the right. When genes are present in TIGR4 but not the test clinical isolate they appear as 
red dots (left) or green dots (right). When genes are present in 06-1805 but not the TIGR4 
genome they appear as green dots (left) and red dots (right) – these genes are identifiable in 
the laboratory reference strain R6 but are absent from TIGR4. Where genes are present in 
both 06-1805 and TIGR4 there is competition to hybridize on the array and the dots appear 
yellow. 
 
For each microarray, one Cy3 labelled DNA sample and one Cy5 labelled DNA sample 
were prepared by heating (for 5 minutes at 95°C) 5mg of DNA and 1ml of random primers 
(Invitrogen,  United  Kingdom)  made  up  to  41.5ml  with  nuclease  free  water  (Ambion/ 
Applied  Biosciences,  United  Kingdom).  This  was  then  snap  cooled  on  ice  and  briefly 
centrifuged. To each was added 5ml 10xREact 2 buffer (Invitrogen, United Kingdom), 1ml 
dNTPs (5mM dATP, 5mM dGTP, 5mM dTTP and 2mM dCTP), 1.5ml Cy3 or Cy5 dCTP 
(GE Healthcare, United Kingdom) and 1ml Large fragment DNA Polymerase I (Klenow)  
(3-9U/ml) (Invitrogen, United Kingdom) and the solution was incubated at 37°C in the dark 
for 90 minutes in a Techegene thermal cycler (Bibby Scientific, United Kingdom). 
Microarrays were prepared by soaking in a prehybridization solution preheated to 65°C 
(composed  of  8.75ml  20xSSC  (Ambion/Applied  Biosciences,  United  Kingdom),  250ml     Chapter 2, 69 
20%  SDS  (Ambion/Applied  Biosciences,  United  Kingdom),  5ml  (100mg/ml)  Bovine 
Serum Albumin (Sigma-Aldrich, United Kingdom) and made up to 50ml of sterile double 
distilled water) for 20 minutes in a Coplin jar (Fisher Scientific, United Kingdom) and 
placed in a Techne Hybridizer HB-1D (Bibby Scientific, United Kingdom). Prehybridized 
arrays were rinsed in 400ml double distilled water for 1 minute and then in 400ml propan-
2-ol (VWR International, USA) for 1 minute. Each array was placed in a 50ml centrifuge 
tube and centrifuged at 1500 rpm for 5 minutes then stored in a dust free box until ready 
for hybridization. 
Cy3 and Cy5 labelled DNA samples were combined into a Qiagen Minelute purification 
column  (Qiagen,  United  Kingdom).  500ml  of  Buffer  PB  was  added  and  centrifuged  at 
13000  rpm  for  1  minute  (Eppendorf  centrifuge  5417C,  USA).  The  flow  through  was 
discarded and 500ml of Buffer PE was added and centrifuged at 13000 rpm for 1 minute. 
Again the flowthrough was discarded then 250ml of Buffer PE was added to the same 
column and centrifuged at 13000 rpm for a minute. Flow through was discarded and then 
the  column  was  spun  again  for  1  minute  at  13000  rpm  then  placed  in  a  fresh  1.5ml 
collection  tube.  15.9ml  of  nuclease  free  water  (Ambion/Applied  Biosciences,  United 
Kingdom) was added to the membrane and centrifuged for 1 minute at 13000 rpm to elute 
DNA for hybridization. 
14.9ml of the Cy3/Cy5 labelled DNA sample was added to 4.6ml of filtered 20xSSC and 
3.5ml of 2% SDS and the resulting solution heated for 2 minutes at 95°C in a Techegene 
thermal cycler (Bibby Scientific, United Kingdom). Lifter slips (Erie Scientific Company, 
USA) were placed on the pre-hybridized microarrays and the DNA solutions pipetted onto 
the bottom left corner to allow the solution to be drawn across the microarray by capillary 
action.  Prepared  microarrays  were  placed  in  a  hybridization  cassette,  sealed  and  then 
submerged in a water bath at 65°C in a Techne Hybridiser HB-1D (Techne, USA) in the 
dark for 20 hours. 
After hybridization, arrays were transferred to a slide rack and washed with agitation in a 
pre-heated solution of 20ml 20xSSC, 1ml 20% SDS made up to 400ml with sterile double 
distilled water for 2 minutes and then transferred to a further solution of 1.2ml 20xSSC 
made  up  to  400ml  with  sterile  double  distilled  water  and  washed  with  agitation  for  4 
minutes.  Microarrays  were  then  placed  in  50ml  centrifuge  tubes  and  dried  by 
centrifugation at 1500 rpm for 5 minutes. The hybridized microarrays were then scanned 
using ScanArray Express ™ (Packard Biosciences Biochip Technologies, Perkin Elmer).     Chapter 2, 70 
2.2.1.2   RNA Comparative Hybridization 
RNA expression experiments were also performed using a common reference design using 
TIGR4 RNA grown to midlog phase (Conway and Schoolnik, 2003). Unlike the DNA 
CGH experiments, 3 biological replicates of each test isolate RNA (i.e. three independent 
RNA extractions from different broth cultures) were hybridized against TIGR4 RNA (from 
the same batch of TIGR4 RNA) with only one technical replicate per biological replicate 
as required for statistical validity (Foster and Huber, 2002). The choice of using an RNA 
reference control  grown to midlog phase was  made as this is an established means of 
determining  a  baseline  for  gene  expression.  It  is  appreciated  that  this  is  not  the  only 
possible  method  and  that  alternatives  such  as  using  genomic  DNA  or  a  mixture  of 
reference  RNA  from  several  sampling  conditions  have  also  been  used  (Conway  and 
Schoolnik, 2003). 
For  each  microarray,  one  Cy3  labelled  cDNA  sample  (2-10mg)  and  one  Cy5  labelled 
cDNA sample (2-10mg) were prepared by heating for 10 minutes at 70°C with 1ml of 
random primers (Invitrogen, United Kingdom) and made up to 11ml with nuclease free 
water (Ambion/ Applied Biosciences, United Kingdom). This was then snap cooled on ice 
and briefly centrifuged. To each was added 5ml 5xFirst strand buffer (Invitrogen, United 
Kingdom), 2.5ml DTT (100mM), 2.3ml dNTPs (5mM dATP, 5mM dGTP, 5mM dTTP and 
2mM  dCTP),  1.7ml  Cy3  or  Cy5  dCTP  (GE  Healthcare,  United  Kingdom)  and  2.5ml 
SuperScript II (200U/ml) (Invitrogen, United Kingdom) and the solution was incubated at 
25°C in the dark for 10 minutes then 42°C for 90 minutes in a Techegene thermal cycler 
(Bibby Scientific, United Kingdom).  
Microarrays were prepared in an identical way to that described above in Section 2.2.1.1. 
Cy3 and Cy5 labelled DNA samples were combined into a Qiagen Minelute purification 
column  (Qiagen,  United  Kingdom).  250ml  of  Buffer  PB  was  initially  added  and 
centrifuged at 13000 rpm for 1 minute (Eppendorf centrifuge 5417C, USA). The rest of the 
procedure  for  preparing  the  hybridization  solution,  hybridizing  the  microarray  and 
scanning is identical to that described in Section 2.2.1.1. 
2.2.1.3   Microarray Normalization for DNA Comparative Genomic 
Hybridization 
Tagged  Image  File  Format  (TIFF)  images  of  the  scanned  microarrays  created  by 
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entered into Bluefuse for Microarrays 3.5 © with the Cy3 labelled image in Channel 1 and 
the Cy5 labelled image in Channel 2. The array gridmap files provided by the Bacterial 
Microarray  Group  at  St  George’s  Hospital,  University  of  London  (BµG@S,  United 
Kingdom) were utilised.   The post processing protocol was devised by Dr Jason Hinds of 
BµG@S  and  comprised  of  initial  exclusion  of  unreliable  results  due  to  poor  quality 
hybridizations with a confidence estimate of less than 0.1. Controls spots on the array were 
identified  using  an  array  gridmap  GenePix  Array  List  (GAL)  file 
(SPv1_1_0_CGH_Gridmap.bcf)  and  data  pertaining  to  control  spot  hybridizations  was 
automatically removed from the analysis. To correct for spatial, intensity and dye related 
effects, normalization was performed using the option, “Global Lowess excluding all with 
text.” Confidence flags were set at their default settings. Replicates of each dye swap were 
combined by fusion. 
CGH was performed in Bluefuse for Microarrays 3.5© using a protocol devised by Dr 
Jason Hinds through the identification of a normal distribution of experimental variability 
and by identifying variability which was two standard deviations from the mean of this 
normal distribution for  all the results for the  TIGR4 and R6  genes represented on the 
microarray. Automated classification of regions of variability was performed by setting a 
ratio threshold for amplification as 1.0 and ratio threshold for deletion at -1.0 with the 
minimum number of clones included in the region in order for it to be classified as an 
amplification or a deletion set at 1. Dye swap processing was enabled. 
Data analysis was completed in Genespring GX 7.3.1 (Agilent Technologies, USA) again 
using protocols devised by Dr Jason Hinds. Output_fused_CGH files were imported into 
Genespring GX 7.3.1 and further normalization was performed after data transformation to 
account for dye swaps. This normalization was performed using the, “Per spot and divided 
by control channel,” protocol with a cross gene error model using the error model for one-
colour data. The error model was based on deviation from 1. The generation of gene lists 
using Genespring  GX 7.3.1 (Agilent Technologies, USA) was accomplished by importing 
the  Bluefuse  for  Microarrays  3.5©    generated  output_fused.xls  files  to  create  an 
experiment whereby the microarray dye swaps for each strain could be analysed using the, 
“Filter on data file,” option. To generate each gene list, a search was performed using the, 
“Type,” column employing the search criteria, “Column values must be not equal to NO 
CHANGE,” and “Value must appear in at least 1 of the selected columns.” The resulting 
gene list could be saved or exported into Microsoft Office Excel 2003, Microsoft®, United 
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2.2.1.4   Microarray Normalization for RNA Expression 
For  RNA  expression  experiments,  normalization  was  performed  (again  using  protocols 
written by Dr Jason Hinds) by importing the Output_fused.xls files into Genespring GX 
7.3.1 (Agilent Technologies, USA) for the 3 biological replicates of each isolate. When 
TIGR4 cDNA was labelled with Cy3 an initial “dye swap” normalization step was used for 
RNA expression experiments. An additional, “Per gene,” normalization step was applied to 
specific samples (serotype 1 isolates) where the isolates being compared involved more 
than one MLST of S. pneumoniae to take into account clustering by MLST rather than by 
the clinical condition being investigated. 
Statistical analysis of RNA expression data generated by Genespring GX 7.3.1 (Agilent 
Technologies,  USA)  was  performed  using  the  statistical  analysis  (ANOVA)  tool.  This 
performs  a  1-way  parametric  test  without  assuming  variances  are  equal.  The  false 
discovery rate was set at 0.05 resulting in a false discovery rate of about 5% of genes. 
Multiple  testing  correction  was  performed  using  a  Benjamini  and  Hochberg  False 
Discovery Rate. No post hoc tests were used. 
The class prediction function on Genespring GX 7.3.1 (Agilent Technologies, USA) was 
used to generate lists of genes which were predictive of invasiveness, brain abscess or 
complicated  pneumonia  respectively,  with  a  predictive  strength  calculation  based  on 
Fishers  Exact  Test.  These  lists  were  then  imported  into  Microsoft  Office  Excel  2003, 
Microsoft®, United Kingdom for comparison. 
2.3 Gene Sequencing and Multi Locus Sequence Typing 
Gene sequencing and MLST of isolates (Enright and Spratt, 1998) was performed at the 
SMPRL using their protocols as outlined below.  
2.3.1 Gene Sequencing 
PCR  products  from  reactions  performed  using  primers  noted  in  Appendix  3  (MWG 
Biotech AG, Germany) which were manufactured to generate the PCR products utilised in 
the manufacture of the microarray were used for sequencing. A semi automated PCR clean 
up  (Clarke  and  Diggle,  2002)  was  performed  using  a  RoboAmp  liquid  handling  robot 
(MWG  Biotech  AG,  Germany).  Likewise,  a  sequence  reaction  using  the  RoboAmp 
thermocycler (MWG Biotech AG, Germany) with a semi automated sequence cleanup was     Chapter 2, 73 
performed  as  per  the  published  method  (Clarke  and  Diggle,  2002).  Sequencing  was 
performed  using  a  MegaBACE™  1000  96-capillary  sequencer  (GE  Healthcare,  United 
Kingdom) and a published protocol (Jefferies et al., 2003).  
2.3.2 Multi Locus Sequence Typing 
MLST was performed using a previously published semi-automated protocol (Jefferies et 
al., 2003). The primers for the seven housekeeping genes used for MLST are listed below. 
Housekeeping Gene  Primer Sequence (5’→3’) 
aroE forward  GCC TTT GAG GCG ACA GC 
aroE reverse  TGC AGT TCA (G/A)AA ACA T(A/T)T TCT AA 
gdh forward  ATG GAG AAA CCA GC(G/A/T/C) AG(C/T) TT 
gdh reverse  GCT TGA GGT CCC AT(G/A) CT(G/A/T/C) CC 
gki forward  GGC ATT GGA ATG GGA TCA CC 
gki reverse  TCT CCC GCA GCT GAC AC 
recP forward  GCC AAC TCA GGT CAT CCA GG 
recP reverse  TGC AAC CGT AGC ATT GTA AC 
spi forward  TTA TTC CTC CTG ATT CTG TC 
spi reverse  GTG ATT GGC CAG AAG CGG AA 
xpt forward  TTA TTA GAA GAG CGC ATC CT 
xpt reverse  AGA TCT GCC TCC TTA AAT AC 
ddl forward  TGC (C/T)CA AGT TCC TTA TGT GG 
ddl reverse  CAC TGG GT(G/A) AAA CC(A/T) GGC AT 
Table   2-1 Primer sequences used for MLST.  
 
2.4 Analysis of Genome Sequences Using the Artemis 
Comparison Tool 
The  Artemis  Comparison  Tool  (ACT)  was  developed  as  a  means  of  visualising 
comparisons of complete genome sequences and their associated annotations (Carver et al., 
2005).    The  genomes  of  the  two  microarray  reference  strains  (TIGR4  and  R6)  were 
compared  with  the  annotated  sequences  for  fully  sequenced  pneumococcal  genomes 
provided as EMBL files by Mr Nicholas Croucher, Wellcome Trust Sanger Institute using     Chapter 2, 74 
the  BLASTN  algorithm  from  the  web  site  DoubleACT  which  is  hosted  by  the  Health 
Protection Agency
6. The resulting files were imported into ACT to allow comparison of 
either  the  TIGR4  or  R6  genomes  with  other  sequenced  strains.  These  sequence 
comparisons  could  then  be  used  to  validate  the  microarray  comparative  genomic 
hybridizations  using  the  same  four  test  strains  when  hybridized  competitively  against 
TIGR4.  
2.5 Quantitative Real Time Polymerase Chain Reaction 
2.5.1 cDNA Synthesis 
2mg  of  high  quality  RNA  (RNA  integrity  number  >  9  on  Agilent  2100  Bioanalyser 
(Agilent  Technologies,  United  Kingdom))  was  mixed  with  2µl  Random  Hexamers 
(Invitrogen™, United Kingdom) and 1 µl RNaseOUT™ (Invitrogen™, United Kingdom) 
and nuclease free water was added (Ambion/Applied Biosystems, United Kingdom) to a 
total volume of 17.5 µl. This was denatured at 70°C for 10 minutes in a Techegene thermal 
cycler (Bibby Scientific, United Kingdom), then put on ice. To each sample were added 
6µl  of  5x  First  Strand  Buffer  (Invitrogen™,  United  Kingdom),  3µl  of  0.1M  DTT 
(Invitrogen™, United Kingdom), 1.5µl  of 10mM dNTP (Invitrogen™, United Kingdom) 
and  2µl of SuperScript® III (Invitrogen™, United Kingdom). The reaction was incubated 
at 42°C for 16 hours and then inactivated by heating to 70°C for 15 minutes. 1µl of E. coli 
RNase  H  (Invitrogen™,  United  Kingdom)  was  added  and  incubated  at  37°C  for  20 
minutes. The concentration of the resulting cDNA was quantified using a Nanodrop ND-
1000 spectrophotometer (Agilent Technologies, United Kingdom). 
 
2.5.2 Quantitative Real Time Polymerase Chain Reaction Protocol 
Quantitative Real Time PCR was performed at SMPRL on a LightCycler® 480 (Roche, 
United  Kingdom).  Pneumococcal  DNA  gyrase  subunit  A  (SP1219)  was  used  as  the 
reference gene and its expression compared to appropriate test genes for each experiment. 
TIGR4 cDNA was used as a positive control and negative controls were nuclease free 
water  and  the  RNA  sample  from  which  cDNA  was  manufactured  (non-reverse 
transcription negative control). Standard curves were constructed using cDNA at dilutions 
of 1:5, 1:50, 1:500, 1:5000 and 1:50,000. Primers were used at a concentration of 1mM and 
                                                 
6 http://www.hpa-bioinfotools.org.uk/pise/double_act.html# {accessed 17
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the total reaction volume was 20ml (5ml cDNA, 10ml LightCycler® 480 SYBR Green I 
Master (Roche, United Kingdom), 3ml nuclease free water, 1ml forward primer and 1ml 
reverse primer). The protocol used consisted of a pre-incubation step for 5 minutes at 95°C 
and then 40 cycles of an amplification step consisting of 10 seconds at 95°C, 20 seconds at 
50°C and 30 seconds at 72°C. The melting curve cycle consisted of 5 seconds at 95°C, 1 
minute at 65°C followed by reaction termination at 72°C then cooling to 40°C for 10 
seconds. The results of the real time PCR experiments were analysed using the software Q-
gene (Muller et al., 2002) for assessment of relative expression levels for genes of interest. 
It  is  important  to  recognise  though  that  qRT-PCR  is  a  more  quantitative  method  of 
comparing gene expression than by using microarrays which are semi-quantitative and so 
there  can  be  notable  differences  in  the  level  of  gene  expression  detected  by  the  two 
methods  with  microarrays  often  underestimating  gene  expression  by  two  to  ten  fold 
(Conway and Schoolnik, 2003). The primers used for qRT-PCR experiments are displayed 
in Appendix 4. 
  
3  Microarray and Genome Sequencing 
Approaches to the Study of Pneumococcal 
Genomic Diversity 
3.1 What is a Microarray? 
A microarray consists of a series of, up to several thousand, nucleic acid targets attached to 
a solid substrate. Hybridization of fluorescently labelled DNA or cDNA probes from test 
genomes using methodology developed in the 1990s from Southern blotting and reverse 
Northern blotting (Guo et al., 1994) can allow assessment of the presence or sequence 
divergence of identifiable genes of interest or assessment of relative expression levels of 
genes  (Bryant  et  al.,  2004,  Ye  et  al.,  2001).  There  are  two  major  classes  of  DNA 
microarrays  –  PCR  product  or  “spotted”  microarrays  and  oligonucleotide  based 
microarrays  (Ye  et  al.,  2001,  Hinds  et  al.,  2002a,  Bryant  et  al.,  2004,  Frieberg  and 
Brunner, 2002). In general, “spotted” microarrays are better for detecting the presence or 
absence  of  entire  genes  and  are  more  economical  (Finkelstein  et  al.,  2002)  whereas 
oligonucleotide  microrrays,  which  have  a  greater  density  of  smaller  probes,  can  detect 
sequence polymorphisms within a gene more readily (Bryant et al., 2004, De Saizieu et al., 
1998, Cassone et al., 2007). For “spotted” DNA microarrays, sequences corresponding to 
single open reading frames are preferable (Rimini et al., 2000).  
Several  advancements  in  the  last  decade  have  driven  the  development  of  microarray 
technology. There has been a great expansion of techniques that have birthed methods for 
fluorescent tagging of DNA and fluorescence scanning. Techniques developed from on-
chip photolithography and inkjet and microjet deposition allow the accurate "spotting" or 
application of DNA to minute areas of solid substrate such as glass  microscope slides 
(which are inert at high temperature, allow covalent binding of DNA to the glass surface, 
tolerate  high  ionic  washes,  have  low  background  fluorescence  and  permit  competitive 
hybridization)  (Hinds  et  al.,  2002a,  Guo  et  al.,  1994,  Dharmadi  and  Gonzalez,  2004), 
membranes (which are larger and only permit single channel hybridizations) (Hinds et al., 
2002a) or microchips. This allows DNA hybridization to be performed against thousands 
of genes simultaneously (Hinds et al., 2002a, Kumar et al., 2005). Fears of bioterrorist 
attacks  and  biological  warfare  have  motivated  a  drive  to  develop  technology  that  can 
rapidly identify pathogens (Wilson et al., 2002, Pannucci et al., 2004, Hashsham et al., 
2004)  and  has  stimulated  the  miniaturisation  of  existing  technologies  for  genomic     Chapter 3, 77 
identification for application and utilisation outwith a laboratory. The complete sequencing 
of bacterial genomes has also provided a backbone template of genes against which strains 
of the same or similar organisms can be compared allowing studies of genomic diversity 
and  genotyping,  refinement  of  taxonomy  and  a  greatly  increased  understanding  of 
pathogenesis since gene expression studies need no longer be performed in isolation but in 
the dynamic context of enzymatic pathways and the adaptation of the organism to a range 
of changes in environmental exposures (Bryant et al., 2004).  
A growing number of human parasites as well as bacterial, fungal and viral pathogens have 
been studied using microarray technology in addition to Streptococcus pneumoniae (De 
Saizieu et al., 1998, Peterson et al., 2000, McCluskey et al., 2002, Martin-Galiano et al., 
2004, McDaniel et al., 2004, Shen et al., 2006a, Orihuela et al., 2004b). In an attempt to 
standardize data produced from  different microarray platforms with different experimental 
designs,  using  different  analysis  methods,  there  exist  guidelines  as  to  the  Minimum 
Information About a Microarray Experiment (MIAME) which should be accessible for any 
microarray  generated  dataset  (Dharmadi  and  Gonzalez,  2004,  Brazma  et  al.,  2001).  In 
order to be compliant with the MIAME guidelines, all microarray data pertaining to these 
experiments are stored in BmG@SBase, the microarray data repository for the Bacterial 
Microarray Group at St George’s Hospital (BmG@S), University of London. 
3.2 Applications of Microarrays  
3.2.1.1.1 Virulence studies 
In the pneumococcus, microarrays allowed a comprehensive analysis of the timing and 
extent  of  activation  of  known  components  of  the  competence  cycle  along  with  the 
identification  of  additional  loci  not  previously  recognised  as  being  involved  in 
pneumococcal competence (Peterson et al., 2000, Peterson et al., 2004, Dagkessamanskaia 
et al., 2004, De Saizieu et al., 1998, De Saizieu et al., 2000, Rimini et al., 2000, Mascher 
et  al.,  2006).  The  identification  of  genes  involved  in  pneumococcal  competence  and 
transformation was also the subject of a recent study using genomic array footprinting 
(Burghout  et  al.,  2007).    Orihuela  et  al  have  demonstrated  different  patterns  of 
pneumococcal  gene  expression  which  occur  when  extracted  from  different  anatomical 
locations in mice (Orihuela et al., 2004b). 
By comparing gene expression at different times in the growth of the pneumococcus, Ko et 
al (Ko et al., 2006), showed that the late log or early stationary phase is the most virulent 
phase  of  pneumococcal  growth.  A  growth  phase  dependent  switch  in  virulence  gene     Chapter 3, 78 
expression has also been described for Helicobacter pylori (Thompson et al., 2003). An 
advantage of the microarray approach to studying gene expression is that they eliminate 
bias generated by prior selection of genes to study which are believed to be involved in 
pathogenesis (Cassone et al., 2007). 
Microarrays  based  on  the  human  genome  have  also  been  used  to  investigate  the  host 
response to pneumococcal virulence factors such as pneumolysin (McDaniel et al., 2004).  
In  bacteria  other  than  pneumococci,  combining  microarray  CGH  with  Bayesian 
phylogenies has allowed the identification of non pathogenic, low pathogenicity and highly 
pathogenic  clades  of  Yersinia  enterocolitica    and  a  hypervirulent  clade  of  Clostridium 
difficile  by  means  of  comparative  phylogenomics  (Howard  et  al.,  2006,  Stabler  et  al., 
2006).  Chizhikov et al have also used a oligonucleotide microarray to detect virulence 
factors in strains of Salmonella, Shigella and Escherichia coli (Chizhikov et al., 2001). 
3.2.1.1.2  Drug Discovery and Development 
As DNA CGH and RNA expression experiments can help identify putative gene functions, 
their  roles  in  metabolic  pathways  or  effects  of  regulatory  systems,  they  are  ideal  for 
speeding  up  the  process  of  identifying  potential  antimicrobial  drug  targets  (Yin  et  al., 
2004, Galperin and Koonin, 1999) or identifying distinct patterns of gene expression in the 
presence  of  antimicrobials.    Bijlsma  et  al,  (Bijlsma  et  al.,  2007)  and  Burghout  et  al 
(Burghout  et  al.,  2007)  have  recently  used  Genomic  Array  Footprinting  (GAF)  which 
combines  random  transposon  mutagenesis  and  microarray  technology  to  create  a  high 
throughput method of identifying essential genes in the pneumococcus which could be 
applied  to  aid  identification  of  proteins  to  target  for  vaccine  and  antimicrobial  drug 
development. 
3.2.1.1.3  Diagnostics 
It is possible to customise microarrays to address specific diagnostic issues (Kumar et al., 
2005). One such application would be to rapidly identify the presence of antimicrobial 
resistance genes (Cassone et al., 2006, Zhu et al., 2007, Grimm et al., 2004, Call et al., 
2003). With regard to the pneumococcus, there have been moves to develop a serotyping 
microarray  although  some  of  these  prove  unable  to  discriminate  between  serotypes, 
although they can discriminate between serogroups (Wang et al., 2007). Other serotyping 
microarrays, although more accurate (Hinds et al., 2008) cannot yet compete against the 
economy and rapidity of serotyping by co-agglutination.  Use of microarray technology to 
perform  MLST  has  also  proven  to  be  unsuccessful  because  of  unacceptably  high     Chapter 3, 79 
misidentifications at polymorphic loci (Swiderek et al., 2005, Vernet et al., 2004). This has 
led to the conclusion that microarrays should not be considered a substitute for classical 
typing techniques (Cassone et al., 2007). Microarrays are also being developed which can 
discriminate  between  pneumococcal  and  other  respiratory  bacterial  and  viral  infections 
(Lin et al., 2007).  
Poor sensitivity and discriminatory power when identifying polymorphic loci, particularly 
when considering homologous sequences between bacterial species has limited the use of 
microarrays  as  a  platform  for  the  rapid,  reliable  identification  of  unknown  organisms 
(Wilson et al., 2002), the simultaneous detection of multiple pathogens or discrimination 
of infection with closely related pathogens (Call, 2005, Palacios et al., 2007) although 
attempts are being made to resolve such issues (Call, 2005, Palacios et al., 2007, Liu et al., 
2004).  It has been estimated that hybridization will be successful if genetic dissimilarity 
between  probe  and  target  is  less  than  10-15%  (Palacios  et  al.,  2007).  This  is  also 
influenced by the location of sequence dissimilarity as hybridization is less successful if 
polymorphisms are located centrally or throughout the probe sequence (Palacios et al., 
2007). Successful hybridization is also influenced less by mismatched GC rich fragments 
than by mismatched AT rich fragments (Palacios et al., 2007).  Microarrays are not well 
suited  to  enable  a  determination  of  pathogen  viability  or  quantification  of  numbers  of 
bacteria present such as would be required to estimate an infectious dose for a significant 
pathogen (Palacios et al., 2007).  
Cassone  et  al  have  suggested  that  to  overcome  inherent  sensitivity  limitations  with 
microarrays,  amplification  of  selected  sequences  could  be  performed  but  notes  that 
introducing this bias may not be acceptable in a clinical setting (Cassone et al., 2007).  
There would likely need to be a PCR-independent, whole genome amplification to avoid 
such bias. For such reasons as these, DNA microarrays may not be destined to become the, 
“standard laboratory tool,” which some have previously suggested (Ye et al., 2001). 
3.3 Microarray Design 
The technology required for microarray manufacture and the methodology behind their 
manufacture are reviewed by several authors (Kumar et al., 2005, Dharmadi and Gonzalez, 
2004,  Ye  et  al.,  2001,  Bryant  et  al.,  2004,  Hinds  et  al.,  2002b,  Hinds  et  al.,  2002a, 
Finkelstein et al., 2002).     Chapter 3, 80 
The SPv1.1 microarrays utilised in this work are manufactured by the Bacterial Microarray 
Group  at  St.  George’s  Hospital,  University  of  London  (BmG@S)  as  a  PCR  product 
microarray which harbours the genes of the entire TIGR4 genome (Tettelin et al., 2001) 
plus 117 genes from the R6 genome (Hoskins et al., 2001) all of which are represented in 
duplicate  and  attached  to  an  aminosilane  coated  glass  slide  (Hinds  et  al.,  2002a).  The 
microarray manufacturing procedures for this pneumococcal microarray are described by 
Hinds et al (Hinds et al., 2002a, Hinds et al., 2002b) and are identical to those published 
for their Staphylococcus aureus (Witney et al., 2005) and Campylobacter jejuni (Dorrell et 
al., 2001) arrays albeit SPv1.1 utilises pneumococcal primers and PCR products.  
Optimised conditions relating to DNA or cDNA concentration used, temperature, buffer 
and  salt  concentrations  are  required  for  hybridization.  Complementary  hybridization 
between  probe  and  target  sequence  results  in  stronger  signal  than  between  probe  and 
mismatches, insertions or deletions (Kumar et al., 2005).       
3.4 Microarray Analysis Methods 
The fluorophores Cy3 and Cy5 have good photostability with a wide range of separation in 
their excitation (550nm for Cy3 and 649nm for Cy5) and emission spectra (570nm for Cy3 
and 670nm for Cy5). The emitted light wavelength allows visualisation of Cy3 as red and 
Cy5 as green (Kumar et al., 2005).  
DNA  CGH  and  RNA  expression  experiments  generate  large  amounts  of  complex  data 
requiring tailored bioinformatics and biostatistical software, the use of which can have 
great impact on the interpretation of results (Kumar et al., 2005).  
In order to address systematic variables introduced into microarray experiments through 
their inherent experimental design such as slide batch heterogeneity, differences in spot 
morphology or different degrees of background signal, a process of data normalization is 
required to allow direct comparisons between microarrays (Kumar et al., 2005, Finkelstein 
et al., 2002).  For the purposes of this work, regressional normalization has been used by 
which a best fit slope is determined as a diagonal line on a scatter plot (Kumar et al., 2005, 
Dharmadi  and  Gonzalez,  2004).  Normalization  can  be  determined  from  this  line  by  a 
variety of statistical methods in the software packages Bluefuse for Microarrays 3.5 © and 
Genespring GX 7.3.1 as illustrated below in Figure 3-1.     Chapter 3, 81 
(A)  (B) 
(C) 
 
 
Figure   3-1 Comparison of normalization methods for CGH of Sample 03-4183. 
Scatter plots A and B correspond to two separate dye swap experiments for sample 03-
4183. In (A) the TIGR4 reference was labelled with Cy3 and in (B) the TIGR4 reference was 
labelled with Cy5. No normalization was performed using Bluefuse for Microarrays 3.5 © and 
Locally Weighted Scatterplot Smoothing (LOWESS) normalization was performed for each 
in Genespring GX 7.3.1.  For both there are significant “tail artefacts” resulting from low 
signal hybridizations and inclusion of signal from control spots. (C) was generated using 
the  normalization  procedure  described  in  Chapter  2  whereby  the  merging  of  both  dye 
swaps,  removal  of  low  signal  artefacts  and  control  spot  artefacts  and  LOWESS 
normalization were performed in Bluefuse for Microarrays 3.5 © with a further “Per spot- 
Divide by Control Channel” normalization step performed on this data in Genespring GX 
7.3.1 resulting in substantially fewer false positive results. 
 
The  most  appropriate  normalization  methodology  for  this  work  was  determined  by  Dr 
Jason Hinds (BmG@S) and is described in Chapter 2.  Normalization can be performed 
within a slide to account for efficiency of dye incorporation and the presence of staining 
artefacts, between the two slides of a dye swap DNA CGH experiment or across slide 
replicates of RNA expression  experiments (Ye et al., 2001).      Chapter 3, 82 
3.5 Microarray Validation Experiments 
3.5.1 Validation of DNA CGH 
A  fully  validated  microarray  should  include  evaluation  of  all  of  the  probes  on  the 
microarray with all potential genomes to which they may be applied (Call, 2005). This 
validation has been performed for SPv1.1 by BmG@S (Hinds et al., 2002a). 
3.5.1.1  Determination of normalized log ratio cut off 
The normalized log ratio cutoff is a means of determining the presence or absence of genes 
from DNA CGH data and is generated by  comparing the hybridization signal strength 
between  the  clinical  isolate  and  TIGR4.  In  order  to  determine  a  cut  off  for  these 
experiments a method by Obert et al was adapted (Obert et al., 2006).  This identified 
genes  SP0278,  SP0410,  SP0458,  SP0568,  SP0764,  SP1018,  SP0104,  SP1381,  SP1799, 
SP1975 and SP2142 on the basis that they have no paralogs, the genes are >50kb apart and 
no one physiological process was oversampled.  The normalized log ratios for these genes 
as  determined  by  Genespring  GX  7.3.1  are  displayed  below  in  Table  3-1.  PCR  was 
performed for these genes on the six serotype 4, ST246 isolates which feature in Chapter 7. 
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SP0104  hdl 
Hydrolase, haloacid dehalogenase-like 
family  1.072  1.04  1.338  0.964  0.986  0.95 
SP0278  pepS  aminopeptidase  0.972  0.924  0.97  0.96  0.931  0.966 
SP0410  ext  Exfoliative toxin, putative  0.815  1.029  1.037  No Hyb  1.898  1.036 
SP0458  dinP  DNA-damage inducible protein P  1.125  0.951  0.825  0.988  1.1  1.037 
SP0568  valS  valyl-tRNA synthetase  0.97  0.943  1.029  0.938  1.027  1.122 
SP0764  pyrDa  Dihydroorotate dehydrogenase A  1.004  1.034  1.132  0.907  1.064  1.197 
SP1018  tdk  thymidine kinase  1.237  1.027  0.959  1.056  1.126  0.976 
SP1381  abcT  ABC transporter, ATP binding protein  0.873  0.887  0.859  0.775  0.817  0.795 
SP1799  str  sugar-binding transcriptional regulator  0.374  0.49  0.425  0.246  0.233  0.278 
SP1975  spoJ  spoIIIJ family protein  0.883  0.989  0.948  1.027  1.07  1.018 
SP2142  rok  ROK family protein  0.896  0.991  0.97  1.002  0.982  1.012 
 
Table   3-1 Normalized log ratios determined by Genespring GX 7.3.1 for genes used to 
determine an appropriate cut-off value. 
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Figure    3-2  Comparison  of  microarray  CGH  result  with  PCR  results  from  the  ST246 
pneumococcal isolates used in Table 3-1.  
Yellow indicates that hybridization occurred on the microarray or that a PCR product was 
obtained. Blue indicates that hybridization did not occur on the microarray or that a PCR 
product was not obtained.   
 
On the basis of these investigations (excluding results for SP1799), a cutoff log ratio (fold 
change) of 2 was decided upon in order to have greater sensitivity by having low numbers 
of false negative hybridizations. Similar previous studies using this (Silva et al., 2006) and 
other (Obert et al., 2006) pneumococcal “spotted” arrays have used a cutoff log ratio of 
1.5. However, using this “tighter” cutoff, it was evident that it was not uncommon to find 
poor agreement between microarray and PCR results (Silva et al., 2006) for genes whose 
normalized log ratio was near the cutoff value. However, even with a less stringent cutoff, 
it is clear that, as illustrated by gene SP1799 above, that there will still be instances of 
discrepant results when determining the presence or absence of a gene by microarray CGH 
or PCR. Probable reasons relate to the choice of microarray used as Joyce et al elucidate, 
saying, 
“typically spotted DNA arrays are not sensitive enough to detect the variability 
in  genes  with  a  single  or  a  limited  nucleotide  polymorphism  (Joyce  et  al., 
2002).”  
False positive hybridizations, which could account for the result for SP0278 in isolate 03-
5339 can be the result of cross hybridization events which are more likely for genes with 
several  alleles  which  could  be  homologous  with  other  genes  (Dorrell  et  al.,  2001).     Chapter 3, 84 
Occasionally false positive hybridizations may occur if a gene is absent but its adjacent 
genes are present (Dorrell et al., 2001).  
Microarray  CGH  may  over-estimate  genomic  diversity  if  absence  of  hybridization  is 
assumed to signify absence of a gene from a test isolate rather than diversity within its 
sequence. In addition a lack of hybridization can be observed where there is no sequence 
diversity between the PCR product and the microarray probe (see Chapter 7). Other groups 
have also documented this occurrence of false negative hybridization with rates as high as 
41% (Peplies et al., 2003). This may possibly be the result of folding of the DNA in the 
hybridization solution into a secondary structure incompatible with hybridization (Palacios 
et al., 2007, Peplies et al., 2003) or overlap of the microarray probe with a hypervariable 
region of the gene (Obert et al., 2006). Whatever the mechanism is, these false negative 
hybridizations call into question the accuracy of identifying regions of diversity in the 
pneumococcal genome using microarray CGH.  
3.5.1.2   Assessment of microarray hybridization accuracy in a 
variable region 
Because of the unpredictable nature of false positive and false negative hybridizations for 
individual  probes  on  microarrays,  it  is  virtually  impossible  to  determine  a  meaningful 
sensitivity  and  specificity  for  the  overall  test.  Issues  of  false  hybridization  should  be 
considered on an individual gene basis, particularly for known hypervariable genes. Obert 
et al consider this for the pneumococcal surface protein pspA when they realised that their 
microarray failed to hybridize for this gene in the majority of tested strains despite its 
successful amplification by PCR from the same strains (Obert et al., 2006). Hybridization 
results described in subsequent chapters are compatible with this observation.  
When  the  hypervariable  genes  which  code  for  components  of  a  pneumococcal  pilus 
(SP0461-SP0468) were considered in serotype 1 isolates of ST227 and ST306, the SPv1.1 
microarray failed to detect any of them although the majority of them were present and 
detectable using PCR (Figure 3-3).      Chapter 3, 85 
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Figure   3-3 An investigation into the accuracy of hybridization and diversity of genes coding 
for the pneumococcal pilus islet rlrA investigated by PCR.  
Yellow indicates the presence of the gene in the isolate by PCR. Blue indicates absence of 
the gene by PCR. All these genes failed to hybridize on the SPv1.1 microarray. 
 
When the PCR products generated using the SP0464 primers were sequenced from the test 
isolates,  they  had  86-99%  similarity  to  SP0464  present  in  TIGR4.  SP0464  did  not 
hybridize by CGH in the sequenced serotype 1 strain INV104B but again a product was 
detectable by PCR with a sequence which showed 93-96% similarity to the TIGR4 SP0464 
as determined by BLAST software
7. Using the Artemis Comparison Tool (ACT) it can be 
seen that a gene with 94% similarity to SP0464 is identifiable in the INV104B genome 
(Figure 3-4) where it is identified as pmrA which is additional evidence to suggest that the 
disparity between hybridization results and PCR for these genes is genuine and due to false 
negative hybridization rather than false positive PCR.  
                                                 
7 http://blast.ncbi.nlm.nih.gov/Blast.cgi {accessed 8th January 2009}     Chapter 3, 86 
 
Figure   3-4 Comparison of SP0464 in the TIGR4 and INV104B genomes using the Artemis 
Comparison Tool (ACT).  
SP0464  in  TIGR4  (top  of  figure)  is  highlighted  demonstrating  94%  similarity  (yellow 
triangles) to the pmrA gene in INV104B (bottom of figure).   
 
This highlights that caution should be exercised in concluding that variable genes (such as 
the components of this pneumococcal pilus) are absent from particular serotypes when 
evidence  is  presented  solely  from  hybridization  based  technology  such  as  CGH  or 
Southern blotting (Barocchi et al., 2006) or from PCR data pertaining to the whole pilus 
(Moschioni et al., 2008) rather than individual genes as noted above and by Bassett et al 
(Basset et al., 2007) as different methodologies can produce different results which can be 
misleading.   
3.5.1.3  Validation of RNA Common Reference Hybridization 
Experimental Design  
The common reference design for RNA expression experiments requires that there is little 
variation in the nucleic  acid used as the control which in these experiments is always 
TIGR4  RNA.  Rather  than  use  TIGR4  DNA  for  our  comparator  in  RNA  expression 
experiments, RNA was preferable albeit total RNA rather than purely mRNA (De Saizieu 
et  al.,  1998).  However,  being  more  variable,  initial  hybridizations  using  TIGR4  RNA 
hybridized against TIGR4 RNA were performed in order to gauge how much variability 
inadvertently  could  be  introduced  into  the  experiment  and  determine  means  by  which 
control TIGR4 RNA variability could be kept to a minimum.       Chapter 3, 87 
3.5.1.3.1  Variation observed in TIGR4 RNA extracted from cultures grown in 
different media batches 
 
Figure    3-5  Comparison  of  TIGR4  gene  expression  from  RNA  extracted  after  growth  in 
different batches of BHI grown on different days.  
Both RNA extractions were performed on cultures grown to midlog optical density 0.6 at 
600nm  demonstrating  that  batch  to  batch  variation  substantially  influences  observable 
differences in gene expression with scatter evident extending past the 2 fold cut off lines 
around the line of equal fluorescence passing through the origin and which would have 
been considered as a significant difference in expression. 
 
Although an increase in expression extending past the chosen fold change cutoff may be 
due to the cumulative effect of many different promoters for one gene (Peterson et al., 
2004), this should not be the case when both the control and test isolates being hybridized 
are from the same genome and so it is legitimate to attribute the variation in Figure 3-5 
above  to  having  been  introduced  by  the  experimental  design.  Similar  findings  were 
considered by Gmuender et al who noted greater variability in hybridization of cDNA 
manufactured from Haemophilus influenzae RNA extracted from different cultures than if 
RNA was extracted from the same culture. They noted about 61 transcripts (about 3% of 
genes on their Affymetrix oligonucleotide based array) to lie above or  below a 2 fold 
change cut off when RNA was taken from different batches of culture and attributed this 
increased variation to different media batches, slightly different inoculum sizes or slightly 
different optical densities when cells were harvested (Gmuender et al., 2001). 
     Chapter 3, 88 
3.5.1.3.2 Variation observed in TIGR4 RNA extracted from cultures grown using 
the same batch of media 
 
 
Figure    3-6  Comparison  of  TIGR4  gene  expression  from  batches  of  RNA  extracted  from 
culture using the same batch of BHI and grown on the same day.  
Both RNA extractions were performed on cultures grown to midlog optical density 0.6 at 
600nm demonstrating substantially less variation in gene expression than Figure 3-5 with 
expressed genes generally all lying well within the lines of 2 fold cut off around the line of 
equal fluorescence passing through the origin.  
 
Based on these results, whenever gene expression experiments have been performed in this 
work, the control channel TIGR4 RNA is always taken, for each hybridization, from the 
same overall culture grown in the same batch of media, from which aliquots have been 
taken for RNA extraction.     Chapter 3, 89 
3.6 Comparisons of Microarray DNA CGH results with 
Sequenced Pneumococcal Genomes 
3.6.1 Choice of Diverse Sequenced Strains 
Isolates considered here have undergone Sanger sequencing. Listed below in Table 3-2 are 
the respective serotypes, MLST and size of genome. They demonstrate diversity in each of 
these  categories  and  are  of  significance  with  regard  to  work  described  in  subsequent 
chapters of this thesis. Genes of the TIGR4 and R6 genomes form the reference genes on 
the  microarray  which  have  been  used  in  these  studies  for  comparative  genomic 
hybridizations.  ATCC700669  is  the  reference  strain  of  the  Spain 
23F-1  Pneumococcal 
Molecular Epidemiology Network (PMEN) clone (Munoz et al., 1991) which is the same 
PMEN  clone  as  isolate  South  Africa  2507  used  in  Chapter  11.  OXC141  is  a  carriage 
serotype 3 isolate of ST180 which forms part of the comparison of invasive and carriage 
serotype 3, ST180 isolates described in Chapter 6. INV104B is of the same serotype and 
sequence  type  as  some  of  the  isolates  associated  with  parapneumonic  manifestations 
considered in Chapter 10 and INV200 features in Chapter 5 in a comparison of CGH data 
from serotype 14, ST9 isolates. 
Isolate  Serotype  MLST  Genome Length (Bp) 
TIGR4  4  205  2160800 
R6  Non Typeable  128  2038400 
ATCC700669  23F  81  2220800 
OXC141  3  180  2036800 
INV104B  1  227  2140800 
INV200  14  9  2098400 
Table   3-2 Sanger sequenced isolates which have been compared with microarray DNA CGH 
results. 
 
3.6.2 Comparison of Microarray DNA CGH results with Genome 
Sequence Data 
3.6.2.1  Diversity of TIGR4 genes in test genomes 
Appendix 5 compares the TIGR4 genes identified as not hybridizing in at least one of the 
four test sequenced genomes with their presence or absence from the sequencing data. The 
Artemis Comparison Tool can be used to visualise these differences between the TIGR4 
reference genome and the test sequenced genomes. This is illustrated in Figure 3-7.      Chapter 3, 90 
 
Figure   3-7 ACT comparison of the TIGR4 genome with the ATCC700669 genome.  
The red lines indicate the presence of homologous genes in both sequences. This screen 
shot indicates that there are no homologs of the TIGR4 genes (top of figure) SP1615-1622 in 
the  ATCC700669  genome  (bottom  of figure),  consistent  with  the  microarray  CGH  results 
which indicated no hybridization of DNA from ATCC700669 to the probes for these genes. 
 
3.6.2.2   Regions of Diversity 
The regions of diversity described in Chapter 1, Table 1-2 were identified from microarray 
CGH studies. On identifying these regions in the sequenced genomes, it is clear that the 
full extent of these regions has not been realised using the microarray CGH method which 
often underestimates the size of the region of diversity.      Chapter 3, 91 
 
Region of 
Diversity 
Size of Region 
identified by CGH 
(Silva et al., 2006) 
Size of Region identified by Sequence Comparison 
(unpublished data from  Nicholas Croucher, 
Wellcome Trust Sanger Institute) 
RD 1  SP0067-0074  SP0066-0075 
RD 2  SP0109-0115  SP0107-0118 
RD 3  SP0163-0168  SP0161-0173 
RD 4  SP0346-0360  SP0342-0366 
RD 5  SP0378-0380  SP0378-0381 
RD 6  SP0394-0397  SP0390-0400 
RD 7  SP0460-0468  SP0459-0471 
RD 8  SP0473-0478  SP0471-0478 
RD 9  SP0531-0544  SP0529-0544 
RD 10  SP0643-0648  No diversity seen in ATCC700669, OXC141, INV104B 
or INV200 
RD 11  SP0644-0666  No diversity seen in ATCC700669, OXC141, INV104B 
or INV200 
RD 12  SP0692-0700  SP0690-0701 
RD 13  SP0888-0891  SP0866-0892 
RD 14  SP0949-0954  SP0948-0954 
RD 15  SP1050-1065  SP1045-1067 
RD 16  SP1129-1147  SP1128-1151 
RD 17  SP1315-1352  SP1306-1354 
RD 18  SP1433-1444  No diversity seen in ATCC700669, OXC141, INV104B 
or INV200 
RD 19  SP1612-1622  SP1610-1623 
RD 20  SP1756-1773  SP1754-1774 
RD 21  SP1793-1799  SP1790-1800 
RD 22  SP1828-1830  SP1827-1833 
RD 23  SP1911-1918  No diversity seen in ATCC700669, OXC141, INV104B 
or INV200 
RD 24  SP1948-1955  SP1946-1956 
RD 25  SP2159-2166  SP2158-2167 
Table   3-3 Comparison of size of regions of diversity identified by microarray CGH with the 
size of the same regions of diversity identified from sequence data. 
 
In  addition,  comparison  of  the  sequences  for  ATCC700669,  OXC141,  INV104B  and 
INV200  identifies  a  further  47  newly  identified  regions  of  sequence  diversity.    These 
regions  are:  SP0020-0022,  SP0027-0032,  SP0054-0055,  SP0079-0083,  SP0137-0139, 
SP0141-0144,  SP0267-0271,  SP0338-0340,  SP0376-0381,  SP0390-0400,  SP0489-0493, 
SP0502-0510,  SP0517-0519,  SP0529-0544,  SP0566-0576,  SP0737-0741,  SP0783-0784, 
SP0794-0795,  SP0825-0828,  SP0873-0875,  SP0881-0885,  SP0866-0893,  SP0906-0908, 
SP0938-0943,  SP0948-0958,  SP1008-1009,  SP1018-1020,  SP1035-1040,  SP1153-1155, 
SP1173-1176,  SP1212-1213,  SP1291-1293,  SP1356-1360,  SP1466-1467,  SP1546-1547, 
SP1563-1564,  SP1706-1707,  SP1739-1742,  SP1782-1784,  SP1827-1833,  SP1848-1851, 
SP1885-1887,  SP1903-1906,  SP1984-1985,  SP1988-1989,  SP2092-2094,  SP2135-2141 
(Nicholas Croucher, Wellcome Trust Sanger Institute, personal communication).     Chapter 3, 92 
3.6.2.3   Identification of R6 genes in test genomes  
The four sequenced genomes were compared to the R6 genome, and no new regions of 
diversity were identified other than those described by Bruckner et al (Bruckner et al., 
2004). The genome sequence data has an advantage over microarray CGH data in that it 
can definitively identify the absence of R6 genes. Although the R6 genes identified as 
present  by  microarray  CGH  were,  in  the  majority  of  cases,  correctly  identified,  the 
microarray approach generated a significant number of false negative hybridizations for R6 
genes and underestimated the number of R6 genes present in each genome. There were two 
false  positive  results  in  the  microarray  CGH  results  as  spr0118  and  spr0966  were 
incorrectly identified as present in isolate ATCC700699. The results of the microarray 
CGH dye swap experiments and the Sanger sequencing results are compared in Figure 3-8 
below. As CGH experiments were performed using TIGR4 and not R6 as the reference 
DNA,  it  is  not  possible  to  draw  any  conclusions  about  the  non  hybridization  to  the 
microarray  probes  as,  for  the  R6  genes  represented  on  the  microarray,  binding  of  test 
isolate DNA to the microarray probes is not competitive against reference R6 DNA in 
these instances.     Chapter 3, 93 
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spr0067  Conserved Hypothetical Protein                         
spr0104   Hypothetical Protein                         
spr0105   Transporter, truncation                         
spr0106   Transporter, truncation                          
spr0107   Hypothetical Protein                         
spr0108   Conserved Hypothetical Protein (similar to comB protein)                         
spr0111   Hypothetical Protein                         
spr0112   Hypothetical Protein                         
spr0113   Hypothetical Protein                         
spr0114  Hypothetical Protein                         
spr0115   Hypothetical Protein                         
spr0116   Hypothetical Protein                         
spr0117   Hypothetical Protein                         
spr0118   Hypothetical Protein                         
spr0119   Hypothetical Protein                         
spr0225   Hypothetical Protein                         
spr0320  Type 2 capsule locus cps2L                         
spr0321  Type 2 capsule locus cps2M                         
spr0322  dTDP-glucose-4,6-dehydratase cpsN                         
spr0323  dTDP-L-rhamnose synthase cpsO                         
spr0416  Hypothetical Protein                         
spr0491  Hypothetical Protein                         
spr0493  Conserved Hypothetical Protein                         
spr0703  Hypothetical Protein                         
spr0800  Hypothetical Protein                         
spr0955   Hypothetical Protein                         
spr0956   Hypothetical Protein                         
spr0957   Tn 5252, relaxase, truncation                         
spr0958   Tn 5252, relaxase, truncation                         
spr0959   Hypothetical Protein                         
spr0960  Similar to positive transcriptional regulator MutR                         
spr0966  Conserved Hypothetical Protein (Probable acid-CoA ligase)                         
spr0972  Conserved Hypothetical Protein                         
spr1042  Immunoglobulin A1 protease                         
spr1093  Conserved Hypothetical Protein                         
spr1114   Conserved Hypothetical Protein (Probable transcriptional regulator)                         
spr1179  Conserved Hypothetical Protein                         
spr1403  Hypothetical Protein                         
spr1404  Conserved Hypothetical Protein                         
spr1478  Hypothetical Protein                         
spr1549  Hypothetical Protein                         
spr1550  Conserved Hypothetical Protein (similar to MutR protein)                         
 
Figure   3-8 Comparison of microarray CGH results for R6 genes with genome sequence data 
for the same genes.  
Red indicates the presence of an R6 gene, identified by either method. Blue indicates the 
absence of the gene from sequence data.      Chapter 3, 94 
3.6.3 Genomic Diversity Identified by Genome Sequence Data 
Alone 
To  illustrate  how  genomic  diversity  may  be  identified  from  pneumococcal  genome 
sequence  data  alone  using  ACT  and  impact  on  the  understanding  of  virulence,  two 
examples of diversity affecting known virulence factors in these isolates are considered – 
serotype 2 capsule genes and IgA1 protease. 
3.6.3.1.1 Serotype 2 capsule genes 
As R6 is an avirulent, non-capsulated laboratory strain derived from a serotype 2 strain, 
called D39, it is not surprising that remnants of the serotype 2 capsule locus remain in the 
R6 genome (Lanie et al., 2007). It is of interest that four of the serotype 2 capsule genes 
(cps2L,  cps2M,  cpsN  and  cpsO)  are  identifiable  in  the  genomes  of  INV104B  and 
ATCC700669 (neither of which are serotype 2) with 94-95% homology to the R6 versions 
of the genes suggesting that they may have been introduced by horizontal gene transfer or 
are fulfilling a function other than solely capsule polysaccharide synthesis. All four of 
these genes are involved in dTDP-rhamnose biosynthesis. This is illustrated below by ACT 
in Figure 3-9.  
 
 
 
 
 
 
 
 
     Chapter 3, 95 
Figure   3-9  ACT comparison of the spr0320-spr0323 genes in OXC141 (A), ATCC700669 (B) 
and INV200 (C).  
The R6 genome is displayed at the top of each figure and the test genome is displayed 
beneath.  In  (A)  the  genes  spr0320-spr0323  are  absent  in  OXC141  but  present  in  both 
ATCC700669 (B) and INV104B (C) with a high degree of homology to their counterparts in 
R6 (identified by the yellow bands). 
 
 
A.  ACT comparison of R6 and OXC141 genomes at region spr0320-spr0323. 
 
 
B.   ACT comparison of R6 and ATCC700669 genomes at region spr0320-spr0323. 
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C.  ACT comparison of R6 and INV200 genomes at region spr0320-spr0323. 
3.6.3.2   IgA1 protease 
A further interesting finding was the presence of the R6 gene spr1042 in all four of the test 
sequences. This is significant as it codes for IgA1 protease which is noted in Chapter 1 as a 
divergent  gene  in  the  pneumococcal  genome  allowing  evasion  of  host  mucosal 
immunoglobulin. Its homolog in TIGR4 is SP0071 which has been identified as a virulence 
factor required in a mouse  pneumonia model  (Hava and Camilli, 2002). Interestingly, the 
TIGR4 allele for this gene is absent from all these four sequenced strains using Sanger 
sequencing and does not hybridize from any of the test strains to the probe for SP0071 on 
the microarray, which is not surprising given its absence from their genomes.  
Nevertheless all four strains have a gene for IgA1 protease but CGH comparisons made 
solely  against  the  genome  of  TIGR4  as  a  reference  genome  could  easily  lead  to  the 
erroneous conclusion that these strains lack IgA1 protease and cast doubt over whether it 
genuinely is required for virulence. This highlights the fact that making assumptions about 
the presence or absence of genes based on comparisons with only one allele of a gene from 
a single reference genome produces a skewed understanding of “core” gene content in 
bacteria with such a high degree of genomic diversity as the pneumococcus. The absence 
of the reference genome allele of a gene does not necessarily equate with the absence of 
the gene per se as other alleles may be represented.        Chapter 3, 97 
3.6.4 Using Pneumococcal Genome Sequences to Identify Gene 
Insertions 
One  significant  limitation  of  a  microarray  CGH  approach  to  understanding  genomic 
diversity is that a microarray cannot identify genes in a genome if there are no probes for 
these  genes  represented  on  the  microarray.  Consequently,  the  microarray  used  for  this 
work cannot identify additional pneumococcal genes which are not present in the TIGR4 
genome  or  the  R6  genome.  It  is  clearly  the  case  that  the  pool  of  genes  which  the 
pneumococcus can host is greater than those present in the TIGR4 and R6 genomes and, 
through transmissible genetic elements and horizontal gene transfer, the pool is not even 
limited by current bacterial species boundaries (Hakenbeck et al., 2001). Knowledge of the 
full test genome sequence and the ability to compare this with other pneumococcal genome 
sequences does allow the identification of regions of genetic material which have been 
inserted into the genome. Such inserted sequences can then be analysed to predict open 
reading frames in silico with software such as GLIMMER (Gene Locator and Interpolated 
Markov ModelER) (Delcher et al., 1999).  Identification of putative functions for these 
genes can be performed using software such as BLAST (Basic Local Alignment Search 
Tool) (Altschul et al., 1990) by comparing known sequences in pneumococci and other 
bacteria in silico (Parkhill, 2002).  
Of the four test sequenced genomes utilised in this chapter, only two (ATCC700669 and 
OXC141) are considered here with regard to the additional genetic material which they 
harbour as they have been sufficiently annotated to identify the putative functions of these 
inserted genes in most cases. In ATCC700669, 202 additional genes were identified in the 
genome  when  compared  to  TIGR4  using  ACT  (Appendix  6)  and  for  OXC141,  123 
additional genes were identified using ACT (Appendix 7).  
In both these genomes, large regions of inserted genetic material appear to relate to the 
integration of genes of bacteriophage origin.  
3.6.4.1   Genetic Material in the ATCC700669 Genome in addition to 
that seen in the TIGR4 genome  
The  full  list  of  additional  genes  identified  in  the  ATCC700669  genome  is  listed  in 
Appendix 6. There is evidence of genetic insertion through bacteriophage integration and 
through transposon activity. A region of 49 genes inserted between the homologs of the     Chapter 3, 98 
TIGR4 genes SP1563 and SP1564 appears to have originated from a bacteriophage and is 
illustrated below using ACT (Figure 3-10). 
 
Figure   3-10: Comparison of gene insertions not present in the TIGR4 genome but present in 
the ATCC700669 genome using ACT.  
This illustrates the absence in TIGR4 of some of the 49 genes present in ATCC700669 
(bottom of figure) which appear inserted between the homologs of the TIGR4 genes (top of 
figure) SP1563 and SP1564. 
 
Also of interest is a region inserted between the homologs of SP1806 and SP1807 which 
codes for components of a pneumococcal phosphotransferase (PTS) system (The diversity 
of pneumococcal genes coding for PTS systems is considered more in Chapter 6). This can 
also be easily visualised in ACT (Figure 3-11).     Chapter 3, 99 
 
Figure   3-11 Comparison of PTS system genes in the TIGR4 genome with the ATCC700669 
genome using ACT.  
This  illustrates  the  absence  of  some  of  the  PTS  system  genes  present  in  ATCC700669 
(bottom of figure) which appear inserted between the homologs of the TIGR4 genes (top of 
figure) SP1806 and SP1807. 
 
Of  greater  clinical  significance  is  the  finding  of  genes  in  the  ATCC700669  genome 
involved  in  tetracycline  resistance  (SPN23F13050)  and  chloramphenicol  resistance 
(SPN23F12590) as ATCC700669 is resistant to multiple classes of antimicrobial (Munoz 
et al., 1991). 
3.6.4.2   Genetic Material in the OXC141 Genome in addition to that 
seen in the TIGR4 genome  
As the OXC141 genome is smaller than that of TIGR4, it was expected that there would be 
less  additional  genetic  material  than  that  identified  in  the  much  larger  ATCC700669 
genome. On comparing the TIGR4 and OXC141 genomes, it is evident that between the 
OXC141 homologs of the TIGR4 genes SP0019 and SP0020, a sizeable amount of DNA 
has  been  inserted.  This  region  has  recently  been  found  to  code  for  a  pneumococcal 
prophage  called  phiOXC  (Dr  Patricia  Romero,  University  of  Glasgow,  personal 
communication). Genes identified by ACT as present in OXC141 but not in TIGR4 are 
displayed in Appendix 7.     Chapter 3, 100 
 
Figure   3-12 Comparison using ACT of the TIGR4 genome with the OXC141 genome using 
ACT demonstrating the insertion site of the phiOXC prophage.  
This comprises 43 additional genes in the OXC141 genome (bottom of figure) which do not 
appear in the TIGR4 genome (top of figure). These genes are inserted between the OXC141 
homologs of the TIGR4 genes SP0019 and SP0020. 
 
3.7 Discussion 
3.7.1 Advantages and Disadvantages of a Genome Sequencing 
Approach to mapping Genomic Diversity compared to 
microarray based CGH investigations 
Full genome sequencing clearly has advantages over microarray based CGH in terms of 
the data it generates and its sensitivity and accuracy. It is not without its own hurdles 
though,  some  of  which  will  now  be  considered.  Although  costs  are  falling,  it  has 
traditionally  been  expensive  and  time  consuming  to  sequence  a  genome,  requiring 
significant capital investment for sequencing hardware and bioinformatics support (Ryan et 
al., 2007). The difficulties of correctly assembling fragments of the genome sequence (and 
the consequent need for specialist bioinformatics support) should not be underestimated,     Chapter 3, 101 
particularly  given  the  fact  that  pneumococcal  genomes  often  exhibit  runs  of  repeat 
sequences such as BOX and RUP. 
It has been calculated that aiming for a US$1000 genome sequencing technology requires a 
10
4 fold reduction in cost per base and a 10
3 fold increase in the number of bases read per 
second (Ryan et al., 2007). When starting this study of pneumococcal genomic diversity in 
2005, such costs and the absence of access to a suitable technological platform on which to 
perform genomic sequencing meant that this was not a practical option for considering the 
genomes of several diverse isolates, particularly as a dye swap CGH experiment of a single 
pneumococcal isolate could be performed for £200 and still provide unique, albeit less 
accurate, insights into the genomic diversity of pneumococcal populations. Over the course 
of  these  investigations,  access  to  sequencing  technology  has  improved  and  the  costs 
involved have decreased which has allowed a selection of the isolates used in the course of 
this work to be sequenced by 454 sequencing  at the Wellcome Trust Sanger  Institute, 
although these are still in the process of being assembled. 
It is expected that in the future, whole genome sequencing will become the gold standard 
for  investigations  of  the  genomic  diversity  of  pneumococci  but,  until  then,  microarray 
based CGH of pneumococcal genomes is an acceptable (and less expensive) option. This 
allows the investigation of a wider range of isolates while the microarray platform can also 
be used to gain new insights into the diversity of expression of pneumococcal genes as 
well as investigating the diversity of their presence. For these reasons, the majority of the 
genomic comparisons performed in this work have been performed using a microarray 
based approach. 
Although full genome sequencing demonstrates advantages over microarray CGH, it is 
worth re-iterating the observation of Parkhill who warns that,  
“All but the most simple annotation is an interpretation of the sequence, and is 
thus subject to error and misinterpretation (Parkhill, 2002).” 
It is also worth re-iterating that although genetic differences can be identified in silico 
between genomes, functional studies are still required to demonstrate the effects of these 
genes to truly establish a role for them in the pathogenesis of pneumococcal disease or 
carriage (Moscoso et al., 2005). Neverthless, these tools, which are in a rapid phase of 
development and improvement are, particularly when used in combination, establishing a 
much more informed understanding of the scale and dynamicity of genomic diversity in 
the pneumococcus and how that relates to its diverse disease presentations.      Chapter 3, 102 
3.7.2 The Distributed Genome Hypothesis and a Pneumococcal 
Supragenome 
These comparisons of pneumococcal isolates, by full genome sequencing or microarray 
CGH, suggest that any individual isolate of pneumococcus contains only a fraction of the 
possible combination of pneumococcal genes. There is a greater pool of genes represented 
by  the  wider  global  pneumococcal  population  (the  pneumococcal  supragenome)  from 
which it can draw upon, under suitable conditions, to adapt to its environment, such as 
occurs during the phenomenon of capsular switching described in Chapter 1.  Sequencing 
of  such  non-essential  regions  of  the  genome  can  greatly  enhance  understanding  of  the 
functions  of  such  genes  and  identify  potential  roles  in  virulence  or  the  generation  of 
antigenic diversity (Mavroidi et al., 2004, Bentley et al., 2006, Bagnoli et al., 2008). For 
instance, a small change in sequence such as a single polymorphism in the rhamnosyl 
transferase gene, wciP, can alter capsule expression from that of serotype 6A to serotype 
6B (Mavroidi et al., 2004).  
Gaining  an  understanding  of  both  the  combination  of  genes  present  in  clinical 
pneumococcal isolates and their allelic forms, may therefore improve understanding of 
pneumococcal  disease  pathogenesis  and  provide  potential  targets  for  therapeutic 
intervention  or  disease  prevention.  Observed  redundancy  in  a  bacterial  genome  is  not 
unique to pneumococci but is also documented in many other bacteria such as Escherichia 
coli and Mycoplasma genitalium  while in bacteria such as Bacillus anthracis there is very 
little diversity (Fraser-Liggett, 2005). Such observations and evidence of genomic diversity 
resulting from horizontal gene transfer have resulted in a “distributed genome” hypothesis 
for such bacteria where virulence traits are acquired by horizontal gene transfer to benefit 
the  bacterial  population  as  a  whole  rather  than  an  individual  organism  (Ehrlich  et  al., 
2008).   
3.7.3 Microarray Limitations 
Before considering the results of the microarray experiments in subsequent chapters, it is 
worth reiterating some of the limitations of this technique and their potential influence on 
the interpretation of results.  
Microarrays can only detect complementary sequences of the genes which are represented 
on them during their manufacture.     Chapter 3, 103 
Microarrays tell us nothing about the location of genes in the genome although this may 
influence hybridization if a probe for a deleted gene is flanked by probes for two genes 
which  remain  present  and  may  result  in  false  positive  hybridization.  False  positive 
hybridizations probably occur infrequently and may also result from cross hybridization by 
homologous genes. 
The absence of hybridization on a microarray is not synonymous with absence of a gene 
from  the  test  genome  but  requires  further  investigation  by  PCR  and  sequencing.  The 
presence of a PCR product of appropriate size may be due to a divergent gene, possibly 
containing single nucleotide polymorphisms, or the gene has the correct sequence but has 
formed a secondary structure in solution which prevents its hybridization. Determining 
whether a gene is absent is particularly difficult if the gene is known to be hypervariable 
and lack of hybridization may be due to the presence of an entirely novel sequence not 
represented on the microarray.  
Microarrays cannot detect multiple copies of genes but the presence of multiple copies in 
an expression experiment may cause an apparent “increase” in expression.  
 
  
4  Genomic Diversity Observed in Phenotypically 
Diverse Pneumococcal Isolates 
4.1 Choice of Diverse Pneumococcal Isolates 
Identified regions of diversity in the TIGR4 genome and those of other pneumococcal 
strains are outlined in Chapter 1 and 3. These have included strains from the USA (Shen et 
al., 2006a, Silva et al., 2006, Hakenbeck et al., 2001), United Kingdom (Silva et al., 2006, 
Joyce et al., 2002), South Africa (Silva et al., 2006, Bruckner et al., 2004, Hakenbeck et 
al., 2001), Norway (Silva et al., 2006), Germany (Bruckner et al., 2004, Hakenbeck et al., 
2001),  Papua  New  Guinea  (Bruckner  et  al.,  2004,  Hakenbeck  et  al.,  2001),  Hungary 
(Bruckner et al., 2004, Hakenbeck et al., 2001, Joyce et al., 2002), Switzerland (Bruckner 
et al., 2004, Hakenbeck et al., 2001), France (Bruckner et al., 2004, Hakenbeck et al., 
2001), Finland (Bruckner et al., 2004, Hakenbeck et al., 2001, Joyce et al., 2002), Taiwan 
(Joyce et al., 2002) and Spain (Bruckner et al., 2004, Hakenbeck et al., 2001, Joyce et al., 
2002) and have often included Pneumococcal Molecular Epidemiology Network (PMEN) 
clones (Bruckner et al., 2004, Silva et al., 2006, Hakenbeck et al., 2001) which are of 
significance both because they are of public health concern due to antimicrobial resistance 
but  also  because  they  are  examples  of  successful  clones  of  pneumococci  which 
demonstrate a selection advantage that has enabled their international spread (McGee et 
al., 2001a).  
In 2001, Hakenbeck et al suggested,  
“Using a large number and a wide spectrum of genetically different strains, one 
could expect a gradual variability among the pneumococcal population, since 
despite the recognition of clonal spread, population analysis suggested a freely 
recombining structure characteristic of transformable organisms (Hakenbeck et 
al., 2001).”  
This conclusion was based on data published by Hall et al who had demonstrated that the 
pneumococcus has an epidemic population structure (Hall et al., 1996). 
This study has chosen 10 isolates for DNA CGH analysis and comparison as preliminary 
work  before  focusing  on  diversity  within  particular  clonal  complexes  and  clinical 
conditions. The isolates were chosen to represent isolates from different countries (United 
Kingdom,  USA,  South  Africa  and  Bolivia)  which  included  PMEN  clones  to  represent 
isolates  of  different  serotypes  and  of  multilocus  sequence  types  which  had  epidemic     Chapter 4, 105 
potential but which were unrelated to each other. The absence of relationship between the 
sequence types was determined using eBURST software (Feil et al., 2004) as the algorithm 
it uses, based on the MLST allelic profiles, is more accurate at determining relationships 
within clonal complexes than software which generates phylogenetic trees. This is because 
frequent  horizontal  gene  transfer  in  the  pneumococcus  has  been  noted  to  affect  the 
construction of phylogenetic trees using housekeeping genes (Feil and Spratt, 2001). 
Isolate  Serotype  MLST  Background Details 
BAA-659  6A  ST376  American  Type  Culture  Collection  (ATCC)  accession 
number for the PMEN clone N. Carolina 
6A-23. The clinical 
background for the isolate is not known. 
BAA-340  14  ST67  ATCC  accession  number  for  the  PMEN  clone 
Tennessee
14-18  (Gherardi  et  al.,  2000).  The  clinical 
background for the isolate is not known but the clone has 
also been detected causing IPD in Scotland (Smith et al., 
2006).  
05-1271  20  ST568  Blood culture isolate from a 12 year old girl in 2005 from 
Paisley, United Kingdom. 
ATCC700904  19A  ST41  ATCC700904  is  the  accession  number  for  the  PMEN 
clone South Africa 
19A-13. Used in CGH experiments by 
Silva  et  al  as  PMEN13  (Silva  et  al.,  2006).  The  clinical 
background for the isolate is unknown. 
BAA-660  35B  ST377  ATCC accession number for the PMEN clone Utah 
35B-24. 
The clinical background for the isolate is not known but 
this clone has been detected in 2000 as a cause of IPD in 
Scotland (Smith et al., 2006). 
05-2565  12F  ST218  Blood stream isolate from a 79 year old man in Glasgow, 
United Kingdom cultured in 2005. 
05-1821  9V  ST156  Blood stream isolate from a 63 year old woman from Ayr, 
United Kingdom cultured in 2005. 
OXC141  3  ST180  Carriage  isolate  from  an  individual  from  Oxford.  It  has 
been sequenced at the Wellcome Trust Sanger Institute. 
ATCC51916  23F  ST37  ATCC accession number for the PMEN clone Tennessee 
23F-4. Identified in 1991 from a patient with meningitis who 
did  not  respond  to  treatment  with  a  cephalosporin 
(McDougal et al., 1995, Sloas et al., 1992). This clone has 
also  been  detected  as  an  infrequent  cause  of  IPD  in 
Scotland (Smith et al., 2006) 
07-2839  9A  ST239  Isolated from the nasopharynx of a 9 year old girl in 2007 
with chronic otitis media from Trinidad, Bolivia. 
Table   4-1 Details of isolates of diverse serotype and MLST used in microarray DNA CGH 
experiments.     Chapter 4, 106 
4.2 Microarray Results 
 
Figure   4-1 Whole pneumococcal genome view of the DNA CGH results for the 10 chosen 
isolates of diverse sequence type generated by Genespring GX 7.3.1.  
Each  horizontal  bar  represents  a  genome  and  each  vertical  coloured  bar  within  these 
represents a gene. Shades of yellow indicate hybridization by both TIGR4 and the test strain 
DNA. Shades of blue indicate hybridization by TIGR4 DNA alone. Shades of red indicate 
hybridization by the test isolate DNA alone and grey indicates no hybridization by either 
TIGR4 DNA or the test strain DNA. It is clear that these hybridization patterns show few 
similarities between the 10 isolates. 
 
4.3 Discussion  
4.3.1 Regions of Diversity in the TIGR4 and R6 Genomes 
Differences between the test isolate genomes and the TIGR4 genome are illustrated in 
Appendix 8. Of the R6 genes represented on the microarray which do not feature in the 
TIGR4 genome it was possible to identify from the hybridization patterns for the 10 test 
isolates all six regions of diversity described by Bruckner et al (Bruckner et al., 2004). 
This is illustrated in Appendix 9. For instance, the entire region spr0102 to spr0119 was 
present  in  strains  ATCC700904  and  07-2839  but  appeared  almost  entirely  lacking 
hybridization  for  strain  05-1271.  The  other  test  isolates  demonstrated  many  different 
combinations of hybridization or absent hybridization for these genes.      Chapter 4, 107 
For the region spr0311 to spr0323, only genes from the smaller cluster spr0320 to spr0323 
were found to hybridize. Again this could be the entire section (ATCC51916 and 05-1271) 
or only smaller sections (07-2839, ATCC700904 and BAA-659) or there could be a total 
lack of hybridization for the entire region (BAA-340, BAA-660, 05-2565, 05-1821 and 
OXC141).  
Similar variable hybridization was seen at the regions of diversity spr0955 to spr0971, 
spr1403 to spr1404 and spr1618 to spr1621. Only isolate 07-2839 showed hybridization of 
any genes within the region of diversity spr1184 to spr1198.  
In  isolate  ATCC700904  there  appears  to  be  a  small  region  of  diversity  at  spr1549  to 
spr1550 with hybridization occurring at these probes for this isolate alone.  Both these 
genes code for hypothetical proteins although spr1550 has sequence similarity to a MutR 
protein. Spr1549 is 393bp in size and spr1550 is 852bp in size. These were noted as highly 
variable genes coding for a putative regulatory protein by Bruckner et al (Bruckner et al., 
2004). 
For these regions of diversity in the R6 genome, it would be of interest to perform CGH of 
DNA from the test strains against R6 DNA as competitive hybridization should then be 
seen for those genes highlighted in red above in Appendix 9. 
Comparative  hybridization  of  TIGR4  DNA  against  test  isolate  DNA  has  elucidated  4 
regions of diversity which do not feature in the list of regions of diversity based on the 
TIGR4 genome identified by Silva et al (Silva et al., 2006) which are shown in Chapter 1 
Table 1-2. The first is a 6.3kb region from SP0303 to SP0311 which mainly relates to 
components of a cellobiose phosphotransferase system. This region features as cluster 2 
identified  by  Bruckner  et  al  (Bruckner  et  al.,  2004).  A  second  region  of  5.7kb  from 
SP0726 to SP0730 was identified in isolate ATCC700904 which showed no hybridization, 
despite  hybridizing  well  for  all  other  strains  (Figure  4-2)  This  was  unexpected  as  the 
isolate ATCC700904 features in the work of Silva et al where it was named PMEN13 and 
this  region  was  not  identified  despite  using  the  same  isolate  on  the  same  version  of 
microarray  with  similar  hybridization  methodologies  (Silva  et  al.,  2006).  This  can  be 
explained as the data analysis methods chosen (such as the normalization methods) are 
different between the two studies. Several genes within this region (SP0726, SP0728 and 
SP0729)  have  been  associated  with  virulence  in  a  serotype  4  mouse  bacteraemic 
pneumonia model (Hava and Camilli, 2002).     Chapter 4, 108 
   
Figure    4-2  Demonstration  of  a  new  region  of  diversity  (SP0726  –  SP0731)  in  the  TIGR4 
genome using Genespring GX 7.3.1.  
Each coloured bar represents a consecutive gene in the TIGR4 genome. Shades of yellow 
and orange indicate that hybridization occurred  with DNA from both TIGR4 and the test 
isolate while shades of blue indicate no hybridization occurred with DNA from the test strain 
but unopposed hybridization by TIGR4 DNA had occurred. 
 
A third shorter region of 5.1kb relates to a putative Type II restriction endonuclease which 
was identified as cluster 9 by Bruckner et al (Bruckner et al., 2004). It was also identified 
as present in serotype 6A isolates from cases of invasive pneumococcal disease but not 
serotypes 6B or 14 by Obert et al (Obert et al., 2006) and was not identified by Silva et al 
which again is likely to be due to the different data analysis methods utilised as Silva et al 
had also studied isolate BAA-659 which was named PMEN23 in their analysis (Silva et 
al., 2006).  
The fourth region of diversity identified by this study which was not identified by Silva et 
al  is  a  2.9kb  region  found  between  SP2180  and  SP2183  which  was  identified  as  not 
hybridizing  in  isolate  07-2839  from  Bolivia.    This  is  illustrated  in  Figure  4-3  below.    Chapter 4, 109 
 
Figure    4-3  Demonstration  of  a  new  region  of  diversity  (SP2180  –  SP2183)  in  the  TIGR4 
genome using Genespring GX 7.3.1.  
Each coloured bar represents a consecutive gene in the TIGR4 genome. Shades of yellow 
and orange indicate that hybridization occurred  with DNA from both TIGR4 and the test 
isolate while shades of blue indicate no hybridization occurred with DNA from the test strain 
but unopposed hybridization by TIGR4 DNA had occurred. 
 
The gene SP2179 falling immediately before this region was identified by Bruckner et al 
as a highly variable gene related to insertion sequence IS1380. The genes SP2180 and 
SP2181  have  been  previously  identified  as  pseudogenes,  particularly  as  SP2180  is 
interrupted by the IS1380 Spn1 element. However, gene expression studies to be described 
later in Chapter 10 using serotype 3 and serotype 1 pneumococci show SP2180, SP2182 
and SP2183 to be expressed in both TIGR4 and the test isolates while SP2181 was not 
expressed in any of these expression experiments. SP2181 was expressed though by the 
strain  South  Africa  2507  but  only  in  response  to  the  addition  of  subtherapeutic 
clarithromycin (Chapter 11). Evidence of their expression under certain conditions does 
suggest that these genes may be functional. 
Bruckner et al identified some regions which were not present in some of their battery of  
international  test  strains  but  were  evident  in  TIGR4  and  R6  (Bruckner  et  al.,  2004). 
SP0505 to SP0508 is such a region. However, this region appears to be present in all the 10     Chapter 4, 110 
strains tested in this chapter.  Bruckner et al also identify the region SP1309 - SP1337 as a, 
“hot spot,” for recombination (Bruckner et al., 2004). These results also concur with this 
observation as this is a region of substantial diversity between strains as illustrated below 
in Figure 4-4. This region is within a slightly larger region of diversity extending from 
SP1309 - SP1347 which is part of the region of diversity 17 described by Silva et al and 
clusters 9 and 10 described by Bruckner et al (Bruckner et al., 2004). 
 
Figure   4-4 Demonstration of a, “hot spot,” for recombination events (SP1309 - SP1337) in 
the TIGR4 genome using Genespring GX 7.3.1.  
Each coloured bar represents a consecutive gene in the TIGR4 genome. Shades of yellow 
and orange indicate that hybridization occurred  with DNA from both TIGR4 and the test 
isolate while shades of blue indicate no hybridization occurred with DNA from the test strain 
but unopposed hybridization by TIGR4 DNA had occurred. 
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4.3.2 Diversity at Particular Genetic Loci 
4.3.2.1  Genes with variable homologs 
Bruckner et al, identified several genes in the TIGR4 and R6 genomes which demonstrated 
highly variable homologs (Bruckner et al., 2004). These are illustrated in Table 4-2 along 
with results from the CGH of the above 10 isolates. These results suggest that either there 
is less variability within the genes of these test isolates or that cross hybridization has 
occurred between variable homologs and probes on this microarray or that the “spotted” 
microarray constructed by BmG@S identifies fewer variable genes than the oligonucleotide 
microarray used by Bruckner et al (Bruckner et al., 2004).      Chapter 4, 112 
 
Gene  Putative Function  Hybridization Result in this Study 
SP0071  Zinc metalloproteinase C  N 
SP0147  Hypothetical protein  P 
SP0257  Hypothetical protein  V 
SP0298  Hypothetical protein  V 
SP0328  IS1380  V 
SP0332  Hypothetical protein  P 
SP0378    P 
SP0379    V 
SP0380    P 
SP0432  IS1167  P 
SP0495  IS1380  V 
SP0642  IS66  P 
SP0643  IS66  P 
SP0644  IS66  V 
SP0666  Hypothetical protein  P 
SP0714  IS1380  V 
SP0813  IS30  P 
SP0814  IS30  P 
SP0826  Hypothetical protein  V 
SP0836  IS1167  P 
SP0949  IS1515  V 
SP1015  IS1167  P 
SP1188  Hypothetical protein  V 
SP1189  Hypothetical protein  V 
SP1262  IS1167  P 
SP1292  SAP domain protein  P 
SP1352  IS1380  P 
SP1418  IS1380  P 
SP1439  IS1380  V 
SP1444  IS1380  P 
SP1503  IS1380  V 
SP1582  IS1167  P 
SP1595  IS1380  V 
SP1639  IS1167  P 
SP1692  IS1167  P 
SP1772  Cell Wall Anchor Protein  V 
SP1927  IS1381  P 
SP2093  Hypothetical protein  P 
SP2179  IS1380  V 
Spr0041  IS1178  Not represented on SPv1.1 microarray 
Spr0042  IS1178  Not represented on SPv1.1 microarray 
Spr0703  Putative sortase  V 
Spr0986  IS1167 truncated  Not represented on SPv1.1 microarray 
Spr0987  IS1167 truncated  Not represented on SPv1.1 microarray 
Spr0988  IS1167 truncated  Not represented on SPv1.1 microarray 
Spr1093  Hypothetical protein  N 
Spr1403  Cell Wall Anchor Protein  V 
Spr1484  Hypothetical protein  V 
Spr1536  Neuraminidase A  Not represented on SPv1.1 microarray 
Spr1549  Putative regulatory protein  V 
Spr1550  Putative regulatory protein  V 
Spr1675  IS1167  Not represented on SPv1.1 microarray 
Spr1676  IS1167  Not represented on SPv1.1 microarray 
Spr1716  IS1167  Not represented on SPv1.1 microarray 
Table   4-2 Highly variable genes with multiple homologs compared with CGH results.   
P = gene hybridized with all test strains; N = gene hybridized with none of the test strains;  
V = gene variably hybridizing in test strains. 
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4.3.2.2  Diversity of zinc metalloproteinases SP1154, SP0664 and 
SP0071  
In 1998, Poulsen et al identified a high degree of diversity of immunoglobulin A1 (IgA1) 
protease genes (SP1154) within the pneumococcus and other closely related streptococcal 
species (Poulsen et al., 1998). This was due to repeat structures which varied in number 
and  sequence  which  was  thought  to  be  related  to  immunogenicity  and  recognition  of 
antigenic diversity (Poulsen et al., 1998). IgA1 protease is a zinc metalloproteinase (zmp) 
and it has subsequently been documented that the pneumococcus has three zmps and that 
the other two, ZmpB (SP0664) and ZmpC (SP0071), show much sequence diversity also 
(Oggioni et al., 2003, Chiavolini et al., 2003). Whether these genes are absent, present or 
duplicated in the pneumococcal genome is also variable. SP0071 is absent from the R6 
genome while SP1154 occurs twice in the genome of the sequenced strain G54 (Oggioni et 
al., 2003). R6 and other pneumococcal genomes do still have a functional IgA1 protease 
despite  SP0071  being  absent  as  discussed  in  Chapter  3.  Chiavolini  et  al  identified 
significant sequence diversity of SP1154 between isolates of serotypes 2, 4, 6, 19F and 23F 
and  of  SP0664  for  serotypes  4  and  23F  (Chiavolini  et  al.,  2003).  The  results  above 
demonstrate diversity as to whether hybridization occurred or not for SP1154 and SP0071. 
Where hybridization did not occur could be the result of the gene being absent or it could 
be present but with such a degree of sequence diversity that it does not hybridize to the 
probe sequence on the microarray which is based on the gene sequence in TIGR4. IgA1 
protease is believed to be present in all pneumococcal strains and serotypes (De Paolis et 
al., 2007). Oggioni et al also suggest that the presence of SP0071 may relate to either 
serotype or the body fluid of origin of the isolate. From a variety of clinical isolates they 
find SP0071 in serotypes 4, 6, 8, 9 and 19F. Over 50% (6/11) of sputum isolates had a 
zmpC  homolog  and  only  1  CSF  isolate.  The  CGH  data  from  this  study  demonstrated 
hybridization of SP0071 only from DNA from a serotype 23F isolate with no hybridization 
from serotypes 3, 6A, 9A, 9V, 12F, 14, 20 or 35B which suggests that the relationship 
between  presence  of  SP0071  with  serotype  is  not  as  straight  forward  as  proposed  by 
Oggioni et al (Oggioni et al., 2003). The issue of a possible relationship between body 
fluid of origin and presence of SP0071 could not be considered with this series of isolates 
as the clinical background for the majority of PMEN clones used is not known. This will 
be  considered  subsequently  using  CGH  data  from  more  adequately  catalogued  clinical 
isolates. 
     Chapter 4, 114 
4.3.2.3  Diversity of SP1051 and Pneumococcal Pathogenicity 
Island 1  
SP1051  is  a  virulence  associated  gene  present  within  the  pneumococcal  pathogenicity 
island 1 which by PCR has been found to be absent from isolates of serotype 1, 6B, 17 and 
35F (Brown et al., 2004). These serotypes did not feature in our chosen isolates for this 
study of diverse isolates and the CGH results for these isolates showed SP1051 to be 
present in all 10 test strains, consistent with the results of Brown et al (Brown et al., 2004). 
4.3.2.4  Diversity of Pneumococcal Pilus Genes 
The region of diversity at SP0460 to SP0470 is related to a pneumococcal pilus (SP0461-
SP0468) and to diversity of choline binding proteins. The whole region was present in 3 of 
the isolates examined (serotypes 6A, 35B and 9A) and the region SP0460 to SP0468 failed 
to  hybridize  in  its  entirety  for  the  other  7  isolates  tested.  This  is  consistent  with  the 
observations of Bruckner et al at this region (Bruckner et al., 2004) and Sjostrom et al, 
who did not identify any consistent relationship between the presence or absence of this 
region by CGH and serotypes 9V, 19F or 14 (Sjostrom et al., 2006). 
4.3.2.5  Diversity of Choline binding proteins 
It has been observed that choline binding protein A (SP2190) which is necessary for cell 
invasion  is  not  expressed  in  25%  of  clinical  strains  (Orihuela  et  al.,  2003).  A  lack  of 
hybridization was not identified for any of the tested isolates for SP2190 so, if this gene 
were not to be expressed in these isolates, it would not be due to its absence in the genome 
of the isolate. 
4.3.2.6  Diversity of Neuraminidase Genes 
Recently it has been described that the presence of neuraminidase C (nanC, SP1326) in 
clinical isolates is more variable than is the case for neuraminidase A or B (Pettigrew et al., 
2006). In the isolates examined here 40% showed nanC to be present which is close to the 
51% of isolates where it was identified by Pettigrew et al (Pettigrew et al., 2006). Again 
though, this phenomenon will be better investigated using a series of clinical isolates where 
the background to the isolates is more fully known.     Chapter 4, 115 
4.4 Conclusions 
These  DNA  CGH  results  relating  to  diverse  isolates  demonstrate  substantial  genomic 
diversity for pneumococcal isolates of diverse multilocus sequence types and serotypes and 
are consistent with the results of similar previous studies. In fact this work has shown such 
diversity to be greater than previously considered in CGH studies with two new regions of 
diversity identified. If a wider range of diverse isolates were assessed, it is probable that 
more new regions of diversity would be identified. It does appear though that identification 
of these regions is dependant on the data analysis methods which are chosen.  These results 
also highlight a need for greater consensus as to what does and what does not comprise a 
region of diversity in the pneumococcal genome. Associations between CGH results and 
individual serotypes, sequence types and the clinical background of strains will be better 
achieved by more focussed studies of banks of particular sequence types and serotypes 
where the clinical background to strains has been adequately documented. 
 
  
5  Genomic Diversity in a Multilocus Sequence 
Type Associated with Invasive Pneumococcal 
Disease (IPD) 
5.1 Serotype 14 and ST9: associations with IPD 
The  significance  of  the  ST9  clonal  complex  is  reviewed  in  Chapter  1,  along  with  its 
association  with  serotype  14  pneumococci.  These  studies  of  DNA  CGH  from  10  ST9 
isolates were planned to assess whether genomic diversity could be identified within a 
clonal complex and also to compare the degree of diversity within isolates of the same 
serotype within that clonal complex compared to isolates of different serotypes within the 
clonal complex.  
5.2 Choice of Isolates 
Details of the 10 chosen ST9 isolates are outlined in Appendix 1. Nine of these were from 
the  strain  collection  at  SMPRL  and  were  chosen  to  try  to  maximise  observations  on 
diversity  by  taking  isolates  from  different  years,  with  different  antibiotic  sensitivity 
profiles, source cultures from different body fluids, sourced from different geographical 
regions in Scotland and from different ages of patients. Even so, only one isolate originated 
from a cerebrospinal fluid specimen (01-5710). Five isolates were chosen of serotype 14 to 
assess  whether  overall  genomic  diversity  is  different  in  phenotypically  similar  isolates 
within a clonal complex. These five included four isolates from Scotland (00-1724, 01-
5710, 02-2445 and 04-1870) and the Sanger sequenced strain INV200 which represents the 
PMEN clone England 
14-9 (Hall et al., 1996) – a clone which also infrequently causes IPD 
in Scotland (Smith et al., 2006).  All 5 isolates are resistant to erythromycin consistent with 
previous  observations  that  95%  of  ST9  isolates  in  Scotland  are  erythromycin  resistant 
(Clarke et al., 2004b) usually resulting from expression of the mefA gene and macrolide 
efflux – the M phenotype (Amezaga et al., 2002). The five isolates which were not of 
serotype 14 were of serotypes 8 (03-2105), 18 (02-1309), 19A (03-1051), 19F (04-1548) 
and 23F (04-1168).     Chapter 5, 117 
5.3 Microarray Results 
 
Figure   5-1 Comparison of diversity within genomes of serotype 14 associated ST9 isolates 
and non serotype 14 ST9 isolates using Genespring GX 7.3.1.  
Shades of yellow and orange indicate that hybridization occurred with DNA from both TIGR4 
and the test isolate while shades of blue indicate no hybridization occurred with DNA from 
the test strain but unopposed hybridization by TIGR4 DNA had occurred. Grey indicates that 
neither  hybridization  of  TIGR4  or  test  isolate  DNA  occurred  or  the  hybridization 
fluorescence was of such low intensity that it was excluded from analysis. Red indicates 
unopposed  hybridization  of  test  isolate  DNA  to  probes  representing  genes  from  the  R6 
genome. The five serotype 14 isolates demonstrate less diversity than the five ST9 isolates 
of different serotypes. The list of genes from the TGR4 genome which are present or non-
hybridizing in the ST9 strains are displayed in Appendix 10 and the list of genes from the R6 
genome which are also present or non-hybridizing in the ST9 strains are in Appendix 11. 
 
5.4 Discussion 
5.4.1 Overall diversity in ST9 
It  has  been  recognised  that  serotype  14  strains  of  different  genetic  backgrounds  have 
different propensities to cause pneumonia in mice and these differences are attributed to 
virulence factors other than the capsule (Mizrachi-Nebenzahl et al., 2004). These CGH 
studies of ST9 pneumococci (and a subgroup of serotype 14, ST9 pneumococci) allow     Chapter 5, 118 
some investigation as to what some of these genetic differences between phenotypically 
identical (serotype 14) pneumococci may be and whether they relate to known virulence 
determinants.  
Obert et al have performed CGH studies on serotype 14 pneumococcal isolates (12 were 
from cases of IPD and 8 were from asymptomatic nasopharyngeal carriage) of unknown 
sequence type. They have correlated the presence of certain genes with either an invasive 
or carriage phenotype for serotype 14 (Obert et al., 2006). As all the serotype 14 isolates 
used in this study of ST9 isolates have an invasive phenotype, it is possible to assess 
whether the CGH results obtained fit with the phenotype expected from the results of Obert 
et al. Unfortunately, the majority of the genes identified by Obert et al as present only in 
serotype 14 isolates with the carriage phenotype can be found in the genomes of the ST9 
serotype  14  isolates  with  invasive  phenotypes.  These  misclassified  genes  are  SP0029, 
SP0093, SP0096-SP0098, SP0117, SP0141, SP0173-SP0182, SP0186, SP0205, SP0256, 
SP0259, SP0288, SP0328, SP0336, SP0343, SP0398-SP0399, SP0495, SP0531-SP0532, 
SP0584, SP0617, SP0711, SP0714, SP0738-SP0740, SP0826, SP0875-SP0876, SP0877, 
SP0907, SP0949, SP1019, SP1065, SP1154, SP1172, SP1773, SP1175, SP1185, SP1198, 
SP1251,  SP1307,  SP1308,  SP1337,  SP1348-SP1349,  SP1351-1352,  SP1366,  SP1418, 
SP1439, SP1441, SP1503, SP1595, SP1642, SP1672-SP1673, SP1677, SP1693, SP1719, 
SP1722, SP1902, SP1947, SP2003, SP2005, SP2158-SP2166, SP2179. It is likely that the 
results of Obert et al have been seriously confounded by not assessing a diverse enough 
sample of serotype 14 isolates from different clonal complexes or by assessing too small a 
sample of isolates.  
Some of the genes identified by Obert et al in serotype 14 pneumococci as present only in 
isolates of invasive phenotype also appeared in the invasive serotype 14 ST9 isolates used 
in this chapter (shown in Appendix 10) but not ST9 isolates which were not serotype 14. 
These genes were SP0389-SP0397, SP0536, SP0540-SP0542, SP0607-SP0608, SP0627-
SP0628,  SP0691-SP0700,  SP0982,  SP1126,  SP1315-SP1321,  SP1324,  SP1326-SP1331, 
SP1556, SP1612-SP1613, SP1679, SP1740, SP1741, SP1755-SP1759, SP1810, SP1911, 
SP2140 and SP2232. It is possible then that these genuinely are only associated with an 
invasive phenotype. 
Some of the genes associated with carriage in serotype 14 are not seen in these invasive 
ST9 CGH results.  These genes are SP1062-SP1064, SP1147, SP1334, SP1335, SP1338, 
SP1340-SP1345, SP1350 and SP1622. However as CGH was not performed on carriage 
ST9 isolates the validity of this association cannot be assessed from this data.     Chapter 5, 119 
5.4.1.1  Macrolide Resistance 
Pneumococcal genomic diversity within the ST9 complex has been alluded to before with 
regard to the antibiotic resistance  genes which  can be  found in isolates from Scotland 
belonging to this clone (Amezaga et al., 2002). This is particularly the case regarding 
macrolide efflux. Bruckner et al associate the region of diversity SP0163 to SP0171 with 
macrolide  efflux  (particularly  SP0168)  and  so  it  is  not  surprising  that  this  has  been  a 
variable region detected by CGH in these ST9 isolates. SP0168 appeared not to hybridize 
in any of the isolates regardless of whether there was a macrolide resistant or sensitive 
phenotype.  SP1110,  another  gene  associated  with  a  macrolide  efflux  pump  function, 
appears to be present in all the isolates. The lack of hybridization of SP0168 could be due 
to the absence of the gene or presence of a divergent sequence which could potentially be 
altering its function as well as its ability to hybridize to the microarray probe.  
Unfortunately the macrolide resistance gene mefA is not represented among the probes on 
the SPv1.1 microarray and so it has not been possible to assess for the presence of this 
gene  by  microarray  CGH.  A  mefA  sequence  has  been  associated  with  a  transposon 
Tn1207.1 in pneumococci (Santagati et al., 2000) and a macrolide efflux genetic assembly 
(MEGA) has also been described in pneumococci on a chromosomal insertion element 
which has more than four different insertion sites in the pneumococcal genome (Gay and 
Stephens, 2001). Macrolide resistance in pneumococci is also conferred by the ermB gene 
which  is  carried  on  transposons  Tn1545  (Clewell  et  al.,  1995,  Courvalin  and  Carlier, 
1987), Tn917 (McDougal et al., 1998) or Tn3872 (McDougal et al., 1998). These represent 
a potentially sizeable source of genetic diversity in the ST9 complex, with a direct effect 
on phenotype, which cannot be detected by CGH using the SPv1.1 microarray. 
5.4.1.2  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
Proteomic analysis has determined that there is an increase in expression of GAPDH in M 
phenotype pneumococci (Cash et al., 1999). Cash et al, identified three different forms of 
GAPDH. The TIGR4 genome contains two genes which code for GAPDH – SP1119 and 
SP2012. Both genes were identified by CGH as present in all five of the serotype 14, ST9 
isolates tested. Microarray based expression studies of these isolates may help to elucidate 
the  potential  role  of  these  two  genes  in  the  increased  generation  of  GAPDH  in  M 
phenotype pneumococci.        Chapter 5, 120 
5.4.2 Regions of Diversity in the TIGR4 and R6 genomes 
The CGH results of the ST9 isolates have demonstrated a region of diversity within the 
isolate 04-1548 where hybridization of a 1.7kb region encompassing the TIGR4 genes 
SP1933 to SP1936 does not occur. This region has not been previously identified in the 
CGH studies of Bruckner et al (Bruckner et al., 2004) (who did not perform CGH on any 
serotype 14 isolates) or Silva et al (Silva et al., 2006) or Obert et al (Obert et al., 2006) 
(both  of  whom  included  several  serotype  14  isolates  in  their  experiments).    SP1933, 
SP1934 and SP1935 code for hypothetical proteins and SP1936 codes for a putative Type 
II restriction modification system regulatory protein. This is illustrated below.   
 
Figure   5-2 Location of a new region of diversity SP1933 – SP1936 identified in isolate 04-
1548. 
 
5.4.3 Diversity at Particular Genetic Loci 
For illustrative purposes, the diversity observed at various regions known to be variable 
will be considered.     Chapter 5, 121 
5.4.3.1  Genes with variable homologs 
The presence or absence of hybridization for forty five genes identified by Bruckner et al 
(Table 4-2) as being highly variable in the TIGR4 and R6 genome could be assessed using 
the SPv1.1 microarray. When all 10 isolates of serotypes 8, 18, 14, 19A, 19F and 23F were 
considered, twenty seven genes (60%) were identified as having variable hybridization but 
if only serotype 14 isolates were considered this fell to only 5 genes (11%) having variable 
hybridization which demonstrates that there is substantially less diversity within isolates of 
the  same  serotype  within  a  MLST  clonal  complex  than  between  isolates  of  different 
serotypes of the same sequence type.   
5.4.3.2  Diversity of zinc metalloproteinases SP0664, SP0071 and 
SP1154 
The diversity of zinc metalloproteinases was discussed in Chapter 4. The CGH of ST9 
isolates has allowed investigation of how much diversity occurs within a clonal complex. 
SP0071 (IgA1 protease) could not be identified by hybridization in the genomes of any of 
the tested ST9 isolates (although hybridization by TIGR4 DNA occurred in all the CGH 
experiments). The R6 gene coding for IgA1 protease, spr1042, was present only in the 
ST9, serotype 8 isolate 03-2105 which suggests that the other strains may have unique 
gene sequences which fulfil this function. As these isolates are from predominantly blood 
cultures  with  only  one  isolate  from  cerebrospinal  fluid,  it  is  possible  to  conclude  that 
SP0071 may be infrequently found in blood or CSF isolates which is compatible with the 
observation of Oggioni et al (Oggioni et al., 2003). SP0664 was identified as present in all 
the ST9 isolates while SP1154 was variably present or not hybridizing in the test ST9 
isolates. 
5.4.3.3  Diversity of SP1051 and Pneumococcal Pathogenicity 
Island 1  
As was the case with the CGH results of isolates of diverse serotype and sequence type 
(Chapter 4), these results of ST9 pneumococci from serotypes 8, 14, 18, 19A, 19F and 23F 
demonstrated that SP1051 was present in all the tested isolates which is again consistent 
with the findings of Brown et al (Brown et al., 2004). 
5.4.3.4  Diversity of Pneumococcal Pilus genes 
The  rrgC  gene  (SP0464)  has  been  used  as  a  marker  for  the  presence  or  absence  of  a 
pneumococcal pilus (Basset et al., 2007) where it has been identified as present in less than     Chapter 5, 122 
10% of serotype 14 isolates (Basset et al., 2007). In the CGH studies of Sjostrom et al 
which focussed particularly on the rlrA pilus islet (SP0461-SP0468) and which included 
three  serotype  14  strains  (two  which  were  ST156  and  one  which  was  ST709),  rrgC 
(SP0464) was present in both ST156 isolates but noted as absent in the ST709, serotype 14 
isolate (Sjostrom et al., 2006). In this series of ST9 isolates, we identified rrgC (SP0464) 
only in isolate 04-1548 (which is serotype 19F) and it failed to hybridize in any of the 
serotype 14 isolates consistent with the findings of Basset et al  (Basset et al., 2007). 
5.4.3.5  Diversity of Choline binding proteins 
As was the case with the isolates in Chapter 4, a lack of hybridization was not identified 
for any of the tested ST9 isolates for choline binding protein A (SP2190) so, if this gene 
were not to be expressed in these isolates as was found in 25% of clinical pneumococcal 
isolates by Orihuela et al (Orihuela et al., 2003), it would not be due to its absence from 
the genome of the isolate. 
5.4.3.6  Diversity of Neuraminidase Genes 
In the isolates examined here 80% showed nanC (SP1326) to be present. It was present in 
all the serotype 14 isolates but did not hybridize in isolates which were serotype 19A and 
23F.  Pettigrew et al  have made an association between the presence of nanC and CSF 
isolates (Pettigrew et al., 2006). These CGH results are compatable with this association as 
nanC was identified in the CSF isolate which was tested (01-5710). 
  
6  Genomic Diversity within a Multilocus Sequence 
Type Accounting for Invasive Pneumococcal 
Disease and Carriage 
6.1 A Review of the Associations of Serotype 3 and 
ST180 with Pneumococcal Carriage or Invasive 
Disease 
The  dichotomy  that  serotype  3  pneumococci  can  cause  disease  with  a  high  associated 
mortality in some individuals while being harmlessly carried in the nasopharynx of others 
has been recognised since the early 20
th century (Blake, 1931). An association between 
serotype 3 pneumococci causing disease more commonly in the elderly than in children is 
also an established observation (Blake, 1931, Cecil et al., 1927) which remains true in 
several countries (Inostroza et al., 2001, Rahav et al., 1997, Shapiro and Austrian, 1994, 
Kyaw  et  al.,  2003,  Bescos  et  al.,  2003,  Martin  and  Brett,  1996).  In  children  from 
Oxfordshire, a serotype 3 associated clone (ST180) had an odds ratio of invasiveness of 
only 0.1 and so was more associated with asymptomatic carriage (Brueggemann et al., 
2003) although it is inappropriate to extrapolate this finding into an adult population as the 
relative risk of invasive disease due to serotype 3 increases over middle age (Scott et al., 
1996). According to the MLST database
8 although predominantly serotype 3 associated, 
ST180 has also been associated with a serotype 19F capsule in Germany and non-typeable 
isolates in South Korea.  
The ability to identify genes present in pathogenic invasive bacteria which are not present 
in  asymptomatically  carried  commensals  or  define  the  genetic  relationships  between 
virulent  and  non-virulent  clones  of  bacteria  (in  order  to  identify  potential  targets  for 
therapeutic  intervention)  has  long  been  a  goal  of  bacterial  comparative  genomics 
(Hollingshead and Briles, 2001, Joyce et al., 2002). Molecular typing such as IS1167-boxA 
genotype fingerprinting demonstrated that carriage isolates belonged to patterns unique to 
carriage suggesting that clones associated with carriage may be distinguished from those 
associated with invasion (Robinson et al., 2001). It has also been suggested that more 
virulent clones of invasive pneumococci tend to have evolved from less virulent clones 
associated with carriage (Robinson et al., 2002). 
                                                 
8 http://spneumoniae.mlst.net/ {accessed 6
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In this chapter, the DNA of serotype 3, ST180 carriage and invasive disease associated 
isolates was used in microarray CGH experiments to investigate whether any genes are 
consistently present in carriage associated isolates and not invasive isolates or vice versa. 
An  assessment  is  then  made  as  to  whether  the  patterns  of  gene  expression  under 
predetermined conditions for these isolates can be used to determine associations between 
carriage and invasive associated isolates. 
6.2 Serotype 3 ST180 Isolates Analysed by Microarray 
CGH 
Details of the isolates used in these CGH experiments are tabulated below: 
Isolate  Phenotype  Clinical Details 
OXC141  Carriage  Isolate from a carriage study in Oxford, United Kingdom. 
03-4183  Carriage  Isolate from a carriage study from The Netherlands. 
03-4185  Carriage  Isolate from a carriage study from The Netherlands. 
03-4155  Carriage  Isolate from a carriage study from The Netherlands. 
03-4156  Carriage  Isolate from a carriage study from The Netherlands. 
07-2838  Carriage  Nasopharyngeal swab isolate obtained from a 9 year old girl in 
Trinidad, Bolivia during June 2007. 
99-4038  Invasive  Blood  culture  isolate  from  a  31  year  old  man  from  Dundee, 
United Kingdom with meningitis.  
99-4039  Invasive  Cerebrospinal  fluid  isolate  from  same  31  year  old  man  from 
Dundee, United Kingdom with meningitis taken on same day as 
99-4038. 
00-3946  Invasive  Cerebral pus isolate from a 60 year old man from Edinburgh, 
United Kingdom. 
06-1705  Invasive  Cerebral  pus  isolate  from  a  15  year  old  girl  from  Glasgow, 
United Kingdom. 
02-1198  Invasive  Umbilical  cord  blood  isolate  from  a  neonate  who  died  within 
hours of delivery in Glasgow, United Kingdom. This isolate is 
named P49 in the paper by Silva et al (Silva et al., 2006). N.b. 
Maternal  and  neonatal  death  within  hours  of  delivery  as  a 
consequence  of  fulminant  infection  due  to  pneumococcal 
endometritis  is  a  recognised  albeit  exceedingly  uncommon 
event (Gransden et al., 1985). 
Table    6-1  Background  to  serotype  3,  ST180  isolates  used  in  the  microarray  CGH 
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6.3 DNA CGH Comparison of Carriage and Invasive 
Isolates of ST180 
Gene lists generated from these CGH experiments are displayed in Appendix 12 (TIGR4 
genes) and Appendix 13 (R6 genes). Figure 6-1 is generated by Genespring GX 7.3.1. and 
indicates that two distinct patterns of hybridization occur with these isolates. Figure 6-2 
focuses  on  the  region  SP2159-SP2166  coding  for  a  phosphotransferase  system  -  the 
presence or non-hybridizing of these genes divides the ST180 isolates into two distinct 
hybridization patterns. 
 
Figure   6-1 Comparison of diversity within genomes of serotype 3 associated ST180 invasive 
and carriage associated isolates using Genespring GX 7.3.1.  
Each coloured bar represents a gene and these are aligned consecutively. Yellow indicates 
hybridization of DNA from both TIGR4 and the test strain. Blue indicates hybridization of 
DNA from TIGR4 but not the test strain and red indicates unopposed hybridization of test 
strain DNA to probes from the R6 genome. The names and countries of origin of the isolates 
are marked. 
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Figure   6-2 Serotype 3, ST180 microarray CGH results demonstrating the presence of the 
genes SP2159 to SP2166 (which code for phosphotransferase system genes) in the Dutch 
isolate 03-4156 and the Bolivian isolate 07-2838 which both have a carriage phenotype.  
Each bar represents a pneumococcal gene. Yellow indicates hybridization of DNA from both 
TIGR4 and the test isolates. Blue indicates hybridization of DNA from TIGR4 but not the test 
isolate. 
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6.4 RNA Expression Differences in Carriage and Invasive 
Isolates of ST180  
6.4.1 Microarray results 
Genes 
Upregulated in 
IPD 
Normalized 
Expression 
Level in 
Carriage 
Isolates 
Normalized 
Expression 
Level in 
Invasive 
Isolates  Function 
SP0576  0.9  22.9  Transcription antiterminator Lict 
SP0640  1.0  4.5  Hypothetical protein 
SP0877  1.0  4.0 
Phosphotransferase  system,  fructose  specific 
IIABC components 
SP0875  1.0  3.3  Lactose phosphotransferase system repressor 
SP0876  1.1  3.1  1-phosphofructokinase, putative 
SP0358  1.0  2.7 
Capsular  polysaccharide  biosynthesis  protein 
Cps4J 
SP0357  1.1  2.4  UDP-N-acetylglucosamine-2-epimerase 
SP0248  1.0  2.3 
Phosphotransferase  system  sugar-specific 
EIIA component 
Genes 
Downregulated 
in IPD 
Normalized 
Expression 
Level in 
Carriage 
Isolates 
Normalized 
Expression 
Level in 
Invasive 
Isolates  Function 
SP0110  0.5  0.1 
ABC  transporter  membrane-spanning 
permease - amino acid transport 
SP0111  0.7  0.2 
Amino  acid  ABC  transporter,  ATP-binding 
protein, putative 
SP0046  0.9  0.4  Amidophosphoribosyl transferase 
SP1503  1.2  0.5  IS1380-Spn1, transposase 
SP1418  1.3  0.5  IS1380-Spn1, transposase 
SP1337  1.3  0.6  IS1380-Spn1, transposase 
SP0050  1.6  0.6 
Phosphoribosylaminoimidazolecarboxamide 
formyltransferase 
Table    6-2  Genes  identified  by  Genespring  GX  7.3.1.  whose  expression  detected  by 
microarray are either significantly upregulated or downregulated in invasive pneumococcal 
disease.  
(P<0.05 with Benjamini and Hochberg correction applied for multiple testing). 
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Gene 
Predictive 
Strength 
for 
Invasive 
Disease  Function 
SP0877  27.0  Fructose specific-phosphotransferase system IIBC component 
SP0875  23.8  Lactose phosphotransferase system repressor 
SP1474  20.9  Glycyl-tRNA synthetase beta chain 
SP1592  16.6  Conserved domain protein 
SP0830  16.6  Hypothetical protein 
SP0066  16.1  Aldose-1-epimerase (mutarotase) 
SP1097  14.9  Similar to GTP pyrophosphokinase 
SP0876  14.7  Fructose-1-phosphate kinase 
SP0833  14.7  Hypothetical protein 
SP0831  14.7  Purine nucleoside phosphorylase (inosine phosphorylase) 
SP1100  14.6  Phosphate acetyltransferase 
SP0629  14.1  Conserved hypothetical protein 
SP0828  12.8  Ribose-5-phosphate epimerase 
SP0829  12.8  Phosphodeoxyribomutase 
SP1701  12.7  Phospho-2-dehydro-3-deoxyheptonate aldolase 
SP2014  12.7  IS630-Spn1, transposase Orf2 
SP2096  12.7  Peptidase, M20/M25/M40 family 
SP1563  12.7  Pyridine nucleotide-disulphide oxidoreductase family protein 
SP0782  12.6  Conserved hypothetical protein 
SP0712  12.0  Lactate oxidase, truncation 
SP1417  12.0  Choline binding protein 
SP2066  11.6  Threonine synthase 
SP2192  11.6  Histidine kinase 
SP0631  11.4  50S Ribosomal protein L1 
SP0605  11.4  Fructose-bisphosphate aldolase 
SP1523  11.4  SWF/SNF family ATP-dependent RNA helicase 
SP0110  11.2 
ABC transporter membrane-spanning permease - amino acid 
transport 
SP1988  11.1  Immunity protein, putative 
SP0834  11.1  Haemolysin-related protein 
SP1193  11.1  Galactose-6-phosphate isomerase, LacA subunit 
SP2002  11.1  Conserved hypothetical protein 
SP1192  11.0  Galactose-6-phosphate isomerase LacB subunit 
SP0715  10.9  Lactate oxidase 
SP1099  10.9 
Ribosomal  large  subunit  pseudouridine  synthase,  RluD 
subfamily 
SP0015  10.9  IS630-Spn1, transposase Orf1 
SP0445  10.9  Acetolactate synthase large subunit 
SP1098  10.9  Conserved hypothetical protein 
SP1591  10.9  Proline dipeptidase 
SP1337  10.8  IS1380-Spn1, transposase 
SP0438  10.8  Glutamyl tRNA-Gln amidotransferase, subunit C 
Table   6-3 Predictive strengths of the top 40 genes whose expression is more associated 
with IPD than carriage in serotype 3 ST180 isolates when grown to midlog at 37° C in BHI.  
Results generated using Genespring GX 7.3.1. gene predictor function. 
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6.4.2 Quantitative Real Time PCR results 
The gene SP0110 which codes for a hypothetical protein and is identified as essential for 
virulence  in  a  mouse  pneumonia  model  (Hava  and  Camilli,  2002)  was  identified  by 
Genespring GX 7.3.1. as significantly downregulated in invasive isolates (Table 6-2) and 
as  being  predictive  of  a  serotype  3,  ST180  isolate  being  invasive  rather  than  carried 
asymptomatically (Table 6-3). However, in Appendix 12 SP0110 does not hybridize in all 
invasive or in all carriage isolates indicating either sequence divergence or absence of the 
gene. This seemingly contradictory phenomenon was investigated by qRT-PCR. No PCR 
product  was  generated  for  isolate  06-1705  confirming  the  CGH  result.  When  the 
expression of SP0110 by 00-3946 (invasive phenotype) was compared to that by OXC141 
(carriage phenotype), it was seen (Figure 6-3) that it was less expressed in the invasive 
isolate but this difference in expression did not reach statistical significance (p=0.547).  
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Figure   6-3 qRT-PCR results comparing expression of SP0110 in the invasive isolate 00-3946 
and the carriage isolate OXC141.  
The mean normalized expression was calculated using Q-gene (Muller et al., 2002) from 3 
replicates and the standard error of the means shown as error bars. Statistical comparison 
was made using an unpaired t-test (Muller et al., 2002). 
 
From this it can be concluded that the process of normalization which was used to pool 
expression data into the categories “invasive” and “carriage” has introduced artefacts in the 
results.  Consequently,  the  genes  identified  by  Genespring  GX  7.3.1.  as  predictive  of     Chapter 6, 130 
invasive disease should not be considered to be predictive without further confirmation 
using  further  qRT-PCR  experiments  to  compare  expression  levels  for  the  other  genes 
identified in Table 6-3. 
6.5 Discussion 
6.5.1 Overall genomic diversity in Serotype 3 ST180 isolates  
The CGH experimental data demonstrates that within serotype 3, ST180 there is much 
similarity in the genomic content of the isolates despite coming from different patients, 
with  different  disease  causing  or  carriage  manifestations  and  from  different  countries. 
PFGE  performed  on  serotype  3  isolates  from  cases  of  meningitis  from  Poland  also 
demonstrated very little diversity within serotype 3 (Skoczynska and Hryniewicz, 2003).  
It has been proposed by Obert et al that there is a core pneumococcal genome and that this 
includes genes such as SP0043-SP0056, SP0241-0242, SP0314, SP0663-0667, SP0730, 
SP0965,  SP1002,  SP1128,  SP1204,  SP1466,  SP1469,  SP1869-72,  SP1923,  SP1937, 
SP2141-SP2146 and SP2239. This was determined by CGH studies of serotype 6A, 6B 
and 14 (Obert et al., 2006). The CGH results from these studies of serotype 3 isolates are 
compatible with the hypothesis of Obert et al as all of these genes hybridize from serotype 
3 isolates with no variability seen.  
Whereas  substantial  similarity  is  seen  in  the  CGH  results  from  isolates  from  Western 
Europe, there is greater diversity in isolate 07-2838 from Bolivia suggesting again that 
geographical location has had an influence on the genomic diversity of pneumococci (see 
Chapter 4 and 9). In 07-2838 there are distinctive hybridization patterns, as SP1335 (a 
hypothetical  protein  of  138  bp)  and  SP1336  (a  Type  II  DNA  modification 
methyltransferase of 1224 bp) are present whereas no hybridization is seen for them in any 
of the European isolates. Likewise SP1339-SP1341 (coding for hypothetical proteins and 
an ABC transporter ATP binding protein) do not hybridize in 07-2838 but are present in all 
tested European isolates. 
Some of the genes identified by CGH as not hybridizing have been found to be essential 
for virulence in serotype 4 pneumococci in a mouse pneumonia model by signature tagged 
mutagenesis  (Hava  and  Camilli,  2002).  Similar  identification  of  genes  essential  for 
virulence  has  been  documented  for  serotype  3  pneumococci  by  signature  tagged 
mutagenesis  (Lau  et  al.,  2001)  but  the  gene  designations  used  in  the  study  are  not     Chapter 6, 131 
comparable with either the TIGR4 or R6 genome nomenclature and so comparison of the 
results by Lau et al and the CGH data observed here is not easily done.   
It  appears  that  the  serotype  3  ST180  genome  can  be  subdivided  into  two  further 
subcategories  based  on  the  hybridization  or  absence  of  hybridization  of  the  regions 
SP0473-SP0478 (present in the two carriage associated isolates 03-4156 and 07-2838 but 
not hybridizing in any of the others) and SP2159 to SP2166 (again present in the two 
carriage associated isolates 03-4156 and 07-2838 but not hybridizing in any of the others).  
The functions of these genes are shown in Table 6-4 Serotype 3 pneumococci are also 
proficient at acquiring exogenous DNA. Shen et al, noted that a serotype 3 strain (BS71 
ST180) had the greatest number of novel sequences which were not found in either the 
TIGR4 or R6 genomes (Shen et al., 2006a).  
Gene  Function  Size (bp) 
SP0473  ROK family protein, xylose repressor protein  1224 
SP0474  PTS system, cellobiose-specific IIC component  1323 
SP0475  Hypothetical protein  1941 
SP0476  PTS, lactose specific IIA component  345 
SP0477  6-phospho-beta-galactosidase  1413 
SP0478  PTS, lactose specific IIBC components  1679 
SP2159  Fucolectin related protein  3117 
SP2160  Hypothetical protein  2295 
SP2161  PTS system sugar specific EII component  801 
SP2162  PTS system sugar specific EII component  774 
SP2163  PTS system IIB component  471 
SP2164  PTS system IIA component  432 
SP2165  Fucose FucU protein  444 
SP2166  L-fuculose phosphate aldolase  639 
Table   6-4 Genes from the two regions SP0473-SP0478 and SP2159-SP2166 which code for 
components of phosphotransferase systems and which are variably present in the genomes 
of serotype 3, ST180 isolates. 
 
6.5.2 A Carriage Genotype versus an Invasive Genotype for ST180 
The ecological niche of invasive pneumococci, at some point prior to invasion, is to be 
carried asymptomatically no matter how brief is that time period of carriage (Robinson et 
al., 2001). Consequently, comparing the gene complement of pneumococci from invasive 
disease with those of carriage is difficult as, although it is relatively easy to identify those 
with an “invasive” phenotype from growth at normally sterile sites, there will always be 
uncertainty  as  to  whether  those  cultured  from  nasopharyngeal  “carriage”  are  truly 
commensal or are in a transient pre-invasive state or are a mixed population of the two 
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It has therefore proven difficult to definitively find robust associations between genotypes 
which  are  more  associated  with  “invasion”  than  they  are  with  “carriage”  as  the  gene 
complement of “carriage” isolates may be similar or identical to those of the “invasive” 
phenotype when assessed by CGH if they happen to be present being carried but in a pre-
invasive state. It is no surprise then to see that serotypes and genotypes which are found in 
the  carrier  state  can  also  be  identified  in  instances  of  invasive  disease  and  vice  versa 
(Muller-Graf et al., 1999). It may be true that some serotypes which cause invasive disease 
are rarely found in carriage studies (for example, serotypes 1 and 5) (Scott et al., 1996). 
This is perhaps due to a very short carrier state prior to invasion or as an artefact resulting 
from the methodology of the carriage study (Hodges et al., 1946, Davies and Lockley, 
1987, Smith et al., 1993). There are many clear instances when such serotypes have been 
identified  in  carriers  and  so  it  is  not  the  case  that  they  are  never  carried  (Chapter  1). 
Claiming strict relationships between genotypes and “carriage” or “invasive” phenotypes is 
unwise as associations  with “carriage” found in one study often may be found in disease 
causing  “invasive”  isolates  in  another  (Robinson  et  al.,  2001)  as  has  been  shown  by 
comparing CGH of “invasive” serotype 14 isolates with genes and regions of diversity 
thought  only  to  be  related  to  a  “carriage”  phenotype  (Obert  et  al.,  2006)  (Chapter  5). 
Indeed  none  of  the  associations  of  regions  of  diversity  associated  with  “carriage”  or 
“invasive” phenotypes proposed by Obert et al (Obert et al., 2006) hold true for these 
serotype 3 isolates as the regions are either present or non-hybridizing or variably present 
or non-hybridizing in both “invasive” and “carriage” phenotypes. 
Rather than considering the phenotypes “carriage” and “invasion” as a direct consequence 
of the gene complement of bacteria, which invariably fails to make a robust association by 
any single method (Obert et al., 2007), it is more helpful to think in terms of probability of 
“carriage” or “invasion.” This can be done through calculating odds ratios of a genotype 
being  associated  with  a  particular  phenotype  (Brueggemann  et  al.,  2003).  Such  an 
approach allows for the influences of gene expression differences and post-translational 
effects and, perhaps more importantly, the influences of host immunity and susceptibility 
to infection (Inostroza et al., 2001).  
There is evidence to suggest that for serotype 3 pneumococci, the sequence of the cap3A 
gene may rapidly change with the introduction of 11-239 bp duplications which result in a 
phenotype which lacks capsule while spontaneous reversion to the wild type gene returns 
the capsule expression (Waite et al., 2001). Point mutations and deletions also occur in the 
serotype 3 capsular gene cps3D resulting in different phase variation phenotypes within a 
serotype  3  population  (McEllistrem  et  al.,  2007).  Transition  between  such  genotypes     Chapter 6, 133 
occurs in a biofilm environment (Waite et al., 2001, McEllistrem et al., 2007). The PCR 
product  “spotted”  microarray  would  not  differentiate  between  the  wild  type  cap3A  or 
cps3D genes and their mutant genes as the serotype 3 capsular genes are not represented on 
this array which consists of genes from TIGR4 and R6 genomes which are not serotype 3. 
Consequently this microarray cannot differentiate  differences in the very genes which may 
be involved in changing an invasive phenotype to a biofilm associated carriage phenotype 
(Waite et al., 2001) particularly as the variants of cps3D also alter transcription and post-
transcriptional events in the serotype 3 biofilm (McEllistrem et al., 2007). However, this 
alternating gene phenomenon is unlikely to be the entire explanation for the recognised 
association of ST180 with carriage in children  and invasive disease in adults which is 
likely also to include an age related change in host immunity. 
The region SP2159-SP2166 is a recognised region of diversity (Silva et al., 2006, Bruckner 
et al., 2004, Obert et al., 2006) and its presence in the pneumococcal genome has been 
associated with invasive disease in serotype 6A isolates and associated with carriage in 
serotype 14 isolates (Obert et al., 2006).  In these CGH investigations of serotype 3 ST180 
isolates hybridization of the region SP2159-SP2166 only occurs in isolates 03-4256 and 
07-2838 which are both carriage isolates. However a much larger sample size of carriage 
and invasive isolates of serotype 3 ST180 isolates would be required to see whether the 
presence of this region is genuinely only present in carriage isolates. 
Obert et al also suggest that a region of diversity from SP1755-SP1772 is required for 
bloodstream entry in mice (Obert et al., 2006). However in none of the serotype 3 invasive 
or carriage isolates did the region SP1758-SP1772 hybridize suggesting that it may not be 
essential for invasion in this serotype.  
Our observations are similar to those of Lindsay et al, who, using a very similar design of 
microarray  based  on  Staphylococcus  aureus  genomes,  demonstrated  that  there  was  no 
association between gene complement and invasive disease and that, 
 “gene combinations necessary for invasive disease may also be necessary for 
nasal colonisation and that community-acquired invasive disease is strongly 
dependent on host factors (Lindsay et al., 2006).”  
6.5.2.1  Genomic Differences in Phosphotransferase (PTS) 
Systems  
It  is  significant  that  the  regions  SP0473-SP0478  and  SP2159-SP2166  relate  to  genes 
associated  with  phosphotransferase  systems  (PTS)  which  are  within  known  regions  of     Chapter 6, 134 
diversity (Bruckner et al., 2004, Silva et al., 2006, Obert et al., 2006). These genes are 
involved in the metabolism of lactose which involves the metabolism of fuculose (Table 6-
5). Therefore, it was anticipated that this may result in differential metabolism of sugars 
between the two subcategories of ST180 isolate (Figures 6-1 and 6-2) which is discussed 
and demonstrated below. 
ST180 Genes involved in 
Lactose metabolism  Gene Function 
SP0474   PTS system, cellobiose-specific IIC component 
SP0064   PTS system, IIA component 
SP0305   Cellobiose phosphotransferase system IIB component 
SP0308   Cellobiose phosphotransferase system IIA component 
SP0310   Cellobiose phosphotransferase system IIC component 
SP0321   PTS system IIA component 
SP0323   PTS system IIB component 
SP0324   PTS system IIC component 
SP0325   PTS system IID component 
SP0476   PTS system, lactose-specific IIA component 
SP0478   PTS system, lactose-specific IIBC component 
SP0577   PTS system, beta-glucosides-specific IIABC components 
SP0645   PTS system IIA component, putative 
SP0647   PTS system IIC component, putative 
SP1684   PTS system IIBC components 
SP2036   PTS system IIA component 
SP2037   PTS system IIB component 
SP2038   Ascorbate-specific PTS system enzyme IIC 
SP2161   PTS system IID component 
SP2162   PTS system IIC component 
SP2163   PTS system IIB component 
SP2164   PTS system IIA component 
SP1185   PTS system, lactose-specific IIBC components 
Table    6-5  Genes  identified  by  Genespring  GX  7.3.1.  which  are  involved  in  lactose 
metabolism. 
6.5.2.1.1 Phenotypic Differences in Sugar Metabolism  
In order to assess whether there were differences in sugar metabolism in ST180 isolates 
with  different  complements  of  PTS  system  genes,  three  representative  isolates  were 
chosen. 07-2838 and 03-4156 both have the genes SP0473-SP0478 and SP2159-SP2166 
while 03-4183 does not hybridize at these regions. Rapid ID 32 Strep API (BioMerieux®, 
France) strips were set up for the three isolates under identical conditions, cultured together 
for the same duration and developed and read concurrently. Figure 6-4 demonstrates the 
result.     Chapter 6, 135 
 
Figure   6-4 Rapid ID 32 Strep API results for three of the carriage associated ST180 isolates 
(07-2838, 03-4283 and 03-4156) for which microarray CGH demonstrated differences in the 
complement of PTS associated genes.  
Minor differences in results were seen for metabolism of sucrose (SAC), D-trehalose (TRE) 
and D-lactose (LAC).   
 
Although the assessment and comparison of colour change using the API system is crude 
and subjective it does suggest a difference in the metabolism of lactose for isolate 03-4183 
compared to 03-4156 and 07-2838 which was predicted by the differences in gene content.  
Figure 6-5 below demonstrates sugar metabolism pathways with the CGH results for all 
the  ST180  isolates  superimposed  and  the  gene  expression  profiles  for  these  genes  are 
displayed in Figure 6-6.     Chapter 6, 136 
 
 
Figure   6-5 Results of Serotype 3 ST180 CGH studies superimposed onto sugar metabolism 
pathways which relate to phosphotransferase system genes.  
In this figure generated by Genespring GX7.3.1, each coloured bar represents one of the 
ST180 isolates. Shades of yellow indicate the presence of genes in the pathway and shades 
of blue indicate lack of hybridization for genes in the pathway.     Chapter 6, 137 
 
Figure   6-6 Results of Serotype 3 ST180 gene expression studies superimposed onto sugar 
metabolism pathways which relate to phosphotransferase system genes.  
In this figure generated by Genespring GX7.3.1 each coloured bar represents one of the 
ST180  isolates.  Shades  of  yellow  indicate  the  expression  of  genes  in  the  pathway  at  a 
baseline level, shades of red and orange indicate upregulation of the genes and shades of 
blue indicate downregulation for genes in the pathway. 
 
Figure  6-5  demonstrates  that  the  ST180s  lack  genes  for  mannitol  metabolism  which 
correlates with the negative result for mannitol (MAN) metabolism in all the API strips. 
(The finding that two of the isolates were expressing such genes in Figure 6-6 is spurious 
and  suggests  that  there  has  been  cross  hybridization  with  this  probe  by  cDNA 
manufactured from RNA generated by another gene). 
It is also possible to see differences in sucrose metabolism which correlate with the API 
results.  Below  in  Figure  6-7  are  compared  the  expression  levels  of  SP1722  (which  is 
specific to sucrose metabolism) generated by Genespring GX 7.3.1 for the ST180 isolates. 
It demonstrates that the expression of this gene is significantly downregulated in all the     Chapter 6, 138 
isolates except 03-4156 which maintains a baseline level of expression. This is compatable 
with the API (SAC) result in Figure 6-4 where sucrose (D-saccharose) metabolism was 
positive (yellow) in isolate 03-4156 but negative (red-orange) in the other isolates. 
    
Figure   6-7 Screen view of Genespring GX 7.3.1 demonstrating the maintenance of baseline 
expression of SP1722 in isolate 03-4156.  
Expression of this gene is downregulated in all other tested ST180 isolates. 
 
A similar difference in the expression of genes for trehalose correlated with the API results 
in Figure 6-4. SP1884 is involved in trehalose metabolism and is downregulated in 03-
4183 compared to 03-4156 as seen in Figure 6-8. This is compatible with the results in 
Figure 6-4 which show that trehalose metabolism is positive in 03-4156 but negative in 03-
4183.     Chapter 6, 139 
 
Figure   6-8 Screen view of Genespring GX 7.3.1 demonstrating that the expression of SP1884 
which is involved in trehalose metabolism.  
In isolate 03-4183 expression of SP1884 is markedly less than that of isolate 03-4156 which 
correlates  with  a  difference  in  API  result  for  trehalose  (TRE)  metabolism  by  API  testing 
(Figure 6-4). It is also noteworthy that the above results suggest increased expression of 
SP1884 and trehalose metabolism in blood (99-4038) compared to cerebrospinal fluid (99-
4039) from the same case of meningitis (Chapter 10). 
 
Correlations between microarray CGH results for sugar metabolism genes which show 
diversity and sugar metabolism results observed by API testing have also been consistently 
documented by Aakra et al when comparing Enterococcus faecalis strains (Aakra et al., 
2007).  In  pneumococci,  Oggioni  et  al  have  noted  that  genomic  variation  in  the  PTS 
systems does influence sugar fermentation (Oggioni et al., 2008).  
It may be that these subtle differences in sugar metabolism  in vitro have a relationship to 
the  transitioning  serotype  3  capsule  genes  and  their  expression  and  are  in  some  way 
involved in the phase variation noted above although unravelling whether there is such a 
relationship is beyond the scope of this thesis.  
 
  
7  Genomic Diversity in Isolates of the Same 
Serotype and Multilocus Sequence Type Related 
to Clinical Manifestation and Outcome 
7.1 Background 
Serotype 4 pneumococci are an important cause of invasive pneumococcal disease (IPD) in 
humans and can cause severe invasive disease in animal models (Sandgren et al., 2005). 
Factors  in  addition  to  the  pneumococcal  capsule  (a  major  virulence  factor  which 
determines the serotype) contribute to disease outcome (Mizrachi-Nebenzahl et al., 2004) 
and  clonal  properties  other  than  serotype  influence  ability  to  cause  invasive  disease 
(Sandgren et al., 2005, Kerr et al., 2006).  
Some virulence associated genes, such as nanC, may not be uniformly distributed within a 
single  sequence  type  (Pettigrew  et  al.,  2006)  and  within  a  sequence  type,  a  virulence 
associated gene can demonstrate sequence diversity which may alter its function (Kirkham 
et al., 2006). The pneumococcus has many genes which are highly variable with multiple 
known alleles such as the pneumococcal surface protein PspA (Roche et al., 2003) but 
even within the housekeeping genes which are the basis of the MLST scheme and which 
are  considered  to  be  much  more  conserved,  divergent  sequences  have  been  identified 
(Diggle  and  Clarke,  2005).    With  this  high  degree  of  variation  in  the  pneumococcal 
genome, it was anticipated that sequence differences, such as point mutations or insertions 
resulting  in  frame  shifts,  may  be  identifiable  which  may  be  contributing  to  different 
clinical presentations.  
It is known that bacteriophages are sources of DNA which, when integrated into bacterial 
genomes, result in greater genomic diversity. Exogenous DNA from bacteriophages can 
code  for  virulence  associated  proteins  such  as  the  lytic  activity  of  the  Pal  enzyme 
belonging to the pneumococcal phage Dp-1(Lopez et al., 2000). Fully functional lysogenic 
phages, defective phages and remnant prophages are widespread amongst pneumococcal 
isolates of different serotypes and different geographical origins (Gindreau et al., 2000, 
Ramirez  et  al.,  1999).  It  has  been  stated  that  the  role  of  conjugative  transposons  and 
bacteriophage needs to be addressed in a clinical setting (Lopez, 2006).      Chapter 7, 141 
It  was  decided  to  investigate  a  series  of  IPD  cases  caused  by  the  same  serotype  and 
sequence type (serotype 4, ST246). Six isolates from patients of similar age, gender, racial 
background  and  geographical  location  were  chosen  for  analysis.  Their  clinical 
manifestations were reviewed and the isolates used to perform microarray CGH, look for 
evidence of bacteriophage carriage and thereby assess whether genomic diversity within 
the  ST246  clone  was  identifiable  which  might  have  contributed  to  the  varied  disease 
presentations.    Isolate  06-1803  was  primarily  used  because  of  the  unusual  clinical 
presentation of the source patient and five isolates were chosen of the same serotype and 
sequence type which originated from patients of similar characteristics using a database 
held at SMPRL. 
7.2 Epidemiological details for Serotype 4 ST246 Test 
Isolates 
Isolate 
Year of 
Isolation 
Age of 
Patient 
Sex of 
Patient  Location  Racial Origin 
Isolate 
Source  Serotype  MLST 
03-5339  2003  37  Male 
North East 
Glasgow  Caucasian 
Blood 
culture  4  ST246 
04-1342  2004  53  Male 
North East 
Glasgow  Caucasian 
Blood 
culture  4  ST246 
04-2239  2004  42  Male 
North East 
Glasgow  Caucasian 
Blood 
culture  4  ST246 
05-1109  2005  56  Male 
North East 
Glasgow  Caucasian 
Blood 
culture  4  ST246 
06-1803  2006  49  Male 
West 
Glasgow  Caucasian 
Blood 
culture  4  ST246 
06-1898  2006  64  Male 
North East 
Glasgow  Caucasian 
Blood 
culture  4  ST246 
Table   7-1 Basic epidemiological information about the source patients from which serotype 
4, ST246 isolates were received. 
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7.3 Clinical Manifestations and Outcomes for Serotype 4 
ST246 Test Isolates 
Isolate  Clinical History 
03-5339 
Diagnosed with bacteraemic pneumonia which did not require intensive care. Antibiotic 
therapy was not documented. 
04-1342 
Diagnosed  with  an  acute  confusional  state  and  bacteraemic  lobar  pneumonia. 
Experienced severe sepsis during first 24 hours of admission. Gradually improved on 
intravenous amoxycillin. 
04-2239 
Presented with pneumonia and septic shock which required immediate intensive care 
management. Initially treated with intravenous ceftriaxone, clarithromycin, inotropes and 
recombinant activated protein C. Required intensive care management for over a month 
but survived. 
05-1109 
Diagnosed  with bacteraemic pneumonia  which did  not require  intensive care.  Patient 
had an uneventful recovery on intravenous amoxycillin. 
06-1803 
Presented  with  concurrent  pneumococcal  meningitis,  pneumonia  and  aortic  valve 
endocarditis.  Required  emergency  aortic  valve  replacement  on  day  2  of  admission. 
Failed  to  settle  on  intravenous  ceftriaxone  and  gentamicin  (despite  being  a  penicillin 
susceptible isolate in vitro). Still failed to settle after addition of intravenous vancomycin 
and developed an aortic root abscess. Finally recovered after 3 months of treatment with 
daptomycin. 
06-1898 
Presented  with  bacteraemic  pneumonia  and  renal  impairment.  Patient  responded  to 
intravenous ceftriaxone and recovered uneventfully. 
Table   7-2 Brief clinical histories of the cases from which serotype 4, ST246 isolates were 
received.  
 
7.4 Bacteriophage induction 
Bacteriophage induction for the six clinical isolates was performed by Dr Patricia Romero 
using the following methodology. Isolates were grown at 37°C until an optical density at 
600nm of between 0.1-0.25 was reached. Mitomycin C was added to a final concentration 
of 100 ng/ml to induce the release of lysogenic bacteriophages. 200  l of each culture 
(before and after the addition of mitomycin C) were added to wells of a 96-well plate in 
triplicate. Growth was monitored by optical density at 600nm in a plate reader (Fluostar 
OPTIMA,  BMG  LABTECH,  Germany).  Bacteriophage  induction  identified  a 
bacteriophage only in isolate 05-1109. 
7.5 Microarray DNA CGH Results 
DNA microarray CGH was performed using the protocols outlined in Chapter 2. One large 
region of diversity from SP1129-SP1146 was evident and is magnified in Figure 7-1. In 
total, 46 gene loci where diversity was evident were identified by CGH (Figure 7-2). 
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Figure   7-1 DNA CGH results for serotype 4, ST246 isolates.  
This figure is produced by Genespring GX 7.3.1. The genes from the TIGR4 and R6 genomes 
featured  on  the  microarray  are  illustrated  as  horizontal  bars  consisting  of  vertical  lines 
representing consecutive genes. Yellow lines indicate where competitive hybridization has 
occurred. Red lines indicate where R6 genes are present and hybridizing in the test isolate 
but are absent from TIGR4. Blue lines indicate genes which are present and hybridizing in 
TIGR4 but not hybridizing with the test isolates. Grey lines indicate that the fluorescence 
intensity of the hybridization has not been high enough to reach a threshold set on Bluefuse 
for Microarrays 3.5 © to filter out low quality hybridizations. The region of diversity between 
SP1129 –SP1146 is magnified. 
 
PCR  (utilising  the  primers  used  to  design  the  probes  (Appendix  3)  attached  to  the 
microarray (MWG Biotech AG, Germany)) demonstrated absence of the gene at 12 of 
these loci (Figure 7-2) and suggested that sequence divergence may account for detection 
of product at the other loci.      Chapter 7, 144 
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SP0031                          
SP0068                          
SP0111                          
SP0165                          
SP0309                          
SP0514                          
SP0532                         
SP0570                          
SP0573                          
SP0949  IS1515, transposase, authentic frameshift  No                   
SP1129   integrase/recombinase, phage integrase family  No                   
SP1130   transcriptional regulator  No                   
SP1131   transcriptional regulator, putative  No                   
SP1132                          
SP1134                          
SP1135                          
SP1136   conserved domain protein  No                   
SP1137                          
SP1138                         
SP1139                          
SP1140   hypothetical protein  No                   
SP1141   hypothetical protein  No                   
SP1142                          
SP1143                          
SP1144                          
SP1145   hypothetical protein  No                   
SP1158                          
SP1181                          
SP1189   hypothetical protein  No                   
SP1254                          
SP1342                          
SP1343                          
SP1350                          
SP1353                          
SP1696                          
SP1718                          
SP1770  glycosyl transferase, family 8  Yes                   
SP1793                          
SP1794   hypothetical protein  No                   
SP1796  ABC transporter, substrate-binding protein  No                   
SP1797                          
SP1799                          
SP1839                          
SP1895                          
SP1896                          
SP1897                          
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Figure   7-2 PCR validation results for genes where are least one of the 6 ST246 isolates did 
not hybridize on the microarray. 
Yellow  indicates  the  presence  of  a  PCR  product  of  the  same  size  as  that  in  the  TIGR4 
genome  (using  the  primers  utilised  in  the  manufacture  of  the  microarray  displayed  in 
Appendix  3)  while  blue  indicates  the  absence  of  a  product.  Where  genes  have  been 
identified  as  absent  (blue)  their  putative  function  is  noted  and  whether  they  have  been 
identified as virulence factors in the development of pneumonia in a mouse model (Hava 
and Camilli, 2002).   
 
Five of the absent genes were absent in all 6 clinical isolates while 7 were strain dependent 
and could be absent or present in the ST246 clinical isolates. 
Isolate 06-1803 demonstrated the greatest number of putative gene deletions, several of 
which were identified as absent solely in this isolate.  
We chose three genes (SP1130, SP1136 and SP1342) where DNA in test isolates did not 
hybridize on the microarray but had demonstrable products using PCR and we sequenced 
the  PCR  products.  This  identified  single  nucleotide  polymorphisms  (SNPs)  in  several 
isolates  when  the  sequenced  genes  were  compared  with  their  TIGR4  sequence  using 
National  Center  for  Biotechnology  Information  (NCBI)  Basic  Local  Alignment  Search 
Tool (BLAST) software. The genetic diversity of SP1130 is illustrated in Figure 7-3. 
 
Figure   7-3 Genomic diversity of the transcriptional regulator gene SP1130.  
The presence or absence of gene SP1130 in the 6 clinical ST246 serotype 4 isolates was 
determined  using  PCR  and  compared  with  results  using  microarray  CGH  where  no 
hybridization occurred for this gene in any of the test isolates. Blue indicates where the 
gene was absent by PCR and yellow indicates that a product was detected which was the 
same  size  as  the  product  from  TIGR4.  Single  nucleotide  polymorphisms  (SNPs)  were 
identified in the sequenced PCR product when compared to the TIGR4 sequence for isolates 
04-1342 and 05-1109. The locations of some of these SNPs are identified in red boxes for 
part of the PCR product from isolate 04-1342. 
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7.6 Discussion 
This investigation has demonstrated genetic diversity within clinical isolates of a single 
clonal  complex  (ST246)  associated  with  one  serotype  (serotype  4)  from  patients  with 
matched epidemiological characteristics using a PCR product microarray as a screening 
investigation. These DNA CGH results were validated using PCR. This work also assessed 
whether there may be additional integrated genetic material by bacteriophage induction. 
A bacteriophage was identified only in isolate 05-1109 which had integrated 32-34kb of 
genetic material. This burden of genetic material represents a source of genomic diversity 
which would otherwise have remained undetected by microarray CGH analysis. This again 
highlights  one  of  the  limitations  of  microarray  DNA  CGH  as  it  can  only  identify  the 
presence of genes which feature in the reference genomes which were used to construct the 
probes on the microarray. Consequently, it may not detect additional genes acquired by 
horizontal  gene  transfer  from  other  bacterial  species  or  from  bacteriophages,  the 
acquisition of which may affect gene expression and subsequently the bacterial phenotype 
and disease presentation.  
It  has  previously  been  recognised  that  the  TIGR4  genome  demonstrates  evidence  of  a 
bacteriophage remnant in a 10.5kb cluster of 19 contiguous open reading frames (from 
SP1129 to SP1147) that is absent from the genome of R6 (Obregon et al., 2003). This 
corresponds exactly with the only significant region of diversity between these clinical 
isolates and TIGR4.  This region of diversity has been previously identified (Silva et al., 
2006)  but  the  presence  of  genes  in  this  region  has  previously  been  associated  with  a 
noninvasive phenotype when described before in serotype 6B isolates (Obert et al., 2006). 
This investigation of serotype 4 isolates from patients with bacteraemic pneumonia and 
other IPD manifestations suggests that if there really is an association with a noninvasive 
phenotype this association may be serotype specific. 
The identification of some of the genes in the SP1129-SP1147 region in some isolates 
suggests that these isolates or their ancestors had carried a bacteriophage. Bacteriophages 
may  therefore  have  a  significant  role  in  the  generation  of  genomic  diversity  in  the 
pneumococcus.  For  these  isolates,  it  appears  that  genomic  diversity  (with  a  possible 
consequence  being  diversity  of  clinical  manifestations)  has  arisen  more  as  a  result  of 
acquiring  additional  genetic  content  rather  than  deletion  of  genetic  material  when 
compared to another serotype 4 strain (TIGR4) as deletion of individual genes within these 
isolates  does  not  appear  to  be  common  when  compared  to  the  TIGR4  genome.  It  is     Chapter 7, 147 
possible  that  the  unique  combination  of  gene  deletions  in  isolate  06-1803  may  have 
contributed to the unusual clinical presentation with simultaneous pneumonia, meningitis 
and endocarditis.  
While considering the pathogenesis of pneumococcal endocarditis, Bruckner et al have 
identified SP1772, a gene coding for a cell wall anchor protein, as homologous to a platelet 
binding glycoprotein in Streptococcus gordonii (Bruckner et al., 2004) and Takamatsu et 
al have considered it important in the causation of endocarditis (Takamatsu et al., 2004). 
Our results do concur with this hypothesis as SP1772 did hybridize in all the test clinical 
strains,  suggesting  that  all  had  the  genetic  potential  to  result  in  endocarditis  if  this 
hypothesis is correct. Only isolate 06-1803 however came from a patient with endocarditis, 
which suggests that there may be other pneumococcal genetic involvement required for the 
development of endocarditis or, perhaps more likely, a requirement for a particular host 
susceptibility such  as underlying valvular pathology.  It is noteworthy that in the CGH 
analysis performed by Bruckner et al, SP1772 appears absent from several of the serotypes 
analysed particularly serotype 3 (Bruckner et al., 2004). Our results from other DNA CGH 
experiments have also demonstrated an absence of hybridization for SP1772 in all serotype 
3  isolates  tested  but  also  in  serotype  23F  (04-1168  and  ATCC51916),  serotype  6A 
(BAA659),  serotype  14  (BAA340),  serotype  20  (05-1271),  serotype  35B  (BAA660), 
serotype 12F (05-2565) and serotype 9V (05-1821). But before it can be concluded that the 
absence  of  SP1772  may  preclude  the  development  of  endocarditis,  it  should  be 
acknowledged that several case series of pneumococcal endocarditis from the mid-20
th 
century  (Austrian,  1957,  Straus  and  Hamburger,  1966,  Finland  and  Barnes,  1970) 
demonstrate that serogroups 3, 6, 14 and 20 can indeed cause endocarditis. As genetic 
analysis  of  these  historical  isolates  is  not  possible,  there  is  no  conclusive  proof  of  a 
pneumococcus without SP1772 being associated with endocarditis but given the universal 
lack of hybridization of SP1772 in all serotype 3 isolates analysed so far by CGH, a claim 
that possession of SP1772 is necessary to cause endocarditis is hard to support. Likewise, 
the glycosyl transferase SP1770, which was identified by signature tagged mutagenesis as 
being essential for virulence in a murine pneumonia model (Hava and Camilli, 2002) does 
not appear to be necessary in the pathogenesis of bacteraemic pneumococcal pneumonia in 
humans. 
These results also highlight the impact that sequence diversity can have on how microarray 
DNA CGH results are interpreted. The results show that even small mutations in gene 
sequence may affect hybridization on our microarray which was evident when there was 
failure to hybridize genes which contained occasional SNPs in the test DNA compared to     Chapter 7, 148 
its  probe.  Shen  et  al  have  also  demonstrated  that  several  pneumococcal  genes  contain 
numerous point mutations and small indels (Shen et al., 2006a). Detection of SNPs using 
microarray technology has been possible in the human genome project (Wang et al., 1998) 
but  in  order  to  do  this  with  higher  specificity  for  pneumococcal  genomes,  a  new 
customised microarray would be required using an oligonucleotide probe approach rather 
than a PCR product probe (Kumar et al., 2005, Palacios et al., 2007, Dorrell et al., 2005). 
This approach would be less successful at detecting larger genes due to the shorter nature 
of the probes employed (Palacios et al., 2007). This has led to the conclusion that,  
“given  the  uncertainties  about  the  extent  of  naturally  occurring  genetic 
polymorphisms in pathogen gene pools, the most practical hybridization-based 
detectors  will  probably  rely  on  longer  probes  that  are  less  sensitive  to 
unexpected  genetic  polymorphism  and  that  also  provide  greater  analytic 
sensitivity compared with shorter oligonucleotide probes (Call, 2005).”  
Silva et al note that isolates of the same serotype and sequence type can behave very 
differently in vivo in animal hosts. These observations on human cases due to the same 
serotype and sequence type with very different clinical courses agree with this observation.  
Figure 7-4 below demonstrates that ST246 is a single locus variant of ST899 and a double 
locus variant of ST2365 and ST695. These serotype 4 related sequence types have been 
associated  with  capsular  switching  and  acquisition  of  a  serotype  19A  capsule  as  a 
conjugate vaccine escape mutation (Brueggemann et al., 2007). Although it has not yet 
been seen, it would seem likely that such a closely related sequence type (ST246), which is 
of obvious virulence in humans, has the potential to switch capsules with serotype 19A to 
escape  vaccine  pressure  but  maintain  the  virulence  associated  with  the  ST246  clonal 
complex (Sandgren et al., 2004).  
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Figure    7-4 Demonstration of the relationship of  ST246 to other closely related sequence 
types using e-BURST version 3 and the MLST database. 
Adapted  from  Brueggemann  et  al  (Brueggemann  et  al.,  2007).  ST247  is  found  to  be  a 
founder  clonal  complex  and  ST246,  ST899  and  ST695  are  co-founders.  Sequence  types 
highlighted in red have been found to have undergone capsular switching in recent years 
and have acquired and express the serotype 19A capsule. 
 
  
8  Genomic Diversity in Nosocomial Outbreaks of 
Pneumococcal Disease 
8.1 Pneumococcal Outbreaks – Definition and Features 
According  to  Health  Protection  Agency  draft  guidelines,  a  cluster  or  outbreak  of 
pneumococcal disease is defined as, 
“two or more cases of serious pneumococcal infection (confirmed or probable) 
reported from a closed setting within a four-week period.” 
Nosocomial outbreaks of IPD, although not common, are well described. Perhaps the first 
description of such a hospital acquired outbreak of pneumococcal pneumonia was at an 
asylum  in  1903  (Sinigar,  1903).  These  outbreaks  are  associated  with  significant 
preventable  morbidity  and  mortality  particularly  in  elderly  (Hansmann  et  al.,  2006, 
Thakker et al., 1998, Bain et al., 1990, Millar et al., 1994, Cartmill and Panigrahi, 1992, 
Dawson et al., 1992, Fiore et al., 1998, Mandigers et al., 1994, Bresnitz et al., 2001, Kludt 
et al., 1997, Gleich et al., 2000, Bescos et al., 2003, Tan et al., 2003, Weiss et al., 2001, 
Quick et al., 1993, Barnes et al., 1995, Gould et al., 1987, Nuorti et al., 1998, Gillespie et 
al., 1997) and paediatric populations (Gupta et al., 2007, Medeiros et al., 1998, Leighton et 
al., 2003, Craig et al., 1999, Cherian et al., 1994, Schroder and Cooper, 1930, O'Brien et 
al., 2000, Strom, 1932, Melamed et al., 2002, Radetsky et al., 1981, Gilman and Anderson, 
1938, Dagan et al., 2000). Remarkably there is, as yet, no consensus as how best to prevent 
or manage them although in 2007 a Health Protection Agency working group issued draft 
interim guidelines for consultation in the United Kingdom.  
Particular serogroups have a predilection for causing outbreaks (Table 8-1) possibly due to 
a genetic factor which has resulted in increased transmissibility. This is unlikely to be due 
solely to capsular properties as, “non-typeable,” uncapsulated pneumococci can also cause 
outbreaks  –  particularly  of  conjunctivitis.  Virtually  all  possible  presentations  of 
pneumococcal disease have been associated with outbreaks as shown in Table 8-2. 
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Pneumococcal 
Serogroup 
Associated with 
Outbreaks  
 
References 
Serogroup 1  (Thakker et al., 1998, Gupta et al., 2007, Musher et al., 1997, Gilman and 
Anderson, 1938, Smeall, 1931, Park and Chickering, 1919, Gratten et al., 
1993, Mercat et al., 1991, DeMaria et al., 1980, Mackenzie et al., 1940, 
Leimkugel et al., 2005, Yaro et al., 2006, O'Brien et al., 2000, Strom, 1932, 
Dagan et al., 2000, Proulx et al., 2002) 
Serogroup 2  (Smillie et al., 1938) 
Serogroup 3  (Bescos et al., 2003) 
Serogroup 4  (Hansmann et al., 2006, Gleich et al., 2000, Bain et al., 1990, Clarke et al., 
2004a, Crum et al., 2003) 
Serogroup 5  (Schroder and Cooper, 1930, Melamed et al., 2002) 
Serogroup 6  (Cartmill and Panigrahi, 1992, Dawson et al., 1992, Radetsky et al., 1981) 
Serogroup 8  (Birtles et al., 2005, Berk et al., 1985) 
Serogroup 9  (Anonymous, 1992, Millar et al., 1994, Mandigers et al., 1994, Gillespie et al., 
1997, Crum et al., 2003) 
Serogroup 12  (Hoge et al., 1994, Jorgensen et al., 2005, Cherian et al., 1994) 
Serogroup 14  (Craig et al., 1999, Fiore et al., 1998, Bresnitz et al., 2001, Tan et al., 2003, 
Medeiros et al., 1998) 
Serogroup 19  (Clarke et al., 2004a, Quick et al., 1993) 
Serogroup 23  (Carter et al., 2005, Barnes et al., 1995, Weiss et al., 2001, Fry et al., 2005, 
Gould et al., 1987, Nuorti et al., 1998) 
Non-Typeable  (Hennink et al., 2006, Martin et al., 2003a, Feingold, 2003, Leighton et al., 
2003, Crum et al., 2004, Carvalho et al., 2003, Buck et al., 2006, Ertugrul et 
al., 1997) 
Table   8-1 Pneumococcal serogroups which can cause disease outbreaks. 
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Pneumococcal 
Manifestation 
Observed in 
Outbreaks 
 
References 
Asymptomatic 
Carriage 
(Jorgensen et al., 2005, Gillespie et al., 1997, Mackenzie et al., 1940, 
Hoge et al., 1994, Musher et al., 1997, Bescos et al., 2003, Carter et al., 
2005, Nuorti et al., 1998, Radetsky et al., 1981, Quick et al., 1993, 
Barnes et al., 1995) 
Pneumonia  (Jorgensen et al., 2005, Gillespie et al., 1997, Mackenzie et al., 1940, 
Lamb and Brannin, 1919, Anonymous, 1992, Smillie et al., 1938, 
Schroder and Cooper, 1930, Hoge et al., 1994, DeMaria et al., 1980, 
Mercat et al., 1991, Millar et al., 1994, O'Brien et al., 2000, Cartmill and 
Panigrahi, 1992, Dawson et al., 1992, Proulx et al., 2002, Musher et al., 
1997, Fiore et al., 1998, Mandigers et al., 1994, Gratten et al., 1993, 
Strom, 1932, Hirsch and McKinney, 1919, Tan et al., 2003, Gilman and 
Anderson, 1938, Park and Chickering, 1919, Bescos et al., 2003, Gleich 
et al., 2000, Kludt et al., 1997, Bain et al., 1990, Hansmann et al., 2006, 
Dagan et al., 2000, Subramanian et al., 2003, Carter et al., 2005, De 
Galan et al., 1999, Nuorti et al., 1998, Bresnitz et al., 2001, Thakker et 
al., 1998, Gupta et al., 2007, Weiss et al., 2001, Quick et al., 1993, Fry et 
al., 2005, Crum et al., 2003, Berk et al., 1985, Gould et al., 1987) 
Empyema  (Jorgensen et al., 2005, Smillie et al., 1938, DeMaria et al., 1980, O'Brien 
et al., 2000, Gupta et al., 2007) 
Meningitis  (Jorgensen et al., 2005, Craig et al., 1999, Yaro et al., 2006, Leimkugel et 
al., 2005, Birtles et al., 2005, Hoge et al., 1994, DeMaria et al., 1980, 
Melamed et al., 2002, Radetsky et al., 1981) 
Blood Stream Infection  (Jorgensen et al., 2005, Cherian et al., 1994, Tan et al., 2003, Bescos et 
al., 2003, Gleich et al., 2000, Kludt et al., 1997, Hansmann et al., 2006, 
Dagan et al., 2000, Carter et al., 2005, Bresnitz et al., 2001) 
Otitis Media  (Gilman and Anderson, 1938, Dagan et al., 2000) 
Conjunctivitis  (Feingold, 2003, Leighton et al., 2003, Martin et al., 2003a, Hennink et 
al., 2006, Cherian et al., 1994, Crum et al., 2004, Carvalho et al., 2003, 
Buck et al., 2006, Medeiros et al., 1998, Ertugrul et al., 1997) 
Septic Arthritis  (Jorgensen et al., 2005, DeMaria et al., 1980) 
Cellulitis  (Jorgensen et al., 2005) 
Peritonitis  (Malloch, 1922) 
 
Table   8-2 Presentation of pneumococcal disease or carriage associated with outbreaks. 
 
8.2 Pneumococcal Typing Methods and Limitations in 
Outbreak Investigations  
8.2.1 Serotyping 
Serotyping,  although  usually  performed  in  a  reference  laboratory,  is  an  important  test 
which can help to rapidly identify links between epidemiologically  connected cases of 
pneumococcal disease and clarify the composition of outbreak clusters. It does however 
have limitations when the cases are due to uncapsulated pneumococci which are “non-
typeable”  by  serotyping.  In  such  cases,  molecular  methods  can  be  more  significant  in 
identifying or refuting links between cases.       Chapter 8, 153 
8.2.2 Molecular typing 
Molecular typing methodologies are reviewed in Chapter 1. Several of these have been 
used to investigate relationships between isolates collected in outbreak situations including 
PFGE (Nuorti et al., 1998, Carter et al., 2005, Subramanian et al., 2003, Martin et al., 
2003a,  Craig  et  al.,  1999,  Bescos  et  al.,  2003,  Barnes  et  al.,  1995),  PBP  Gene 
fingerprinting (Gillespie et al., 1997, Barnes et al., 1995), Ribotyping (Cherian et al., 1994, 
Dagan et al., 2000), RFEL (De Galan et al., 1999), BOX-PCR (Ertugrul et al., 1997), 
Random  Amplified  Polymorphic  DNA  analysis  (RAPD)  (Melamed  et  al.,  2002) 
fluorescence-based  Amplified  Fragment  Length  Polymorphism  analysis 
(fbAFLP)(Hennink et al., 2006) and MLST (Birtles et al., 2005, Leimkugel et al., 2005, 
Clarke et al., 2004a, Yaro et al., 2006, Martin et al., 2003a) although several publications 
describing  pneumococcal  outbreaks  predate  the  development  of  these  methods.  This 
chapter  features  the  first  description  of  microarray  technology  being  utilised  in  the 
molecular typing of pneumococcal outbreak associated isolates and thereby the first to 
consider the clonal nature of such isolates at the level of the whole pneumococcal genome. 
8.3 Background to Chosen Outbreaks 
8.3.1 Serogroup 1 ST227 
The significance of serogroup 1 pneumococci to the contemporary global epidemiology of 
this organism is reviewed in Chapter 1.  
It was possible to identify isolates from two patients involved in a historical serogroup 1 
related outbreak from a care of the elderly ward in Glasgow in 1996 (Thakker et al., 1998). 
These isolates were stored frozen at SMPRL. This allowed us to revisit the microbiology 
of the outbreak investigation with the benefit of MLST and microarray technology. Neither 
isolate was from the index case who had presented with an aggressive pneumonia and died 
within 24 hours of the onset of symptoms. Both isolates were from direct contacts of the 
index patient though. These secondary cases had developed bacteraemic pneumonia and 
the stored isolates had been obtained from blood cultures. One of these secondary cases 
also died within 24 hours of the onset of symptoms and the other died within 3 days of the 
onset of symptoms.   
MLST of the two serogroup 1 isolates showed them to both be ST227. This itself is of 
significance as this outbreak predates the start of the expansion of the ST306 clone in     Chapter 8, 154 
Scotland and is compatible with the hypothesis that ST227 was the dominant serogroup 1 
clone in Scotland in the 1990s.  
8.3.2 Serogroup 4 ST206 
This outbreak occurred in 2002 in a care of the elderly ward in a hospital in the West of 
Scotland  and  affected  four  patients  aged  between  79  and  98.  All  the  cases  developed 
bacteraemic  pneumonia  and  all  succumbed  to  their  infections.  Isolates  were  available 
stored frozen at SMPRL from blood cultures for all four cases. Serotyping found all the 
isolates to be serogroup 4. These isolates had previously had MLST and all were ST206, a 
finding  which  has  previously  been  used  to  illustrate  the  utility  of  MLST  in  outbreak 
investigations (Clarke et al., 2004a). 
Serogroup 4 pneumococci appear to have a particular association with outbreaks in elderly 
care facilities (Gleich et al., 2000, Hansmann et al., 2006, Clarke et al., 2004a, Bain et al., 
1990, Kludt et al., 1997).  
8.4 Microarray CGH analysis of Outbreak Isolates 
Unlike  the  microarray  investigations  so  far  which  have  been  directed  at  identifying 
diversity  in  the  pneumococcal  genome,  this  chapter  is  focussed  on  assessing  whether 
outbreak clinical isolates can be shown to be clonal. Hackenbeck et al, demonstrated that 
there  is  less  diversity  in  isolates  of  the  same  PMEN  clone  than  from  different 
pneumococcal serogroups (Hakenbeck et al., 2001). Isolates which are epidemiologically 
related in an outbreak setting are likely to be clonal, usually from a point source or index 
case.  However,  as  the  pneumococcus  readily  undergoes  genetic  recombination,  the 
circulating population of pneumococci which do not form part of the outbreak may no 
longer demonstrate as  clonal a population structure as the outbreak strains, allowing a 
distinction between the two populations to be made. CGH performed on a PCR product 
microarray should therefore be able to distinguish outbreak strains from those which are 
not related.  
Microarrays  have  previously  been  used  during  outbreak  investigations  of  rotavirus 
(Chizhikov,  2002),  viral  haemorrhagic  fever  (Palacios  et  al.,  2007),  Streptococcus 
pyogenes (Smoot et al., 2002) and Campylobacter jejuni (Leonard et al., 2003) but this has 
been their first use in the investigation of outbreak related invasive pneumococcal disease. 
The  investigation  using  outbreak  related  strains  of  Streptococcus  pyogenes  and     Chapter 8, 155 
Campylobacter jejuni also utilized a PCR product “spotted” microarray which was able to 
successfully discriminate strains belonging to separate outbreaks whereas the rotavirus and 
viral haemorrhagic fever studies used oligonucleotide microarrays. 
For these studies, genomic DNA was prepared and DNA CGH hybridizations and analysis 
was  performed  using  the  protocols  in  Chapter  2  with  TIGR4  DNA  as  the  reference 
genome. Dye swap experiments were performed for each isolate. 
8.4.1 CGH Results from Serogroup 1 Outbreak 
 
Figure   8-1 Comparison of CGH results for serotype 1 outbreak associated isolates.  
Genes  are  represented  consecutively  by  Genespring  GX  7.3.1  from  left  to  right  by  a 
coloured line. Yellow indicates that competitive hybridization occurred with both DNA from 
the test isolate and TIGR4. Blue lines indicate that DNA from TIGR4 hybridized but DNA 
from the test isolate did not. Grey lines indicate that either no hybridization occurred or that 
the  fluorescence  intensity  of  the  hybridization  that  did  occur  was  too  low  to  pass  the 
threshold value in Bluefuse for Microarrays 3.5 © to be included in the analysis. Red lines 
indicate  that  no  DNA  from  TIGR4  hybridized  but  DNA  from  the  test  isolate  hybridized  – 
usually  to  probes  from  the  R6  genome  but  occasionally  because  of  false  negative 
hybridization of TIGR4 DNA to a TIGR4 gene. Red arrows indicate the two outbreak related 
serogroup  1,  ST227  isolates  which  can  be  easily  distinguished  from  isolates  of  other 
serogroups which have been sequenced at the Wellcome Sanger Institute (Chapter 3) but 
which are not easily distinguished from other serogroup 1 isolates (Chapter 10).      Chapter 8, 156 
 
Serotype 1 Outbreak    Serotype 1 Outbreak 
96-5891  96-5892    96-5891  96-5892 
SP0067   SP0067        spr0105  
SP0068   SP0068     spr0111   spr0111  
SP0069   SP0069     spr0112   spr0112  
SP0070   SP0070     spr0113   spr0113  
SP0071   SP0071     spr0114   spr0114  
SP0072        spr0115   spr0115  
   SP0074     spr0116   spr0116  
SP0076        spr0117   spr0117  
SP0080        spr0118   spr0118  
SP0093        spr0119   spr0119  
SP0110   SP0110     spr0225     
SP0111   SP0111        spr0317  
SP0112   SP0112     spr0320   spr0320  
SP0113   SP0113     spr0321   spr0321  
   SP0124     spr0322   spr0322  
SP0126        spr0323   spr0323  
SP0244           spr0957  
   SP0308     spr0958   spr0958  
SP0350   SP0350        spr0959  
SP0351   SP0351     spr0962     
SP0352   SP0352     spr0965     
SP0353           spr0972  
SP0354   SP0354     spr1403   spr1403  
SP0355   SP0355     spr1404   spr1404  
   SP0356     spr1550   spr1550  
SP0357   SP0357     spr1618   spr1618  
SP0358   SP0358     spr1619   spr1619  
SP0359   SP0359     spr1620   spr1620  
SP0360   SP0360     spr1621   spr1621  
SP0452        spr1818     
SP0460   SP0460        
SP0461   SP0461        
SP0462   SP0462        
SP0463   SP0463        
SP0464   SP0464        
SP0465   SP0465        
SP0466   SP0466        
SP0467   SP0467        
SP0468   SP0468        
SP0509           
SP0535           
SP0548           
SP0560           
   SP0569        
SP0570           
SP0574           
SP0696           
   SP0773        
SP1036           
SP1037           
SP1047   SP1047        
SP1048   SP1048        
   SP1049        
SP1050   SP1050        
SP1051   SP1051        
SP1052   SP1052        
SP1053   SP1053        
SP1054   SP1054        
SP1055   SP1055        
SP1056   SP1056        
SP1057   SP1057        
SP1059   SP1059        
SP1060   SP1060        
SP1061   SP1061        
SP1062   SP1062        
SP1063   SP1063        
SP1064   SP1064        
   SP1143        
SP1144   SP1144        
SP1145   SP1145        
   SP1146        
   SP1188        
   SP1189        
SP1221   SP1221        
SP1222   SP1222        
SP1304           
SP1318           
SP1336           
SP1439           
SP1503           
SP1615   SP1615        
SP1616   SP1616        
SP1617   SP1617        
SP1618   SP1618        
SP1619   SP1619        
SP1620   SP1620        
SP1621   SP1621        
SP1622   SP1622        
SP1791           
SP1796   SP1796        
SP1797   SP1797        
SP1798   SP1798        
SP1799   SP1799        
   SP1819        
   SP1835        
   SP1866        
SP1948   SP1948        
SP1949   SP1949        
SP1950   SP1950        
SP1951   SP1951        
SP1952   SP1952        
SP1953   SP1953        
SP1954   SP1954        
SP1955           
 
Figure   8-2 Genelists created from CGH analysis of dye swap experiments for serotype 1, 
ST227 isolates 96-5891 and 96-5892.      Chapter 8, 157 
The list of genes from the TIGR4 genome which were identified as not hybridizing to the 
array in one or both isolates is on the left and the list of genes from the R6 genome which 
did not hybridize is on the right. Where results have been highlighted in colour, PCR of the 
gene  was  performed  using  the  primers  displayed  in  Appendix  3  used  to  make  the  PCR 
probe for that gene on the microarray (MWG Biotech AG, Germany). Yellow indicates that a 
PCR product of the correct size could be identified by PCR and gel electrophoresis. Blue 
indicates that no PCR product was identified. 
 
8.4.2 Discussion of CGH Results for Serogroup 1 Outbreak 
These results again demonstrate some limitations of performing CGH on this “spotted” 
microarray particularly if trying to use the results as a “typing” tool (see also Chapter 3). In 
some cases when the array identified genes which had not hybridized, PCR corroborated 
with the array adding confidence to the conclusion that the genes were truly absent from 
the test genome (highlighted blue in Figure 8-2). However, in a substantial number of 
instances,  PCR  identified  the  gene  as  present  in  both  isolates  96-5891  and  96-5892 
(highlighted yellow in Figure 8-2) indicating that false negative hybridization for these 
genes had occurred in the microarray dye swap experiments. Possible reasons for this are 
identified and discussed in Chapter 3.  
Many  of  these  false  negative  hybridizations  are  occurring  within  known  regions  of 
diversity  in  the  pneumococcal  genome  (Table  1-2)  which  suggests  that  the  lack  of 
hybridization may be due to the presence of the genes in the test genome having such a 
dissimilar sequence to that in TIGR4 that hybridization does not occur with the probe on 
the microarray. This issue of poor sensitivity does not necessarily mean that microarray 
based DNA CGH could not be used to group outbreak isolates into a cluster as it can 
readily distinguish between serogroups but the discrimination between ST227 and ST306 
(which  are  part  of  the  same  clonal  complex  within  serogroup  1  and  are  double  locus 
variants as demonstrated in Figure 8-3) is poorer and may not be sufficient to distinguish a 
hybridization pattern specific to outbreak related isolates for this serogroup.      Chapter 8, 158 
 
Figure   8-3 Relationships of MLST sequence types constructed using eBURST version 3
9 of 
all isolates in the MLST database which express serotype 1 capsule.  
Blue dots indicate STs which are founders of clones from which single locus variants are 
demonstrated in black. Yellow dots indicate STs which are subgroup founders. ST306 is a 
founder clone with ST227 a subgroup founder which is a double locus variant of ST306. 
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8.4.3 CGH Results from Serogroup 4 Outbreak 
 
Figure   8-4 Comparison of CGH results for serotype 4 outbreak isolates.  
Genes  are  represented  by  Genespring  GX  7.3.1  consecutively  from  left  to  right  by  a 
coloured line. Yellow indicates that competitive hybridization occurred with both DNA from 
the test isolate and TIGR4 hybridizing. Blue lines indicate that DNA from TIGR4 hybridized 
but  DNA  from  the  test  isolate  did  not.  Grey  lines  indicate  that  either  no  hybridization 
occurred or that the fluorescence intensity of the hybridization that did occur was too low to 
pass the threshold value in Bluefuse for Microarrays 3.5 ©  to be included in the analysis. 
Red  lines  indicate  that  no  DNA  from  TIGR4  hybridized  but  DNA  from  the  test  isolate 
hybridized to probes from the R6 genome. Red arrows indicate the four serogroup 4, ST206 
isolates  which  can  be  easily  distinguished  from  the  ST246,  serogroup  4  isolates  tested 
(Chapter 7) and isolates of other serogroups which have been sequenced at the Wellcome 
Trust Sanger Institute (Chapter 3).      Chapter 8, 160 
 
Serotype 4 ST206 Outbreak 
02-1471  02-1317  02-1358  02-1359 
      SP0059     
SP0076         SP0076  
   SP0113        
SP0114           
SP0115   SP0115   SP0115   SP0115  
SP0116           
   SP0132        
      SP0191     
         SP0304  
SP0431           
      SP0452     
      SP0512     
SP0548           
SP0600           
      SP0683     
SP0815           
   SP0906   SP0906     
   SP0908        
      SP1058     
   SP1579        
      SP1866     
         SP1921  
spr0104   spr0104   spr0104   spr0104  
spr0105   spr0105   spr0105   spr0105  
   spr0107        
spr0112   spr0112   spr0112   spr0112  
spr0113   spr0113   spr0113   spr0113  
spr0114   spr0114   spr0114   spr0114  
spr0115   spr0115   spr0115   spr0115  
spr0116   spr0116   spr0116   spr0116  
spr0117   spr0117   spr0117   spr0117  
spr0118   spr0118   spr0118   spr0118  
spr0119   spr0119   spr0119   spr0119  
spr0587           
         spr0960  
         spr1550  
spr1191           
spr1193           
 
Figure   8-5 Genelists created from CGH analysis of dye swap experiments for serogroup 4, 
ST206 isolates.  
The list of genes from the TIGR4 genome which were identified as not hybridizing to the 
array in one or both isolates is placed at the top of the list and genes from the R6 genome 
which did not hybridize are below these. Where results have been highlighted in colour, 
PCR of the gene was performed using the primers displayed in Appendix 3 used to make 
the PCR probe for that gene on the microarray. Yellow indicates that a PCR product of the 
correct size could be identified by gel electrophoresis. Blue indicates that no PCR product 
was identified. 
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8.4.4 Discussion of CGH Results from the Serogroup 4 Outbreak 
Compared to the results using serogroup 1 isolates, the serogroup 4 ST206 isolates could 
be readily distinguished from other serogroup 4 isolates and those of other serogroups by 
their  hybridization  pattern.  In  addition,  far  fewer  genes  were  identified  as  having 
discrepant hybridization results between the four outbreak isolates.  
This CGH experiment also demonstrated an unforeseen benefit of having more than one 
pneumococcal genome represented on the microarray as the gene complement of the test 
isolates was very similar to that of TIGR4 (ST205) as they are part of the same clonal 
complex  and  are  only  single  locus  variants  of  each  other  as  determined  by  eBURST 
(Figure 8-6). Consequently, the majority of genes showed no differences in hybridization 
between test isolate genomes and the TIGR4 control genome. Differences were however 
apparent between the complement of R6 related genes present in the test isolates.  
 
 
Figure    8-6  e-BURST  version  3.0  representation  of  serogroup  4  related  MLST  clonal 
complexes.  
This identifies the outbreak strain ST206 as a single locus variant of TIGR4 ST205 with both 
lying in the same clonal complex. ST246 lies within a completely different clonal complex. 
Blue dots indicate that an ST is the probable founder of a clonal complex and yellow dots 
indicate a probable subgroup founder.     Chapter 8, 162 
8.5 Discussion 
8.5.1 Possible role for Microarrays in Public Health Outbreak 
Investigations 
The results of both these outbreak investigations suggest that this microarray shows good 
discrimination between pneumococcal isolates of different serogroups and between isolates 
of  different  clonal  complexes  within  a  serogroup  but  it  is  not  sensitive  enough  to 
demonstrate whether outbreak related isolates are identical in terms of genetic content. 
Undoubtedly such a high degree of resolution would give useful insights into how quickly 
pneumococcal genomes mutate and diverge from their “parent” genome in vivo during the 
direct human to human transmission usually implicated in pneumococcal outbreaks.  
However  this  high  degree  of  resolution  would  not  necessarily  be  required  for  the 
microarray to be a useful tool to link pneumococcal isolates cultured from proven cases, 
suspected  cases  and  asymptomatic  carriers  during  an  outbreak  investigation  and 
discriminate whether they form an outbreak related cluster or not. Even so, it does not offer 
any significant advantage over MLST for this purpose and should not be considered a 
replacement  for  MLST  where  such  facilities  exist.  A  further  practical  consideration  to 
address regards a comparison of costs for a microarray based investigation compared to an 
MLST based one. Leaving aside capital costs and labour costs, the cost for a complete 
microarray CGH dye swap experiment is £200 which compares poorly with £30 for MLST 
of an isolate (Mathew Diggle, SMPRL, personal communication). 
8.5.2 Genomic Diversity of Chosen Outbreak Related Strains 
The  CGH  results  for  these  outbreak  isolates  also  further  demonstrate  diversity  within 
pneumococcal genomes. The serogroup 4, ST206 isolate CGH results all demonstrate the 
presence of genes from the region of diversity within the R6 genome between spr0102 and 
spr0119 which was first described by Bruckner et al (Bruckner et al., 2004) and relates to 
arginine biosynthesis although PCR results for these genes suggest many of these to be 
false positive hybridizations and the genes to be absent by PCR. The other five regions of 
diversity in the R6 genome described by Bruckner et al appear to be present by CGH 
hybridization  in  the  serogroup  4,  ST206  genomes.  The  serogroup  1,  ST227  genomes 
appear to contain genes from 5 of the 6 regions of diversity in the R6 genome while having 
greater diversity of genes identifiable in the TIGR4 genome.  
9  Genomic Diversity in a Paediatric Carriage 
Population in the Bolivian Amazon 
9.1 Background 
9.1.1 Reasons for this Study 
In  order  to  investigate  the  genomic  diversity  of  a  defined  carriage  population  of 
pneumococci, it was decided to perform a nasopharyngeal carriage study in a paediatric 
population as access to isolates from existing carriage studies was not possible. Rather than 
re-examine pneumococcal carriage in a population where the serotypes and sequence types 
were  already  well  documented,  an  opportunity  was  available  to  integrate  this  study  of 
pneumococcal carriage into a newly established programme for the prevention of hearing 
impairment in the Beni region of Bolivia where a substantial amount of acquired deafness 
in children is due to the sequelae of acute otitis media or bacterial meningitis (at least 39% 
of deafness in children in Beni, Bolivia results from the sequelae of bacterial meningitis 
(Santana-Hernandez,  2006)).  Both  otitis  media  and  meningitis  commonly  have  a 
pneumococcal aetiology and are potentially preventable using a pneumococcal conjugate 
vaccine as has been the case in Brazil (Brandileone et al., 2003).  Consequently the project 
had  the  dual  aims  of  providing  paediatric  carriage  isolates  of  pneumococci  for  further 
investigations of their genomic diversity and of eliciting some basic epidemiological data 
regarding pneumococcal carriage (in  a region where none existed) with a view to enabling 
more informed planning of strategies to prevent morbidity and mortality associated with 
pneumococcal  disease.    The  mortality  rate  from  pneumococcal  meningitis  is  47%  in 
Salvador, Brazil (Ko et al., 2000), 37% in under five year olds in Guatemala (Asturias et 
al., 2003) and 33% in Paraguayan children (Lovera and Arbo, 2005), a substantial amount 
of which may be preventable by vaccination.   
9.1.2 Association of Pneumococcal Carriage and Acute Otitis 
Media 
Pneumococcal carriage can be as high as 90% in healthy children under the age of three in 
developing countries (Obaro and Adegbola, 2002). Pneumococci account for 35-40% of 
cases of acute otitis media (Echaniz-Aviles, 2001). It is estimated that pneumococcal otitis 
media affects 70% of children at some time and 5-10% of these develop sequelae such as     Chapter 9, 164 
chronic otitis media with effusion, mucosal granulation, mastoiditis, ossicular erosion and 
fixation or cholesteatoma (Echaniz-Aviles, 2001). Commenting on the chronic sequelae of 
acute otitis media in Latin America, Garcia et al make the observation that,  
“Chronic  otitis  and  hearing  loss  are  common  in  developing  countries,  and 
reduction of this morbidity would be an important public health contribution. 
Further research is warranted (Garcia et al., 2006).” 
Identification of pneumococci being carried in the nasopharynx can be used for surrogate 
identification of strains responsible for otitis media without having to resort to tympanic 
aspiration  (Harper,  1999).  The  antimicrobial  susceptibility  patterns  of  nasopharyngeal 
isolates usually reflect the antibiotic susceptibility rates of invasive isolates taken during 
the same time period and usually demonstrate the same serotypes although the rank order 
of serotypes may differ between carriage and invasive disease with a smaller subset of 
serotypes responsible for invasive disease (Kellner et al., 1998). 
It has been determined that nasopharyngeal carriage of pneumococci results in higher rates 
of onset of otitis media than those seen in non carriers (Leach et al., 1994, Faden et al., 
1997). There is some suggestion that there are also racial differences in the incidence of 
pneumococcal otitis media (Klein, 1981).  
Once  established,  acute  otitis  media  can  then  result  in  higher  rates  of  pneumococcal 
nasopharyngeal carriage resulting from impaired local immunity and resulting in a vicious 
cycle of carriage and disease (Garcia-Rodriguez and Martinez, 2002).   
9.1.3 Issues regarding Pneumococcal conjugate vaccination in 
Latin America for the prevention of otitis media and carriage 
It  is  known  that  pneumococcal  conjugate  vaccination  (PCV)  has  many  benefits  and 
included  among  them  are  a  reduction  of  nasopharyngeal  carriage  (O'Brien  and  Dagan, 
2003, Obaro and Adegbola, 2002) (which is not achieved by pneumococcal polysaccharide 
vaccines), promotion of herd immunity (O'Brien and Dagan, 2003, Obaro and Adegbola, 
2002) and a reduction in episodes of pneumococcal and non pneumococcal acute otitis 
media,  reduction  in  cases  of  recurrent  otitis  media  and  in  numbers  of  tympanic  tube 
insertions (Arguedas et al., 2005, Echaniz-Aviles, 2001).  These results although mainly 
observed in developed countries of Europe and North America have been replicated in 
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A working group of the Pan American Health Organisation (PAHO) and the Pneumococcal 
Vaccines Accelerated Development and Introduction Plan (PneumoADIP) of the Global 
Alliance for Vaccines and Immunization (GAVI) has determined that countries in Latin 
America should,  
“strive to introduce the pneumococcal (conjugate) vaccine when it becomes 
affordable (Garcia et al., 2006).”  
Bolivia  is  eligible  for  GAVI  vaccine  fund  support  (Scott,  2007).  The  World  Health 
Organization (WHO) also advocates implementation of pneumococcal conjugate vaccine 
as a priority in developing countries as part of its Global Action Plan for the Prevention 
and Control of Pneumonia (Greenwood, 2008).  As of August 2008, PCV has  not been 
utilised  in  Bolivia  (Anonymous,  2008)  although  their  current  paediatric  vaccination 
schedule  comprises  BCG,  Polio,  components  of  a  pentavalent  vaccine  (Diphtheria, 
Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae B), Measles Mumps and Rubella 
(MMR)  and  Yellow  Fever  (PAHO,  2007).  Vaccine  coverage  is  around  84%  (PAHO, 
2007).  
However, due to the serotype constitution of the 7 valent pneumococcal conjugate vaccine 
(PCV-7) coverage of the serotypes causing  IPD is less in Latin America than in other 
regions of the world (Hausdorff et al., 2000a). This poorer PCV-7 coverage demonstrates a 
further need to elucidate regional pneumococcal epidemiology, particularly in developing 
countries (Camargos et al., 2006).  The success of PCV-7 in Africa and the USA,  
“poses a challenge to public health physicians throughout the world to quantify 
the burden of pneumococcal disease in their region and estimate the potential 
benefits of PCV use (Scott, 2007).”  
9.1.4 Pneumococcal surveillance in Latin America 
Surveillance  of  IPD  has  been  performed  in  Latin  America  through  a  co-ordinated 
programme  of  the  PAHO  Special  Program  for  Vaccines  and  Immunization  (SVI)  and 
Regional System for Vaccines (SIREVA) which was initiated in 1993 (Di Fabio et al., 
1997). Isolates from blood, cerebrospinal, pleural, peritoneal or synovial fluid from cases 
aged less than 5 years with a diagnosis of pneumococcal meningitis, bacteraemia without a 
focus, septic arthritis, peritonitis or the WHO clinical criteria for pneumonia are reportable 
(Di Fabio et al., 1997) although it is recognised that IPD is frequently under-reported in 
young children even in developed countries (Hausdorff et al., 2000a). Initially limited to 
Argentina, Brazil, Chile, Colombia, Mexico and Uruguay, the surveillance was extended in     Chapter 9, 166 
1998 to several other countries in the region including Bolivia (Garcia et al., 2006) with 
laboratory  support  from  an  international  external  quality  assurance  program  from  the 
National Centre for Streptococcus in Edmonton, Canada (Lovgren et al., 2007).   
The  results  of  this  surveillance  demonstrate  that  the  serotype  distribution  causing  IPD 
appears to have been stable since 1993, albeit with minor regional differences (Garcia et 
al., 2006) but that antibiotic resistance is increasing (Di Fabio et al., 1997, Garcia et al., 
2006, Kertesz et al., 1998, Di Fabio et al., 2001). Molecular typing is not currently a 
feature of this surveillance although some smaller scale molecular typing studies have been 
performed in a handful of countries particularly regarding penicillin resistant pneumococci 
(Tomasz et al., 1998).  The common serotypes causing IPD in Latin America are serotypes 
14, 6A, 6B, 5, 1, 23F, 19F, 18C, 19A, 9V, 7F, 3, 9N and 4 (Di Fabio et al., 2001). Little is 
known about pneumococcal carriage in the region. 
9.1.5 Location of Study 
Bolivia is the poorest country in Latin America (Santana-Hernandez, 2006) and 64% of the 
population do not have sufficient income to cover basic needs (PAHO, 2007). The highest 
percentage of deaths from pneumonia (15-20%)  in the under five age group in the whole 
of Latin America (Fuchs et al., 2005) is found in Bolivia. Bolivian children also have the 
highest probability of dying before age five in the whole of Latin America (Fuchs et al., 
2005). They also have the highest infant mortality rate of around 54 per 1000 live births 
(Fuchs et al., 2005, PAHO, 2007) and Bolivia has the highest maternal mortality in Latin 
America at 230 per 100,000 live births (Santana-Hernandez, 2006, PAHO, 2007). Beni 
region lies in the Eastern lowlands of Bolivia and is home to a dispersed population of 
around 407,000 people of which around 90,000 live in Trinidad, the provincial capital 
(Santana-Hernandez, 2006). Bordering the Beni region to the West lies the Tropical Andes 
region which is the greatest region of biodiversity in the world
10 with many unique species 
of animals and plants, although it is not known how this affects the diversity of prokaryotic 
life in the region.   
                                                 
10 http://www.biodiversityhotspots.org/xp/hotspots/andes/Pages/default.aspx {accessed 11th 
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Figure   9-1 Map of Bolivia.
11 
This demonstrates the locations of Trinidad and Beni within the Beni Region (red arrows).   
 
In February 2007, the Beni region of Bolivia experienced the worst flooding in 25 years 
with extensive displacement of the population of Trinidad many of whom were temporarily 
housed in refugee camps until flood waters abated. Swabbing for this study began in May 
2007 soon after these camps had been closed as people had been able to return home and 
children returned to school.  
9.2 Materials and Methods 
The project involved collaboration between Fundacion Totai (a health charity in Trinidad, 
Bolivia), Laboratorios Altstadt (a private clinical laboratory, Trinidad, Bolivia), SMPRL at 
Stobhill General Hospital, Glasgow, United Kingdom and the Faculty of Biological and 
Life Sciences, University of Glasgow, Glasgow, United Kingdom. 
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9.2.1 Specimen Collection, Storage and Transportation 
The design of this carriage study was constructed in accordance with the standard method 
of the WHO working group (O'Brien and Nohynek, 2003) and an earlier method devised 
for  a  Latin  American  context
12.  Dacron  polyester  tipped  swabs  (Medical  Wire  and 
Equipment, UK) were couriered from the United Kingdom for nasopharyngeal swabbing 
as was Skim Milk Tryptone Glucose Glycerin (STGG) broth media (O'Brien et al., 2001) 
which had been manufactured, sterilized and quality controlled as 1ml aliquots at SMPRL 
in cryotubes (Sarstedt AG & Co., Germany) to use as a short term transport and storage 
media at -20°C.  
Microbiological media is not readily available in Bolivia so 5% horse blood agar (E & O 
Media Services Limited, United Kingdom) was couriered from the United Kingdom as 
were  optochin  discs  (Oxoid,  United  Kingdom)  and  Transwabs  (TSCswabs,  United 
Kingdom). The use of 5% horse blood rather than blood agar with gentamicin (Converse 
and  Dillon,  1977),  colistin-nalidixic  acid  or  colistin-oxolinic  acid  was  a  necessary 
deviation from the published standard method (O'Brien and Nohynek, 2003).  
Nasopharyngeal  swabs  were  taken  by  an  experienced  otolaryngologist  (Dr  Santana-
Hernandez).  If  nasopharyngeal  swabbing  was  not  tolerated  or  not  possible  in  younger 
children, oropharyngeal swabs were performed. The tips of the Dacron polyester swabs 
were then cut off and stored in STGG and either plated onto 5% horse blood agar on the 
same day or stored at -20°C until they could be cultured. After plating out and culturing the 
naso- or oropharyngeal secretions, alpha haemolytic colonies were subcultured onto 5% 
horse  blood  agar  for  optochin  sensitivity  testing.  Optochin  sensitive  alpha  haemolytic 
organisms  were  presumed  to  be  pneumococci.  Incubation  was  performed  at  37°C  in  a 
carbon dioxide enriched atmosphere using candle jars at Laboratorios Altstadt, Trinidad, 
Bolivia.  
Pure cultures of presumed pneumococci were stored at room temperature on Transwabs 
(TSCswabs, United Kingdom) until ready for transportation abroad. At this point they were 
subcultured  onto  5%  horse  blood  agar  to  obtain  fresh  pure  cultures  which  were  then 
inoculated onto new Transwabs for international transportation by air (Inverarity et al., 
2007).  
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Facilities for serotyping in Latin America are sparse (Camargos et al., 2006). Although 
serotyping  and  antimicrobial  susceptibility  testing  is  possible  in  La  Paz  at  Laboratorio 
Nacional  de  Referencia  en  Bacteriologia  Clinica,  MLST  is  not  possible  in  Bolivia. 
Arranging international transportation of the pure isolates was fraught with difficulties. 
Transportation was eventually co-ordinated by a cargo and logistics company Inbolpack 
S.R.L., Bolivia to the Reference Laboratory for Meningococci, Madrid, Spain who kindly 
then  redirected  the  isolates  from  Spain  to  SMPRL  using  the  courier  company  Fedex. 
Transportation of isolates from Trinidad, Bolivia to Glasgow, United Kingdom took 42 
days on Transwabs under conditions which were not environmentally controlled. 
Blood agar with neomycin (Oxoid, United Kingdom) was used at SMPRL to resuscitate 
pneumococci by culturing isolates received on Transwabs for 48 hours under anaerobic 
conditions.  Isolates  which  had  survived  transportation  were  further  subcultured  on  5% 
horse blood agar and stored at -80° on Protect beads (TSC Ltd, United Kingdom).  
9.2.2 Epidemiological Data Collection and Analysis 
In May and June 2007, 601 children were assessed as part of the Programa De Prevencion 
Del  Deficit  Auditivo  En  Beni  and  had  nasopharyngeal  or  oropharyngeal  swabs  taken 
during this process after informed consent from a parent or guardian. This was performed 
at nine educational institutions (six in Trinidad, Beni and three in Riberalta, Beni). Basic 
epidemiological data was also collected regarding the child’s age, gender, location, number 
of people living in their house (particularly other inhabitants under two years of age or 
aged two to five), whether they lived with a person who smoked and whether they had 
received penicillin in the previous 30 days. 
Statistical  analysis  of  epidemiological  data  was  performed  by  Mr  Paul  Johnson  at  the 
Robertson  Centre  for  Biostatistics,  University  of  Glasgow  using  R  version  2.6.0  for 
Windows. 
9.2.3 Ethical Considerations 
Ethical approval for this study was received in the United Kingdom via the NHS Research 
Ethics  Committee  approval  process  (REC  Ref  06/S0704/6)  from  the  North  Glasgow 
University Hospitals NHS Division East Office Research Ethics Committee and in Bolivia 
from the Colegio Medico De Bolivia Filial Beni.      Chapter 9, 170 
9.3 Results 
9.3.1 Epidemiological Data 
202  carriers  of  optochin  sensitive,  alpha  haemolytic  organisms  were  identified 
demonstrating a  carriage rate of 34%. Characteristics of the carriers compared to non-
carriers were investigated by Mr Paul Johnson, Robertson Centre for Statistics, University 
of Glasgow using Odds Ratios of carriage and univariate and multivariate models. These 
results are displayed below in Table 9-1.  
Carrier status, N (%)  Odds ratio (95% CI) 
Characteristics     Negative 
(N=399) 
Positive 
(N=202) 
   Univariate 
models 
Multivariate 
model 
Age in Trinidad 
(N=493) 
0-5 
6+ 
38 (64.4%) 
275 (63.4%) 
21 (35.6%) 
159 (36.6%)     1.0 
0.6 (0.3, 1.1) 
1.0 
0.7 (0.4, 1.3) 
Age in Riberalta 
(N=107) 
0-5 
6+ 
26 (96.3%) 
59 (73.8%) 
1 (3.7%) 
21 (26.2%)     1.0 
9.3 (1.2, 72.5) 
1.0 
9.4 (1.2, 76.9) 
Gender  Female 
Male 
182 (73.4%) 
217 (61.5%) 
66 (26.6%) 
136 (38.5%)     1.0 
1.7 (1.1, 2.4) 
1.0 
1.6 (1.1, 2.4) 
Household size  2-5 
6-9 
10+ 
95 (66.9%) 
165 (65.0%) 
93 (62.8%) 
47 (33.1%) 
89 (35.0%) 
55 (37.2%) 
  
1.0 
1.1 (0.7, 1.8) 
1.0 (0.6, 1.7) 
  
Children aged 2-5 
at home 
Yes 
No 
154 (62.1%) 
205 (68.1%) 
94 (37.9%) 
96 (31.9%)     1.0 
0.8 (0.6, 1.1)    
Children aged < 2 
at home 
Yes 
No 
130 (64.4%) 
229 (66.0%) 
72 (35.6%) 
118 (34.0%)     1.0 
1.1 (0.7, 1.5)    
Live with a 
smoker 
Yes 
No 
163 (65.2%) 
195 (65.9%) 
87 (34.8%) 
101 (34.1%)     1.0 
1.0 (0.7, 1.4)    
Residence  Riberalta 
Trinidad 
85 (79.4%) 
313 (63.5%) 
22 (20.6%) 
180 (36.5%)     1.0 
1.9 (0.8, 4.5) 
 1.0 
15.2 (1.6, 146.3) 
Table   9-1 Odds ratios for pneumococcal carriage risk factors estimated from univariate and 
multivariate models.  
In both univariate and multivariate models the clustering of samples within schools was 
accounted for by fitting a mixed effects logistic regression model with random intercepts. 
The multivariate model  was selected by backwards deletion of fixed effects that did not 
significantly improve the model based on a likelihood ratio test. The final model contained 
fixed effects of age, gender and residence and an interaction between age and residence. 
Odds ratios are expressed with 95% confidence intervals in brackets. 
 
9.3.2 Antibiotic Resistance 
Of the 202 isolates identified as optochin sensitive and alpha haemolytic in Bolivia, only 
54 were viable when they arrived in Glasgow after delays in transit ex vivo in sub-optimal     Chapter 9, 171 
conditions. Of these 54 isolates, very little antimicrobial resistance was detected as shown 
in Table 9-2 below. Further details regarding these isolates are displayed in Appendix 2. 
Antimicrobial 
Agent 
Number of Fully 
Sensitive 
Isolates 
Number of 
Intermediately 
Sensitive 
Isolates 
Number of 
Resistant 
Isolates 
% Sensitivity 
Penicillin  50  4  0  92% 
Erythromycin  53  1  0  98% 
Vancomycin  54  0  0  100% 
Chloramphenicol  54  0  0  100% 
Tetracycline  52  0  2  96% 
Cotrimoxazole  46  8  0  85% 
 
Table   9-2 Antibiotic sensitivity for the 54 optochin sensitive Bolivian isolates.  
 
Of  the  4  isolates  with  intermediate  sensitivity  to  penicillin  which  were  found,  2  were 
serotype  17F  (ST2973  and  ST3267),  1  was  serotype  24F  (ST  3770)  and  1  was  non-
typeable.  The  non  typeable  isolate  also  had  intermediate  sensitivity  to  erythromycin, 
cotrimoxazole and was resistant to tetracycline. The MLST of this non-typeable isolate 
also proved to be atypical with only one known allele being identifiable. The optochin 
sensitivity of the isolate was subsequently reviewed and found to be smaller (18mm) when 
grown in a carbon dioxide enriched atmosphere compared to air (25mm) leading to the 
conclusion that this isolate taxonomically was a Streptococcus pseudopneumoniae rather 
than a pneumococcus according to the definition suggested by Keith and Murdoch (Keith 
and Murdoch, 2008).  
The  highest  rate  of  antibiotic  non-susceptibility  was  to  cotrimoxazole  which  showed 
intermediate  sensitivity  in  8  isolates  (serotypes  23A  (ST2974),  24F  (ST3770),  34 
(ST1902), 4 (ST332), 6B (ST4015) 16F (ST3771), 16A (ST4016).  
9.3.3 Serotyping of Bolivian Isolates 
The results of serotyping the 53 surviving pneumococcal isolates are illustrated as a pie 
chart in Figure 9-2 below.     Chapter 9, 172 
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Figure   9-2 Serotype distribution of 53 Bolivian pneumococcal carriage isolates. 
 
9.3.4 MLST of Bolivian Isolates 
The majority of the pneumococcal isolates recovered had new, unique  MLST profiles. 
Details of the MLST profiles for the 32 newly discovered sequence types in Bolivia are 
displayed in Table 9-3. 
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Number 
of 
isolates 
Sequence 
Type  aroe  gdh  gki  recP  spi  xpt  ddl 
1  2973  13  5  4  1  8  14  7 
3  2974  1  8  2  9  6  4  6 
1  2975  2  5  4  1  6  1  1 
1  2976  16  5  9  8  8  14  7 
1  3267  7  5  4  1  6  25  7 
1  3429  7  5  62  5  6  4  14 
1  3430  12  5  5  5  6  3  5 
1  3431  12  5  87  1  6  1  8 
1  3432  7  17  4  16  6  7  17 
1  3509  8  5  1  5  8  14  7 
1  3534  2  16  89  1  10  79  28 
1  3535  16  10  4  32  6  14  6 
1  3536  7  13  4  6  3  6  8 
1  3537  15  17  4  16  6  26  8 
1  3538  7  25  4  5  15  20  18 
1  3539  7  5  62  16  6  79  14 
1  3540  1  5  5  5  6  3  5 
1  3767  5  5  1  5  8  6  7 
1  3768  15  5  5  5  1  1  14 
1  3769  1  5  4  18  32  48  8 
2  3770  7  5  8  6  6  37  8 
1  3771  15  5  9  5  6  3  6 
1  3852  16  10  4  1  6  14  5 
1  3853  1  10  4  5  15  20  18 
1  3854  2  16  4  1  10  79  28 
1  3855  25  17  4  16  6  96  17 
1  3856  7  5  4  5  6  37  1 
1  3857  12  5  2  16  6  37  1 
1  3858  21  33  62  1  10  28  15 
2  4015  7  47  1  2  51  1  14 
1  4016  7  47  1  2  51  7  14 
Table    9-3  MLST  profiles  for  the  newly  discovered  sequence  types  currently  unique  to 
carriage isolates from Bolivia.  
 
Of the sequence types which were already defined and identifiable on the pneumococcal 
MLST database, the previously documented serotype and geographical associations are 
entered in Table 9-4.  
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MLST 
Associated 
Serotype(s)  Associated Locations 
Disease 
Phenotype 
923  13  The Gambia  Not known 
180  3 
Begium, Brazil, Canada, Denmark, Germany, Italy, 
Poland, Portugal, South Korea, Spain, Sweden, 
Taiwan, The Netherlands, UK, USA. 
Carriage 
and 
Invasive 
191  7F 
Brazil, Denmark, Italy, Finland, Germany, Hungary, 
Norway, Poland, Sweden, Switzerland, The 
Netherlands, UK, Uruguay, 
Carriage 
and 
Invasive 
239  6, 9V, 20  Hungary, Poland, UK  Invasive 
280  9V  Brazil, Vietnam 
Carriage 
and 
Invasive 
332  20  Norway  Invasive 
387  23F  Brazil, Vietnam  Invasive 
404  8  Brazil, Italy, Poland, UK 
Carriage 
and 
Invasive 
776  23F  Argentina  Invasive 
1150  6A  France, Portugal 
Carriage 
and 
Invasive 
1902  34  USA  Not known 
1989  3  Germany  Invasive 
2440  6A  UK  Invasive 
2880  19A  Brazil  Invasive 
Table   9-4 Serotype and geographical associations of sequence types identified in Bolivia, 
which have also been identified in other regions
13. 
 
9.4 Discussion 
It has been said that molecular epidemiological studies of pneumococcal populations in 
Latin America are few due to the high costs and logistical difficulties encountered in the 
region (Tomasz et al., 1998, Castanheira et al., 2003). This has also been the conclusion of 
those involved in this study. The unpredictable infrastructure which resulted in prolonged 
delays of these specimens in transit has undoubtedly influenced these results since about 
75% of isolates did not survive international transportation. Nevertheless although this has 
introduced  a  selection  bias  into  our  sample,  this  does  not  appear  to  have  limited  the 
observed extent of genomic and phenotypic diversity which may actually now be under-
represented in this remaining collection of isolates. This introduction of bias should be 
considered when interpreting these results. It is also worth considering that these results 
from children may not necessarily be extrapolated to an adult population (Borer et al., 
2001). 
                                                 
13 http://spneumoniae.mlst.net/ {accessed 9
th December 2008} 
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9.4.1 Epidemiological Data 
It is well known that pneumococcal carriage is highest in the under two age group. In 
Papua New Guinea, carriage rates as high as 60% have been observed in neonates with 
carriage of the same serotype ranging from 5 to 290 days (Gratten et al., 1986). In Latin 
America, pneumococcal carriage in pre-school children can also reach 60%, falling to 35% 
in primary school age children and reaching 25% in high school aged children (Echaniz-
Aviles, 2001). The majority of the children who were swabbed fall into the primary school 
age category and so our finding of a carriage rate of 34% is entirely compatible with this 
previous observation. Although we did not swab adults, it is recognised that pneumococcal 
carriage in adults without young children is only around 6% whereas the carriage rate in 
adults with young children is as high as 18-30% (Echaniz-Aviles, 2001). It has also been 
postulated that pneumococcal transmission tends to be between young siblings and peers 
rather than from adults to children (Lloyd-Evans et al., 1996). It is difficult to account for 
the higher odds of carriage among boys identified by this study although it may relate to 
different behaviour or standards of personal hygiene. 
In a study of pneumococcal carriage in a Brazilian urban slum, Reis et al recently found no 
association  between  the  number  of  household  members  (used  as  an  indicator  of 
overcrowding) and pneumococcal carriage. This was a surprise finding as overcrowding 
has been considered to be a risk factor for pneumococcal carriage. This study in Trinidad 
and  Riberalta  also  found  no  association  between  number  of  household  members  and 
pneumococcal  carriage,  despite  some  very  densely  populated  dwellings  (some  children 
living with up to 30 people) resulting from population displacement from flooding. It is 
possible  that  overcrowding  aids  transmission  when  carriage  rates  are  low  and  that  a 
threshold may be reached over which it is less of an influence because the density of 
pneumococcal carriage is already high. However, Reis et al did identify school attendance 
as  an  independent  risk  factor  for  pneumococcal  carriage  (Reis  et  al.,  2008).  All  the 
children which we swabbed attended school or kindergarten which might be influencing 
the carriage rate seen in this study. It has not been possible to adequately account for the 
higher  odds  of  carriage  in  older  children  from  Riberalta  and  this  requires  further 
consideration. 
9.4.2 Implications for Otitis Media 
Serotypes 1, 3, 5, 12F, 19A and 19F are associated with otitis media (Shouval et al., 2006). 
These  serotypes  are  also  frequently  responsible  for  IPD  in  Latin  America  and     Chapter 9, 176 
unsurprisingly some of these featured in the nasopharyngeal isolates of this study.  It is 
also  unsurprising,  that  given  this  combination  of  factors,  otitis  media  is  a  significant 
manifestation  of  pneumococcal  disease  in  Beni.  Two  of  the  children  who  carried 
pneumococci  and whose isolates survived transportation had ear infections.  Isolate 07-
2827  (serotype  13,  ST923)  was  associated  with  acute  otitis  media.  Isolate  07-2839 
(serotype 9A, ST239) was associated with chronic otitis media (see Chapter 4). 
It has been proposed that early age of infection and multiplicity of bacterial types may 
contribute to prolonged bacterial carriage and to Eustachian tube damage resulting in otitis 
media (Leach et al., 1994, Faden et al., 1997). The results of this study in Bolivia are 
consistent with this proposition. 
Although PCV-7 prevents otitis media due to vaccine included serotypes, there is evidence 
that there is poorer activity against serotype 19F which can persist in middle ear fluid 
(Regelmann, 2005). That observation and the finding of serotype 19F in this collection of 
carriage isolates suggests PCV-7 may not prove very effective in preventing otitis media in 
Beni. 
9.4.3 Antibiotic Resistance 
One striking observation regarding this Bolivian pneumococcal strain collection is the low 
level of antimicrobial non-susceptibility. It is possible that this has resulted from a survival 
advantage with antimicrobial susceptible pneumococci able to survive for longer ex vivo, 
although  such  a  phenomenon  has  not  previously  been  described.  Another  plausible 
explanation  may  relate  to  the  relative  geographical  inaccessibility  of  Trinidad  and 
Riberalta compared to other Bolivian towns as it is only in the last decade that Trinidad has 
had a main road connecting it to larger cities while Riberalta remains accessible mainly by 
the air. These may be barriers to substantial mixing of pneumococcal populations, which 
may  so  far  have  prevented  the  introduction  of  antimicrobial  resistant  clones  of 
pneumococci. 
There  is  some  published  data  relating  to  antimicrobial  resistance  among  pneumococci 
causing invasive disease in Bolivia. From 2000-2003 from surveillance of a small sample 
of IPD isolates (n=45) penicillin resistance was as high as 31%, erythromycin resistance 
was 13%,  chloramphenicol resistance was 13% and cotrimoxazole resistance was 22% 
(Anonymous, 2004). This is compatible with surveillance of IPD isolates from other Latin 
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21.1% in Mexico (Camargos et al., 2006).  In Peru it has been seen that the penicillin 
resistance  rate  is  higher  (42.9%)  in  IPD  isolates  than  pneumococcal  carriage  isolates 
(15.1%) (Cullotta et al., 2002) so this could explain the difference in antimicrobial non-
susceptibility demonstrable in our carriage isolates compared to higher  rates from  IPD 
isolates assessed as part of national surveillance. 
Regional differences within countries affecting antimicrobial non-susceptibility rates are 
well recognised and have been observed in Brazil (Reis et al., 2008) and Chile (Inostroza 
et al., 1998). This may also be a factor influencing our results. Bolivia is a country of vast 
contrasts.  The  capital,  La  Paz,  where  the  national  clinical  microbiology  reference 
laboratory  is  located  is  on  the  Andean  Highland  Plateau  while  Beni  is  in  the  lowland 
Amazonian  basin.  These  contrasting  geographical  locations  are  mirrored  by  climatic 
differences and ethnic differences in the human population all of which may be influencing 
the  pneumococcal  population  structure.      In  Vietnam  for  instance,  higher  levels  of 
penicillin resistance in pneumococci are associated with living in urban rather than rural 
settings (Quagliarello et al., 2003, Parry et al., 2000) which may be the case in Bolivia as 
Trinidad and Riberalta which are not large towns. (The population of Trinidad is around 
90,000 unlike the capital city, La Paz, with a population of around 1,600,000.) 
In this collection of strains from Bolivia, the antimicrobial with the highest rates of non-
susceptibility  was  cotrimoxazole.  This  has  been  observed  in  other  Latin  American 
countries (Reis et al., 2008, Tomasz et al., 1998). Interestingly, serotype 6B is associated 
with cotrimoxazole resistance in Brazil (Brandileone et al., 1998), Colombia (Vela et al., 
2001, Castaneda et al., 1998) and Mexico (Echaniz-Aviles et al., 1998) but of the eight 
cotrimoxazole non-susceptible isolates in this Bolivian collection, only one was serotype 
6B. 
Our results are comparable with the situation in other Latin American countries in the 
1980s  and  early  1990s.  When  pneumococcal  carriage  isolates  were  investigated  in 
Uruguay in the 1980s, intermediate resistance to penicillin was seldom observed but 37.2% 
were resistant to cotrimioxazole (Mogdasy et al., 1992). Again cotrimoxazole resistance in 
carriage isolates  in Colombian children from 1993-94 was 40% but little erythromycin or 
chloramphenicol  resistance  was  detectable  (Leal  and  Castaneda,  1997).  In  Brazil  from 
1988-92, resistance to cotrimoxazole affected 30% of isolates but had been only 1% pre 
1988 (Sessegolo et al., 1994). Cotrimoxazole resistance remained high in Brazil during the 
1990s (Rey et al., 2002a, Rey et al., 2002b, Mendonca-Souza et al., 2004) and is also high 
in Peru at 56.9% (Cullotta et al., 2002). It is possible that socioeconomic factors in Beni,     Chapter 9, 178 
poor  access  to  antimicrobials,  antimicrobial  prescribing  practices  or  geographical 
inaccessibility until the late 1990s have resulted in a pneumococcal population which more 
readily  mirrors  that  of  other  Latin  American  countries  twenty  years  ago  rather  than 
currently.  
We observed a low rate of penicillin non-susceptibility. It is noteworthy that surveillance 
in  the  Brazilian  provinces  that  neighbour  Beni  demonstrates  higher  rates  of  penicillin 
nonsusceptibility.  In  North  Brazil  from  1993-96  pneumococcal  penicillin  non-
susceptibility was 15.8%, in Central West Brazil it was 16.9% and in South Brazil it was 
9.5% (Brandileone et al., 1998). Much penicillin non-susceptibility in Latin America is due 
now to a serotype 14 which has been seen in Argentina (Rossi et al., 1998, Albarracin Orio 
et al., 2008), Uruguay (Coffey et al., 1999) and Colombia (Vela et al., 2001). We however 
did not see penicillin non-susceptibility affecting serotype 14 pneumococci. 
In  this  study,  macrolide  resistance  was  rare  and  this  has  often  been  the  case  for 
pneumococci in  Latin America (Tomasz et al., 1998). Erythromycin resistance in non-
typeable  isolates  has  been  seen  in  Brazil  where  it  was  due  to  the  MLSB  phenotype 
(Mendonca-Souza et al., 2004). 
Levels of pneumococcal penicillin resistance in Latin America are increasing (Camargos et 
al., 2006). Four PMEN clones have accounted for much of this resistance – Spain 
23F-1, 
Spain 
6B-2, Spain 
9V-3 and Czech Republic 
14-10 (Camargos et al., 2006, Wolf et al., 2000, 
Castanheira et al., 2003, Vela et al., 2001). Recently the England 
14-9 clone has resulted in 
clonal expansion of macrolide resistance in Brazil (Mendonca-Souza et al., 2004) along 
with  the  clones  Taiwan
23F-15  and  Colombia
5-19  in  Colombia  (Tamayo  et  al.,  1999, 
Gamboa et al., 2002), Mexico (Echaniz-Aviles et al., 2008, Gamboa et al., 2002) , Brazil 
and Guatemala (Gamboa et al., 2002). 
It has been proposed that there is an apparent inverse relationship between the level of 
penicillin resistance and genetic diversity in Latin American pneumococci (Tomasz et al., 
1998).  As  penicillin  resistance  becomes  more  prevalent  it  is  usually  due  to  particular 
clones which begin to dominate the pneumococcal population, reducing its diversity. Our 
results are compatible with this as, being at a stage where no antimicrobial resistant clones 
appear to be found in the pneumococcal population in Beni, there is substantial genomic 
and phenotypic diversity. However, Beni is an exception when compared to other Latin 
American regions and it is likely that clonal expansion of antimicrobial non-susceptible 
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9.4.4 New MLST Profiles 
Of  the  countries  in  Latin  America  which  have  been  able  to  perform  MLST  on 
pneumococcal  isolates,  it  is  not  uncommon  to  find  several  sequence  types  which  are 
unique  to  an  individual  country.  A  search  of  the  S.  pneumoniae  MLST  database 
demonstrates that currently Argentina has identified 21 unique sequence types, Chile has 2 
unique  sequence  types,  Columbia  has  12  unique  sequence  types  and  Uruguay  has  18 
unique  sequence  types.  Nevertheless,  given  that  there  were  3768  known  individual 
sequence types in October 2008, the proportion of previously undescribed sequence types 
to known sequence types in the study of this relatively small collection of pneumococcal 
isolates is staggering, albeit not unique.  Reis et al, 2008 found 11 novel sequence types in 
carriage isolates from a Brazilian slum (Reis et al., 2008) and  Zemlickova et al, found that 
35 of 60 sequence types from IPD isolates from various Latin American countries had new 
MLST profiles (Zemlickova et al., 2005). Four of these accounted for 40% of the isolates 
showing significant geographical spread of particular clones within Latin America which 
were not seen in other regions of the world (Zemlickova et al., 2005). 
It has been noted before that individual housekeeping genes are about ten times more likely 
to evolve by recombination than by mutation (Feil et al., 2000b).  In keeping with this, 
most of the new sequence types identified in this study were new combinations of existing 
genes while the number of previously unidentified genes were substantially fewer. 
The new sequence types which are identified in this study add to the understanding of 
pneumococcal population dynamics. ST 3540 is newly identified as a subgroup founder in 
a clonal complex where ST2883 is the existing founder. ST3430 and ST3540 are single 
locus variants of each other and ST776 is a double locus variant of ST3540. Consequently 
these three Bolivian associated sequence types (ST776, ST3430 and ST3540) all appear as 
part of the same serotype 23F associated clonal complex while ST2974 does not (Figure 9-
3). 
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Figure   9-3 New Sequence Types associated with serotype 23F which provide new insight 
into their relationship within a clonal complex.  
New sequence types discovered in this study are indicated by red arrows. 
 
The association of ST3770 (serotypes 7C and 24F) and ST2974 (serotypes 23A, 23F and 
38) each with multiple capsular types suggests that they are readily influenced by capsular 
switching even although there is no vaccine pressure to promote this.    
Without virulence studies of these isolates in animal models or MLST surveillance of IPD 
isolates in Bolivia, it is unknown what the disease causing potential of these new sequence 
types may be. It is also feasible to propose that since there is such a degree of previously 
undescribed variation in the relatively stable housekeeping genes utilised in the MLST 
scheme that there will be even greater diversity in hypervariable genes in these isolates 
which merits further investigation.  
9.4.5 New Insights into Existing Clonal Complexes 
Where  pre-existing  sequence  types  could  be  identified  in  this  Bolivian  pneumococcal 
strain collection, some further insights into the existing pneumococcal clonal complexes is 
possible although the relative absence of MLST data from Latin America can be limiting.     Chapter 9, 181 
Zemlickova et al, performed MLST on 185  IPD isolates from preschoolers in 5  Latin 
American countries (Zemlickova et al., 2005). Their study focussed on serotypes 1, 3, 5, 
6B, 7F, 14 and 23F. The greatest genetic diversity was identifiable in serotypes 6B, 14 and 
23F. In our series serotype 23F is very diverse with several different STs represented as 
has been shown in  Figure 9-3 above. The  association of ST776 with serotype 23F by 
Zemlickov et al was also seen in one of the Bolivian isolates (Zemlickova et al., 2005).  
Zemlickova et al also identified ST191 as a common Latin American sequence type found 
in  all  5  countries  assessed  which  was  associated  with  serotype  7F  (Zemlickova  et  al., 
2005). This association was also seen with the finding of a serotype 7F, ST191 isolate in 
the  Bolivian  strain  collection.  ST191  was  also  identifiable  in  Argentina  in  a  penicillin 
susceptible non typeable isolate (Albarracin Orio et al., 2008). 
ST1902 is relatively commonly seen in the Bolivian strain collection and although mainly 
associated with serotype 34, one isolate was of serotype 38. ST239 is a new association 
with serotype 9A seen in this study. 
A  further  MLST  study  of  pneumococcal  carriage  isolates  was  recently  published  from 
Brazil. However, none of the carriage sequence types seen in the slums of Salvador in 
Brazil apart from ST180 (Reis et al., 2008) are seen in Beni despite many of the same 
serotypes being seen. As reviewed in Chapter 1 and investigated further in Chapters 6 and 
10,  ST180  is  a  relatively  common  sequence  type  seen  internationally  associated  with 
serotype 3 in studies of both carriage and invasive pneumocoocal isolates and so it is not a 
surprise to find it also in Bolivia. 
What  was  surprising  was  to  find  ST180  existing  concurrently  with  ST1989  in  the 
nasopharynx of the same child while both genotypes expressed the same phenotype as 
serotype 3 mucoid isolates and were thereby indistinguishable by any method other than 
molecular typing. Multiple sequence types within a serotype at the same point in time have 
not  been  described  before  in  the  same  individual.  Carriage  of  dual  or  triple  serotypes 
concurrently has been documented before (Gratten et al., 1989, Charalambous et al., 2008, 
Sa-Leao et al., 2002) but molecular analysis demonstrated homogeneous patterns of the 
same genotype within each serotype (Sa-Leao et al., 2002). Likewise, carriage of multiple 
sequence types at the same time has been demonstrated but it has not been clear if these 
isolates were from the same serotype (Oriyo et al., 2006). Serotype switching of a single 
nasopharyngeal carriage associated RFEL type has also been demonstrated over time in an 
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a single individual (Sluijter et al., 1998). Demonstrating this phenomenon again with other 
serotypes may be possible if multiple colony picks were used for MLST – although this 
would significantly increase the cost of such molecular epidemiological studies. However, 
it  has  been  recently  argued  that  single  colony  picks  are  currently  acceptable  for  such 
studies (Charalambous et al., 2008). Demonstrating co-existent sequence types within the 
same clonal complex of the same serotype within an individual from a serotype known to 
readily cause biofilms, greatly adds to our understanding of how conditions occur in vivo 
in the human host to promote genetic exchange. 
From  our  experience  with  typing  this  small  strain  collection  from  Bolivia  though,  we 
would  strongly  urge  caution  in  extrapolating  associations  of  clonal  complexes  with 
invasion  or  carriage  phenotypes  calculated  from  very  different  pneumococcal  and  host 
populations (Brueggemann et al., 2003) into geographical regions where both serotype 
distribution and MLST composition of the pneumococcal population are very different. 
9.4.6 Common Serotypes and STs which comprise them 
The  serotypes  which  occurred  most  frequently  in  this  Bolivian  strain  collection  were 
serotypes 6A, 9A, 34, 23F, 10A, 19A and 38. Often these were associated with novel 
sequence  types.  By  using  eBURST  software  and  the  existing  pneumococcal  MLST 
database it is possible to see whether these new sequence types add to understanding of 
pneumococcal clonal complexes. This was the case with serotype 23F as seen in Figure 9-
3. However, for the other common serotypes the Bolivian sequence types associated with 
them did not link to any of the currently known clonal complexes known to be associated 
with such serotypes. This is illustrated below for serotype 38.     Chapter 9, 183 
   
Figure   9-4 e-BURST version 3
14 diagram of serotype 38 pneumococci.  
New sequence types from Bolivia are highlighted by red arrows but these do not feature as 
being closely related to any known clonal complexes.  
 
9.4.7 Serotype Distributions in Latin America and Bolivia 
The coverage of pneumococcal serotypes included in vaccines is usually assessed using 
data from surveillance of isolates obtained from cases of invasive disease as these are of 
greater immediate risk to health than the more diverse carriage isolates. However, carriage 
isolates  provide  a  greater  pool  to  allow  capsular  switching  to  occur  and  serotype 
replacement  of  vaccine  escape  serotypes  to  become  more  prevalent  which  limits  the 
effectiveness of the vaccine in the long term. Regarding the risk of serotype replacement, 
the prevalence of nasopharyngeal carriage in developing countries is considerably higher 
than developed countries and so the probability of exposure to a non vaccine serotype is 
greater  which facilitates serotype replacement. It should also be appreciated that serotype 
distribution in younger children < 6 months or 6-29 months may be different which could 
affect estimates of vaccine coverage depending on the age of the study population which 
was surveyed (Scott, 2007).  
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9.4.7.1  Invasive Pneumococcal Disease Serotype Distribution 
IPD surveillance data from Bolivia is available from 2000-2003
15 and is displayed below in 
Figure 9-5. 
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Figure   9-5 Distribution of pneumococcal serotypes causing invasive disease in Bolivia 
(n=45) from 2000-2003. 
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This serotype distribution is similar to that seen previously in Bolivia (Anonymous, 2004) 
and  elsewhere  in  Latin  America.  Common  serotypes  causing  IPD  from  SIREVA 
surveillance in Latin America are serotypes 14, 5, 1, 6A/B, 23F, 7F, 9V, 19F, 18C, 19A 
and  9N  (Camargos  et  al.,  2006).  This  distribution  is  reproducible  in  country  and  city 
specific studies of IPD in Latin America although there are inevitably minor changes in the 
rank order as evident in Table 9-5 below. 
Country  IPD Serotype Distribution  Years of 
Study 
Reference 
Argentina  14, 5, 6B, 1, 18C, 19F, 9V, 12F, 4, 23F, 7F, 6A, 
33F, 9A, 3, 23B, 15, 7B, 20 and 7C 
2000-2005  (Tregnaghi et 
al., 2006b, 
Tregnaghi et 
al., 2006a) 
Argentina  14, 5, 1, 6B, 7F, 19A, 9V, 23F, 19F and 18C  1993-2003  (Vescina et 
al., 2006) 
Brazil  1, 6B, 18C, 14, 5, 3, 6A, 23F, 19F and 38  1977-1988  (Taunay et al., 
1990) 
Brazil  14, 6B, 23F, 5, 19F, 6A, 1 and 4  1988-1992  (Sessegolo et 
al., 1994) 
Brazil  14, 3, 6B, 19F, 6A, 23F, 18C, 4, 8, 10A, 9N and 7F  1995-1999  (Reis et al., 
2002) 
Brazil  1, 5, 6A, 6B, 9V, 14, 18C, 19F and 23F  1977-2000  (Brandileone 
et al., 2003) 
Chile  1, 14, 5, 6B  1989-1993  (Levine et al., 
1998) 
Colombia  1, 4, 5, 6B, 8, 14, 19A, 19F and 23F  2006-2007  (Benavides et 
al., 2008) 
Mexico  23F, 19F, 6B, 14, 19A, 6A and 9V  1996-2006  (Echaniz-
Aviles et al., 
2008) 
Mexico  23F, 6B, 14, 19A, 6A, 9V, 19F, 11A, 15A, 2, 10A, 
18C, 42, 16 and 22F 
1992-1993  (Echaniz-
Aviles et al., 
1995) 
Table   9-5 Serotypes accounting for IPD in various Latin American countries over 3 decades. 
 
There is evidence that the regional pattern of serotype distribution causing IPD in Latin 
America is different from other parts of the world.  Serotype 1 and 5 are among prevalent 
causes of IPD in Latin America and are less evident elsewhere (Di Fabio et al., 2001, 
Hausdorff  et  al.,  2001,  Kertesz  et  al.,  1998).  In  Brazil  serotypes  1,  5  and  18C  are 
particularly associated with meningitis (Brandileone et al., 2003). This has implications for 
vaccine coverage when vaccine included serotypes are determined by epidemiology from 
North America and Western Europe. Serotypes 1 and 5 are absent from our carriage study 
in keeping with the view that they are only carried for short periods (Laval et al., 2006) 
and are more invasive (Smith et al., 1993) than other serotypes. Invasive potential does not 
always equate with disease severity though and it is serotypes 6, 23F, 7F, 8 and 35B which 
are associated with fatal outcomes from IPD in Colombia (Rios et al., 1999).      Chapter 9, 186 
9.4.7.2  Carriage Serotype Distributions in Latin America 
Studies  of  carriage  serotypes  in  Latin  America  are  not  as  common  as  those  for  IPD 
isolates. The results of recent examples are summarised in Table 9-6 below. 
Country  Carriage Serotype Distribution  Years of 
Study 
Reference 
Brazil  14, 6B, 6A, 19F, 10A, 23F and 18C  2000-2001  (Laval et al., 
2006) 
Brazil  19F, 6A, 23F, 18C, 34, 23B, 11A, 19A, 16F, 22F, 
14, 16B, 10A, 21, 15B, 29 and 3 
2000-2001  (Reis et al., 
2008) 
Peru  23F, 6A, 6B, 15B, NT, 19F, 14, 34, 23B, 9V, 19A, 
21, 4, 10A, 11A, 16F, 17F, 24F, 35F and 38 
2000  (Cullotta et al., 
2002) 
Venezuela  23F, 6A, 15B, 6B and 19F  2004-2005  (Rivera-
Olivero et al., 
2007) 
Table    9-6  Serotypes  associated  with  pneumococcal  carriage  in  various  Latin  American 
countries. 
 
The  distribution  of  serotypes  represented  by  these  recent  carriage  studies  show  great 
similarity to that of the Bolivian carriage isolates and there is greater similarity than there 
is of the Bolivian carriage isolate serotypes with the serotype distribution of IPD isolates of 
other Latin American countries (Table 9-5).  There is also greater similarity between the 
carriage serotypes in Bolivia and otitis media associated serotypes in Costa Rica (serotypes 
19F, 6B, 9V, 16F, 14, 23F, 3 and 6A) than there tends to be with IPD isolates (Arguedas et 
al., 2005). 
This  is  all  in  keeping  with  previous  observations  that  the  diversity  of  nasopharyngeal 
carriage isolates tends to be greater than that of IPD isolates (Robinson et al., 2001, Takala 
et al., 1996).  
9.4.7.3  Emerging Serotypes and Bolivia 
Many serotypes which are being recognised in other parts of the world and often associated 
with  serotype  replacement  in  response  to  conjugate  vaccination  are  identifiable  in  this 
small collection of carriage strains from vaccine naïve children in Bolivia. Serotype 38 is 
an emerging serotype which can cause fatal meningitis (Baker et al., 2005). Serotype 7F is 
an  emerging  serotype  in  the  USA  (Byington  et  al.,  2008)  and  possibly  a  colonizing 
serotype  of  short  duration.  Serotypes  3  (McEllistrem  et  al.,  2007,  McEllistrem  et  al., 
2005), 6B (Carlisle et al., 2001, Syrogiannopoulos et al., 2001, Gherardi et al., 2003)  and 
19A  (Singleton  et  al.,  2007,  Pichichero  and  Casey,  2007)  are  emerging  serotypes  and 
feature in the carriage population in Beni where we have identified entirely novel sequence     Chapter 9, 187 
types    associated  with  serotype  19A.  19A  is  not  included  in  7,  9  or  11  valent  PCVs 
(Camargos et al., 2006) but is included in a new 13 valent PCV (Kieninger et al., 2008).  
9.4.8 Implications for Conjugate Vaccine Implementation 
The introduction of conjugate vaccination against Haemophilus influenzae B has had a 
significant  positive  impact  on  Haemophilus  meningitis  in  Latin  America  (Laval  et  al., 
2003) and so there are hopes that pneumococcal conjugate vaccination will have similar 
benefits. It is recognised that PCV-7 vaccine coverage in Latin America is poorer than that 
seen for USA and Europe, Africa and Oceania and this relates to the greater diversity of 
pneumococcal serotypes causing IPD in Latin America (particularly serotypes 1 and 5) 
(Hausdorff et al., 2000a). The coverage of carriage serotypes is even less than that for IPD 
isolates (Laval et al., 2006). 
It is estimated that PCV-7 (which is active against serotypes 4, 6B, 9V, 14, 18C, 19F and 
23F) covers 65% of invasive serotypes in Argentina, Brazil, Chile, Colombia, Mexico and 
Uruguay  (Garcia  et  al.,  2006,  Di  Fabio  et  al.,  2001).  But  more  regional  surveillance 
studies, such as have been performed in Brazil, have estimated coverage ranging from 58% 
to as low as 36% (Camargos et al., 2006, Laval et al., 2006, Reis et al., 2008, Brandileone 
et al., 2003).  Based on this data from Bolivia, PCV-7 will only cover 18% of carriage 
serotypes.  This  could  theoretically  rise  to  28%  coverage  taking  into  account  cross 
reactivity against the non-vaccine serotype 6A. Carriage of 6B and 19F can be reduced by 
9  valent  vaccine  (Mbelle  et  al,  1999)  and  an  11  valent  PCV  has  been  under  trial  in 
Argentina and Chile (Laval et al, 2003). However, increasing the valency of the vaccine 
and introducing cover against serotypes 1, 5 and 7F only increases the coverage in Beni to 
20%  (30%  if  considering  cross  reactivity  with  6A).    A  new  13  valent  PCV  covering 
serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (Kieninger et al., 2008) is 
likely to be the most useful of the PCVs if introduced in Bolivia. 
There will undoubtedly be many health benefits to the introduction of PCV if it becomes 
affordable in Bolivia. However, in Beni, the low coverage of the PCV-7 vaccine included 
serotypes and the high frequency of serotypes associated with serotype replacement and 
capsular switching along with emerging serotypes would suggest that the usefulness of the  
PCV-7 vaccine may be shorter lived than has been the case in North America and Western 
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9.4.9 Implications for Protein Vaccines 
If the high rate of new MLST sequence types and the finding of new regions of diversity 
by microarray CGH in Bolivian carriage isolates (Chapters 4 and 6) is an indicator of 
substantial, as yet unrecognised, genomic diversity in the pneumococcal genome of the 
isolates from Bolivia then this has implications for other genes coding for proposed protein 
vaccine  candidates.  For  instance,  pneumococcal  surface  protein  A  is  such  a  vaccine 
candidate but the gene which codes for it is already known to show substantial variation in 
pneumococci from Argentina (Mollerach et al., 2004) and Columbia (Coral et al., 2001). If 
the  diversity  of  such  genes  was  also  assessed  in  these  Bolivian  isolates  there  may  be 
evidence for even greater diversity than was known before. 
9.5 Conclusions 
In conclusion, this paediatric carriage study from the Beni region of Bolivia demonstrates 
not just substantial phenotypic (serotype) diversity but dramatic genomic diversity in this 
region known for great biodiversity. This has enormous implications for the introduction 
and design of conjugate vaccines which, although suitable for North America and Western 
Europe, have much less utility in Latin America. We agree with Levine et al that there 
remains a need for ongoing bacteriological surveillance in the region (Levine et al., 2006). 
  
10  Genomic Diversity and Gene Expression in 
Specific Invasive Pneumococcal Disease 
Manifestations 
10.1 Background 
Since the 1990s it has been realised that pneumococcal virulence is a function of both 
expression of capsular genes and the genotype of the pneumococcus involved (Kelly et al., 
1994).  In  the  initial  phase  of  lung  infection,  phenotypic  variants  of  the  pneumococcal 
capsule have been identified by Hammerschmidt et al (Hammerschmidt et al., 2005) where 
the ability to adhere to epithelial cells was enhanced by limited or no capsule expression. 
The ability to survive in different host environments may relate to phase variation and its 
effect on capsule and surface protein expression (Allegrucci and Sauer, 2008). 
Attempts  to  understand  the  role  of  genes  other  than  capsular  genes  in  virulence  often 
focussed on individual genes in an arbitrary in vitro environment or a particular in vivo 
animal model. Genome sequencing of the pneumococcus then allowed a rapid expansion 
of  genes  identified  as  having  a  potential  role  in  virulence  and  an  understanding  that 
virulence genes (microbial specific factors that contribute to the survival and growth of a 
pathogen in vivo (Hava et al., 2003)) could be identified,  
“specifically in nasopharyngeal colonization or bacterial sepsis or meningitis, 
depending on the screening tools used (Hollingshead and Briles, 2001).”  
These tools were to include signature tagged mutagenesis in animal models (Hava and 
Camilli, 2002, Hava et al., 2003, Polissi et al., 1998, Lau et al., 2001), microarray studies 
(Orihuela et al., 2004b), genomic array fingerprinting (which combines microarray and 
random  transposon  mutagenesis  approaches)  (Bootsma  et  al.,  2007),  differential 
fluorescence  induction  (Marra  et  al.,  2002)  or  in  silico  sequence  comparisons  of 
orthologous genes (Hiller et al., 2007). Such studies have lead to a conclusion that there 
are  host  tissue  specific  and  serotype  specific  virulence  factors  often  relating  to 
transcriptional regulation (Hava et al., 2003).  This suggests that  focusing on serotypes 
biased  towards  colonization  or  invasion  may  identify  key  genes  involved  in  virulence 
(Hava et al., 2003).  Such an approach using microarrays has been termed “pathotyping” or 
detecting  the  presence  of  groups  of  several  associated  virulence  factors  which  may 
constitute a fundamental attribute of the physiology or pathogenicity of a bacteria (Cassone     Chapter 10, 190 
et al., 2007, Stabler et al., 2006, Korczak et al., 2005, Bekal et al., 2003, Pannucci et al., 
2004) or disease state (Ehrlich et al., 2008). 
With regard to pneumococi, in 1998 a study by Polissi et al found evidence that there were 
virulence  factors  specific  for  causing  pneumonia  which  were  not  required  to  cause 
septicaemia in mice (Polissi et al., 1998). Using serotype 2 (D39 Xen 7) and serotype 4 
(TIGR4) RNA extracted directly from laboratory infected mouse blood, rabbit CSF and 
tissue  culture  with  Detroit  pharyngeal  epithelial  cells,  Orihuela  et  al  demonstrated 
differences  in  expression  could  be  identified  for  certain  genes  for  these  different 
environments which represented invasive sites and carriage respectively (Orihuela et al., 
2004b).  Extrapolation  of  these  results  to  human  disease  is  hampered  by  the  potential 
confounding introduced  by the species differences of the two animal models used and 
difficulties  comparing  the  expression  results  from  in  vivo  animal  models  with  in  vitro 
results  from  tissue  culture.  Using  genomic  subtraction  followed  by  dot  blot  screening 
rather than  a microarray approach, Pettigrew et  al, identified two pneumococcal  genes 
more  frequently  associated  with  middle  ear  infections  than  bloodstream  infections, 
meningitis or carriage (Pettigrew and Fennie, 2005). 
This chapter outlines an approach taken using a DNA “spotted” microarray to investigate 
its  utility  in  elucidating,  through  identifying  differences  in  gene  complement  and  gene 
expression, the pathogenesis of serotype 1 associated pneumococcal empyema, serotype 3 
associated pneumococcal meningitis and serotype 3 associated cerebral abscesses.  
10.2 Serotype 1 Bacteraemic Pneumococcal Pneumonia 
with Parapneumonic Complications 
10.2.1  Background 
There has been a substantial recent increase in the incidence of pneumococcal pneumonia 
complicated by necrotizing pneumonia, parapneumonic effusions or empyema, particularly 
affecting children and occurring in developed (Byington et al., 2005c, Obando et al., 2006, 
Calbo and Garau, 2005, Rees and Spencer, 1997, Fletcher et al., 2006, Blanc et al., 2007, 
Lin et al., 2006, Thumerelle et al., 2005, Obando et al., 2008, Eastham et al., 2004) and 
developing countries (Kanungo and Rajalakshmi, 2001). This is in contrast to dramatic 
declines  in  the  incidence  of  pneumococcal  empyema  during  the  mid-twentieth  century 
(Finland  and  Barnes,  1978,  Nowak,  1939,  Weese  et  al.,  1973,  Bartlett  et  al.,  1974,     Chapter 10, 191 
Bechamps et al., 1970, Clagett, 1973, Chonmaitree and Powell, 1983, Taryle et al., 1978) 
and the high incidence at the start of the twentieth century (Glynn and Digby, 1923) which 
are  reviewed  in  Chapter  1.  About  10%  of  cases  of  pneumococcal  pneumonia  can  be 
complicated by empyema in children (Kerem et al., 1994). Cases of haemolytic uraemic 
syndrome are also described as complications of pneumococcal pneumonia with empyema 
(Lee et al., 2006). The clinical manifestations and molecular epidemiological studies of 
these  conditions  have  been  particularly  well  described  in  the  USA  (Tan  et  al.,  2002, 
Byington et al., 2002, Gonzalez et al., 2004, Byington et al., 2006, Hardie et al., 1996), 
England (Eltringham et al., 2003, Eastham et al., 2004, Fletcher et al., 2006, Ramphul et 
al., 2006) and Taiwan (Hsieh et al., 2004, Lin et al., 2006, Shen et al., 2006b). In its 
severest form it may result in spontaneous discharge through the thoracic wall (empyema 
necessitates)  (Freeman et al., 2004) but in most cases drainage requires some form of 
surgical intervention (Hardie et al., 1996). Paediatric empyema can also be a manifestation 
within a serotype 1 outbreak (Gupta et al., 2007).  
The majority of cases in the USA and England are caused by Streptococcus pneumoniae 
serotype 1 (Byington et al., 2006, Eastham et al., 2004, Ramphul et al., 2006, Fletcher et 
al., 2006, Byington et al., 2002). In addition to serotype 1, serotypes 3, 14, 19A, 5, 6B, 9V, 
23F  and  4  have  been  identified  as  causes  of  pneumococcal  empyema  in  the  United 
Kingdom (Sheppard et al., 2008, Eltringham et al., 2003, Ramphul et al., 2006, Eastham et 
al., 2002). Serogroups 14, 9, 6, 19, 18, 12 and 29 have been associated with empyema in 
Utah, USA (Byington et al., 2002, Byington et al., 2005a). In France, serotypes 1, 3, 5, 6B, 
7F,  9V,  14,  18C,  19A  and  23F  have  been  observed  (Bekri  et  al.,  2007)  and  in  Spain 
serotypes 1, 5, 3, 14, 19A, 7F, 6A and 9V have been identified (Obando et al., 2008). 
Serotypes  3  and  19A  have  also  been  identified  as  vaccine  escape  serotypes  causing 
empyema in the USA (Byington et al., 2006, Byington, 2007, Byington et al., 2005a). 
In  a  comparable  case  series  from  Taiwan,  cases  were  predominantly  caused  by  S. 
pneumoniae  serotype  14  and  serotype  1  did  not  feature  at  all  (Hsieh  et  al.,  2004). 
Similarly,  preliminary  results  from  other  Asian  countries  (China,  Indonesia,  Korea, 
Taiwan, Thailand and Vietnam) suggested that serotypes 14 and 19 were commoner than 
serotype  1  from  pleural  fluid  cultures  (Kilgore  et  al.,  2006)  indicating  geographical 
variations in the epidemiology of pneumococcal empyema.  
In Scotland, S. pneumoniae serotype 1 accounts for 14% of all IPD (Diggle and Edwards, 
2006)  which  includes  cases  of  complicated  pneumococcal  pneumonia.  An  increase  in 
incidence  in  paediatric  empyema  has  also  been  documented  in  Scotland  although  the     Chapter 10, 192 
molecular  epidemiology  of  the  pneumococcal  component  of  this  has  not  yet  been 
elucidated (Roxburgh et al., 2008, Roxburgh and Youngson, 2007). 
Unpublished  data  from  England  and  Wales  demonstrate  that  a  mixed  population  of 
serotype 1 pneumococci (ST227 and ST306) are responsible for cases of pneumococcal 
empyema (Robert George, Health Protection Agency, personal communication) and data 
from Spain (ST228, ST306, ST304 and ST2373) also shows diversity in the empyema 
causing serotype 1 isolates (Obando et al., 2006, Brueggemann et al., 2006, Obando et al., 
2008).  In the USA, until 2003, cases were predominantly ST227 (Gonzalez et al., 2004, 
Byington, 2007, Byington et al., 2005c, Byington et al., 2005b, Brueggemann et al., 2003) 
but since 2003 serotype 1 associated sequence types have included ST306, ST304 and 
ST2126  (Byington  et  al.,  2008).  The  population  dynamics  of  serotype  1  pneumococci 
causing invasive disease do suggest that it can change rapidly within a geographical region 
(Lamb et al., 2008, Hedlund et al., 2003, Henriques Normark et al., 2001) and between 
geographical regions resulting in a diverse global population (Brueggemann et al., 2003). 
It is noteworthy that genetic variation in the structure of pneumolysin (a pneumococcal 
virulence factor) from clinical isolates of ST306 serotype 1 S. pneumoniae has recently 
been shown to be associated with different biological behaviour of the toxin (Kirkham et 
al., 2006), indicating that genetic differences in the bacteria could account for different 
disease manifestations with this serotype and sequence type.  
Several non-culture molecular (Eltringham et al., 2003, Le Monnier et al., 2006, Lahti et 
al., 2006, Saglani et al., 2005, Eastham et al., 2002, Menezes-Martins et al., 2005, Poulter 
et al., 2005) and antigen based methods (Ploton et al., 2006, Boersma et al., 1993, Le 
Monnier et al., 2006, Porcel et al., 2007) have been used to investigate the cause of culture 
negative parapneumonic effusion and empyema and molecular techniques may be more 
useful in surveillance than culture (Sheppard et al., 2008) as pneumococci can be cultured 
from  less  than  5-16%  of  pleural  fluid  specimens  (Kilgore  et  al.,  2006,  Obando  et  al., 
2006).   
Substantial concern exists because the pneumococcal conjugate vaccine (PCV-7) presently 
licensed for children, Prevnar® (Wyeth Pharmaceuticals, USA), and introduced into the 
childhood vaccination schedule in the United Kingdom in 2006 does not prevent invasive 
diseases due to serotype 1 S. pneumoniae (Fletcher et al., 2006).     Chapter 10, 193 
In  this  series  of  experiments  representative  isolates  stored  at  SMPRL  which  could  be 
identified as originating from patients with parapneumonic complications of bacteraemic 
pneumococcal pneumonia were used. Their MLST data was reviewed and the isolates were 
utilised  in  microarray  experiments  using  DNA  CGH  and  RNA  expression  approaches. 
Serotype  1  isolates  from  patients  with  bacteraemic  pneumonia  without  parapneumonic 
complications were identified for use as controls to establish baseline expression levels for 
genes which were differentially expressed in cases with parapneumonic complications.  
10.2.2  Choice of Isolates for Microarray Studies 
Seventeen  patients  from  six  hospitals  in  Central  Scotland  who  had  undergone 
pleurocentesis and who grew serotype 1 pneumococci from an invasive site were identified 
from the database at SMPRL. Of these seventeen cases, four were aged under eighteen 
years. MLST results showed 12/17 (71%) were ST306 and 5/17 (29%) were ST227. From 
these, five isolates were chosen from patients who had documented empyema or effusion 
complicating bacteraemic pneumonia and two separate isolates (one each of ST306 and 
ST227)  were  identified  from  the  database  from  patients  with  bacteraemic  pneumonia 
without  parapneumonic  complications  to  act  as  controls.  Details  of  these  isolates  are 
outlined below in Table 10-1.     Chapter 10, 194 
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MLST  ST306  ST227  ST306  ST227  ST227  ST306  ST306 
Patient Age 
(Years)  26  51  33  70  7  36  4 
Parapneumonic 
complication  None  None  Empyema  Effusion  Empyema  Effusion  Effusion 
Source of 
Bacteria  Blood  Blood 
Pleural 
Pus  Blood  Blood  Blood  Blood 
Table   10-1 Details of isolates used in microarray experiments in Chapter 10.  
All 7 isolates were used in DNA CGH dye swap experiments. 5 isolates were used in RNA 
expression experiments (06-1805 and 05-1519 were not used). 
 
10.2.3  DNA CGH Experiments 
The results of the microarray DNA CGH experiments for serotype 1 isolates are displayed 
in Appendix 14 and Appendix 15. 
10.2.4  RNA Expression Experiments     Chapter 10, 195 
10.2.4.1  Microarray Results 
TIGR4 Genes Upregulated in Parapneumonic Complications 
TIGR4 
Gene 
Expression 
Level in 
Controls 
Expression 
Level in 
Cases  Gene Function 
SP0044  1.0  3.9 
Phosphoribosylaminoimidazole-
succinocarboxamide synthetase 
SP0045  0.9  5.5  Phosphoribosylformylglycinamide synthetase 
SP0046  1.0  7.2  Amidophosphoribosyl transferase 
SP0047  0.9  6.4 
Phosphoribosylformylglycinamide cyclo-ligase;  
Phosphoribosylaminoimidazole synthetase 
SP0048  1.0  6.2 
Phosphoribosylglycinamide formyltransferase;  
5'-phosphoribosylglycinamide transformylase 1 
SP0049  1.0  5.7 
vanZ protein, putative;  Teicoplanin resistance 
protein 
SP0050  1.0  5.5 
Phosphoribosylaminoimidazolecarboxamide 
formyltransferase 
SP0051  1.0  4.2 
Phosphoribosylamine--glycine ligase;  
Phosphoribosylglycinamide synthetase 
SP0053  1.0  3.2 
Phosphoribosylaminoimidazole carboxylase, 
catalytic subunit 
SP0054  1.0  4.5 
Phosphoribosylaminoimidazole carboxylase, 
ATPase subunit;  Phosphoribosyl glucinamide 
formyltransferase 
SP0073  1.0  2.2  Conserved hypothetical protein 
SP0287  1.0  3.0 
Xanthine/uracil permease family protein;  
Conserved hypothetical protein 
SP0288  1.0  2.4  Conserved hypothetical protein 
SP0645  0.9  2.0 
PTS system IIA component, putative;  
Phosphotransferase system sugar-specific EII 
component 
SP1229  1.0  2.7  Formate--tetrahydrofolate ligase 
SP1326  0.9  5.1  Neuraminidase, putative 
SP1327  1.0  5.2  Conserved hypothetical protein 
SP1328  0.9  3.3  Sodium:solute symporter family protein 
SP1526  0.9  2.8 
ABC transporter, ATP-binding protein authentic 
frameshift 
SP1527  0.9  2.8 
ABC transporter substrate-binding protein - 
oligopeptide transport 
SP1587  1.0  2.8  Oxalate:Formate Antiporter 
TIGR4 Genes Downregulated in Parapneumonic Complications 
TIGR4 
Gene 
Expression 
Level in 
Controls 
Expression 
Level in 
Cases  Gene Function 
SP1884  1.2  0.4 
Trehalose PTS system, IIABC components;  
Phosphotransferase system, trehalose-specific 
IIBC component 
SP2148  0.9  0.2  Arginine deiminase 
SP2150  0.9  0.2  Ornithine transcarbamoylase 
SP2151  1.0  0.2  Carbamate kinase 
SP2152  0.9  0.2 
Conserved hypothetical integral membrane 
protein 
SP2153  0.9  0.2 
Peptidase, M20/M25/M40 family;  Conserved 
hypothetical protein 
Table   10-2 Genes which are significantly up or down-regulated when isolates are grown to 
midlog under standardised conditions. 
p<0.05 determined using ANOVA 1 way test with Benjamini and Hochberg corrections. False 
discovery rate set at 0.05 on data filtered to demonstrate greater than two fold differences 
from  the  line  of  equality  (where  fluorescence  intensity  of  control  and  test  channels  are 
equal). Data was also initially normalized by sequence type to take account of clustering 
effects  due  to  MLST.  Controls  were  isolates  03-2672  and  04-2225  as  these  were  not     Chapter 10, 196 
associated  with  parapneumonic  complications.  Cases  were  all  other  isolates  with 
parapneumonic  complications.  Genes  highlighted  in  red  have  been  associated  with 
virulence in a serotype 4 mouse model of pneumonia (Hava and Camilli, 2002). 
 
TIGR4 
Gene 
Predictive 
Strength  Gene Function 
SP0045  6.64  Phosphoribosylformylglycinamide synthetase 
SP0046  7.94  Amidophosphoribosyl transferase 
SP0047  6.64  Phosphoribosylaminoimidazole synthetase 
SP0048  5.74 
Phosphoribosylglycinamide formyltransferase;  5'-
phosphoribosylglycinamide transformylase 1 
SP0049  7.17  VanZ protein, putative;  Teicoplanin resistance protein 
SP0051  9.55 
Phosphoribosylamine--glycine ligase;  Phosphoribosylglycinamide 
synthetase 
SP0053  6.59  Phosphoribosylaminoimidazole carboxylase, catalytic subunit 
SP0054  6.64  Phosphoribosyl glucinamide formyltransferase 
SP0097  5.74  Conserved domain protein;  Hypothetical protein 
SP0239  7.23  Conserved hypothetical protein 
SP0287  6.64 
Xanthine/uracil permease family protein;  Conserved hypothetical 
protein 
SP0834  5.74 
Hemolysin-related protein;  Conserved hypothetical protein, 
truncation 
SP0853  5.74  Hypothetical protein 
SP0937  5.74  Conserved hypothetical protein 
SP1069  6.64 
Conserved hypothetical protein;  ABC transporter substrate-
binding protein - unknown substrate 
SP1229  7.17  Formate--tetrahydrofolate ligase 
SP1316  9.18  V-type sodium ATP synthase, subunit B 
SP1486  7.23  Degenerate transposase (orf1) 
SP1524  6.64  Aminotransferase, class II 
SP1587  6.64  Oxalate:Formate Antiporter 
SP1965  6.04  Hypothetical protein 
SP1978  6.64  Diaminopimelate decarboxylase 
SP1979  9.55  Pur operon repressor;  Activator of purine biosynthetic genes 
SP1988  5.74  Immunity protein, putative;  Conserved hypothetical protein 
SP2125  6.64  Conserved hypothetical protein 
SP2145  7.23 
Antigen, cell wall surface anchor family;  Conserved hypothetical 
protein 
SP2151  6.64  Carbamate kinase 
SP2152  6.64  Conserved hypothetical integral membrane protein 
SP2153  6.64  Peptidase, M20/M25/M40 family;  Conserved hypothetical protein 
SP2156  7.23  SPFH domain/Band 7 family;  Conserved hypothetical protein 
Table    10-3  Genes  identified  as  being  associated  with  the  occurrence  of  parapneumonic 
complications when grown to midlog in Brain Heart Infusion.  
Highlighted genes have  been associated with virulence in a  serotype 4  mouse model of 
pneumonia (Hava and Camilli, 2002). 
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10.2.4.2  Quantitative RT-PCR Results 
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Figure    10-1  Comparison  of  the  Mean  Expression  Levels  for  genes  SP0054,  SP0045  and 
SP2153 by qRT-PCR. 
Mean Expression Levels and standard errors were calculated from 3 experimental replicates 
for  control  isolate  (03-2672)  from  serotype  1,  ST306  associated  bacteraemic  pneumonia 
without  parapneumonic  complications  and  test  isolate  (06-1370)  from  serotype  1,  ST306 
associated paediatric empyema.  
  
10.2.5  Discussion Regarding a Genetic Basis for 
Pneumococcal Parapneumonic Complications 
Cases  of  complicated  pneumococcal  pneumonia  in  Scotland  result  from  a  mixed 
population of serotype 1 S. pneumoniae (ST227 and ST306) similar to the situation being 
seen in other European countries and the USA.  
Although only two sequence types of S. pneumoniae appear to be involved in Scotland, 
CGH  analysis,  using  microarrays,  indicates  substantial  variation  in  genes  among  test 
isolates of ST227 and ST306 at regions other than the conserved housekeeping genes used 
in the MLST typing system. 
Analysis of bacterial RNA expressed under standardized, predetermined growth conditions 
shows there to be variation in the regulation of pneumococcal genes which could account 
for  differences  in  virulence  and  the  clinical  presentation  and  progression  of  these 
infections. Using site directed mutagenesis, many of these genes have been shown to code     Chapter 10, 198 
for virulence factors and have a role in causing pneumonia in a murine model (Hava and 
Camilli,  2002).  However,  the  growth  conditions  used  in  these  experiments  to  grow  S. 
pneumoniae  for  RNA  extraction  may  not  accurately  mimic  those  found  in  the  pleural 
cavity (Byington et al., 2002) where other genes may undergo  expression and regulation. 
It is of note that the pleural environment also varies with cases requiring a decortication 
drainage procedure more likely to have substantially raised lactate dehydrogenase levels 
(Tan et al., 2002, Himelman and Callen, 1986).   
However, these experiments do suggest that no single virulence factor will account for the 
increased virulence in serotype 1 pneumococci causing complicated pneumonia but rather 
this may be due to a constellation of virulence factors being up and down regulated in the 
pleural cavity. In keeping with this hypothesis is the fact that penicillin resistance alone 
does not affect the outcome of paediatric pneumococcal empyema (Paganini et al., 2001, 
Hardie  et  al.,  1998).  Indeed,  subtherapeutic  antibiotic  levels  of  susceptible  and 
nonsusceptible antimicrobials in the pleural space (Saglani et al., 2005, Giachetto et al., 
2004) may be contributing to the patterns of expression of virulence genes in empyema 
formation (Byington et al., 2002) (see Chapter 12). 
Recently  in  Taiwan,  microarray  technology  has  been  used  to  assess  the  effect  of  zinc 
metalloproteinase  B  mutations  in  S.  pneumoniae  isolates  causing  cases  of  complicated 
pneumonia  (Hsieh  et  al.,  2008).  These  expression  studies  were  performed  with 
pneumococcal cultures at early log phase (OD600nm of 0.2) with serotype 14 isolates of 
ST46 and a single locus variant (SLV) of ST328 and the media used for culture was not 
disclosed. They chose to compare the gene expression of a pleural fluid isolate from a child 
with pneumococcal empyema (serotype 14, ST46) and a blood culture isolate from a child 
with  bacteraemic  necrotizing  pneumococcal  pneumonia  with  empyema  (serotype  14, 
ST46) with a “control” blood culture isolate from a child with uncomplicated bacteraemic 
pneumonia (serotype 14, SLV of ST328). This comparison resulted in the identification of 
only  two  genes  with  a  two  fold  increase  in  gene  expression  –  SP0664  (zinc 
metalloprotease) and SP1572 (nonheme iron-containing ferritin).  
Neither of these genes appeared in the list of differentially expressed genes identified in 
this comparison of serotype 1 isolates. This should not be too surprising as this study has 
used a different serotype, ensured that “control” isolates are matched for sequence type and 
grown cultures in a defined medium (BHI broth) to mid-logarithmic rather than early-
logarithmic phase – all of which will affect which genes are expressed at the point of RNA 
extraction and which genes are identified during analysis of microarray results. It is not     Chapter 10, 199 
surprising either that genes identified as associated with virulence may not actually be 
required in all cases of invasive disease (Blomberg et al., 2007). 
A significant shortcoming in the use of the microrray to study pneumococcal virulence is 
its inability to identify genes other than those from the sequenced genomes for TIGR4 and 
R6. If an increase in virulence in serotype 1 pneumococci has occurred due to the recent 
acquisition of genes from other bacteria or bacteriophages, microarray analysis will not be 
able to detect the presence of such  genes.  By  detecting variation (and the absence) of 
several genes coding for virulence factors in test isolates as illustrated in Appendix 14 and 
Appendix 15, it may be postulated that these virulence factors do not play a significant role 
in the development of cases of complicated pneumonia. Included amongst these are genes 
which code for the first pneumococcal pilus to be described which does not appear to be 
expressed by any of the serotype 1 isolates analysed on the array. These genes are absent 
from two serotype 1 ST306 strains associated with parapneumonic complications (06-1370 
and  03-3038)  which  are  being  sequenced  using  454  technology  at  the  Sanger  Institute 
(Nicholas Croucher, Wellcome Trust Sanger Institute, personal communication). However, 
the  genes  for  a  recently  described  second  pneumococcal  pilus  (Bagnoli  et  al.,  2008) 
identified in the fully sequenced serotype 1, ST227 strain INV104B which are not present 
in TIGR4 (and not identifiable by microarray DNA CGH) are present in the ST306 isolates 
06-1370, 03-3038 and 03-2672 from preliminary 454 sequencing at the Sanger Institute 
(Nicholas Croucher, Wellcome Trust Sanger Institute, personal communication), consistent 
with the findings of Bagnoli et al, who identified this pilus in serotype 1 ST227 and ST306 
isolates. This pilus is involved in adherence to cells of the respiratory tract and so may play 
a role in the development of bacteraemic pneumonia and parapneumonic complications 
although this requires further investigation.  
Given the concentrations of DNA or RNA (minimum 2µg per 25µl reaction per array) 
required from test isolates it is unlikely that this microarray analysis could be performed 
directly on nucleic acid extracted from clinical samples but would require initial culture of 
the  organism  or  a  nucleic  acid  amplification  step  which  may  introduce  unacceptable 
confounding of results. This is unfortunate as the majority of pleural fluid cultures from 
cases of complicated pneumonia are negative due to prior administration of antibiotics 
(Byington et al., 2002, Eltringham et al., 2003). It may be possible to design a suitable 
microarray to identify isolates likely to result in parapneumonic complications using the 
genes  identified  here  but  using  a  more  sensitive  platform  such  as  an  oligonucleotide 
microarray.  Such  microarrays  are  already  being  used  to  investigate  host  responses  to     Chapter 10, 200 
respiratory infections  and have been designed and used for typing and detecting clinically 
relevant virulence determinants in Staphylococcus aureus isolates (Spence et al., 2008). 
It is possible using the gene predictor function of Genespring GX 7.3.1 to, in silico, create 
a list of genes implicated in causing parapneumonic complications (Table 10-3). It has 
been  suggested  that  the  presence,  by  microarray  hybridization,  of  a  region  SP1050  to 
SP1053  is  associated  with  highly  virulent  serotype  1  isolates  (Harvey  et  al.,  2007). 
However, our CGH results demonstrate a lack of hybridization for this region and these 
genes  do  not  feature  in  the  list  of  those  thought  to  be  predictive  of  parapneumonic 
complications.  
Such complications may resolve without invasive interventions or may require traditional 
management approaches of thoracocentesis by tube drainage or open surgery (Meyerovitch 
et  al.,  1985).  There  is  some  suggestion  that  surgery  is  more  likely  to  be  required  for 
serotype 14 pneumococci while tube drainage is more likely to be sufficient alone for 
serotype 1 (Tan et al., 2000). Less invasive strategies are now being utilized (Playfor et al., 
1997)  and  microarray  analysis  of  bacterial  gene  expression  could  allow  more  rapid 
identification of patients at greater risk of empyema or parapneumonic effusion, if these 
predicted genes are being expressed. Patients infected with isolates expressing these genes 
may  potentially  benefit  from  earlier  treatment  with  intra-pleural  administration  of 
fibrinolytic  agents  (Rosen  et  al.,  1993,  Playfor  et  al.,  1997,  Thomson  et  al.,  2002, 
Handman and Reuman, 1993, Sahn, 2007, Kornecki and Sivan, 1997, De Benedictis et al., 
2000, Kothandapani et al., 2006, Campbell, 1995, Hawkins et al., 2004, Hamm and Light, 
1997, Feola et al., 2003) or thoracoscopic decortication  (Playfor et al., 1997, Sahn, 2007, 
Kercher et al., 2000, Stovroff et al., 1995, Gates et al., 2004, Wong et al., 2005, Hawkins 
et al., 2004, Hamm and Light, 1997, Schultz et al., 2004) potentially improving clinical 
outcome and reducing hospital length of stay (Thomson et al., 2002, Hoff et al., 1991, 
Wong et al., 2005, Sahn, 2007).  
The  recent  introduction  of  Prevnar®  (Wyeth  Pharmaceuticals,  USA),  into  the  United 
Kingdom paediatric vaccination schedule may actually facilitate an even greater increase 
in incidence of invasive serotype 1 associated disease by providing a niche for its clonal 
expansion by removing competition from other serotypes. Serotype 1 should be included in 
future pneumococcal conjugate vaccine formulations (Hanquet et al., 2008) such as the 13 
valent PCV currently under trial (Kieninger et al., 2008).     Chapter 10, 201 
Orihuela  et  al,  demonstrated  that  the  purine  synthetic  genes  SP0045-SP0055  were 
significantly  upregulated  in  mouse  blood  (Orihuela  et  al.,  2004b).  Although 
bioluminescent imaging was performed on these mice before exanguination, it was not 
disclosed  whether  there  were  parapneumonic  complications  evident.  It  is  likely  that 
pneumonia was present as the mice had been infected intratracheally. This is important to 
establish as our data suggests that the upregulation of the purine synthetic genes is not 
simply a response to their presence in the bloodstream.   
Although the majority of isolates which we used for microarray experiments had originated 
from bloodstream infections, one isolate 03-3038 had been grown from pleural pus.  In 
addition, our analysis considered gene expression of two control isolates grown from the 
blood  cultures  of  two  cases  of  bacteraemic  pneumonia  without  parapenumonic 
complications from which we established a baseline gene expression for comparison with 
isolates  from  bacteraemic  pneumonia  cases  with  parapneumonic  complications.  This 
should  remove  any  potential  influence  of  the  bloodstream  source  of  isolates  on  gene 
expression leaving us to conclude that the genes which we identify as being differentially 
expressed  are  due  solely  to  changes  which  are  associated  with  the  presence  of 
parapneumonic complications.  
It is also noteworthy that the expression of the purine synthesis gene SP0044 is noted to be 
temperature  dependent,  being  upregulated  above  37°C  but  downregulated  below  37°C 
(Pandya et al., 2005). As patients with empyema often have prolonged, persisting fevers 
this may be an important survival response by pneumococci to adapt to thermal changes in 
the host environment. 
Alternatively,  the  change  in  expression  of  these  purine  synthesis  genes  may  not  relate 
directly to the parapneumonic complications but be part of a nonspecific stress response. 
SP0044 and SP0045 have been found to be downregulated in response to vancomycin 
stress (Haas et al., 2005). It has not been possible to fully review the antibiotic therapy to 
which these isolates had been exposed in the past although it is known that the patients 
infected with 03-3038 and 03-2672 did not receive vancomycin. Likewise these isolates 
have  been  subcultured  and  stored  frozen  in  glycerol  stocks  prior  to  culture  for  RNA 
extraction and so it is unlikely that any preceding antibiotic therapy in the source patient 
would be influencing these results unless treatment has resulted in a stable mutation.          Chapter 10, 202 
10.3 Pneumococcal Meningitis 
10.3.1  Serotype 3 Association with Meningitis 
Serotype  3  is  the  commonest  serotype  recovered  from  cases  of  meningitis  in  Poland 
(Skoczynska and Hryniewicz, 2003) and was recently described as accounting for 18% of 
adult cases of pneumococcal meningitis in Sweden (Sjostrom et al., 2006) although in the 
1980s  it  was  the  commonest  serotype  associated  with  pneumococcal  meningitis  there 
(Burman  et  al.,  1986).  It  was  also  the  commonest  serotype  to  be  recovered  from 
cerebrospinal fluid in Boston, USA from 1935 to 1972 (Finland and Barnes, 1977a). The 
proposal by Orihuela et al that serotype 3 does not readily enter the bloodstream or CSF 
because of a large amount of capsule based on a murine model of infection (Orihuela et al., 
2003) is incompatible with these epidemiological observations in human populations. It is 
not often that studies have documented which sequence types are present in serotype 3 
meningitis  associated  isolates.  However,  ST180  serotype  3  is  strongly  associated  with 
development  of  meningitis  rather  than  carriage  in  a  Brazilian  slum  (Reis  et  al.,  2008) 
although  the  authors  do  recognise  that  this  association  may  be  more  a  feature  of  the 
serotype 3 capsule than the genotype (Reis et al., 2008). 
Adjunctive treatments which may disrupt inflammatory cascades as additional treatment 
strategies (while being treated with appropriate antibiotics) are sought and agents which 
inhibit  CSF  cytokines,  matrix  metalloproteinases  and  reactive  oxygen  species  show 
promise  (Davis  and  Greenlee,  2003).  Identification  of  new  potential  targets  for  such 
adjunctive strategies may bring significant breakthroughs.    
10.3.2  Serotype 3 ST180 DNA CGH Hybridizations 
The results of microarray DNA CGH experiments relating to the isolates 99-4038 and 99-
4039 are displayed compared to all other CGH tested ST180 isolates in Figure 6-1 and in 
Figure 10-2 below. 
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Figure    10-2  CGH  comparisons  of  isolates  99-4038  (cultured  from  blood)  and  99-4039 
(cultured from CSF). 
Isolates are cultured from specimens taken from the same patient taken on the same day 
and  comparison  is  generated  by  Genespring  GX  7.3.1.  Each  individual  coloured  bar 
represents  a  single  gene  from  the  TIGR4  or  R6  genomes.  Shades  of  yellow  and  orange 
indicate  competitive  hybridization  of  DNA  from  both  TIGR4  and  the  test  isolates.  Blue 
indicates absence of hybridization for DNA from the test isolate but hybridization by TIGR4 
DNA. Red indicates hybridization of test DNA to probes from the R6 genome. 
 
As both isolates were harvested from the same patient on the same day, the discrepant 
hybridization results between the two isolates for 39 genes was a surprise and a concern. 
PCR (using TIGR4 as the positive control and PCR grade water as the negative control) 
was performed for these discrepant genes and a product was obtained for both isolates in 
each case, indicating that the discrepancies were due to insensitivity of the microarray 
hybridization rather than differences in the genomes of the isolates.  PCR performed at a 
further 20 genes which did not hybridize for either isolate on the array indicated a product 
of  identical  size  to  that  in  TIGR4  at  all  20  loci  which  again  highlights  the  lack  of 
sensitivity  for  DNA  hybridizations  and  limited  ability  of  the  microarray  to  accurately 
detect  true  differences  in  the  genetic  complement  of  pneumococcal  genomes,  as  was 
discussed in Chapter 3.      Chapter 10, 204 
 
Array DNA CGH Result  PCR Result 
Gene  99-4038  99-4039  99-4038  99-4039 
SP0068             
SP0069             
SP0074             
SP0115             
SP0166             
SP0168             
SP0352             
SP0355             
SP0467             
SP0575             
SP0697             
SP1060             
SP1064             
SP1132             
SP1141             
SP1144             
SP1318             
SP1323             
SP1342             
SP1762             
SP1763             
SP1765             
SP1766             
SP1770             
SP1771             
SP1948             
SP2164             
Figure   10-3 Comparison of microarray DNA CGH results for isolates 99-4038 and 99-4039 
with PCR results for the same genes using DNA from the same isolates. 
Blue indicates an absence of hybridization whereas  yellow indicates hybridization in the 
CGH experiments and the generation of a PCR product of identical size to that in TIGR4 in 
the PCR experiments.  
 
Although the PCR results highlighted the frequency of false negative hybridizations, there 
were  never  any  discrepancies  in  the  PCR  results  for  the  same  gene  between  the  two 
isolates  from  blood  and  CSF.    Based  on  the  combination  of  results  from  DNA 
hybridizations and PCR validation of discrepant results, it was concluded that a significant 
difference  in  the  gene  complement  of  the  two  isolates  in  terms  of  gene  deletions  was 
unlikely  although  the  possibility  of  single  nucleotide  polymorphisms  or  insertions  of 
genetic material could not be discounted.  To investigate this further, both isolates are 
undergoing 454 sequencing at the Wellcome Trust Sanger Institute.     Chapter 10, 205 
10.3.3  Serotype 3 ST180 RNA Expression Experiments 
Gene 
Normalized 
Intensity 
Ratio in 
Blood 
Normalized 
Intensity 
Ratio in 
CSF  Function 
Upregulated in CSF 
SP2075  1.1  5.3  ABC transporter, ATP-binding/permease protein 
SP2073  1  4.6  ABC transporter, ATP-binding/permease protein 
SP0231  0.9  3.8  Adenylate kinase (ATP-AMP transphosphorylase) 
SP1869  1.1  3  Iron-compound ABC transporter, permease protein 
SP1872  1  2.8 
Iron-compound ABC transporter, iron-compound-
binding protein 
SP0054  0.9  2.8 
Phosphoribosylaminoimidazole carboxylase, ATPase 
subunit 
SP1871  1  2.8  Iron-compound ABC transporter, ATP-binding protein 
SP2074  1  2.3  Degenerate transposase 
SP0507  1  2.2 
Type I restriction enzyme EcoKI specificity protein (S 
protein) 
SP1659  1  2.1  Isoleucyl-tRNA synthetase 
SP2072  1  2.1  Glutamine amidotransferase, class-I 
Downregulated in CSF 
SP2215  1  0.1  30S Ribosomal protein S2 
SP2214  1  0.1  Translation elongation factor Ts 
SP0496  0.9  0.1  Na/Pi cotransporter II-related protein 
SP0488  1  0.1  Conserved hypothetical protein 
SP0577  0.9  0.1 
PTS system, beta-glucosides-specific IIABC 
components 
SP0578  1.1  0.1  6-phospho-beta-glucosidase 
SP1572  1.1  0.1 
DNA binding protein starved cells-like peroxide 
resistance protein 
SP0800  1  0.2  Hypothetical protein 
SP0517  1  0.2  Class I heat-shock protein (molecular chaperone) 
SP0487  1  0.2  Hypothetical protein 
SP1626  1.1  0.2  30S Ribosomal protein S15 
SP1215  0.9  0.2  Formate-nitrate transporter 
SP0489  1  0.2  PAP2 family protein 
SP0631  1  0.2  50S Ribosomal protein L1 
SP0490  1  0.2  Hypothetical protein 
SP1293  1.2  0.2  50S Ribosomal protein L19 
SP0630  1.1  0.2  50S Ribosomal protein L11 
SP0492  1  0.2  Hypothetical protein 
SP0373  1  0.3  Conserved hypothetical protein 
SP0649  0.9  0.3   
SP1472  1  0.3  Oxidoreductase, putative 
SP1184  0.9  0.3  6-phospho-beta-galactosidase 
SP2106  1  0.3  Glycogen phosphorylase family protein 
SP0107  1  0.3  LysM domain protein 
SP0493  1  0.3 
DNA-directed RNA polymerase, delta subunit, 
putative 
SP1027  1  0.3  Conserved hypothetical protein 
SP0564  0.9  0.3  Hypothetical protein 
SP1185  1  0.3  PTS system, lactose-specific IIBC component 
SP1471  1  0.3  Oxidoreductase, putative 
SP1739  1  0.4  KH domain protein 
SP1449  1  0.4  C3-degrading proteinase 
SP1786  1  0.4  Conserved hypothetical protein 
SP2226  0.9  0.4  Conserved hypothetical protein 
SP2216  1  0.4  General stress protein GSP-781     Chapter 10, 206 
SP2058  1  0.4  Queuine tRNA-ribosyltransferase 
SP0058  1  0.4  Transcriptional regulator, GntR family 
SP2063  1.1  0.4  Conserved hypothetical protein 
SP0457  1  0.4  Bacitracin resistance protein 
SP1674  1  0.4 
Phosphosugar-binding transcriptional regulator, 
putative 
SP1975  1  0.4  SpoIIIJ family protein 
SP1470  0.9  0.5  Thiamine biosynthesis protein ApbE, putative 
SP0375  1  0.5 
6-phosphogluconate dehydrogenase, 
decarboxylating 
SP0376  1  0.5  DNA-binding response regulator 
SP1111  1  0.5  Conserved hypothetical protein 
SP0247  1  0.5  Transcriptional regulator 
SP2057  1  0.5  Hypothetical protein 
SP2150  1  0.5  Ornithine transcarbamoylase 
Table   10-4 Comparison of Normalized Expression Ratios of genes differentially expressed 
when expression levels in CSF are compared to blood. 
Results are for isolates of serotype 3, ST180 cultured from the same patient on the same 
day  using  a  one  tailed  ANOVA  with  significance  set  at  P<0.05  and  the  Benjamini  and 
Hochberg  correction  used  for  multiple  testing.  The  expression  levels  in  blood  are 
normalized  against  themselves  to  generate  a  baseline  for  comparison  with  expression 
levels in CSF. Genes highlighted in red have been associated with virulence in a serotype 4 
mouse pneumococcal pneumonia model (Hava and Camilli, 2002). 
 
Gene  Fold Change in CSF (Orihuela et al., 2004b)  Fold Change in CSF 
(This study) 
SP0517  -3.1  -5.0 
SP1975  -2.2  -2.5 
SP1572  -2.4  -11.0 
SP2058  -3.1  -2.5 
SP0488  -2.9  -10.0 
SP0800  +2.1  -5.0 
Table   10-5 Comparison of the fold change differences in expression for genes identified as 
being downregulated in CSF in this study with results from similar work by Orihuela et al 
(Orihuela et al., 2004b).     Chapter 10, 207 
 
Gene  Fold Change in Blood 
(Orihuela et al., 2004b) 
Expression in CSF 
compared to blood  
(This study) 
SP0457  +2.5  Downregulated 
SP0054  +6.9  Upregulated 
SP0231  -3.8  Upregulated 
SP1572  -8.4  Downregulated 
SP0630  -4.7  Downregulated 
SP0631  -5.0  Downregulated 
SP1626  -3.5  Downregulated 
SP2073  +2.2  Upregulated 
SP0107  +2.7  Downregulated 
SP0488  -4.7  Downregulated 
SP0800  +4.5  Downregulated 
SP2063  +4.9  Downregulated 
Table   10-6 Comparison of results for genes identified as significantly up or down regulated 
in CSF with their fold change levels as detected in mouse blood by Orihuela et al (Orihuela 
et al., 2004b).  
+ indicates upregulation while – indicates downregulation. 
 
10.3.4  Discussion regarding Serotype 3 Associated 
Pneumococcal Meningitis 
10.3.4.1  Phenotypic variants within Serotype 3 
In the serotype 3 pneumococcus, it has been elucidated that mutations in the genome can 
result in phenotypic variants generated in response to a change in the host environment 
(particularly  within  a  biofilm  environment).  These  are  likely  to  have  an  adaptational 
advantage  for  survival  in  a  more  hostile  environment.  Until  recently,  only  one  such 
mechanism  had  been  described  –  phase  variation.  But  now  non  phase  variable  colony 
variants  which  are  generated  in  response  to  an  environmental  change  have  also  been 
described (Allegrucci and Sauer, 2008, Allegrucci and Sauer, 2007). 
10.3.4.1.1  Phase Variants 
The phenomenon of phase variation is described in Chapter 1. The transparent phenotype 
has  more  cell  wall  phosphorylcholine,  less  capsular  polysaccharide  and  has  different 
surface proteins compared to the opaque phenotype (Ring et al., 1998, Weiser and Kapoor, 
1999). Although they did not assess any serotype 3 isolates, Ring et al found that the 
transparent  phenotype  resulted  in  increased  invasion  of  pneumococci  across  the  blood 
brain barrier by as much as 6 fold compared to opaque phenotype (Ring et al., 1998) 
whereas opaque variants survive better than transparent in the bloodstream and are integral     Chapter 10, 208 
to  invasive  infection  (Overweg  et  al.,  2000b).  Higher  rates  of  transformation  occur  in 
transparent  variants  compared  to  opaque  so  it  seems  that  less  capsule  (transparent 
phenotype) enhances transformation (Weiser and Kapoor, 1999). It has been proposed that 
the change in cell surface components which occurs in phase variation (Overweg et al., 
2000b) is important for pathogenicity (Bruckner et al., 2004). The reversible nature of the 
capsular mutations which account for these phase variants in serotype 3 is considered in 
Chapter 6. 
10.3.4.1.2   Non revertible variants 
In addition to phase variation, serotype 3 pneumococci also generate mucoid and non-
mucoid  variants  by  a  different  mechanism  entirely  (a  large  deletion  in  the  cps3DSU 
capsule operon) (Allegrucci and Sauer, 2008). This occurs at high frequency and unlike 
phase  variants,  these  are  not  revertible  (Allegrucci  and  Sauer,  2008).  It  has  also  been 
demonstrated  that  hydrogen  peroxide  plays  a  role  in  their  emergence  (Allegrucci  and 
Sauer,  2008).  Hydrogen  peroxide  is  also  known  to  be  mutagenic  in  several  other 
pneumococcal serotypes, triggering frameshifts resulting from the reversible gain and loss 
of  single  bases,  deletions  resulting  from  recombination  and  substitutions  of  guanine 
residues – the net result of which can change the pneumococcal phenotype as has been 
shown by spontaneous mutation to optochin resistance (Pericone et al., 2002, Battig and 
Muhlemann, 2007) or rifampicin resistance (Battig and Muhlemann, 2007). 
These mutants which are unable to revert to wild type serotype 3 capsule expression may 
be at a disadvantage in blood stream infections but it is plausible, although unproven, that 
they have enhanced ability to penetrate CSF by crossing the blood brain barrier or have a 
survival advantage in the CSF. It is established that the production of hydrogen peroxide 
by pneumococci is implicated in the pathogenesis of pneumococcal meningitis where it 
contributes to neuronal apoptosis (Braun et al., 2002), causes ciliary stasis of ependymal 
cells (Hirst et al., 2000), vasodilation and subsequent increased cranial pressure (Hoffman 
et al., 2007). If hydrogen peroxide is a stimulus to mutation and the generation of non-
revertible  phenotypic  variants  it  may,  in  the  same  microenvironment  create  an  altered 
phenotype able to cross the blood brain barrier by a paracellular route (Koedel et al., 2002) 
precisely in a region whose integrity has been compromised by simultaneous hydrogen 
peroxide  induced  vasodilation.  This  would  challenge  current  beliefs  that  pneumococci 
cross the blood brain barrier by a transcellular route (Koedel et al., 2002). Intriguingly, a 
gene which codes for a protein thought to be a peroxide resistance protein or non-heme 
iron-containing ferritin (SP1572) is downregulated in CSF compared to blood suggesting a 
need for peroxide resistance in blood but not once past the blood brain barrier – a finding     Chapter 10, 209 
also documented by Orihuela et al (Orihuela et al., 2004b).  The ability to generate non-
revertible phenotypic variants is not unique to serotype 3 but Allegrucci et al also have 
observed  this  in  serogroup  19  pneumococci  (Allegrucci  and  Sauer,  2008)  which  could 
explain why some serotypes are more prone to cause meningitis and is entirely compatible 
with epidemiological observations that serotype 19F is associated with causing meningitis 
with a high associated mortality (Skoczynska and Hryniewicz, 2003, Burman et al., 1986, 
Reis et al., 2002, Urwin et al., 1996). 
10.3.4.2  Choline binding protein A 
It  has  been  shown  that  choline  binding  protein  A  (CbpA  or  SP2190)  is  necessary  for 
pneumococci to cross the blood brain barrier (Ring et al., 1998, Orihuela et al., 2004a, 
Orihuela et al., 2003) by binding to the human polymeric immunoglobulin receptor (pIgR) 
and crossing the capillary endothelium by transcytosis (Koedel et al., 2002). This is related 
to a transparent phase variant phenotype as the transparent phase variant expresses greater 
amounts of CbpA (Ring et al., 1998).  When grown in BHI broth as planktonic cultures, 
CbpA is expressed in both isolates from blood and CSF at low levels but the fact that it is 
found to be expressed is compatible with the above hypothesis. Interestingly, Orihuela et al 
did not identify a difference in expression of SP2190 in blood or CSF using serotype 2 
(D39 Xen 7) and serotype 4 (TIGR4) pneumococci using microarray experiments either 
even when bacteria were harvested straight from rabbit CSF (Orihuela et al., 2004b). 
10.3.4.3  The role of iron 
At the start of this chapter it was noted that transcriptional regulators often play a role in 
virulence. SP0376 is such a gene. Its homolog in R6 nomenclature is spr0336 but it is also 
known as RitR (Repressor of Iron Transport) or the orphan response regulator and is one of 
the pneumococcal two component systems which can sense changes in the environment 
and elicit a transcriptional response (Paterson et al., 2006).   
RitR has been identified as having a role in iron transport in the pneumococcus (Ulijasz et 
al., 2004a). Expression of RitR represses iron uptake in vitro by downregulating an iron 
carrier protein piuA (Ulijasz et al., 2004a). Intriguingly, there is a relationship between iron 
and hydrogen peroxide as iron catalyses the production of deleterious oxygen free radicals 
from hydrogen peroxide by means of the Fenton reaction (Ulijasz et al., 2004a, Pericone et 
al.,  2003).  Consequently,  the  pneumococcus  will  decrease  iron  concentrations  in  the 
presence  of  hydrogen  peroxide.  The  results  above  suggest  that  SP0376  (RitR)  is 
downregulated  in  the  CSF  while  two  of  the  genes  which  it  regulates  SP1869  (Iron-    Chapter 10, 210 
compound  ABC  transporter,  permease  protein)  and  SP1872  (Iron-compound  ABC 
transporter, iron-compound-binding protein) are upregulated in the CSF as shown in Figure 
10-4.  
 
Figure   10-4 Comparison of the significant differences in expression of SP0376 and SP1872 
in isolates 99-4038 (blood origin) and 99-4039 (CSF origin) 
This  figure  is  generated  by  Genespring  GX  7.3.1.  The  white  lines  indicate  the 
downregulation of SP0376 in the CSF isolate and upregulation of SP1872 in the CSF isolate. 
 
These differences in gene expression were also investigated by RT-PCR as demonstrated 
below in Figure 10-5.     Chapter 10, 211 
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Figure   10-5 qRT-PCR results relating to gene expression of SP0376 (RitR) in blood and CSF 
isolates and the upregulation of SP1869 and SP1872 in a CSF isolate compared to a blood 
isolate.  
P values for the difference in mean normalized expression between blood and CSF isolates 
were calculated using an unpaired t-test calculated by Q-gene software (Muller et al., 2002) 
and were for SP0376 (p = 0.121), SP1869 (p = 0.005) and SP1872 (p = 0.014). Error bars 
indicate standard errors of the mean normalized expression calculated by Q-gene.  
 
It was unexpected that the difference in mean normalized expression for SP0376 (RitR) 
when tested by qRT-PCR did not reach statistical significance whereas the differences in 
expression  of  the  two  genes  which  SP0376  regulates  (SP1869  and  SP1872)  were 
significantly different by both microarray and qRT-PCR approaches. This still suggests 
that in this case of human meningitis, a non revertible mutation or an environmental factor 
may have affected the expression of RitR so that expression levels are higher in the blood 
than the CSF with a consequent increase in iron uptake in CSF compared to blood. This 
may  be  a  response  to  the  bloodstream  environment  being  rich  in  bound  iron  but  the 
potential interplay with hydrogen peroxide cannot be ignored. If, as proposed above, the 
pneumococcus generates hydrogen peroxide locally at the blood/endothelial surface after 
binding via choline binding protein A, the effects of this may be the generation of stable     Chapter 10, 212 
non  revertible  mutations  and  a  compromised  blood  brain  barrier  resulting  from  local 
vasodilation and/or neuronal apotosis at the same site. It is entirely plausible that, within 
the blood, at this region of local hydrogen peroxide release, iron concentrations are being 
regulated by RitR to remain low locally to aid survival of the pneumococcus by preventing 
the Fenton reaction.  Such a critical role may also explain why neither RitR nor the iron 
compound ABC transporters SP1869-SP1872 are located in a known region of diversity in 
the pneumococcal genome (Silva et al., 2006). 
SP1871 (another iron compound ABC transporter) also appeared to be upregulated in CSF. 
Pandya et al found that SP1871 is significantly affected by temperature changes being 
upregulated at 29°C, 33°C and 40°C when compared to 37°C. It was one of only 8 genes 
upregulated at 40°C (Pandya et al., 2005). Both hypothermia or hyperthermia and body 
temperature  dysregulation  may  be  a  host  response  to  intracranial  pathology  including 
infection and so the temperature related upregulation of this gene may be important for the 
survival of the pneumococcus within the CSF once it has passed the blood brain barrier, 
established infection and is responding to further changes in the host environment.  
10.4 Pneumococcal Cerebral Abscess 
10.4.1  Background 
Pneumococcal  cerebral  abscesses    are  uncommon  but  are  associated  with  significant 
morbidity (40% of survivors are left with neurological deficits) and high mortality (case 
fatality  rate  of  35%  in  one  series)  despite  appropriate  antibiotic  therapy  and  surgery 
(Grigoriadis and Gold, 1997). Serotype 3 pneumococci have historically been associated 
with cerebral abscesses (Fincher, 1946, Anonymous, 1970, Colman and Hallas, 1983) and 
in  a  rat  experimental  meningitis  model,  serotype  3  pneumococcal  infections  have  a 
preponderance  to  cause  cortical  necrosis  and  abscess  formation  whereas  serotype  1 
infections  are  more  associated  with  cortical  haemorrhage  and  not  abscess  formation 
(Ostergaard et al., 2004). 
The MLST records of pneumococcal isolates grown from cerebral abscess pus in Scotland 
were identified and serotype 3 isolates chosen in order to perform microarray DNA CGH 
and RNA expression experiments to identify virulence associated genes in order to gain 
further understanding of the pathogenesis of this condition.     Chapter 10, 213 
10.4.2  Serotype and MLST distribution of Cerebral Abscess 
Associated Pneumococci in Scotland 
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Figure   10-6 Distribution of pneumococcal serotypes associated with cerebral abscesses in 
Scotland 1993-2007 (n=9). 
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Figure   10-7 Distribution of pneumococcal MLSTs associated with cerebral abscesses in 
Scotland 1993-2007 (n=9). 
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10.4.3  Serotype 3 ST180 DNA CGH Hybridizations 
Microarray CGH was performed on two cerebral abscess associated isolates (00-3946 and 
06-1705).  These results feature in Figure 6-1 in Chapter 6.  
10.4.4  RNA Expression of Serotype 3 ST180 Cerebral 
Abscess Associated Isolates 
RNA was extracted and utilised in microarray expression experiments according to the 
procedures  outlined  in  Chapter  2.  Data  analysis  in  Genespring  GX  7.3.1,  involved 
normalizing  the  invasive  serotype  3,  ST180  related  data  from  Figure  6-1  into  two 
categories  of  cerebral  abscess  or  non-cerebral  abscess  related  isolates  and  the  gene 
expression levels in these two merged categories were compared (Table 10-7). The gene 
prediction function of Genespring GX 7.3.1 was used to generate a list of 30 genes whose 
expression was associated with the presence of a cerebral abscess. 
Gene 
Normalized 
Intensity 
Ratio in 
non 
cerebral 
abscess 
ST180s 
Normalized 
Intensity 
Ratio in 
Cerebral 
abscess 
ST180s  Gene Function 
Upregulated in cerebral abscess 
spr0957  1.3  102.3  SpR6: Tn5252, relaxase, truncation 
SP0110  0.9  6.0 
ABC transporter membrane-spanning 
permease - amino acid transport 
SP0111  1.1  3.1 
ABC transporter ATP-binding protein - 
amino acid transport 
Downregulated in cerebral abscess 
SP1185  0.9  0.3 
PTS system, lactose-specific IIBC 
component 
SP0577  1.2  0.3 
PTS system, beta-glucosides-specific IIABC 
components 
SP1686  1.1  0.5  Oxidoreductase, Gfo/Idh/MocA family 
SP1688  1.1  0.5  ABC transporter, permease protein 
 
Table   10-7 Genes identified by Genespring GX 7.3.1. as upregulated or downregulated  in 
cerebral abscess associated serotype 3 ST180 isolates compared to non cerebral abscess 
related serotype 3 ST180 isolates.  
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Gene 
Predictive Strength for 
Cerebral Abscess  Function 
SP0877  27.0 
Fructose specific-phosphotransferase system 
IIBC component 
SP1474  20.9  Glycyl-tRNA synthetase beta chain 
SP1592  16.6  Conserved domain protein 
SP0830  16.6  Hypothetical protein 
SP0066  16.1  Aldose-1-epimerase (mutarotase) 
SP1097  14.9  Conserved hypothetical protein 
SP0831  14.7 
Purine nucleoside phosphorylase (inosine 
phosphorylase) 
SP0876  14.7  Fructose-1-phosphate kinase 
SP0833  14.7  Hypothetical protein 
SP1100  14.6  Phosphate acetyltransferase 
SP0834  14.4  Hemolysin-related protein 
SP0629  14.1  Conserved hypothetical protein 
SP0829  12.8  Phosphopentomutase 
SP0828  12.8  Ribose 5-phosphate isomerase 
SP1563  12.7 
Pyridine nucleotide-disulphide oxidoreductase 
family protein 
SP1701  12.7  Phospho-2-dehydro-3-deoxyheptonate aldolase 
SP2096  12.7  Peptidase, M20/M25/M40 family 
SP1192  11.4  Galactose-6-phosphate isomerase, LacB subunit 
SP1193  11.4  Galactose-6-phosphate isomerase LacA subunit 
SP0110  10.7 
ABC transporter membrane-spanning permease 
- amino acid transport 
SP0782  9.6  Conserved hypothetical protein 
SP0605  5.9  Fructose-bisphosphate aldolase 
SP2192  5.9  Sensor histidine kinase 
SP0445  5.5 
Acetolactate synthase, large subunit, 
biosynthetic type 
SP2002  5.4  Conserved hypothetical protein 
SP0015  5.1  IS630-Spn1, transposase Orf1 
SP1591  4.7  Proline dipeptidase 
SP1988  4.6  Conserved hypothetical protein 
SP1417  4.3  Choline binding protein 
SP0438  4.3  Glutamyl tRNA-Gln amidotransferase, subunit C 
Table   10-8 Genes identified by Genespring GX 7.3.1. as predictive of a cerebral abscess 
associated phenotype when compared to non cerebral abscess related serotype 3 ST180 
isolates.  
 
10.4.5  Discussion regarding pneumococcal cerebral 
abscesses 
This  is  the  first  case  series  of  pneumococcal  cerebral  abscesses  to  be  described  from 
Scotland and the first to investigate which sequence types are implicated. These results are 
consistent with historical case reports and animal model experiments which demonstrate 
serotype 3 pneumococci as being associated with cerebral abscess formation. Only the 
cases caused by serotype 4 and 19F were preventable using the PCV-7 conjugate vaccine     Chapter 10, 216 
formulation  with  78%  of  cases  not  preventable,  highlighting  a  need  for  alternative 
prevention strategies or conjugate vaccination with higher valency vaccines. 
Such alternative strategies would benefit greatly from further understanding of the genetic 
basis of the pathogenesis of this condition. Microarray CGH experiments demonstrate that 
the cerebral abscess associated serotype 3 isolates show much genomic diversity at 14 
known  regions  of  diversity  when  compared  to  the  fully  sequenced  serotype  4 
pneumococcal isolate, TIGR4 (shown in Appendix 12). When compared to each other, 
there is much less genetic diversity between the serotype 3 cerebral abscess isolates despite 
their origins from different patients, in different parts of Scotland and occurring six years 
apart.    Consequently,  development  of  a  preventive  strategy  which  focused  on  utilising 
these conserved genes or their transcripts could be successful in preventing up to a third of 
cases.  
However,  caution  is  required  in  interpreting  these  results  as  the  RT-PCR  experiment 
described in Chapter 6 comparing the gene expression of SP0110 in the cerebral abscess 
associated  isolate  (00-3946)  and  non  cerebral  abscess  related  isolate  (OXC141) 
demonstrated  that  there  was  no  significant  difference  in  their  gene  expression  by  that 
method  and  that  the  results  generated  by  Genespring  GX  7.3.1  were  likely  spurious 
resulting from the normalization procedure used to merge the expression data into two 
categories.  This highlights the need for independent confirmation of data generated from 
microarray gene expression experiments and the dangers of indiscriminately applying in 
silico results to clinical cases (Chuaqui et al., 2002).   
10.5 Overall Discussion Regarding Gene Associations 
with Invasive Pneumococcal Disease Manifestations 
This  series  of  investigations  using  microarray  technology  to  investigate  the  potential 
influence  that  genomic  diversity  has  on  determining  disease  manifestations  of  IPD 
demonstrated several factors which require consideration when interpreting the results.  
One basic assumption from this approach has been that the disease manifestation relates 
solely to the genotype and consequent phenotype of the pneumococcus and it does not 
consider host factors to be contributing. This clearly is not the case as pathology is the 
result of an interplay between host and pathogen and the 50 to 100 fold higher incidence of 
IPD in immunocompromised human hosts with HIV (Flannery et al., 2006) compared to     Chapter 10, 217 
the non-HIV infected population or the effect of patient age on the distribution of serotypes 
causing IPD (Inostroza et al., 2001), demonstrates that host factors do contribute to the 
incidence and manifestations of IPD.  
A further assumption has been that microarray technology is a suitable platform by which 
to accurately compare pneumococcal genomes. The results of DNA based CGH in this 
chapter  are  similar  to  those  in  previous  chapters  in  that  they  indicate  that  lack  of 
hybridization  of  a  gene  cannot  be  assumed  to  mean  that  the  gene  is  absent  from  the 
genome as lack of hybridization is often due to the gene being present (as demonstrated by 
PCR) but in a form which is not complementary to the TIGR4 sequence based probe on the 
microarray. This level of insensitivity makes interpretation of the significance of lack of 
hybridization impossible without further validation by PCR and/or genome sequencing and 
so the microarray CGH approach using this “spotted” PCR product microarray alone can 
only at best be regarded as a screening tool to allow a focus on particular regions where 
genes may show sequence diversity when compared to the TIGR4 genome.  
This  is  not  to  say  that  the  microarray  does  not  have  a  role  in  the  investigation  of 
pathogenesis as the above studies using the microarray to analyse RNA expression have 
shown.  By  this  approach,  significant  insights  into  potential  mechanisms  of  disease  for 
pneumococcal meningitis and empyema have been possible which can now be utilised to 
develop  new  diagnostic  tests,  develop  possible  pharmacological  therapies  or  target 
therapeutic interventions. Nevertheless, significant caution is required when extrapolating 
in silico results to a wider population as has been demonstrated with our investigations into 
cerebral abscess pathogenesis where genes could be identified as significant which clearly 
are not when investigated by another method (qRT-PCR). This is likely to be the end result 
of a series of factors such as poorly chosen “control” isolates, study of too small a number 
of  isolates  and  over-dependance  on  statistical  procedures  to  merge  a  diverse  bacterial 
population into two categorical variables of cerebral abscesses being present or absent. 
This has introduced confounding such as that produced by high expression of a gene (e.g. 
SP0110) in one isolate when the gene is not actually present in all isolates of that category 
which may suggest overall significance but biologically cannot be significant if it is not 
actually present in the genome of some cases.  
These  results  do  highlight  other  issues  relating  more  generally  to  experimental  design 
when investigating pneumococcal pathogenesis as they add to a growing body of evidence 
that suggests that with clinical isolates, source tissue or body fluid may influence gene 
expression and the overall results of an investigation (Ogunniyi et al., 2007, Orihuela et     Chapter 10, 218 
al., 2004a) and so documentation of the details of the source isolate should be regarded as 
essential. There are also implications regarding choice of media for in vitro cultures as 
arbitrarily chosen in vitro conditions may not be representative of in vivo conditions and 
alterations  in  culture  conditions  do  affect  virulence  gene  expression  in  many  bacterial 
species (Pandya et al., 2005). Pneumococci, even when in pure culture grown from a single 
colony, may not be homogeneous populations but, as stated by Weiser et al,  
“an  isolate  should  be  considered  a  mixed  population  of  phenotypes  which 
differ in amounts of capsular polysaccharide, teichoic acid and choline binding 
proteins (Weiser and Kapoor, 1999).”  
As early as 1981, Andersson et al saw that pneumococcal isolates cultured from different 
body sites had different abilities to colonise the nasopharynx and cause invasive disease in 
a mouse model but were unable at that time to determine a genetic basis for such different 
behaviour (Andersson et al., 1981).  
Ideally, investigations of pneumococcal gene expression would be most representative if 
performed  from  specimens  taken  directly  from  a  human  patient.  Apart  from  ethical 
considerations such as informed consent, which would need to be broached in advance of 
an  individual  falling  ill  from  an  incapacitating  severe  manifestation  of  IPD  such  as 
meningitis and the confounding effects of antimicrobial therapy which would be unethical 
to withhold, there are technical difficulties in obtaining sufficient quantities of bacterial 
RNA directly from blood separated from host human RNA (Shaw and Morrow, 2003) 
although this has been possible on occasion in mice (Orihuela et al., 2004b).   
The  recent  description  of  non  revertible  colony  variants  resulting  from  stable  point 
mutations triggered by local hydrogen peroxide (Allegrucci and Sauer, 2008) together with 
existing understanding of the reversible serotype 3 capsular mutations found in opaque and 
transparent phase variants (Waite et al., 2001, McEllistrem et al., 2007) is of significance 
if these results are due to biofilm-derived, non revertible colony variants from different 
body sites whose particular phenotypes have been selected for adaptation to different host 
environments. Determining this is likely to be beyond the resolving capacity of a “spotted” 
microarray  approach  though,  particularly  when  the  genes  which  are  most  likely  to  be 
involved (the serotype 3 capsular genes) are not represented by probes on this microarray. 
King et al, compared gene expression of opaque and transparent phenotypes of serotype 
6A and 6B strains on a “spotted” microarray though and identified 24 genes which were 
significantly differentially expressed between the two phenotypes (King et al., 2004). Of 
these 24 genes, only SP2150 (ornithine carbomyltransferase) appears in our comparison of     Chapter 10, 219 
serotype  3  isolates  99-4038  and  99-4039  suggesting  that  the  differences  we  see  in 
expression of blood and CSF isolates are not due to phase variation. Although the genes 
involved in phase variation may differ between serotypes and isolates (King et al., 2004), a 
non revertible mutation triggered by hydrogen peroxide rather than phase variation fits 
more with the current body of evidence implicating hydrogen peroxide in the pathogenesis 
of cerebral damage and the control of iron metabolism in limiting the toxicity of hydrogen 
peroxide to the pneumococcus. Given the substantial number of permutations of minor 
point mutations now documented in the house-keeping genes (chosen as they were not 
thought to vary substantially) employed in the MLST scheme, it seems rational that point 
mutations in other essential genes will be occurring with the potential to alter virulence. 
The observation of this occurrence affecting pneumolysin (Jefferies et al., 2007, Kirkham 
et al., 2006), is further supporting evidence to corroborate this hypothesis.  Significantly, 
preliminary data from 454 sequencing of these two strains identifies 31 SNPs which are 
present  in  99-4039  compared  to  99-4038  (Nicholas  Croucher,  Wellcome  Trust  Sanger 
Institute). Although none of these occur in the serotype 3 capsular genes or ritR, three of 
these  are  of  substantial  interest  as  they  occur  within  the  open  reading  frames  of 
transcriptional regulators. CcpA and  LysR  (SP0927) are affected by transpositions and 
interestingly  a  deletion  is  present  in  the  CSF  associated  ArgR  gene.  Although  no 
significant differences in expression for these genes were noted in our analysis using the 
current parameters, there may still be an undetected, biologically significant, differential 
expression of these mutant genes in blood and CSF sufficient to cause downstream effects 
which may alter the expression of ritR or genes coding for iron binding and this requires 
further investigation. 
Finally, it has been proposed that for any particular pneumococcal isolate it will,  
“probably carry only the particular subsets of genes that permit them to cause 
the  distinct  forms  of  disease  associated  with  each  strain  (Orihuela  et  al., 
2003).” 
 If that is so, then it should be possible to identify  core sets of  genes associated with 
different  disease  manifestations  such  as  we  have  attempted  to  generate  using  the 
Genespring GX 7.3.1 gene predictor tool. By comparing such lists, when generated from a 
large enough sample of relevant isolates, it may be possible to infer whether a particular 
isolate has the potential for more than one disease manifestation and identify core subsets 
of genes which could be targeted for therapeutic interventions. 
  
11   Diversity of Pneumococcal Gene Expression in 
Response to an Antibiotic 
11.1 Physicochemical Properties of Clarithromycin 
Clarithromycin  is  a  14-membered  macrolide  antibiotic  which  is  structurally  related  to 
erythromycin through substitution at the 6
th carbon atom of the erythronolide ring with a 
methoxy group (Hardy et al., 1992, Hardy et al., 1988) as shown in Figure 11-1. Unlike 
erythromycin  it  is  acid  stable  and  undergoes  hepatic  metabolism  to  a  compound  with 
antimicrobial  activity  –  14hydroxyclarithromycin  (Hardy  et  al.,  1992).  It  has  55% 
bioavailability  in  its  oral  form  (Jain  and  Danziger,  2004)  and  reaches  peak  tissue 
concentrations 4 hours after oral administration (Hardy et al., 1992) being excreted via 
urine and bile (Jain and Danziger, 2004). The serum half life is approximately 5 hours 
(Jain and Danziger, 2004). Tissue (particularly lung and nasal tissue) concentrations are 
higher  than  those  in  blood  which  accounts  for  its  effectiveness  against  a  range  of 
respiratory  bacterial  pathogens  (Hardy  et  al.,  1992,  Jain  and  Danziger,  2004).    It  also 
penetrates well intracellularly into alveolar macrophages (Jain and Danziger, 2004). 
 
Figure   11-1 Structure of clarithromycin. 
Figure is adapted from (Hardy et al., 1992)) with the methoxy group which differentiates 
clarithromycin from erythromycin circled in red.     Chapter 11, 221 
11.2 Mechanism of Action of Clarithromycin 
Like all macrolides, clarithromycin  exerts its antibacterial action by preventing protein 
synthesis. It does this by binding reversibly to 23S ribosomal RNA in the 50S subunit of 
bacterial  ribosomes  (Jain  and  Danziger,  2004).  Two  theories  exist  as  to  how  protein 
synthesis is disrupted. The first is that peptidyl transfer reactions are inhibited resulting in 
incomplete peptide chains detaching from the ribosome. The second is that dissociation of 
peptidyl-tRNA from the ribosome is stimulated, resulting in immature proteins (Jain and 
Danziger, 2004). Clarithromycin is classed as a bacteriostatic antibiotic but it has been 
shown to be bactericidal against the pneumococcus (Jain and Danziger, 2004).  
11.3 Resistance Mechanisms associated with 
Clarithromycin 
The diverse mechanisms of macrolide resistance are outlined in Chapter 1.  
11.4 Putative Effects of Clarithromycin at Subtherapeutic 
Concentrations 
11.4.1  Anti-inflammatory and Immunomodulatory Effects 
Shinkai et al define immunomodulation as,  
“the activity of suppressing the prolonged activation of the inflammatory and 
immune  system  that  can  lead  to  adverse  effects  on  the  host;  but  without 
globally  affecting  the  innate  immune  responses  as  would  be  seen  with  an 
immunosuppressive agent (Shinkai et al., 2005).” 
For instance, in a murine model of pneumococcal pneumonia, a macrolide (HMR 3004) 
has been shown to inhibit interleukin 6 and nitric oxide synthesis (Chu, 1999). 
In their review Shinkai et al also note that,  
“macrolides have been reported to regulate prolonged or hyperinflammation by 
effects on cellular immunity, suppressing the production of pro-inflammatory 
cytokines  and  reactive  oxygen  species,  blocking  the  activation  of  nuclear 
transcription  factors,  inhibiting  neutrophil  activation  and  mobilization, 
accelerating neutrophil apoptosis and improving mucus clearance (Shinkai et 
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Tsai  and  Standiford  review  the  mechanisms  of  action  of  macrolides  on  pleural 
inflammation, respiratory  tract infection, airways inflammation, pulmonary fibrosis and 
immune  mediated  lung  diseases  (Tsai  and  Standiford,  2004).  Because  of  these  effects,  
clarithromycin has an established role in the management of diffuse panbronchiolitis and 
cystic fibrosis because of its immunomodulatory effects rather than antibacterial effects 
(Amsden, 2005, Shinkai et al., 2005).  
11.4.2  Anti-neoplastic Effects 
Clarithromycin  increases  the  production  of  interferon-γ  and  interleukin  4  by  T-cells 
resulting in a decrease in tumour growth in a murine model of primary lung cancer. It also 
enhances CD8
+ T-cell cytotoxicity and Natural Killer cell activity (Tsai and Standiford, 
2004,  Hamada  et  al.,  2000).  The  net  result  of  the  actions  has  been  demonstrated  as 
reduction in primary tumour size and reduction in lung metastases and increased tumour 
apotosis (Tsai and Standiford, 2004). A further effect of clarithromycin on tumours is to 
affect the formation of blood vessels (Yatsunami et al., 1999). The clinical application of 
this was to demonstrate a survival benefit in patients with advanced non-small cell lung 
cancer in patients receiving clarithromycin (Mikasa et al., 1997). 
11.4.3  Transcriptional modulation 
At  concentrations  below  its  Minimum  Inhibitory  Concentrations  (MIC),  the  macrolide 
antibiotic erythromycin has been shown to influence the transcription of 5-10% of bacterial 
genes in Salmonella typhimurium which, despite altering gene expression in some cases by 
10-100 fold, had little effect on growth (Goh et al., 2002). Interestingly at concentrations 
above  the  MIC,  few  transcriptional  changes  occurred.  Clarithromycin  also  alters  gene 
transcription at sub therapeutic concentrations in S. typhimurium (Tsui et al., 2004). By 
demonstrating this phenomenon of hormesis (a different response to a molecule at low 
concentration  (transcriptional  regulation)  compared  to  higher  concentration  (growth 
inhibition), Tsui et al postulate that,  
“subinhibitory concentrations identify responses that more accurately  reflect 
antibiotic mode of action and … these effects might represent the “natural” role 
of antibiotics, since in the environment the concentrations of these molecules 
rarely attain inhibitory levels (Tsui et al., 2004).”     Chapter 11, 223 
11.4.4  Disruption of Quorum Sensing 
Although not demonstrated in the pneumococcus, macrolide antibiotics have the ability to 
alter bacterial cell to cell signalling (quorum sensing) within colonies of Pseudomonas 
aeruginosa resulting in the regulation of virulence factors which may account for improved 
clinical outcomes when macrolides are administered to patients with cystic fibrosis and 
bronchiectasis colonised with biofilms of P. aeruginosa against which macrolides have no 
conventional anti-bacterial activity (Tateda et al., 2004). As pneumococci may also form 
biofilms, it is reasonable to postulate that macrolides may have a role in affecting the 
quorum sensing between pneumococci. 
Tsui  et  al  after  demonstrating  effects  of  subtherapeutic  macrolide  antibiotics  on  S. 
typhimurium suggest (Tsui et al., 2004): 
“The  transmission  of  signals  from  ribosome  to  RNA  polymerase  due  to 
subinhibitory  macrolides  could  involve  the  release  of  small  amounts  of 
incomplete  polypeptides,  interference  with  ribosome  assembly,  induction  of 
translation errors, or possibly interactions of small molecules with RNA. The 
sequelae of all these events may be low-level stress responses that act through 
one of the many bacterial sigma factors to activate or repress specific sets of 
transcripts.  These  changes  might  also  result  in  compensating  effects  on  the 
transcription of nodes of linked metabolic networks.” 
11.4.5  Effects on Virulence Factors 
It  has  been  established  that  macrolide  antibiotics  reduce  the  production  of  the 
pneumococcal  virulence  factor  pneumolysin  when  administered  in  concentrations  both 
above and below their established breakpoint concentrations and it is postulated that this 
may account for their beneficial clinical effects even when administered to patients with 
pneumonia infected with macrolide resistant strains of S. pneumoniae (Anderson et al., 
2007, Fukuda et al., 2006).   
11.5 Role of Clarithromycin in the Management of IPD 
Unlike  the  USA,  macrolide  monotherapy  is  only  recommended  for  the  treatment  of 
community acquired pneumonia (CAP) in the United Kingdom in patients who have failed 
to respond to a course of amoxicillin with non severe CAP although dual therapy of a 
macrolide with amoxicillin is preferred in this circumstance. A macrolide may be used as 
an alternative to amoxicillin for oral therapy in non-severe CAP where there is evidence of     Chapter 11, 224 
penicillin hypersensitivity. Erythromycin or clarithromycin may be used intravenously in 
combination with ampicillin or benzylpenicillin when oral therapy is contraindicated in 
non  severe  CAP  or  in  combination  with  a  beta  lactamase  stable  antibiotic  like  co-
amoxyclav or a second or third generation cephalosporin (BTS, 2001). 
There is no role for macrolide antibiotics in the management of pneumococcal meningitis 
nor are they advised in the empiric treatment of otitis media, empyema or cerebral abscess 
(Gilbert et al., 2008).  
11.6 Experimental Design to Assess Pneumococcal Gene 
Expression in the Presence of Subtherapeutic 
Clarithromycin Concentrations  
11.6.1  Growth of Strain South Africa 2507 for RNA Extraction 
Three 50ml aliquots of fresh BHI broth taken from the same batch were each inoculated 
with 500ml of a freshly thawed glycerol stock of strain South Africa 2507 (total viable 
count = log10 8.392 CFU/ml). These were incubated in a water bath at 37°C and the optical 
density monitored until it reached midlog (Optical Density = 0.6 at 600nm).  
At this point, 10ml of each of the three cultures was removed and centrifuged at 5000 rpm 
at room temperature. The supernatant was decanted and the pellet immediately frozen in 
liquid nitrogen and stored at -80°C prior to RNA extraction.  
The  remaining  culture  was  split  into  paired  18ml  aliquots.  From  one  of  each  pair, 
clarithromycin was added to a final concentration of 5mg/L while no changes were made 
to its corresponding culture and both samples were returned to the water bath to incubate at 
37°C.  After 15 minutes (when the cultures were still in the logarithmic growth phase as 
shown in Figure 11-4),  10ml of culture from  each pair  was extracted,  centrifuged  and 
frozen in liquid nitrogen as above.  
11.6.2  RNA Extraction from Strain South Africa 2507  
This was performed according to the protocols described in Chapter 2. The quality of the 
RNA  was  assessed  using  an  Agilent  2100  Bioanalyzer  (Agilent  Technologies,  United     Chapter 11, 225 
Kingdom) which identified all samples as having an RNA Integrity Number between 9.8 
and 10.  
11.6.3  Microarray Comparative Genomic Hybridization 
Analysis 
Three separate RNA preparations were used for each microarray hybridization experiment 
from each of 3 categories: Strain South Africa 2507 at midlog prior to the addition of 
clarithromycin  versus  TIGR4  at  midlog,  Strain  South  Africa  2507  15  minutes  after 
reaching midlog but with the addition of clarithromycin 5mg/L versus TIGR4 at midlog 
and Strain South Africa 2507 15 minutes after reaching midlog without the addition of 
clarithromycin versus TIGR4 at midlog. 
Hybridization and data analysis was performed according to protocols in Chapter 2. 
11.6.4  Quantitative RT-PCR Validation of Microarray Data 
Using the three biological replicates of RNA prepared above at midlog and then in the 
presence and absence of clarithromycin 15 minutes after midlog, cDNA was synthesised 
according  to  the  protocol  in  Chapter  2.  cDNA  concentrations  were  measured  using  a 
NanoDrop®  ND-1000  spectrophotometer  (NanoDrop®  Technologies,  USA)  and  the 
cDNA  was  then  used  in  a  qRT-PCR  reaction  using  SYBR®  Green  in  a  Roche 
Lightcycler® 480 (Roche Applied Science, United Kingdom).  The expression of three 
genes (whose expression was identified on the microarray as being altered in the presence 
of  5mg/L  clarithromycin  (SP0740,  SP0800  and  SP1631))  was  examined  by  qRT-PCR 
(Figure 11-5). The primer sequences used were those used in the manufacture of the PCR 
product amplicons utilised in the manufacture of the microarray displayed in Appendix 3. 
The expression of the genes pneumolysin and ErmB was also investigated using qRT-PCR 
(Figure  11-6).  TIGR4  and  GyrA  RNA  were  used  as  a  positive  control  and  negative 
controls were nucleic acid free water (no cDNA negative control) and the original RNA 
(no reverse transcription control). Standard curves were constructed and qRT-PCR reaction 
efficiencies  were  calculated  using  Microsoft  Office  Excel  2003  (Microsoft®,  United 
Kingdom) and comparison of the mean normalized gene expressions in the presence and 
absence of 5mg/L clarithromycin at the same time point was calculated using Q Gene 
(Muller et al., 2002). 
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11.7 Strain South Africa 2507 
11.7.1  Antibiotic sensitivities 
The  antibiotic  sensitivities  of  South  Africa  2507  have  previously  been  determined  and 
published  for  erythromycin  (MIC>256mg/L),  clarithromycin  (MIC>256mg/L)  and 
ceftriaxone (MIC = 0.5mg/L)(Anderson et al., 2007). 
11.7.2  Calculation of Clarithromycin Minimum Inhibitory 
Concentration (MIC) 
Calculation  of  a  MIC  for  clarithromycin  for  isolate  South  Africa  2507  was  performed 
initially using a clarithromycin E-test (AB Biodisk, Sweden) with confluent colonies of 
South Africa 2507 grown on Mueller Hinton agar with 5% horse blood (E&O Laboratories 
Limited, United Kingdom) using TIGR4 as a control pneumococcal isolate with known 
sensitivity to clarithromycin. This demonstrated an MIC of clarithromycin for isolate South 
Africa 2507 of >256mg/L while the MIC for clarithromycin for TIGR4 was 0.125mg/L. 
To  further  assess  the  MIC  of  clarithromycin  for  South  Africa  2507,  the  agar  dilution 
method of the British Society of Chemotherapy (Andrews, 2001) was adapted to allow 
assessment of the growth of South Africa 2507 in the presence of 512mg/L and 1024mg/L 
clarithromycin  using  TIGR4  as  a  control  isolate  sensitive  to  clarithromycin.  This 
determined a clarithromycin MIC of 1024mg/L for South Africa 2507 (Figure 11-2).     Chapter 11, 227 
 
Figure   11-2 Growth of isolate South Africa 2507 to determine MIC to clarithromycin. 
Isolates grown on IsoSensitest Agar (Oxoid Limited, United Kingdom) with 5% horse blood 
(E&O Laboratories Limited, United Kingdom) containing 512 mg/L clarithromycin (Sigma-
Aldrich®,  United  Kingdom)  on  the  left  and  1024  mg/L  clarithromycin  (Sigma-Aldrich®, 
United Kingdom) on the right. South Africa 2507 colonies are clearly visible in the presence 
on 512 mg/L clarithromycin while there are no TIGR4 colonies. There were no colonies of 
either South Africa 2507 or TIGR4 in the presence of clarithromycin 1024 mg/L indicating a 
clarithromycin MIC for South Africa 2507 of 1024 mg/L.  
 
11.7.3  Growth Curves for Strain South Africa 2507 in Brain 
Heart Infusion  
Isolate South Africa 2507 was grown in BHI broth in order to demonstrate a growth curve 
and determine when cultures would reach their midlog growth phase for the addition of 
clarithromycin 5mg/L. Cultures were grown in triplicate.  
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Figure   11-3 Growth curve of isolate South Africa 2507 when grown in Brain Heart Infusion 
broth.  
Optical densities were determined using a WPA Biowave C08000 Cell Density Meter set at 
600nm. The curve is constructed using the mean optical density calculated from 3 separate 
cultures with error bars demonstrating standard errors of the mean optical density.  
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Figure   11-4 Comparison of the growth of South Africa 2507 in Brain Heart Infusion broth 
without clarithromycin added and the influence of adding clarithromycin. 
Clarithromycin was added to a final concentration of 5mg/L when the culture reached an 
optic density of 0.6 at 600nm. The mean of three data points are shown with error bars 
indicating  standard  errors  where  these  were  significant  enough  to  be  illustrated.  In  the 
presence of clarithromycin, there was initially continued growth of the isolate, then growth 
inhibition and lysis for several hours.  
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11.7.4  Typing of Strain South Africa 2507 
Strain South Africa 2507 has previously been determined as serotype 23F and by BOX-
PCR  fingerprinting,  it  is  related  to  the  multiply  antibiotic  resistant  pneumococcal 
Pneumococcal Molecular Epidemiology Network (PMEN) clone Spain
23F-1 (Anderson et 
al., 2007). MLST performed at SMPRL found it to be ST81. 
11.8 Microarray results 
The  list  of  genes  identified  by  Genespring  GX  7.3.1  (Agilent  Technologies,  USA)  as 
significantly  up  or  downregulated  are  displayed  in  Appendix  16  (Bonferonni  multiple 
testing  correction  used)  and  Appendix  17  (Benjamini  and  Hochberg  multiple  testing 
correction used).     Chapter 11, 230 
11.9 Quantitative Real Time PCR results 
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Figure   11-5 Mean Normalized Expression Levels identified by qRT-PCR for genes SP0740, 
SP0800 and SP1631. 
Expression  was  measured  at  15  minutes  after  midlog  in  the  presence  and  absence  of 
clarithromycin  5mg/L  as  calculated  by  Q-Gene  software  with  standard  errors  marked.  P 
values  were  calculated  using  a  one-tailed  t-test  and  were  0.0002,  0.0006  and  0.0002  for 
SP0740, SP0800 and SP1631 respectively.     Chapter 11, 231 
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Figure   11-6 Mean Normalized Expression Levels identified by qRT-PCR for genes ErmB and 
pneumolysin (PLY). 
Expression  was  measured  at  15  minutes  after  midlog  in  the  presence  and  absence  of 
clarithromycin 5mg/L as calculated by Q-Gene with standard errors marked. P values were 
calculated  using  a  one-tailed  t-test  and  were  0.02  and  0.03  for  ErmB  and  pneumolysin 
respectively. 
 
11.10  Discussion 
This  series  of  experiments  utilised  the  SPv1.1  pneumococcal  microarray  as  a  tool  to 
examine pneumococcal gene expression and investigate the effect of subtherapeutic, sub-
MIC  clarithromycin  on  a  multiresistant  pneumococcus  (South  Africa  2507).  This 
highlights the power of this technology when applied to the field of drug discovery as it 
has an enormous  ability to elucidate the mechanisms of action of antimicrobial agents     Chapter 11, 232 
under  predetermined  conditions,  potentially  identifying  new  targets  for  antimicrobials, 
enhancing understanding of resistance mechanisms and aiding in the understanding of the 
function of, as yet, uncharacterised genes (Shaw et al., 2003). It also allows observation of 
changes at non target genes or pathways which would have been missed using single gene 
studies and technologies (Shaw et al., 2003). 
In  order  to  achieve  this  goal,  experimental  design  is  of  fundamental  importance.  This 
required  standardisation  of  every  step  with  the  growth  of  bacteria  in  parallel  in  three 
replicates under identical conditions from the same batch of media and then performing 
RNA extractions and microarray hybridizations in parallel under identical conditions so as 
to  reduce  variation  produced  by  experimental  noise  rather  than  gene  expression.  This 
included maintaining broth culture at 37°C for as long as possible when removing aliquots 
for RNA extraction and optical density measurements as temperature change can affect 
pneumococcal gene expression (Pandya et al., 2005). The benefit of such an approach is 
also highlighted by Gmuender et al  in their investigation of the effects of novobiocin and 
ciprofloxacin on the transcriptome of Haemophilus influenzae (Gmuender et al., 2001). 
Our  finding  that  sampling  gene  expression  from  our  control  culture  (without 
clarithromycin added) at 15 minutes after reaching midlog with the expression at midlog 
and demonstrating little, if any, change (Figure 11-7) suggests that there have been no 
significant artefacts of stress responses introduced as result of the manipulation of cultures 
and the process of splitting them at midlog (Conway and Schoolnik, 2003).     Chapter 11, 233 
 
Figure    11-7  Comparison  of  strain  South  Africa  2507  gene  expression  demonstrated  by 
microarray  at  midlog  and  15  minutes  later  growing  in  the  presence  and  absence  of 
subtherapeutic clarithromycin (5mg/L).  
Genes  which  were  significantly  up  or  down  regulated  (P<0.05)  were  identified  using 
Genespring GX 7.3.1 (Agilent Technologies, USA) using a one way ANOVA test with a false 
discovery  rate  set  at  0.05  and  Bonferonni  multiple  testing  correction  used.  Normalized 
expression  levels  at  15  minutes  after  midlog  are  colour  coded  by  Genespring  GX  7.3.1 
according  to  the  spectrum  of  colours  on  the  left  of  the  diagram  with  red  indicating 
significant up-regulation when compared to baseline (expression level at 15 minutes after 
midlog  with  no  clarithromycin  added)  and  blue  indicating  significant  down-regulation 
compared  to  this  baseline.  Comparison  of  the  expression  levels  of  these  differentially 
expressed  genes  at  this  baseline  versus  expression  at  midlog  (prior  to  exposure  to 
clarithromycin)  demonstrates  no  significant  difference  in  expression  indicating  that  the 
changes  in  expression  seen  in  the  presence  of  5mg/L  of  clarithromycin  are  due  to  the 
presence of clarithromycin and are not influenced by the more advanced timepoint in the 
logarithmic  growth  phase  of  the  bacteria.  Genes  are  identified  using  the  TIGR4 
nomenclature. 
 
The choice of antibiotic concentration (5mg/L clarithromycin) had been predetermined to 
be compatible with previous studies using the South Africa 2507 strain at subtherapeutic 
concentrations  (Anderson  et  al.,  2007).  There  is  no  consensus  regarding  the  best 
concentration  of  antimicrobial  to  use  for  such  mechanism  of  action  determining 
transcriptional experiments. Gmuender et al advocated using a concentration around that of 
the MIC (Gmuender et al., 2001). Hutter et al performed gene expression profiling using a 
B. subtilis spotted microarray with 37 antimicrobials including clarithromycin (Hutter et 
al., 2004). They found that the antimicrobial concentration was crucial for determining the     Chapter 11, 234 
mechanism  of  action  in  microarray  expression  experiments  and  that  subinhibitory 
concentrations  were  best.  They  also  suggested  that  after  one  hour  of  treatment  with 
antimicrobial, the optical density at 600nm of the treated culture should not exceed 15% 
less than that of its control. Shaw et al recommend using low doses and early time points to 
reduce effects of secondary inhibition by downstream targets (Shaw et al., 2003) for their 
work  with  E.  coli.  At  concentrations  below  its  MIC,  erythromycin  has  been  shown  to 
influence the transcription of 5-10% of bacterial genes in S. typhimurium which, despite 
altering gene expression in some cases by 10-100 fold, had little effect on growth (Goh et 
al.,  2002).  Interestingly  at  concentrations  above  the  MIC,  few  transcriptional  changes 
occurred. Freiberg et al also make a point of predetermining treatment time and antibiotic 
dose (Freiberg et al., 2004).  Brazas and Hancock point out that although most studies 
suggest using subinhibitory concentrations of antimicrobial and early time points to rule 
out the complicating effects of secondary targets this may restrict the discovery of effects 
that contribute to the mechanism of action by nature of them being downstream effects 
(Brazas  and  Hancock,  2005).  They  advocate  testing  multiple  agents  under  multiple 
conditions  to  elucidate  direct  from  indirect  effects  (Brazas  and  Hancock,  2005).  It  is 
important to appreciate that transcript levels do not reflect all regulatory processes in a cell 
as  they  cannot  demonstrate  the  effects  of  post-transcriptional  modification  of  proteins 
(Frieberg and Brunner, 2002) and so a proteomic approach (Bandow et al., 2003) is also 
beneficial although more laborious (Freiberg et al., 2004).   
In this study, it has been possible to analyse our results by ANOVA using Bonferonni 
multiple testing correction to identify a stringent set of genes whose expression have been 
altered  by  the  presence  of  clarithromycin,  (Appendix  16).  The  majority  of  these  are 
involved in amino acid synthesis (valine, leucine, isoleucine, glycine, serine, threonine, 
lysine, phenylalanine, tyrosine and tryptophan).  
When the ANOVA analysis is performed using the less stringent Benjamini and Hochberg 
multiple  testing  correction  (Appendix  17)  a  larger  number  of  significant  genes  is 
generated, which gives a broader insight into the multiple effects on the transcriptome. The 
functions  of  these  genes  include  ribsosomal  proteins,  aminoacyl  t-RNA  synthetases, 
translation factors as well as amino acid biosynthesis. This is significant as these are all 
required for fully functioning ribosomes (Jenni and Ban, 2003). It is of particular interest 
that  the  genes  for  ribosomal  proteins  L4  and  L23  are  significantly  upregulated  in  the 
presence of subtherapeutic clarithromycin as these proteins are fundamental to the escape 
of nascent polypeptides from the ribosomal exit tunnel with L23 mediating the interaction 
of  such  polypeptides  with  cytosolic  chaperones  and  protein  targeting  factors  with  L4     Chapter 11, 235 
known to be a site targeted by macrolide antibiotics (Jenni and Ban, 2003). L23 is involved 
in protein translation and folding. Mutations of L23 result in the accumulation of misfolded 
proteins which can be lethal to bacteria (Kramer et al., 2002). In addition, L23 is also 
implicated in the recruitment of the signal recognition particle for the targeting of secretory 
and transmembrane proteins (Keenan et al., 2001).  The ribosomal proteins L6, L14 and 
L7/L12  are also significantly upregulated and these have been identified as part of the 
structure of a translation factor binding centre in the polypeptide exit channel (Ban et al., 
1999). Consequently, the upregulation of these genes is consistent with an adaptational 
response  to  counter  a  reduction  in  function  of  the  ribosome  when  targeted  even  by 
subtherapeutic  levels  of  clarithromycin.    The  upregulation  of  ribosomal  proteins  and 
aminoacyl t-RNA synthetases in response to exposure to the macrolide erythromycin has 
also been documented in cultures of H. influenzae (Evers et al., 2001). 
Several of the genes identified by the ANOVA analysis using the Benjamini and Hochberg 
multiple testing correction (Appendix 17) have been identified as virulence factors in a 
murine model of serotype 4 pneumococcal pneumonia (Hava and Camilli, 2002). These 
genes are SP0385, SP0445, SP0622, SP0645, SP0766, SP0797, SP0807, SP0856, SP0943, 
SP0979, SP0986, SP1032, SP1112, SP1115, SP1154, SP1175, SP1378, SP1591, SP1633, 
SP1715, SP1780, SP1815, SP1891, SP1970, SP2098, SP2175, SP2176 and SP2239.  
As  noted  above,  transcriptional  profiling  using  microarrays  has  been  performed  for  a 
variety of micro-organisms with the majority of studies performed on B. subtilis and E. coli 
(Frieberg and Brunner, 2002, Freiberg et al., 2004). Such studies allow the generation of 
large databases of expression profiles of the mechanism of action of known antimicrobials 
against which agents with unknown mechanisms of action can be compared (Hutter et al., 
2004, Sabina et al., 2003, Shaw and Morrow, 2003, Freiberg et al., 2005, Freiberg et al., 
2004). There is however a dearth of data relating to transcriptional profiling of the effects 
of antimicrobial agents on pneumococci (Freiberg et al., 2004).  
It  has  been  demonstrated  that  pneumococci  respond  to  antibiotic  stress  (from 
aminoglycosides and fluoroquinolones but not erythromycin or tetracycline) by activating 
their  competence  regulatory  cascade  and  increasing  their  rate  of  genetic  exchange 
(Prudhomme et al., 2006). It is also noteworthy that this study did not see any effect of 
clarithromycin on the expression of genes involved in competence. This may have been a 
result  of  the  time  point  chosen  being  too  early  or  too  late  to  see  the  activation  of 
competence genes, as it is characteristically a short lived effect, but the result is compatible 
with the observation by Prudhomme et al that erythromycin had no effect on competence     Chapter 11, 236 
(Prudhomme et al., 2006). This antibiotic effect on competence has not been profiled using 
microarrays although they have been used to profile the effect of competence stimulating 
peptide (CSP) on pneumococci (Peterson et al., 2004) and CSP itself has been shown to 
have antibacterial activity (Oggioni et al., 2004). Only two microarray based studies have 
been published which look directly at the transcriptional profile changes of pneumococci 
directly  in  response  to  antimicrobials  –  the  effects  of  puromycin,  tetracycline, 
chloramphenicol and erythromycin on R6 gene expression (Ng et al., 2003) and the effects 
of vancomycin on TIGR4 gene expression (Haas et al., 2005). 
Ng et al performed microarray gene expression studies of Streptococcus pneumoniae with 
different classes of translation inhibiting antibiotics at sublethal concentrations (Ng et al., 
2003). Although their experimental methodology differed in many respects to those used 
here,  as  they  utilised  an  Affymetrix  array  based  on  the  genome  of  the  non  virulent 
pneumococcus R6 and exposed their cultures to 10 minutes of four different classes of 
translation  inhibiting  antibiotics  (puromycin,  tetracycline,  chloramphenicol  and 
erythromycin), our results with clarithromycin are remarkably similar to those obtained 
with  the  structurally  similar  erythromycin.  Both  studies  identified  altered  regulation  of 
genes  from  the  following  functional  categories:  ribosomal  proteins  (80%  congruence 
between  studies),  aminoacyl  tRNA  synthetases  (100%  congruence),  translation  factors 
(50%  congruence)  and  amino  acid  biosynthesis  (58%  congruence).  The  table  below 
outlines the similarities between the results from both studies and compares the degree and 
direction of the change in gene expression.      Chapter 11, 237 
 
Functional 
category and 
gene 
R6 Gene 
Nomenclature 
TIGR4 Gene 
Nomenclature 
Relative Fold 
Change when 
exposed to 10 
minutes of 
sublethal 
erythromycin 
(Ng et al, 2003) 
Relative Fold 
Change when 
exposed to 15 
minutes of 
5mg/L 
clarithromycin. 
Ribosomal 
Proteins 
       
rpsD  spr0078  SP0085  1.9  4.1 
rpsJ  spr0187  SP0208  1.4  1.8 
rplC  spr0188  SP0209  1.5  2.2 
rplD  spr0189  SP0210  1.6  2.0 
rplW  spr0190  SP0211  1.6  2.4 
rpsS  spr0192  SP0213  1.7  2.2 
rplV  spr0194  SP0214  1.8  1.8 
rplP  spr0196  SP0216  1.7  2.6 
rpmC  spr0197  SP0217  1.7  2.1 
rplX  spr0200  SP0220  1.9  2.0 
rplE  spr0201  SP0221  1.7  1.9 
rplF  spr0204  SP0225  1.7  2.3 
rplR  spr0205  SP0226  1.6  2.1 
rpsP  spr0682  SP0775  1.4  1.6 
rplJ  spr1212  SP1355  1  2.4 
rpsR  spr1394  SP1539  2.3  1.9 
Aminoacyl 
tRNA 
synthetases 
       
serS  spr0372  SP0411  -1.9  -3.8 
valS  spr0492  SP0568  -3.0  -4.2 
pheS  spr0507  SP0579  -13.2  -5.0 
pheT  spr0509  SP0581  -2.7  -4.9 
glyS  spr1328  SP1474  -2.2  -6.1 
glyQ  spr1329  SP1475  -2.5  -6.4 
thrS  spr1472  SP1631  -2.3  -6.8 
ileS  spr1502  SP1659  -3.6  -4.5 
tyrS  spr1910  SP2100  -2.2  -1.9 
hisS  spr1931  SP2121  -2.2  -2.9 
Translation 
Factors 
       
infC  spr0861  SP0959  1.4  1.8 
Amino Acid 
Biosynthesis 
       
aspC  spr0035  SP0035  -1.8  -1.4 
ilvE  spr0758  SP0856  -3.1  -4.3 
asd  spr0918  SP1013  -3.0  -3.4 
dapA  spr0919  SP1014  -2.1  -2.1 
gdhA  spr1181  SP1306  -3.1  -4.4 
metA  spr1434  SP1576  -2.1  -2.7 
trpC  spr1634  SP1814  -2.2  -4.1 
trpD  spr1635  SP1815  -2.4  -5.4 
ilvD  spr1935  SP2126  -2.5  -2.0 
Table   11-1 Comparison of the effects of sublethal erythromycin and clarithromycin on 
pneumococcal gene expression.     Chapter 11, 238 
These  similarities  suggest  there  to  be  a  signature  pattern  of  gene  expression  for 
erythromycin and clarithromycin as they are structurally similar 14-membered macrolide 
antibiotics.  Ye  et  al  note  that  different  classes  of  compound  often  generate  such  a 
characteristic signature of expression (Ye et al., 2001). Expression profiles generated by 
different antibiotic classes often differ significantly from each other (Freiberg et al., 2004, 
Goh  et  al.,  2002)  but  subtle  differences  can  occur  within  subclasses  of  the  same 
antimicrobial class (Gmuender et al., 2001). Also, different classes of compound acting on 
the same target gene do not always have the same effect (Brazas and Hancock, 2005). 
Interestingly,  whereas  Ng  et  al  identified  increased  amounts  of  purine  biosynthesis  in 
response to all four translation inhibitor classes, particularly affecting the pur gene cluster, 
the only gene from this cluster to be influenced by clarithromycin in South Africa 2507 
was purB where the effect of clarithromycin was to downregulate expression whereas Ng 
et al found it to be upregulated (Ng et al., 2003). Likewise we did not see any effect of 
clarithromycin on the putative PurR regulator (spr1793) which had been demonstrated by 
Ng  et  al  with  erythromycin  (Ng  et  al.,  2003),  suggesting  subtle  differences  in  the 
influences of different antibiotics from the same class of translation inhibitor. Ng et al 
demonstrated  that  when  sublethal  erythromycin  influences  gene  expression  in  R6,  the 
relative  fold  change  increases  with  increasing  doses  of  erythromycin.    A  relationship 
between degree of gene expression determined by microarray and dose of antibiotic is also 
documented by Shaw et al in E. coli to a range of antibiotic classes at a range of doses 
(Shaw et al., 2003). As only one dose of clarithromycin was used here, it is imposible to 
comment as to whether this result is reproducible with clarithromycin although it would 
seem plausible. 
In addition to ribosomal effects and translational effect, clarithromycin unexpectedly was 
found to have effects on the cell membrane in B. subtilis (Brazas and Hancock, 2005, 
Hutter et al., 2004). The effects of erythromycin on the B. subtilis transcriptome at several 
time  points  have  been  documented  by  Lin  et  al  with  similar  effects  to  this  study  on 
ribosomal proteins (Lin et al., 2005). 
The  genes  which  feature  on  our  microarray  are  predominantly  taken  from  the  TIGR4 
genome. As the TIGR4 isolate is not resistant to macrolide antibiotics, neither the ermB 
gene nor the mefA macrolide resistance genes feature on the array. This is an unfortunate 
limitation of the array as no comment can be made as to the influence of subtherapeutic 
clarithromycin on the expression levels of these genes in isolate South Africa 2507 by this 
method. However, by RT-PCR it was possible to demonstrate the upregulation of the ermB     Chapter 11, 239 
and pneumolysin  genes  (Figure 11-6). The TIGR4 genome sequence does contain two 
genes which code for putative macrolide efflux proteins – SP1110 and SP0168. SP1110 
lies in a region of diversity associated with macrolide efflux by Bruckner et al (Bruckner et 
al.,  2004).  SP1110  is  downregulated  in  the  presence  of  subtherapeutic  clarithromycin 
possibly  as  survival  of  the  bacteria  is  not  threatened.  Expression  of  SP1110  may  be 
activated to aid survival in an environment where high levels of macrolide compounds are 
present. The addition of clarithromycin to cultures at 5mg/L does not appear to influence 
expression of SP0168. It is clear though that subtherapeutic clarithromycin rapidly alters 
the expression of a constellation of genes in the pneumococcus and not just antibiotic 
resistance  associated  genes.  This  is  consistent  with  the  other  known  effects  that 
clarithromycin  has  as  an  immunomodulatory  agent  (Shinkai  et  al.,  2005,  Tsai  and 
Standiford,  2004),  on  suppressing  chronic  pulmonary  inflammation  (Chu,  1999),  on 
pneumococcal virulence factors (Speer et al., 2003, Anderson et al., 2007, Fukuda et al., 
2006) as well as on transcriptional modulation (Tsui et al., 2004).  It is also clear that 
antibiotics do not have single, straight forward targets or effects on bacteria (Brazas and 
Hancock, 2005, Shaw and Morrow, 2003) and that our understanding of their effects in 
vivo is likely to be far too simplistic. Rather than considering antibiotics acting on single 
targets,  it  may  be  more  accurate  to  regard  them  as  having  effects  on  interconnected 
networks (Watts and Strogatz, 1998, Conway and Schoolnik, 2003) as has been proposed 
by Tsui et al (Tsui et al., 2004) which may explain how seemingly unconnected pathways 
respond to a single antimicrobial agent. Such a perspective may more readily explain the 
“natural”  role  of  antimicrobial  compounds  produced  by  micro-organisms  at  low 
concentrations in the environment (Tsui et al., 2004).  This should not come as a surprise 
as it is recognised that subinhibitory antibiotic concentrations have many effects on some 
bacteria  such  as  disordered  growth  and  altered  virulence  (Gemmell  and  Lorian,  1996) 
which are not as evident at therapeutic concentrations, demonstrating the biphasic adaptive 
response known as hormesis (Calabrese and Baldwin, 2002). 
There are risks to drawing too many conclusions though from this limited two-condition 
experimental strategy. These results should be placed in an appropriate biological context 
with  corroborating  physiological,  biochemical  and  genetic  experiments  (Conway  and 
Schoolnik, 2003). It would be revealing to expand this work to include further time points 
and antimicrobial concentrations, different growth media and also different pneumococcal 
strains (Frieberg and Brunner, 2002). Demonstrating in vivo transcriptional responses will 
be a significant step forward rather than drawing conclusions from exponentially growing 
planktonic laboratory cultures (Conway and Schoolnik, 2003). This has been attempted for 
Vibrio cholerae with rice water stool from patients with cholera (Merrell et al., 2002) and     Chapter 11, 240 
in tissue cultures of epithelial and endothelial cell lines for Neisseria meningitidis (Dietrich 
et al., 2003) but appropriate reproducible strategies have yet to be devised for invasive 
pneumococcal infections. 
  
12  Concluding Thoughts 
Despite the limitations of a CGH approach to genome comparisons due to low sensitivity 
of  hybridization  and  the  realisation  that  high  levels  of  false  negative  hybridizations  to 
microarray probes (relating to hypervariable genes) made interpretation of the absence of 
hybridization unreliable without confirmatory PCR and sequencing, such a CGH approach 
has allowed documentation of pneumococcal genomic diversity. Further work using this 
approach, although more expensive, would be better suited to oligonucleotide Affymetrix 
type arrays since they are able to discriminate single nucleotide polymorphisms and would 
have fewer false negative hybridizations for hypervariable genes.  
In a series of 10 isolates of unrelated serotype and MLSTs, previously undescribed regions 
of diversity in the pneumococcal genome were discovered. By focusing on isolates of one 
MLST (ST9), it has been possible to demonstrate less diversity among isolates of the same 
serotype (serotype 14) than multiple serotypes of the same MLST. Focusing further on 
isolates matched by serotype and MLST and clinical manifestation it has been possible to 
show a role that bacteriophages have in generating genomic diversity and to suggest a role 
that  single  nucleotide  polymorphisms  may  play  in  influencing  disease  manifestations. 
These studies are compatible with the proposal that pneumococcal populations share and 
can tap into a “supragenome” which is larger than any genome held by a single isolate. 
Despite, this high level of genomic diversity at a population level it has also been possible 
to demonstrate a more clonal structure of pneumococcal populations in the early stages of 
transmission  within  an outbreak  situation  when  there  has  been  less  time  for  the  many 
mechanisms which generate diversity to have influenced the pneumococcal genome. 
By  assessing  transcriptional  profiles  from  standardized  and  reproducible  culture  and 
extraction  processes,  it  has  been  possible  to  identify  genes  which  are  associated  with 
disease  phenotypes  in  serotype  1  associated  pneumococcal  pneumonia  with 
parapneumonic  complications  and  pneumococcal  cerebral  abscesses.  In  addition  it  has 
been possible to identify apparently stable genomic differences between serotype 3 isolates 
from blood and cerebrospinal fluid (CSF) from the same patient and identify differential 
expression  of  iron  transport  proteins  in  the  two  body  fluids  and  relate  different  sugar 
metabolism pathways in serotype 3 isolates to the presence and expression level or absence 
of  phosphotransferase  system  genes.  Such  findings  may  be  important  in  further 
understanding  the  pathogenesis  of  pneumococcal  meningitis  or  provide  a  point  for 
therapeutic intervention to prevent invasion into CSF.       Chapter 12, 242 
Through  collecting  nasophayngeal  isolates  from  children  in  a  geographical  region  of 
substantial biodiversity, 32 new and currently unique MLST profiles have been discovered 
along with the, previously undescribed, co-incident dual carriage of two different sequence 
types of the same serotype, providing new insights (when CGH was performed) into the 
genomic diversity of the pneumococcus and the facilitation that a shared ecological niche 
and shared serotype may have in gene transfer.   
By  investigating  the  effect  of  a  subtherapeutic  antibiotic  (clarithromycin)  on  the  gene 
expression of a pneumococcal isolate new insights have been gained into the diversity of 
genes which respond to an antibiotic rich environment providing insights into how the 
pneumococcus both responds to this threat to survival and may communicate this response 
to  other  pneumococci  and  allowing  a  greater  understanding  of  why  subtherapeutic 
antibiotics may have many other clinical effects other than simply bacterial killing. 
Such a high degree of genomic diversity in the pneumococcus has undoubtedly contributed 
to its success as a frequent paediatric nasopharyngeal commensal and a global pathogen 
(which continues to cause severe manifestations such as pneumonia, meningitis and otitis 
media) as such diversity benefits the population of bacteria to increase survival in the face 
of the stresses of a range of host environments and therapeutic interventions.  Therefore, 
these studies of the pneumococcal “supragenome” demonstrate that multiple forces have 
shaped  its  evolution  such  as  gene  loss/genome  reduction,  genome  rearrangement  and 
acquisition  of  genetic  material  through  horizontal  gene  transfer  (Fraser-Liggett,  2005) 
resulting  in  a  dynamic  organism  and  placing  it  as  one  of  the  commonest  and  most 
successful pathogens known to man.  
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Appendix 1: Streptococcus pneumoniae isolates 
used in microarray experiments 
 
Appendix 1 
Details of isolates used on for microarray CGH experiments including source body fluid of 
isolate, age of source, antibiotic sensitivities, serotypes and MLST. R = Resistant, S = 
Sensitive, I = intermediate, NT = Not tested, B = Blood culture, C = CSF culture, P = Pleural 
Fluid culture, U = Unknown. 306 
Appendix 2: Antibiotic Sensitivities and Typing of 
Streptococcus pneumoniae isolates from Bolivia. 
Antibiotic Sensitivity 
Isolate  Serotype  MLST 
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07-2801  17F  2973  0.125  0.16  3  0.125  0.19  0.75 
07-2802  21  3852  0.023  0.047  3  0.125  0.125  0.75 
07-2803  11A  280  0.016  0.032  3  0.125  0.19  0.75 
07-2804  4  3767  0.016  0.032  3  0.125  0.25  0.75 
07-2805  34  1902  0.023  0.032  2  0.19  0.5  0.75 
07-2806  23A  2974  0.012  0.032  3  0.5  0.25  0.5 
07-2807  19A  2975  0.032  0.032  4  0.125  0.25  0.75 
07-2808  38  2974  0.003  0.047  3  0.5  0.25  0.75 
07-2809  19F  2976  0.016  0.023  3  0.19  0.19  0.5 
07-2810  23A  2974  0.016  0.047  3  0.75  0.25  0.75 
07-2811  34  1902  0.016  0.023  1.5  0.094  0.19  0.75 
07-2812  24F  3770  0.016  0.016  2  2  0.19  0.75 
07-2813  14  387  0.19  0.016  2  0.064  0.125  0.75 
07-2814  6A  3853  0.023  0.047  3  0.5  0.38  0.75 
07-2815  34  1902  0.016  0.032  2  0.25  0.125  0.75 
07-2816  16F  3768  0.012  0.016  2  0.25  0.19  0.75 
07-2817  6A  1150  0.047  0.016  1.5  0.125  0.19  0.75 
07-2818  8  404  0.012  0.047  2  0.125  0.25  0.38 
07-2819  4  332  0.016  0.016  3  1.5  1.5  0.38 
07-2820  38  3534  0.008  0.023  2  0.125  0.125  0.38 
07-2821  23F  776  0.016  0.047  2  0.094  0.25  0.75 
07-2822  6A  2440  0.016  0.023  2  0.38  0.19  0.75 
07-2823  19A  2880  0.032  0.016  1  0.25  0.125  0.75 
07-2824  34  1902  0.016  0.047  2  1.5  0.19  0.5 
07-2825  4  3509  0.016  0.016  1.5  0.125  0.19  0.75 
07-2826  7F  191  0.008  0.016  2  0.064  0.19  0.75 
07-2827  13  923  0.016  0.047  1.5  0.125  0.19  0.5 
07-2828  10A  3535  0.012  0.047  3  0.25  0.25  0.75 
07-2829  23B  3536  0.125  0.016  1.5  0.5  0.25  0.5 
07-2830  38  1902  0.016  0.032  2  0.125  0.25  0.38 
07-2831  6B  4015  0.047  0.032  2  2  0.19  0.5 
07-2832  6B  4015  0.023  0.032  1.5  0.38  0.25  0.5 
07-2833  9A  3537  0.023  0.016  2  0.094  0.25  0.5 
07-2834  12A  3538  0.012  0.032  2  0.38  0.25  0.75 
07-2835  16F  3771  0.012  0.047  2  1  0.19  0.75 
07-2836  10A  3539  0.016  0.032  1.5  0.125  0.25  0.75 
07-2837  16A  4016  0.064  0.032  1.5  1.5  0.25  0.38 
07-2838  3  180/1989  0.008  0.032  3  0.094  0.75  0.75 
07-2839  9A  239  0.023  0.032  2  0.125  0.25  0.5 
07-2840  7C  3769  0.012  0.032  1.5  0.125  0.19  0.75 
07-2841  23F  3540  0.023  0.032  1.5  0.25  0.25  0.75 
07-2843  13  784  0.023  0.032  2  0.125  0.25  0.75 307 
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07-2844  6A  3854  0.012  0.047  3  0.125  0.25  0.75 
07-2845  9A  3855  0.064  0.032  2  0.125  0.25  0.75 
07-2846  6A  3856  0.008  0.032  2  0.38  0.19  0.75 
07-2847  24F  3770  0.064  0.032  1.5  0.25  0.125  0.5 
07-2848  21  3857  0.016  0.064  2  0.094  0.25  0.5 
07-2849  17F  3267  0.064  0.047  2  0.094  0.125  0.75 
07-2850  19A  3858  0.016  0.032  2  0.094  0.125  0.5 
07-2851  10A  3429  0.016  0.047  3  0.125  0.25  0.75 
07-2852  23F  3430  0.023  0.032  3  0.25  0.38  0.5 
07-2853  35F  3431  0.016  0.023  2  0.094  16  0.5 
07-2854  11A  3432  0.008  0.047  3  0.125  0.25  0.75 
Appendix 2 
Antibiotic sensitivities and Typing of 53 Nasopharyngeal pneumococcal isolates retrieved 
from school children in the Beni region of Bolivia. Minimum Inhibitory Concentrations for 
stated antibiotics are documented as tested by E-test and should be interpreted as fully 
sensitive,  intermediate  sensitivity  or  resistant  using  the  following  criteria  set  by  the 
manufacturers AB Biodisk (Sweden): 
Antibiotic  Sensitive MIC  Intermediate 
Sensitivity MIC 
Resistant MIC 
Penicillin  <0.06  0.12 - 1  >2 
Erythromycin  <1  2  >4 
Chloramphenicol  <4  Not Applicable  >8 
Co-trimoxazole  <0.5  1 - 2  >4 
Tetracycline  <2  4  >8 
Vancomycin  <1     
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Appendix 3 
Primer  Sequence  Primer  Sequence 
SP0031_f  TACTCTCCATGCCTTACTCGGT  SP0031_r  TTGATTAACCTGACTGCACAGG 
SP0067_f  CTGGAGCAGTTTTGACAAATGA  SP0067_r  GCCACAAATTCTCCTTTGATTC 
SP0068_f  GGAGTGCCTTTCCAACTTCTAA  SP0068_r  CATAGTGACCAGATTTCCCGTT 
SP0069_f  TCAGAGGAATTGGCTGGTAGAT  SP0069_r  AGTACCAGTGTGGTCCGACTTT 
SP0072_f  ATGCAGATTGCAGGAATCATCT  SP0072_r  TCAAATCAACATTTTCTGTGGG 
SP0074_f  CAGGAGAGTTTTACCGTCCATC  SP0074_r  ATTGCGTTCCTGTGGATCTAGT 
SP0104_f  TGGAACCCTCGTTGATAGTTCT  SP0104_r  AGATCTGCTTGCTCTCCAAATC 
SP0111_f  GATGATGAAACGGTCGAGTACA  SP0111_r  CGATAATGACTGTTTTCCCCTC 
SP0113_f  GGTTTGGACACATCAGTTGCTA  SP0113_r  GCTCCTATCTGATGCGCTATTT 
SP0115_f  AGATGATGTATCTTGATGGGGG  SP0115_r  ATATGCGATTGCTCCACCTAGT 
SP0165_f  GTTCGGTAGGTGCCAGTAATGT  SP0165_r  TTGCTTTACGCAATCCTACCTC 
SP0166_f  CTTCAACAATTTTCCCCAAAAG  SP0166_r  ATAACCTGCTGCTCATTCACCT 
SP0168_f  TCATTCGCATCATTTTTACAGG  SP0168_r  ACCAAGAAGTTGATGTGGAGGT 
SP0278_f  GAATTGGCACATCTAATCGTGA  SP0278_r  AAGTGACATAACCATCTGCACG 
SP0309_f  AGATTGAACAACAACGTCGAGA  SP0309_r  TGGGGAAAATAATAATAGGCGA 
SP0350_f  TTGATTCAGAAGGTCCGGTTAT  SP0350_r  GCCATCTAACTCCGTCTTCATC 
SP0352_f  GAATATCGTTTCTTCAGACGGC  SP0352_r  CAAAGCCAAACAATCTTTTTCC 
SP0355_f  TATGTTACATGGTGCAACGGAT  SP0355_r  GATTCCGCAAATTTTTCAAGAG 
SP0356_f  GGAATTGGGAATTTAGTTGCTG  SP0356_r  AACGGCTAATCCATAACACCAC 
SP0410_f  TTTTAGATACGTTGCCGGTTCT  SP0410_r  CTGTGATAATGGTTGGGAAGGT 
SP0458_f  ACAAGTCTGTGGGACTCCAGAT  SP0458_r  GAGCAAGACTTTTTCGTTTGGT 
SP0461_f  AATTTCCACTTGAGTTCCCTGA  SP0461_r  AAGGCAATCGTCAAAAAGTGAT 
SP0462_f  CTGGGACATACACCTTGACAGA  SP0462_r  ATTCAATCGCTTTCCGTTTTTA 
SP0463_f  AGAATGACTGAAGGTTTGGCAT  SP0463_r  ATTACAAATTCTGCCCCAGCTA 
SP0464_f  TGGAGAACTATCAGGAGGTGGT  SP0464_r  TTTCATGACTTTGAACATTGCC 
SP0465_f  ACCATTTTTATCAGCATCCCTTT  SP0465_r  ATGGATGGTGAATCAGAAAGAAA 
SP0466_f  CGAGTGGAATCAAATCAACAAA  SP0466_r  TGCTGCAATAAATTCTTCCTCA 
SP0467_f  GAAAAAGAAAGGCGTCTCAGAA  SP0467_r  GTCGATTACGATACACGCGATA 
SP0468_f  CGGAGGGATATGAGGTCAATTA  SP0468_r  TAAACGTGCTAGCTTCCACAAA 
SP0509_f  AGTTCTTGACCCAAAACTTGGA  SP0509_r  AACTCCAACACGACCATTTTCT 
SP0514_f  GCAGGTTCTTGTTCGATTCTTC  SP0514_r  CAAACAACAAGACCACCTGAGA 
SP0532_f  TATGGATACTGAAATGCTTGCG  SP0532_r  AGTCCCAATTTATCACCAACCA 
SP0568_f  TGTCAAAATCGAAAAACGTGTC  SP0568_r  ACCCAGAAGAAGATGATGTCGT 
SP0570_f  GATTTTCCTAGAGAAGCCGTGA  SP0570_r  TATTCTTTTCCGTTGCCATCTT 
SP0573_f  CAAGGAGGTGACTCTTATGGCT  SP0573_r  CAAGAAAAACTCACTATCCCCA 
SP0574_f  GCTCTCAGTTCGAGGAGATGTT  SP0574_r  ACGACCTTCAACTCCTTATCCA 
SP0575_f  TCGTGAAAAGGTAATCGGCTAT  SP0575_r  TATGAATCCGACCTGCATACTG 
SP0697_f  GCGGTGAATTAAAGAGAATTGG  SP0697_r  GGCTCACATGAATGAATTGAAA 
SP0740_f  CAGAAGAGAGGCAGTCGAATTT  SP0740_r  CAAATCATAAAGCCAGTCGTCA 
SP0764_f  AGAAGAGGTCAAAAACTCAGCG  SP0764_r  TTGATAAAAGGCGTGAACATTG 
SP0800_f  GAATTAAACCAGCAGCTTCCTC  SP0800_r  CAAAGGCAAGAGCAGTTGATAA 
SP0949_f  AGCTCATTATGACCCTCCGTTA  SP0949_r  GTTTTCTGCGGTTACGATAAGG 
SP1018_f  AGCAAGGAAAAGGTGTTGTGAT  SP1018_r  ATCTGGATCTGTTCTCCATCGT 
SP1048_f  TATGGAATGCTAAGCCGGATAC  SP1048_r  TTCCATTGTATTTCCTTGTTGG 
SP1049_f  GTGGAGTGTTGCTACAACGAAA  SP1049_r  GGATTTTTATTGTCAAAATTGCCT 
SP1053_f  AGATGTGAAAGCTCAACGTCAA  SP1053_r  TTGAAGGAATCTTTTCCTCCCT 
SP1059_f  GAAAATTTGGAATTGTCGGAAG  SP1059_r  AATGGCAAGTGCTACTATGTGC 
SP1060_f  GGCCGATATGAAAAATAAATACG  SP1060_r  GCCAAACAATTTAAAGCGTGAT 
SP1063_f  TGATCAATTAAGGCACAAATCG  SP1063_r  AGGGATTTAACTGACCAATCCA 
SP1064_f  ACCCAAATATCGTCGTCAAATC  SP1064_r  TATTTCGCCAGTAAACGGATCT 
SP1129_f  AATCAAAAAGAATGGCCAAAGA  SP1129_r  TTATTGATGCTGATAACACCGC 
SP1130_f  CATGGCGACTCTATGGAAAAAT  SP1130_r  AAACAATTTCTGAAGGTGCGAT 309 
SP1131_f  TAAAGAAAACAAGATGCGTGGA  SP1131_r  TGCCTTTGCTTGAGTTTTGTTA 
SP1132_f  GCTACAACCCTTGATAACTGGG  SP1132_r  ACACATCTGACGGACGATAGAA 
SP1134_f  GAACGAGCAACAGGCTACTTTT  SP1134_r  GGTACTGCTCCAACTCCTCACT 
SP1135_f  TTAGCGAAGAAAATGGCCTAAG  SP1135_r  CATTGCCTCCTCAAACTTCTCT 
SP1136_f  GATGAGGTAATGGCTGAAATCC  SP1136_r  CCAATCTTCATAGCTGGTAGGC 
SP1137_f  CCTATTGTGAACAATGCCAAGA  SP1137_r  AATACGGCTATAATTCCGCTCA 
SP1138_f  GGTTAGTTTGCCACACTTGGTT  SP1138_r  ACACTTTTCATGGGGTGAGAAA 
SP1139_f  TGATGGAGAAAGGCTTTGTTTT  SP1139_r  TGAATTGCTCCATGTCAATTTC 
SP1140_f  AGACAAAGCATGTCAAAAAGCA  SP1140_r  ACTTCCTCAATTTCCAACCTCA 
SP1141_f  TGACTTAGGGGAATTTTTCCAA  SP1141_r  TATTTCCGTTTCATCCTCGTTT 
SP1142_f  CTCAAGTGGTATTTCATGCGAG  SP1142_r  ATAATATCCGCTGACAAGCTCC 
SP1143_f  TTGAGTTGTTAAGCCAACATGG  SP1143_r  GGGTGTTTTCTGTGTCCTTTTC 
SP1144_f  GAGGAGATGAGCGGTGTTAGTC  SP1144_r  AACCTGCTCATGCTCTAATGGT 
SP1145_f  TTTTAATAGCGCCCGAAAATTA  SP1145_r  ACTGATGATACTTGCTCTGCGA 
SP1158_f  GAAATTGATTTGATTGTCCTGA  SP1158_r  CATGAAAAAGAAAACAATAGCAA 
SP1181_f  TTATCACCTCGTTTCCTACTACT  SP1181_r  TTGTTTTTGTATTTGAATGATGAGC 
SP1189_f  TTGTTTTGAATGTTGATGGGAA  SP1189_r  AGGACCAAGATTGAAACGAAAA 
SP1254_f  AGCCAAAGAACGTAAGCGTAAC  SP1254_r  AGAATGCTTCAATTTCTGGGTT 
SP1323_f  AGCTGTTTCCCAAGAAGAATTG  SP1323_r  TTTGCATCATTTTCCTTGATTG 
SP1336_f  AGTGCTTGGGATTTTGTGAGAT  SP1336_r  TCTGGTGTCATACAAGGAATCG 
SP1342_f  GTATTCTGGGTTGGTCAGCAAT  SP1342_r  TCCGTTATTATCATGTTCAGCG 
SP1343_f  GGACGGGTTTTGTTAGACACTC  SP1343_r  ATTTGTTTAACGCCTTTCCTGA 
SP1350_f  GCGTTATTATAAGCTCCCCAAA  SP1350_r  CAAATAAATAGCCCCATCCTCA 
SP1353_f  CCAGTCTTTGAGAGCGATAAGC  SP1353_r  AAAACAAAAATCCTGCCAAAGA 
SP1381_f  GTCAGTATCATTTCACCCAGCA  SP1381_r  ACTGTCTTCCCTTTTTGTGCAT 
SP1696_f  TCAAAAAGAAACGAGGACTCTCA  SP1696_r  TTTTTGCTTCCTTCTTTTGGAA 
SP1718_f  TGTTGTCTGAAACTATTAGCCTTTT  SP1718_r  TTTGAGTAACTCCTTTTTCCTCG 
SP1762_f  TCCGTTTTTGATGTTATGCAAG  SP1762_r  TTGATGCATTCGTTCAGGATAC 
SP1763_f  GATTCAATCCTTGGCAGTTAGC  SP1763_r  TCAAACAAAACAAAAAGCATGG 
SP1765_f  ATTGGGGAGAAAAATGGAAGTT  SP1765_r  CAGCTCCTCAGAACAATCACAC 
SP1766_f  CTTCAATGCTGGTGTTCTCTTG  SP1766_r  CCCACCAAACTTCTCTTAGACG 
SP1770_f  TATTGCGTCAGAGTGGTTTTTG  SP1770_r  CATGCTCCATCTCACAACTAGC 
SP1771_f  TTATGTGACCTTTGTGGACTCG  SP1771_r  AATCCATTCATTTGGAAAATCG 
SP1793_f  TTACTGCTAGCTGTGCGTCTTC  SP1793_r  AGCGCATCTGCTAAAGAATACC 
SP1794_f  TTGGAGGAACTGATGAAGAACA  SP1794_r  CTCCCCTTTGTAAGCTCTCTCA 
SP1796_f  ATGGGCACATTTACTCATTTCC  SP1796_r  TATTTTGCACAGATTGGAGTGG 
SP1797_f  TGCTCGTAAAAGAATTGGGAAT  SP1797_r  TACAAGTTGCAATGGTTCCAAG 
SP1799_f  CGTCAGGAATTCCCTTTGTTAG  SP1799_r  ATCAAACAAAATACGAACCGCT 
SP1839_f  ACCCTTTATACCATGTTGGTGC  SP1839_r  TAGACGATTTCCCTGAACCTGT 
SP1895_f  GGATCGGTTCTGATTTTAGTGC  SP1895_r  GAAGTCATTCCAGAACCAAAGG 
SP1896_f  TTCCCAGCTGTTTTATCTGGTT  SP1896_r  GCATAACCGAATTGGTTGTTTT 
SP1897_f  GCTATACCGATGTTATCGGAGC  SP1897_r  TTGACCATGCCTTGTTTATCAC 
SP1948_f  TCAAACGAAAAATTTTGTGGAAA  SP1948_r  TAATAGGAGTAGGCGTCCAACG 
SP1949_f  ACAGATGGTGCTGACCCTAGAT  SP1949_r  TTTTTCTTGTTGTCTTTGCCAC 
SP1975_f  GGCTGTGTCAATGTCGATAAAA  SP1975_r  ACACTAGCTGGTGAGAAGAGGG 
SP2142_f  GGTATGAGGCGCTTAGCTCTTA  SP2142_r  ACCGTGTATTCTTCGTAGGCAT 
SP2164_f  GCAGAAATGTTTGTTGGTGAGA  SP2164_r  CCGTGACAAAGCCACATTATTA 
 
 
Appendix 3 Primer sequences used in the manufacture of the S. pneumoniae microarray 
SPv1.1 and used for confirmatory PCR. Forward primers are on the left and reverse primers 
are on the right of the table. 
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Appendix 4 
Gene  Sequence (5'-3') 
SP0045 f  AGTTGTGGACAAGGATGTC 
SP0045 r  CAAAGGTACCAGACATGGA 
SP0054 f  CACCGCAACAATATCCTGTCTA 
SP0054 r  GCATGGAGTTTGATGACTGGTA 
SP0110 f  TTGGTTTTCAAGATAGGGCTGT 
SP0110 r  TTCGTTTTTGCTGCTCTTCATA 
SP0314 f  TTACAATGGCGATTTGAGTCAC 
SP0314 r  CCCAAACTCCTTGTTTAGCATC 
SP0376 f  CCTCTCCATGGCTCTTC 
SP0376 r  CATCAAGCTTGCTCCGTA 
SP0740 f  CAGAAGAGAGGCAGTCGAATTT 
SP0740 r  CAAATCATAAAGCCAGTCGTCA 
SP0800 f  GAATTAAACCAGCAGCTTCCTC 
SP0800 r  CAAAGGCAAGAGCAGTTGATAA 
SP1342 f  GTATTCTGGGTTGGTCAGCAAT 
SP1342 r  TCCGTTATTATCATGTTCAGCG 
SP1343 f  GGACGGGTTTTGTTAGACACTC 
SP1343 r  ATTTGTTTAACGCCTTTCCTGA 
SP1350 f  GCGTTATTATAAGCTCCCCAAA 
SP1350 r  CAAATAAATAGCCCCATCCTCA 
SP1631 f  ATTCGAATCTGGCGTAACAACT 
SP1631 r  GACGATAGATAGTCAAACCGCC 
SP1869 f  CTTTCCATCGGCTAGTCT 
SP1869 r  TGCGACCATGAGTTTGG 
SP1872 f  GACCTAGTGGGAACTGTC 
SP1872 r  CACCGATGGCAAGGGTA 
SP2153 f  GCTACCATTCTTGCTCCT 
SP2153 r  GGCTTCGGCATAAATATCC 
SP1923f  TGCAGAGCGTCCTTTGGTC 
SP1923r  CTCTTACTCGTGGTTTCCAACTTGA 
SP1219f  TATGGGGTTTGTCTGGGGTC 
SP1219r  GCGCGAGCTCTTCCTGATGT 
ErmBf  GAAAAGGTACTCAACCAAATA 
ErmBr  AGTAACGGTACTTAAATTGTTTAC 
Appendix 4 
Primer sequences used for qRT-PCR experiments. 
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Appendix 5 
Comparison of microarray DNA CGH results with genome sequence data.  
Blue  indicates  absence  of  hybridization  of  the  gene  while  yellow  indicates  a  positive 
hybridization by DNA from the test isolate. In the sequencing results,  blue indicates the 
absence of the gene and yellow indicates the presence of the gene. Genes are identifiable 
using the TIGR4 genome nomenclature. Where these genes are indicated in red, they have 
been identified by signature tagged mutagenesis in a murine pneumonia model as being 
required for virulence (Hava and Camilli, 2002).   314 
Appendix 6 
 
Gene  Function 
SPN23F00250  Putative Phage Integrase (pseudogene) 
SPN23F00260  Putative type 1 Restriction Enzyme Related Protein 
SPN23F00280  Putative Phage Protein 
SPN23F00290  Plasmid Stabilisation System Protein 
SPN23F00300  Putative Uncharacterized Protein  
SPN23F00310  Putative Phage DNA Binding Protein 
SPN23F00320  Putative Uncharacterized Protein  
SPN23F00330  Putative DNA Binding Protein 
SPN23F00340  Putative Uncharacterized Protein  
SPN23F00350  Putative Uncharacterized Protein  
SPN23F00360  Putative Peptidoglycan Hydrolytic Amidase (pseudogene) 
SPN23F00370  Putative Membrane Protein 
SPN23F00380  Putative DNA Binding Protein 
SPN23F00710  Putative ATP/GTP Binding Protein 
SPN23F00830  Conserved Hypothetical Protein 
SPN23F00840  Putative Uncharacterized Protein  
SPN23F00850  Conserved Hypothetical Protein 
SPN23F00860  Putative Gene Fragment 
SPN23F01260  Putative Membrane Protein 
SPN23F01270  Putative Membrane Protein 
SPN23F01840  Regulatory Protein (Orthologue of SP0189 in TIGR4) 
SPN23F03210 
Capsule Biosynthesis Tyrosine Protein Kinase (Orthologue of 
SPD_0318 in D39) 
SPN23F03220 
Undecaprenylphosphate glucosephosphotransferase (Orthologue of 
SPD_0319 in D39) 
SPN23F03230  Putative Rhamnosyl Transferase (Orthologue of SPD_0320 in D39) 
SPN23F03250 
Oligosaccharide Repeat Unit Polymerase Unit wzy (Orthologue of 
SPD_0323 in D39) 
SPN23F03260  Putative Glycosyltransferase WchA 
SPN23F03270  Putative Glycosyltransferase WchW 
SPN23F03280 
Capsule Biosynthesis Repeating Unit Flippase (Orthologue of 
SPD_0325 in D39) 
SPN23F03290  Putative Glycerol Phosphotransferase WchX 
SPN23F03300  Putative Glycerol-2-Phosphate Dehydrogenase WchY 
SPN23F03310  Putative Nucleotidyl Transferase WchZ 
SPN23F03320  Putative Phosphotransferase 
SPN23F03330 
Glucose-1-Phosphate Thymidyl Transferase (Orthologue of 
SPD_0328 in D39) 
SPN23F03340 
dTDP-4-keto-6-deoxyglucose-3,5-epimerase RmlC (Orthologue of 
SPD_0329 in D39) 
SPN23F03350 
dTDP-glucose-4,6-dehydratase RmlB (Orthologue of SPD_0330 in 
D39) 
SPN23F03360 
dTDP-4-dehydrorhamnose reductase RmlD (Orthologue of SPD_0331 
in D39) 
SPN23F03370  Putative Transposase 
SPN23F06010  Putative Pneumococcal Surface Protein 
SPN23F06180  Putative Uncharacterized Protein  
SPN23F07060  Putative Uncharacterized Protein  
SPN23F07070 
ABC-type Antimicrobial Peptide Transporter, Permease Component, 
Putative 
SPN23F07080  Putative ABC Transporter ATP-binding Protein 
SPN23F07090  Putative Exported Protein 
SPN23F09740  Tn5252 orf10 protein (Orthologue of SPD_0934 in D39)  315 
SPN23F09750  Tn5252 orf9 protein (Orthologue of SPD_0935 in D39) 
SPN23F09780  Tn5252 Relaxase 
SPN23F09800   Putative Lantibiotic Modifying Enzyme 
SPN23F09840  Putative Membrane Protein 
SPN23F09850  Putative Membrane Protein 
SPN23F10590  Zinc Metalloproteinase ZmpD (Orthologue of SPD_0577 in D39) 
SPN23F12240  Putative Phosphosugar-Binding Transcriptional Regulator 
SPN23F12250  Putative Membrane Protein 
SPN23F12270  Putative IS861 Transposase Orf1 
SPN23F12410  Integrase 
SPN23F12420  Conserved Hypothetical Protein 
SPN23F12430  Relaxase (Orthologue of SP1056 in TIGR4) 
SPN23F12440  Putative Mobilisation Protein (Orthologue of SP1055 in TIGR4) 
SPN23F12450  Putative Mobilisation Protein (Orthologue of SP1054 in TIGR4) 
SPN23F12460  Putative Uncharacterized Protein  
SPN23F12470  Putative DNA Helicase II, UvrD 
SPN23F12480  Hypothetical Protein 
SPN23F12490  Putative Uncharacterized Protein  
SPN23F12500  Putative Uncharacterized Protein  
SPN23F12510  Putative NTPase Protein 
SPN23F12520  Hypothetical Protein 
SPN23F12530  Putative Phosphoserine Phosphatase 
SPN23F12540  Hypothetical Protein 
SPN23F12550  Hypothetical Protein 
SPN23F12560  Hypothetical Protein 
SPN23F12570  Putative Uncharacterized Protein  
SPN23F12580  Replication Protein 
SPN23F12590  Putative Chloramphenicol Acetyltransferase 
SPN23F12600  Putative Uncharacterized Protein  
SPN23F12610  Putative Uncharacterized Protein  
SPN23F12620  Zeta Toxin 
SPN23F12630  Putative Epsilon Antitoxin (Orthologue of SP1050 in TIGR4) 
SPN23F12640  Putative Uncharacterized Protein  
SPN23F12650  Putative Uncharacterized Protein  
SPN23F12660  Putative Uncharacterized Protein  
SPN23F12670  Putative Uncharacterized Protein  
SPN23F12680  Putative Uncharacterized Protein  
SPN23F12690  Putative Lantibiotic Transport/Processing ATP Binding Protein 
SPN23F12700  Putative Lantibiotic Synthetase 
SPN23F12701  Putative Lantibiotic Precursor 
SPN23F12710  Putative Lantibiotic ABC Transporter 
SPN23F12720  Putative Lantibiotic ABC Transporter 
SPN23F12730  Putative Lantibiotic ABC Transporter 
SPN23F12740  Putative Membrane Protein 
SPN23F12750  Transcriptional Regulator 
SPN23F12760  Putative Membrane Protein 
SPN23F12770  Putative Uncharacterized Protein  
SPN23F12780  Putative Conjugative Transposon DNA Recombination Protein 
SPN23F12790  Putative Group II Intron Reverse Transcriptase/Maturase 
SPN23F12820  Putative Uncharacterized Protein  
SPN23F12830  Putative Uncharacterized Protein  
SPN23F12840  Putative Conjugal Transfer Protein 
SPN23F12850  Putative Conjugal Transfer Protein 
SPN23F12860  Putative Uncharacterized Protein  
SPN23F12870  Putative Uncharacterized Protein  
SPN23F12880  Putative Uncharacterized Protein  
SPN23F12890  Putative Conjugal Transfer Protein TraG 316 
SPN23F12900  Putative Uncharacterized Protein  
SPN23F12910  Putative Uncharacterized Protein  
SPN23F12920  Conserved Hypothetical Protein 
SPN23F12930  Conserved Hypothetical Protein 
SPN23F12940  Conjugative Transposon Protein 
SPN23F12950  Conjugative Transposon Protein 
SPN23F12960  Conjugative Transposon FtsK/SpoIIIE-family protein 
SPN23F12970  Putative Conjugative Transposon Replication Initiation Factor 
SPN23F12980  Conjugative Transposon Protein 
SPN23F12990  Conjugative Transposon Protein 
SPN23F13000  Putative Conjugative Transposon Membrane Protein 
SPN23F13030  Putative Cell Wall Hydrolase 
SPN23F13040  Putative Conjugative Transposon Exported Protein 
SPN23F13050  Conjugative Transposon Tetracycline Resistance Protein 
SPN23F13060  Putative Conjugative Transposon Regulatory Protein 
SPN23F13061  Putative Uncharacterized Protein  
SPN23F13070  Putative Conjugative Transposon Regulatory Protein 
SPN23F13080  Excisionase 
SPN23F13090  Putative Integrase 
SPN23F13160  Putative Replication Initiator Protein 
SPN23F13170  Putative Uncharacterized Protein  
SPN23F14470  Putative Transposase 
SPN23F14540  Putative IS1239 Putative Transposase 
SPN23F15110  Putative Collagen-like Surface Anchored Protein 
SPN23F15120  Putative Mga-like Regulatory Protein (Ortholog of SPD_1377 in D39) 
SPN23F15300  Antiholin 
SPN23F15310  Holin 
SPN23F15320  Putatuve Uncharacterized Prophage Protein 
SPN23F15330  Phage Structural Protein 
SPN23F15340  Putative Platelet Binding Phage Protein 
SPN23F15350  Phage Tail Protein 
SPN23F15360  Putative Phage Minor Tail Protein 
SPN23F15370  Putative Phage Gp15 Protein 
SPN23F15380  Hypothetical Phage Protein 
SPN23F15390  Hypothetical Phage Protein 
SPN23F15400  Hypothetical Phage Protein 
SPN23F15410  Hypothetical Phage Protein 
SPN23F15420  Hypothetical Phage Protein 
SPN23F15430  Hypothetical Phage Protein 
SPN23F15440  Hypothetical Phage Protein 
SPN23F15450  Putative Phage Capsid Protein 
SPN23F15460  Putative Phage Scaffolding Protein 
SPN23F15470  Minor Capsid Protein 
SPN23F15490  Putative Minor Capsid Protein 
SPN23F15500  Putative Phage Terminase Large Subunit 
SPN23F15510  Hypothetical Phage Protein 
SPN23F15520  Putative Phage Protein 
SPN23F15530  Putative Phage Protein 
SPN23F15540  Putative Phage Protein 
SPN23F15550  Hypothetical Phage Protein 
SPN23F15560  Hypothetical Phage Protein 
SPN23F15570  Putative Phage Protein 
SPN23F15580  Putative Phage Protein 
SPN23F15590  Hypothetical Phage Protein 
SPN23F15600  Putative Phage Protein 
SPN23F15610  Putative Phage Protein 
SPN23F15620  Putative Phage Holliday Junction Resolvase 317 
SPN23F15630  Phage Protein 
SPN23F15640  Phage Protein 
SPN23F15650  Phage Protein 
SPN23F15660  Putative Phage Protein 
SPN23F15670  Putative DNA Methylase 
SPN23F15680  Putative Single Strand DNA-binding protein 
SPN23F15700  Putative Phage Protein 
SPN23F15710  Phage Single Strand DNA Binding Protein 
SPN23F15720  Putative Phage Protein 
SPN23F15730  Putative Phage Protein 
SPN23F15740  Putative Phage Protein 
SPN23F15750  Hypothetical Phage Protein 
SPN23F15760  Putative Phage DNA Binding Protein 
SPN23F15770  Putative DNA Binding Protein 
SPN23F15780  Hypothetical Phage Protein 
SPN23F15790  Phage Protein 
SPN23F15800  Phage Integrase 
SPN23F17430  Site Specific Recombinase 
SPN23F17440  Hypothetical Protein 
SPN23F17450  Putative Membrane Protein 
SPN23F17460  Conserved Hypothetical Protein 
SPN23F17760  Putative Glycosyl Transferase 
SPN23F17960  Putative Otitis Media Associated p41 
SPN23F17970  Conserved Hypothetical Protein 
SPN23F17980  Putative ATPase 
SPN23F18180  Putative Membrane Protein 
SPN23F18190  Conserved Hypothetical Protein 
SPN23F18200  Putative Choline Sulfatase 
SPN23F18210  Sugar Phosphotransferase System (PTS) IIC Component 
SPN23F18220 
Putative Lactose/Cellobiose-specific Phosphotransferase System 
(PTS) IIA Component 
SPN23F18230 
Sugar Phosphotransferase System (PTS) Lactose/Cellobiose-specific 
Family IIB Component 
SPN23F18240  Conserved Hypothetical Protein 
SPN23F18250  Sugar Phosphotransferase (PTS) IIC Component 
SPN23F18260  Putative ROK Family Repressor Protein 
SPN23F18640  Putative Restriction Enzyme 
SPN23F18650  Putative DNA Modification Methylase 
SPN23F18990  ABC Transporter ATP-Binding Protein 
SPN23F19000  Transport System Permease Protein 
SPN23F19010  Putative Substrate Binding Protein 
SPN23F19700  Conserved Domain Protein 
SPN23F19710  Putative Uncharacterized Protein  
SPN23F20090  Putative Exported Protein 
SPN23F21700  IS1381 Transposase 
SPN23F21701  IS1381 Transposase 
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Gene  Function 
SPNOXC00180  Unknown Function 
SPNOXC00190  Unknown Function 
SPNOXC00200  Unknown Function (Orthologue of SPN23F00280) 
SPNOXC00210  Unknown Function (Orthologue of SPN23F15770) 
SPNOXC00220  Unknown Function 
SPNOXC00230  Unknown Function 
SPNOXC00240  Unknown Function 
SPNOXC00250  Unknown Function 
SPNOXC00260  Unknown Function 
SPNOXC00270  Unknown Function 
SPNOXC00280  Unknown Function 
SPNOXC00290  Unknown Function 
SPNOXC00300  Unknown Function 
SPNOXC00310  Unknown Function 
SPNOXC00320  Unknown Function 
SPNOXC00330  DNA Replication Protein (Orthologue of SP1137 in TIGR4) 
SPNOXC00340  Unknown Function 
SPNOXC00350  Unknown Function 
SPNOXC00360  Unknown Function (Orthologue of SPN23F15600) 
SPNOXC00370  Unknown Function 
SPNOXC00380  Transcriptional Activator 
SPNOXC00390  Site Specific Recombinase 
SPNOXC00400  Unknown Function 
SPNOXC00410  Unknown Function 
SPNOXC00420  Unknown Function 
SPNOXC00430  Unknown Function 
SPNOXC00440  Unknown Function 
SPNOXC00450  Unknown Function 
SPNOXC00460  Capsid Protein 
SPNOXC00470  Unknown Function 
SPNOXC00480  Unknown Function 
SPNOXC00490  Unknown Function 
SPNOXC00500  Unknown Function 
SPNOXC00510  Unknown Function 
SPNOXC00520  Tail Protein 
SPNOXC00530  Unknown Function 
SPNOXC00540  Unknown Function 
SPNOXC00550  Unknown Function 
SPNOXC00560  Unknown Function 
SPNOXC00570  Unknown Function 
SPNOXC00580  Unknown Function 
SPNOXC00590  Unknown Function 
SPNOXC00600  Unknown Function (Orthologue of SPN23F15310) 
SPNOXC01370  Unknown Function 
SPNOXC01440  Hypothetical Protein 
SPNOXC01480  Conserved Hypothetical 
SPNOXC01500  Unknown Function (Orthologue of SPD_0114 in D39) 
SPNOXC01510  Unknown Function (Orthologue of SPD_0115 in D39) 
SPNOXC01520  Unknown Function (Orthologue of SPD_0117 in D39) 
SPNOXC01530  Unknown Function 
SPNOXC01540  Unknown Function 319 
SPNOXC01550  Unknown Function (Orthologue of SPD_0119 in D39) 
SPNOXC01560  Unknown Function (Orthologue of SPD_0120 in D39) 
SPNOXC01570  Unknown Function  
SPNOXC01580  Unknown Function (Orthologue of SPD_0122 in D39) 
SPNOXC01590  Putative Membrane Protein (Orthologue of SPN23F01260) 
SPNOXC01600  Putative Membrane Protein (Orthologue of SPN23F01270) 
SPNOXC01610 
Hypothetical Protein (Orthologue of SPN23F01280, SPD_2086 
in D39 and SP0116 in TIGR4) 
SPNOXC01850  Hypothetical Protein (Orthologue of SPN23F01520) 
SPNOXC02670 
Putative AraC-family Transcriptional Regulator (Orthologue of 
SPN23F02341, SPD_0228 in D39) 
SPNOXC03530  Putative IS630-Spn 1 Transposase (Pseudogene) 
SPNOXC03570  Tyrosine kinase Wzc 
SPNOXC03580  IS1548 Transposase 
SPNOXC03590  UDP-glucose-6-dehydrogenase Ugd 
SPNOXC03600   Serotype 3 Capsule Synthase 
SPNOXC04440 
Putative Uncharacterised Protein (Orthologue of 
SPN23F04330 and SPD_2116 in D39) 
SPNOXC04780  Putative Membrane Protein 
SPNOXC05230 
Putative Uncharacterised Protein (Orthologue of 
SPN23F05150 and SPD_0495 in D39) 
SPNOXC05350  Putative IS1239 Transposase 
SPNOXC05460 
Putative Transposase (Orthologue of SPN23F05390, 
SPD_0520 in D39 and SP2301 in TIGR4) 
SPNOXC05760  IS1381 Transposase orfA 
SPNOXC05770  IS1381 Transposase orfB 
SPNOXC05790 
50S Ribosomal Protein L11 (Orthologue of SPN23F05690 and 
SPD_0550 in D39) 
SPNOXC05810 
Putative Uncharacterized Protein (Orthologue of 
SPN23F05710 and SP2306 in TIGR4) 
SPNOXC06450 
Putative L-lactate Oxidase-Related Protein (Orthologue of 
SPN23F06370, SPD_0619 in D39 and SP0712 in TIGR4) 
SPNOXC07350 
Putative Transposase (Orthologue of SPN23F07370, SP2472 
in TIGR4) 
SPNOXC08130  Putative Uncharacterized Protein 
SPNOXC08970 
Putative Uncharacterized Protein (Orthologue of 
SPN23F09220, SPD_0883 in D39 and SP0997 in TIGR4) 
SPNOXC09530 
Tn5252 orf10 Protein (Orthologue of SPN23F09740, 
SPD_0934 in D39 and SP1054 in TIGR4) 
SPNOXC09550 
Tn5252 relaxase (Orthologue of SPN23F09780, SPD_2181 in 
D39 and SP1056 in TIGR4) 
SPNOXC09560  D-Ala D-Ala Ligase A 
SPNOXC09570  Enolase 
SPNOXC09580  Branched Chain Amino Acid Aminotransferase 
SPNOXC09590   Transketolase 
SPNOXC09600  Transketolase 
SPNOXC09610  Acetylornithine Aminotransferase 
SPNOXC09620  Nucleoside Diphosphate Kinase 
SPNOXC09630  2-Isopropylmalate Synthetase 
SPNOXC09640  Unknown Function 
SPNOXC09650  Unknown Function 
SPNOXC09660  Phosphonopyruvate decarboxylase 
SPNOXC09670  tRNA Synthetase 
SPNOXC09680  Unknown Function 
SPNOXC09690  Unknown Function 
SPNOXC09700  Unknown Function 
SPNOXC09730  ABC Transporter 
SPNOXC09740  Unknown Function 
SPNOXC09750  Site Specific Recombinase 320 
SPNOXC09760  Unknown Function 
SPNOXC09770  Unknown Function 
SPNOXC10350  Putative IS630-Spn 1 Transposase 
SPNOXC10920  Ion Channel Transport Protein 
SPNOXC11710  Conserved Hypothetical Protein 
SPNOXC11720  Putative Uncharacterized Protein 
SPNOXC12560  Putative ABC Transporter ATP-binding protein 
SPNOXC15800  Putative Transposase 
SPNOXC15810  Putative Membrane Protein (Orthologue of SPN23F18180) 
SPNOXC15820  Conserved Hypothetical Protein (Orthologue of SPN23F18190) 
SPNOXC15830  Putative Choline Sulfatase (Orthologue of SPN23F18200) 
SPNOXC15840 
Sugar Phosphotransferase System (PTS) IIC Component 
(Orthologue of SPN23F18210) 
SPNOXC15850 
Putative Lactose/Cellobiose-specific Phosphotransferase 
System (PTS) IIA Component 
SPNOXC15860 
Sugar Phosphotransferase System (PTS), Lactose/Cellobiose-
specific family IIB Component 
SPNOXC15870  Conserved Hypothetical Protein (Orthologue of SPN23F18240) 
SPNOXC15880 
Sugar Phosphotransferase System (PTS), IIC component 
(Orthologue of SPN23F18250, SPD_0424 in D39 and SP0474 
in TIGR4) 
SPNOXC16750  Transcriptional Regulator 
SPNOXC16760  Unknown Function 
SPNOXC16770  Unknown Function 
SPNOXC17150 
Putative Secreted Protein (Orthologue of SPN23F19690, 
SPD_1746 in D39 and SP1947 in TIGR4) 
SPNOXC18280 
Degenerate Transposase (Orthologue of SPN23F20990, 
SPD_2259 in D39 and SP2459 in TIGR4) 
SPNOXC19050  Glycosyl hydrolase 
SPNOXC19070  Unknown Function 
SPNOXC19100  ABC Transporter Permease 
SPNOXC19110  ABC Transporter 
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Appendix 8 List of genes from the TIGR4 genome which are present or non hybridizing in 10 
strains of diverse serotype and diverse MLST from diverse geographical regions.  
Gene  lists  generated  by  Genespring  GX  7.3.1  for  each  strain  indicating  regions  of 
differential hybridization between the test strains and TIGR4. Yellow indicates hybridization 
by both TIGR4 DNA and the test strain DNA. Blue indicates the absence of hybridization by 
test strain DNA and unopposed hybridization by TIGR4 DNA. Genes whose names appear in 
white have been identified as  required for virulence in a mouse bacteraemic pneumonia 
model (Hava and Camilli, 2002). 
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Appendix 9 List of genes from the R6 genome which are present or non hybridizing in 10 
strains of diverse serotype and diverse MLST from diverse geographical regions. 
Gene lists generated by Genespring GX 7.3.1 for each strain indicating regions where genes 
present  in  both  the  test  isolates  and  the  R6  genome  have  hybridized.  Red  indicates 
hybridization by the test strain DNA.  326 
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Appendix 10 List of genes from the TIGR4 genome which are present or non hybridizing in 
10 ST9 strains. 
Gene  lists  generated  by  Genespring  GX  7.3.1  for  each  strain  indicating  regions  of 
differential hybridisation between the test strains and TIGR4. Yellow indicates hybridisation 
by both TIGR4 DNA and the test strain DNA. Blue indicates the absence of hybridization by 
test strain DNA and unopposed hybridization by TIGR4 DNA. Genes whose names appear in 
white have been identified as  required for virulence in a mouse bacteraemic pneumonia 
model (Hava and Camilli, 2002). 
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Appendix 11 List of genes from the R6 genome which are present or non hybridizing in 10 
ST9 strains. 
Gene lists generated by Genespring GX 7.3.1 for each strain indicating regions where genes 
present  in  both  the  test  isolates  and  the  R6  genome  have  hybridized.  Red  indicates 
hybridization by the test strain DNA.  
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Appendix 12 List of genes from TIGR4 genome which are present or non hybridizing in 10 
strains of serotype 3, ST180. 
Gene  lists  generated  by  Genespring  GX  7.3.1  for  each  strain  indicating  regions  of 
differential hybridization between the test strains and TIGR4. Yellow indicates hybridization 
by DNA from both TIGR4 and the test strain. Blue indicates hybridization of DNA from TIGR4 
and  not  the  test  strain.  Genes  highlighted  in white  have  been  identified as  essential  for 
virulence in a mouse pneumonia model (Hava and Camilli, 2002).   333 
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Appendix 13 List of genes from the R6 genome which are present or non hybridizing in 10 
strains of serotype 3, ST180. 
Gene lists generated by Genespring GX 7.3.1.  Red indicates genes from the R6 genome 
which are found in the test strains but are not present in TIGR4. 
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Appendix 14 List of genes from TIGR4 genome which are present or non hybridizing in 
serotype 1 isolates.  
Gene  lists  generated  by  Genespring  GX  7.3.1  for  each  strain  indicating  regions  of 
differential hybridization between the test strains and TIGR4. Yellow indicates hybridization 
by DNA from both TIGR4 and the test strain. Blue indicates hybridization of DNA from TIGR4 
and  not  the  test  strain.  Genes  highlighted  in white  have  been  identified as  essential  for 
virulence in a mouse pneumonia model (Hava and Camilli, 2002) 
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Appendix 15 List of genes from the R6 genome which are present or non hybridizing in 
serotype 1 strains.  
Gene  lists  generated  by  Genespring  GX  7.3.1.  Results  of  Microarray  CGH  serotype  1 
isolates. Red indicates genes from the R6 genome which are found in the test strains but 
are not present in TIGR4. 337 
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Gene 
P-
value 
No 
Clarithromycin 
Normalised 
Expression 
Level 
Post 
Clarithromycin 
Normalised 
Expression 
Level 
Common 
Name  Putative Function 
Downregulated 
SP1128  0.0080  0.994  0.062  eno  phosphopyruvate hydratase 
SP0499  0.0031  1.022  0.101  pgk  phosphoglycerate kinase 
SP0565  0.0152  0.988  0.133  SP_0565  hypothetical protein 
SP1631  0.0004  1.021  0.151  thrS  threonyl-tRNA synthetase 
SP0605  0.0010  1.018  0.154  fba 
fructose-bisphosphate 
aldolase 
SP1475  0.0069  1.050  0.163  glyQ 
glycyl-tRNA  synthetase 
subunit alpha 
SP1474  0.0455  1.021  0.167  glyS 
glycyl-tRNA  synthetase 
subunit beta 
SP0580  0.0312  1.027  0.185  SP_0580 
acetyltransferase,  GNAT 
family 
SP0581  0.0129  0.950  0.193  pheT 
phenylalanyl-tRNA 
synthetase subunit beta 
SP1445  0.0045  0.971  0.194  guaA 
bifunctional  GMP 
synthase/glutamine 
amidotransferase protein 
SP1298  0.0182  1.021  0.207  SP_1298  DHH subfamily 1 protein 
SP1659  0.0069  0.992  0.222  ileS  isoleucyl-tRNA synthetase 
SP1960  0.0179  0.973  0.222  rpoC 
DNA-directed  RNA 
polymerase subunit beta' 
SP0745  0.0016  0.998  0.224  upp 
uracil 
phosphoribosyltransferase 
SP1306  0.0459  1.009  0.227  gdhA  glutamate dehydrogenase 
SP1961  0.0497  0.959  0.230  rpoB 
DNA-directed  RNA 
polymerase subunit beta 
SP1220  0.0184  1.016  0.233  ldh  L-lactate dehydrogenase 
SP0568  0.0239  0.985  0.236  valS  valyl-tRNA synthetase 
SP0856  0.0094  1.038  0.240  ilvE 
branched-chain  amino  acid 
aminotransferase 
SP1630  0.0420  1.035  0.246  SP_1630  hypothetical protein 
SP1907  0.0286  1.023  0.256  groES  co-chaperonin GroES 
SP0857  0.0219  1.027  0.266  SP_0857   
SP1476  0.0110  1.013  0.269  SP_1476  hypothetical protein 
SP1477  0.0089  1.031  0.273  SP_1477  hypothetical protein 
SP0411  0.0329  1.061  0.278  serS  seryl-tRNA synthetase 
SP0400  0.0176  0.990  0.283  tig  trigger factor 
SP0623  0.0276  1.041  0.288  pepV  dipeptidase PepV 
SP1384  0.0216  1.001  0.292  SP_1384  hypothetical protein 
SP1013  0.0008  0.990  0.294  asd 
aspartate-semialdehyde 
dehydrogenase 
SP0797  0.0151  1.008  0.297  pepN  aminopeptidase N 
SP0281  0.0012  0.989  0.302  pepC  aminopeptidase C 
SP2230  0.0023  1.003  0.307 
ABC-
NBD 
ABC transporter, ATP-binding 
protein 
SP0823  0.0152  1.017  0.327  glnP 
amino  acid  ABC  transporter, 
permease protein 
SP1655  0.0199  1.007  0.335  gpmA  phosphoglyceromutase 
SP1291  0.0444  1.013  0.343  SP_1291  Cof family protein 
SP2121  0.0488  1.010  0.348  hisS  histidyl-tRNA synthetase 
SP1290  0.0078  1.000  0.355  SP_1290  hypothetical protein 338 
SP1576  0.0281  0.998  0.365  metA 
homoserine  O-
succinyltransferase 
SP1279  0.0111  1.012  0.365  nth  endonuclease III 
SP1845  0.0357  0.996  0.365  exoA  exodeoxyribonuclease 
SP1891  0.0018  0.994  0.366  amiA 
oligopeptide ABC transporter, 
oligopeptide-binding  protein 
AmiA 
SP1647  0.0023  0.998  0.367  pepO  endopeptidase O 
SP1008  0.0038  0.990  0.389  pepT  peptidase T 
SP1296  0.0045  1.000  0.395  SP_1296  hypothetical protein 
SP1574  0.0166  0.975  0.402  tpiA  triosephosphate isomerase 
SP1575  0.0014  0.992  0.403  SP_1575  hypothetical protein 
SP0436  0.0273  1.001  0.411  gatB 
aspartyl/glutamyl-tRNA 
amidotransferase subunit B 
SP1470  0.0485  0.995  0.413  apbE 
thiamine  biosynthesis  protein 
ApbE, putative 
SP1781  0.0196  1.009  0.429  SP_1781  hypothetical protein 
SP1743  0.0390  0.966  0.436  SP_1743  hypothetical protein 
SP0438  0.0386  1.032  0.442  gatC 
aspartyl/glutamyl-tRNA 
amidotransferase subunit C 
SP1591  0.0298  1.010  0.442  pepQ  proline dipeptidase 
SP0788  0.0320  0.978  0.462  metG  methionyl-tRNA synthetase 
SP1413  0.0054  1.001  0.466  hprK  HPr kinase/phosphorylase 
SP2176  0.0252  1.002  0.473  dltA 
D-alanine--D-alanyl  carrier 
protein ligase 
SP1985  0.0399  1.004  0.498  ksgA 
dimethyladenosine 
transferase 
Upregulated 
SP1734  0.0157  1.013  2.071  sunL 
rRNA  methyltransferase 
RsmB 
SP0217  0.0340  1.013  2.118  rpmC  50S ribosomal protein L29 
SP1667  0.0468  1.002  2.155  ftsA  cell division protein FtsA 
SP0218  0.0198  0.982  2.212  rpsQ  30S ribosomal protein S17 
SP0807  0.0006  0.997  2.218  ezrA 
septation  ring  formation 
regulator EzrA 
SP1968  0.0103  1.005  2.237  coaD 
phosphopantetheine 
adenylyltransferase 
SP1540  0.0222  1.008  2.240  ssbA 
single-strand  DNA-binding 
protein 
SP1739  0.0096  1.001  2.369  SP_1739  hypothetical protein 
SP1115  0.0138  1.027  2.406  rggD 
transcriptional  regulator 
MutR, putative 
SP1602  0.0250  1.035  2.474  phnA  phnA protein 
SP1264  0.0051  1.016  2.622  SP_1264  hypothetical protein 
SP0215  0.0328  1.019  2.711  rpsC  30S ribosomal protein S3 
SP1362  0.0308  0.964  2.956  mecA  adaptor protein 
SP0740  0.0018  1.002  3.077  SP_0740  MutT/nudix family protein 
SP0026  0.0279  0.960  3.421  SP_0026  hypothetical protein 
SP0742  0.0134  1.048  4.889  SP_0742  hypothetical protein 
SP0800  0.0009  1.002  10.524  SP_0800  hypothetical protein 
Appendix 16 Genes present in strain South Africa 2507 identified as differentially expressed 
15  minutes  after  midlog  when  growing  in  BHI  broth  in  the  presence  and  absence  of 
clarithromycin 5mg/L (Bonferonni correction).  
The  genes  which  are  significantly  up  or  down  regulated  (P<0.05)  were  identified  using 
Genespring GX 7.3.1 (Agilent Technologies, USA) using a one way ANOVA  t-test with a 
false discovery rate set at 0.05 and using Bonferonni multiple testing correction. Expression 
differences of less than 2 fold difference were excluded. The P values resulting from the t-
test comparing expression in the presence and absence of clarithromycin for each gene and 
the putative functions of the genes are noted. Genes involved in amino acid synthesis are 339 
highlighted  green,  transcriptional  regulators  in  orange  and  ribosomal  proteins  are 
highlighted in yellow. 340 
Appendix 17 
Gene  P-value 
No 
Clarithromycin 
Normalised 
Expression 
Level 
Post 
Clarithromycin 
Normalised 
Expression 
Level 
Common 
Name  Putative Function 
Downregulated 
SP1128  0.0004  0.994  0.062  eno  phosphopyruvate hydratase 
SP0499  0.0002  1.022  0.101  pgk  phosphoglycerate kinase 
SP0565  0.0004  0.988  0.133  SP0565  hypothetical protein 
SP1631  0.0002  1.021  0.151  thrS  threonyl-tRNA synthetase 
SP0605  0.0002  1.018  0.154  fba  fructose-bisphosphate aldolase 
SP1475  0.0003  1.050  0.163  glyQ 
glycyl-tRNA  synthetase  subunit 
alpha 
SP1474  0.0007  1.021  0.167  glyS 
glycyl-tRNA  synthetase  subunit 
beta 
SP0567  0.0037  0.932  0.167  SP0567  hypothetical protein 
SP0445  0.0046  1.044  0.168  ilvB 
acetolactate  synthase  catalytic 
subunit 
SP1583  0.0016  0.998  0.185  entB  isochorismatase family protein 
SP0580  0.0005  1.027  0.185  SP0580  acetyltransferase, GNAT family 
SP1815  0.0007  1.034  0.190  trpD 
anthranilate 
phosphoribosyltransferase 
SP0581  0.0004  0.950  0.193  pheT 
phenylalanyl-tRNA  synthetase 
subunit beta 
SP1445  0.0003  0.971  0.194  guaA 
bifunctional  GMP 
synthase/glutamine 
amidotransferase protein 
SP1142  0.0297  0.994  0.198  SP1142  hypothetical protein 
SP0579  0.0085  1.000  0.199  pheS 
phenylalanyl-tRNA  synthetase 
subunit alpha 
SP1812  0.0363  1.000  0.202  trpB  tryptophan synthase subunit beta 
SP1584  0.0024  1.023  0.202  codY  transcriptional repressor CodY 
SP1057  0.0287  0.976  0.205  SP1057 
transcriptional  regulator  PlcR, 
putative 
SP1298  0.0005  1.021  0.207  SP1298  DHH subfamily 1 protein 
SP0875  0.0415  0.986  0.218  fruR 
lactose  phosphotransferase 
system repressor 
SP0409  0.0324  1.146  0.219  mip  hypothetical protein 
SP1489  0.0037  1.021  0.219  tuf  elongation factor Tu 
SpR6-0323 0.0103  1.084  0.222  cpsO   
SP1659  0.0003  0.992  0.222  ileS  isoleucyl-tRNA synthetase 
SP1960  0.0005  0.973  0.222  rpoC 
DNA-directed  RNA  polymerase 
subunit beta' 
SP0745  0.0002  0.998  0.224  upp  uracil phosphoribosyltransferase 
SP1651  0.0032  1.028  0.226  tpx  thiol peroxidase 
SP1306  0.0007  1.009  0.227  gdhA  glutamate dehydrogenase 
SP1473  0.0009  0.958  0.228  SP1473  hypothetical protein 
SP1961  0.0007  0.959  0.230  rpoB 
DNA-directed  RNA  polymerase 
subunit beta 
SP0159  0.0339  1.442  0.231  SP0159  hypothetical protein 
SP1753  0.0044  1.014  0.232  dctA   
SP1220  0.0005  1.016  0.233  ldh  L-lactate dehydrogenase 
SP2239  0.0075  0.981  0.235  SP2239  serine protease 
SP0568  0.0005  0.985  0.236  valS  valyl-tRNA synthetase 
SP0856  0.0004  1.038  0.240  ilvE 
branched-chain  amino  acid 
aminotransferase 341 
SP1814  0.0100  1.002  0.244  trpC 
indole-3-glycerol-phosphate 
synthase 
SP1630  0.0006  1.035  0.246  SP1630  hypothetical protein 
SP1811  0.0475  0.987  0.250  trpA 
tryptophan  synthase  subunit 
alpha 
SP1907  0.0005  1.023  0.256  groES  co-chaperonin GroES 
SP1578  0.0239  0.854  0.259  SP1578  methyltransferase, putative 
SP0857  0.0005  1.027  0.266  SP0857   
SP1476  0.0004  1.013  0.269  SP1476  hypothetical protein 
SP0328  0.0113  1.000  0.271  SP0328  IS1380-Spn1 transposase 
SP1499  0.0020  1.001  0.272  bta 
bacterocin  transport  accessory 
protein 
SP1477  0.0004  1.031  0.273  SP1477  hypothetical protein 
SP0411  0.0005  1.061  0.278  serS  seryl-tRNA synthetase 
SP2240  0.0021  1.053  0.279  spo0J  spspoJ protein 
SP0507  0.0011  0.944  0.279  hsdS 
type  I  restriction-modification 
system, S subunit, putative 
SP0400  0.0005  0.990  0.283  tig  trigger factor 
SP2026  0.0059  1.021  0.287  adhE 
alcohol  dehydrogenase,  iron-
containing 
SP0623  0.0005  1.041  0.288  pepV  dipeptidase PepV 
SP1906  0.0109  0.888  0.290  groEL  chaperonin GroEL 
SP1384  0.0005  1.001  0.292  SP1384  hypothetical protein 
SP1013  0.0002  0.990  0.294  asd 
aspartate-semialdehyde 
dehydrogenase 
SP0797  0.0004  1.008  0.297  pepN  aminopeptidase N 
SP1064  0.0071  1.090  0.297  SP1064  transposase, IS200 family 
SP0281  0.0002  0.989  0.302  pepC  aminopeptidase C 
SP2230  0.0002  1.003  0.307 
ABC-
NBD 
ABC  transporter,  ATP-binding 
protein 
SP0746  0.0013  0.996  0.308  clpP 
ATP-dependent  Clp  protease 
proteolytic subunit 
SP0766  0.0120  0.990  0.318  sodA 
superoxide  dismutase, 
manganese-dependent 
SP1813  0.0210  1.087  0.321  trpF 
N-(5'-phosphoribosyl)anthranilate 
isomerase 
SP0622  0.0058  1.015  0.326  nrd  nitroreductase family protein 
SP1498  0.0009  1.058  0.327  pgm  phosphoglucomutase 
SP0823  0.0004  1.017  0.327  glnP 
amino  acid  ABC  transporter, 
permease protein 
SP0501  0.0059  1.044  0.332  glnR 
transcriptional  regulator,  MerR 
family 
SP1577  0.0024  0.962  0.335  apt 
adenine 
phosphoribosyltransferase 
SP1655  0.0005  1.007  0.335  gpmA  phosphoglyceromutase 
SP1027  0.0033  1.048  0.338  SP1027  hypothetical protein 
SP0459  0.0066  1.073  0.338  pfl  formate acetyltransferase 
SP1291  0.0007  1.013  0.343  SP1291  Cof family protein 
SP1280  0.0058  0.999  0.344  SP1280  hypothetical protein 
SP0502  0.0115  1.061  0.344  glnA  glutamine synthetase, type I 
SP0858  0.0038  0.993  0.346  SP0858  hypothetical protein 
SP2121  0.0007  1.010  0.348  hisS  histidyl-tRNA synthetase 
SP1290  0.0004  1.000  0.355  SP1290  hypothetical protein 
SP0055  0.0040  0.999  0.358  SP0055  hypothetical protein 
SP1576  0.0005  0.998  0.365  metA 
homoserine  O-
succinyltransferase 
SP1279  0.0004  1.012  0.365  nth  endonuclease III 
SP1845  0.0006  0.996  0.365  exoA  exodeoxyribonuclease 
SP1891  0.0002  0.994  0.366  amiA  oligopeptide  ABC  transporter, 342 
oligopeptide-binding protein AmiA 
SP1647  0.0002  0.998  0.367  pepO  endopeptidase O 
SP1412  0.0009  0.961  0.375  lgt 
prolipoprotein  diacylglyceryl 
transferase 
SP1780  0.0049  1.001  0.376  pepF  oligoendopeptidase F, putative 
SP0798  0.0058  0.996  0.376  ciaR 
DNA-binding  response  regulator 
CiaR 
SP1177  0.0011  1.001  0.378  ptsH  phosphocarrier protein HPr 
SP2206  0.0053  0.954  0.378  SP2206 
ribosomal  subunit  interface 
protein 
SP1714  0.0428  1.035  0.382  SP1714 
transcriptional  regulator,  GntR 
family 
SP1145  0.0364  1.181  0.382  SP1145  hypothetical protein 
SP1246  0.0221  0.946  0.385  SP1246  Cof family protein 
SP0340  0.0321  0.998  0.385  luxS  S-ribosylhomocysteinase 
SP1130  0.0180  0.994  0.387  SP1130  transcriptional regulator 
SP1008  0.0003  0.990  0.389  pepT  peptidase T 
SP1154  0.0136  0.945  0.395  SP1154  immunoglobulin A1 protease 
SP1296  0.0003  1.000  0.395  SP1296  hypothetical protein 
SP0176  0.0052  0.999  0.395  ribA 
3,4-dihydroxy-2-butanone  4-
phosphate  synthase/GTP 
cyclohydrolase II 
SP1574  0.0005  0.975  0.402  tpiA  triosephosphate isomerase 
SP1295  0.0118  1.105  0.403  crcB  crcB protein 
SP1575  0.0002  0.992  0.403  SP1575  hypothetical protein 
SP0730  0.0012  0.985  0.403  spxB  pyruvate oxidase 
SP0408  0.0147  0.910  0.406  dagA 
sodium:alanine  symporter  family 
protein 
SP0204  0.0074  0.999  0.407  SP0204  acetyltransferase, GNAT family 
SP0713  0.0051  0.989  0.410  lysS  lysyl-tRNA synthetase 
SP0436  0.0005  1.001  0.411  gatB 
aspartyl/glutamyl-tRNA 
amidotransferase subunit B 
SP1470  0.0007  0.995  0.413  apbE 
thiamine  biosynthesis  protein 
ApbE, putative 
SP0799  0.0016  1.009  0.416  ciaH  sensor histidine kinase CiaH 
SP1715  0.0128  0.969  0.420 
ABC-
NBD 
ABC  transporter,  ATP-binding 
protein 
SP1415  0.0116  0.964  0.421  nagB 
glucosamine-6-phosphate 
isomerase 
SP1176  0.0037  1.012  0.426  ptsI 
phosphoenolpyruvate-protein 
phosphotransferase 
SP1781  0.0005  1.009  0.429  SP1781  hypothetical protein 
SP0385  0.0123  0.998  0.436  SP0385  hypothetical protein 
SP1743  0.0006  0.966  0.436  SP1743  hypothetical protein 
SP2125  0.0366  0.981  0.437  SP2125  hypothetical protein 
SP0816  0.0066  1.002  0.437  SP0816  hypothetical protein 
SP0437  0.0333  0.902  0.440  gatA 
aspartyl/glutamyl-tRNA 
amidotransferase subunit A 
SP1069  0.0036  0.990  0.440 
ABC-
SBP  hypothetical protein 
SP0438  0.0006  1.032  0.442  gatC 
aspartyl/glutamyl-tRNA 
amidotransferase subunit C 
SP1591  0.0005  1.010  0.442  pepQ  proline dipeptidase 
SP1243  0.0022  0.965  0.449  zwf 
glucose-6-phosphate  1-
dehydrogenase 
SP2175  0.0041  1.026  0.449  dltB  dltB protein 
SP1014  0.0092  0.940  0.451  dapA  dihydrodipicolinate synthase 
SP0867  0.0089  0.998  0.453 
ABC-
NBD 
ABC  transporter,  ATP-binding 
protein 
SP0516  0.0062  0.961  0.455  grpE  heat shock protein GrpE 343 
SP1970  0.0009  1.019  0.457  asnA  asparagine synthetase AsnA 
SP1505  0.0008  0.966  0.457  SP1505  membrane protein 
SP0056  0.0040  0.954  0.460  purB  adenylosuccinate lyase 
SP0788  0.0005  0.978  0.462  metG  methionyl-tRNA synthetase 
SP2069  0.0021  1.008  0.465  gltX  glutamyl-tRNA synthetase 
SP1413  0.0003  1.001  0.466  hprK  HPr kinase/phosphorylase 
SP0828  0.0099  1.025  0.470  rpiA  ribose-5-phosphate isomerase A 
SP0824  0.0280  1.000  0.470  glnQ 
amino acid ABC transporter, ATP-
binding protein 
SP0869  0.0367  1.082  0.470  SP0869  aminotransferase, class-V 
SP2058  0.0037  0.961  0.471  tgt  queuine tRNA-ribosyltransferase 
SP1112  0.0012  1.011  0.471  SP1112  degV family protein 
SP1633  0.0096  1.006  0.471  rr01  DNA-binding response regulator 
SP1221  0.0025  1.000  0.471  spnII 
type  II  restriction  endonuclease, 
putative 
SP0688  0.0033  1.027  0.472  murD 
UDP-N-acetylmuramoyl-L-alanyl-
D-glutamate synthetase 
SP2176  0.0005  1.002  0.473  dltA 
D-alanine--D-alanyl carrier protein 
ligase 
SP0173  0.0053  1.000  0.475  mutL  DNA mismatch repair protein 
SP1471  0.0160  1.013  0.475  SP1471  oxidoreductase, putative 
SP0979  0.0103  0.997  0.476  pepB  oligoendopeptidase F 
SP0981  0.0020  0.985  0.477  prsA  foldase protein PrsA 
SP1378  0.0007  0.984  0.478  SP1378  hypothetical protein 
SP0784  0.0059  0.989  0.479  gor  glutathione reductase 
SP0205  0.0234  0.996  0.483  nrdG 
anaerobic  ribonucleoside-
triphosphate  reductase  activating 
protein 
SP1175  0.0110  1.019  0.485  phtA  hypothetical protein 
SP1244  0.0011  1.002  0.490  ftsY 
signal recognition particle-docking 
protein FtsY 
SP1985  0.0006  1.004  0.498  ksgA  dimethyladenosine transferase 
SP0682  0.0165  1.083  0.498  SP0682  hypothetical protein 
SP1247  0.0007  1.013  0.500  smc  hypothetical protein 
SP1068  0.0018  1.032  0.503  ppc 
phosphoenolpyruvate 
carboxylase 
SP0868  0.0218  1.068  0.508  SP0868  hypothetical protein 
SP1693  0.0203  1.090  0.514  nanA   
SP2126  0.0187  1.052  0.515  ilvD  dihydroxy-acid dehydratase 
SP1887  0.0172  1.111  0.519  amiF 
oligopeptide  ABC  transporter, 
ATP-binding protein AmiF 
Upregulated 
SP1422  0.0207  0.916  1.859  SP1422  hypothetical protein 
SP0210  0.0089  0.939  1.915  rplD  50S ribosomal protein L4 
SP0224  0.0017  0.970  1.948  rpsH  30S ribosomal protein S8 
SP1035  0.0045  0.956  1.954 
ABC-
NBD 
iron-compound  ABC  transporter, 
ATP-binding protein 
SP0984  0.0027  0.963  1.960  gpmB 
phosphoglycerate  mutase  family 
protein 
SP1356  0.0025  0.989  1.989  trzA  chlorohydrolase 
SP0739  0.0008  0.976  2.000  mta 
transcriptional  regulator,  MerR 
family 
SP1105  0.0018  0.980  2.025  rplU  50S ribosomal protein L21 
SP0220  0.0123  1.000  2.026  rplX  50S ribosomal protein L24 
SP0004  0.0007  0.987  2.030  SP0004  translation-associated GTPase 
SP0974  0.0146  0.997  2.032  secG 
preprotein  translocase  subunit 
SecG 
SP0943  0.0059  0.971  2.040  gidA 
tRNA  (uracil-5-)-
methyltransferase Gid 344 
SP0991  0.0007  0.982  2.049  pfs 
5'-methylthioadenosine/S-
adenosylhomocysteine 
nucleosidase 
SP1734  0.0004  1.013  2.071  sunL  rRNA methyltransferase RsmB 
SP2008  0.0088  0.958  2.080  secE 
preprotein  translocase  subunit 
SecE 
SP1083  0.0016  1.020  2.084  SP1083  hypothetical protein 
SP0209  0.0016  0.963  2.098  rplC  50S ribosomal protein L3 
SP0226  0.0017  0.996  2.098  rplR  50S ribosomal protein L18 
SP1198  0.0145  0.992  2.106  SP1198  hypothetical protein 
SP1992  0.0159  1.002  2.113  SP1992 
cell  wall  surface  anchor  family 
protein 
SP0217  0.0006  1.013  2.118  rpmC  50S ribosomal protein L29 
SpR6-0464 0.0263  0.996  2.119  hk13 
sensor  histidine  kinase  BlpH, 
putative 
SP2000  0.0339  1.014  2.122  rr11  DNA-binding response regulator 
SP1926  0.0321  0.900  2.132  SP1926  hypothetical protein 
SP0779  0.0037  1.013  2.139  trmD 
tRNA  (guanine-N(1)-)-
methyltransferase 
SP0002  0.0008  0.997  2.147  dnaN  DNA polymerase III subunit beta 
SP0191  0.0311  0.995  2.150  SP0191  hypothetical protein 
SP1667  0.0007  1.002  2.155  ftsA  cell division protein FtsA 
SP1643  0.0292  0.997  2.164  SP1643  hypothetical protein 
SP1034  0.0159  0.999  2.168 
ABC-
MSP 
iron-compound  ABC  transporter, 
permease protein 
SP1084  0.0036  1.011  2.182  map  methionine aminopeptidase 
SP0613  0.0048  1.046  2.185  SP0613 
metallo-beta-lactamase 
superfamily protein 
SP0227  0.0037  1.019  2.194  rpsE  30S ribosomal protein S5 
SP1429  0.0464  1.065  2.197  SP1429  peptidase, U32 family 
SP0213  0.0011  1.016  2.200  rpsS  30S ribosomal protein S19 
SP0218  0.0005  0.982  2.212  rpsQ  30S ribosomal protein S17 
SP0807  0.0002  0.997  2.218  ezrA 
septation ring formation regulator 
EzrA 
SP1170  0.0333  0.992  2.224  SP1170  hypothetical protein 
SP1081  0.0021  0.990  2.229  murZ 
UDP-N-acetylglucosamine  1-
carboxyvinyltransferase 
SP1427  0.0364  1.094  2.230  SP1427  peptidase, U32 family 
SP1541  0.0044  1.003  2.237  rpsF  30S ribosomal protein S6 
SP0225  0.0032  0.981  2.237  rplF  50S ribosomal protein L6 
SP1968  0.0004  1.005  2.237  coaD 
phosphopantetheine 
adenylyltransferase 
SP1540  0.0005  1.008  2.240  ssbA  single-strand DNA-binding protein 
SP0231  0.0076  1.001  2.241  adk  adenylate kinase 
SP0964  0.0263  0.917  2.255  pyrD  dihydroorotate dehydrogenase 1B 
SP0419  0.0442  0.934  2.273  fabK 
enoyl-(acyl-carrier-protein) 
reductase 
SP2214  0.0028  0.964  2.274  tsf  elongation factor Ts 
SP0211  0.0020  0.933  2.277  rplW  50S ribosomal protein L23 
SP0219  0.0166  0.999  2.281  rplN  50S ribosomal protein L14 
SP2152  0.0091  0.968  2.294  SP2152  hypothetical protein 
SP0380  0.0411  1.058  2.301  SP0380  hypothetical protein 
SP2156  0.0027  1.048  2.303  SP2156  SPFH domain/Band 7 family 
SP1032  0.0319  0.999  2.326 
ABC-
SBP 
iron-compound  ABC  transporter, 
iron compound-binding protein 
SP1354  0.0108  1.028  2.333  rplL  50S ribosomal protein L7/L12 
SP0992  0.0067  0.997  2.334  SP0992  hypothetical protein 
SP1293  0.0081  1.003  2.362  rplS  50S ribosomal protein L19 
SP1601  0.0010  0.993  2.365  SP1601  hypothetical protein 345 
SP1739  0.0004  1.001  2.369  SP1739  hypothetical protein 
SP0650  0.0010  0.989  2.378  SP0650  hypothetical protein 
SP0741  0.0030  1.023  2.378  SP0741  hypothetical protein 
SP1115  0.0004  1.027  2.406  rggD 
transcriptional  regulator  MutR, 
putative 
SP1600  0.0022  1.033  2.456  SP1600  hypothetical protein 
SP1666  0.0036  0.995  2.463  ftsZ  cell division protein FtsZ 
SP2116  0.0179  0.993  2.471  SP2116  hypothetical protein 
SP1033  0.0261  1.000  2.471 
ABC-
MSP 
iron-compound  ABC  transporter, 
permease protein 
SP1602  0.0005  1.035  2.474  phnA  phnA protein 
SP0212  0.0431  0.996  2.493  rplB  50S ribosomal protein L2 
SP0024  0.0091  0.974  2.511  SP0024  hypothetical protein 
SP1355  0.0010  1.053  2.527  rplJ  50S ribosomal protein L10 
SP2007  0.0008  0.950  2.539  nusG 
transcription  antitermination 
protein NusG 
SP2215  0.0008  1.002  2.553  rpsB  30S ribosomal protein S2 
SP0783  0.0037  1.055  2.565  bioY  hypothetical protein 
SP0986  0.0122  0.998  2.566  SP0986  hypothetical protein 
SP0216  0.0037  0.999  2.568  rplP  50S ribosomal protein L16 
SP1208  0.0016  1.027  2.576  udK  uridine kinase 
SP0185  0.0061  0.999  2.586  corA 
magnesium  transporter,  CorA 
family 
SP0969  0.0051  0.991  2.609  era  GTP-binding protein Era 
SP1264  0.0003  1.016  2.622  SP1264  hypothetical protein 
SP0215  0.0005  1.019  2.711  rpsC  30S ribosomal protein S3 
SP0420  0.0332  0.917  2.744  fabD 
acyl-carrier-protein  S-
malonyltransferase 
SP0645  0.0101  0.987  2.750  PTS-EII 
PTS  system  IIA  component, 
putative 
SP0025  0.0085  0.988  2.781  SP0025  hypothetical protein 
SP0817  0.0447  1.000  2.795  SP0817  MutT/nudix family protein 
SP0111  0.0345  1.084  2.808 
ABC-
NBD 
amino acid ABC transporter, ATP-
binding protein, putative 
SP1586  0.0037  1.031  2.886  SP1586 
ATP-dependent  RNA  helicase, 
putative 
SP1171  0.0058  0.977  2.940  SP1171 
hydrolase,  haloacid 
dehalogenase-like family 
SP2117  0.0220  1.043  2.944  SP2117  hypothetical protein 
SP1922  0.0017  1.076  2.948  SP1922  hypothetical protein 
SP1362  0.0005  0.964  2.956  mecA  adaptor protein 
SP2062  0.0089  0.904  2.994  marR 
transcriptional  regulator,  MarR 
family 
SP0740  0.0002  1.002  3.077  SP0740  MutT/nudix family protein 
SP0430  0.0033  0.998  3.107  SP0430  hypothetical protein 
SP1821  0.0156  1.000  3.283  ccpA 
sugar-binding  transcriptional 
regulator, LacI family 
SP0423  0.0263  0.846  3.313  accB 
acetyl-CoA  carboxylase  biotin 
carboxyl carrier protein subunit 
SP0421  0.0418  0.928  3.358  fabG 
3-ketoacyl-(acyl-carrier-protein) 
reductase 
SP1197  0.0037  0.976  3.397  SP1197  hypothetical protein 
SP0026  0.0005  0.960  3.421  SP0026  hypothetical protein 
SP0427  0.0200  0.844  3.464  accA 
acetyl-CoA  carboxylase  subunit 
alpha 
SP0426  0.0261  0.933  3.676  accD 
acetyl-CoA  carboxylase  subunit 
beta 
SP0424  0.0269  0.889  3.721  fabZ 
(3R)-hydroxymyristoyl-(acyl 
carrier protein) dehydratase 346 
SP0425  0.0304  0.909  3.793  accC 
acetyl-CoA  carboxylase  biotin 
carboxylase subunit 
SP2098  0.0056  1.005  3.816  SP2098  membrane protein 
SP0422  0.0292  0.885  3.935  fabF 
3-oxoacyl-(acyl  carrier  protein) 
synthase II 
SP0085  0.0017  0.983  4.016  rpsD  30S ribosomal protein S4 
SP2003  0.0162  0.999  4.164 
ABC-
NBD 
ABC  transporter,  ATP-binding 
protein 
SP0742  0.0004  1.048  4.889  SP0742  hypothetical protein 
SP2216  0.0040  1.011  4.997  gSP781  secreted 45 kd protein 
SP0800  0.0002  1.002  10.524  SP0800  hypothetical protein 
SP2063  0.0087  0.932  15.672  SP2063  LysM domain-containing protein 
SP0107  0.0008  1.088  34.684  SP0107  LysM domain protein 
Appendix 17 Genes present in strain South Africa 2507 which are identified as differentially 
expressed 15 minutes after midlog when growing in BHI broth in the presence and absence 
of clarithromycin 5mg/L (Benjamini and Hochberg correction).  
The  genes  which  are  significantly  up  or  down  regulated  (P<0.05)  were  identified  using 
Genespring GX 7.3.1 (Agilent Technologies, USA) using a one way ANOVA  t-test with a 
false  discovery  rate  set  at  0.05  and  Benjamini  and  Hochberg  multiple  testing  correction 
used. Expression differences with less than 2 fold differences were excluded. The P values 
resulting  from  the  t-test  comparing  expression  in  the  presence  and  absence  of 
clarithromycin  for  each  gene  and  the  putative  functions  of  the  genes  are  noted.  Genes 
involved in amino acid synthesis are highlighted green, transcriptional regulators in orange 
and  ribosomal  proteins  are  highlighted  in  yellow.  Genes  highlighted  in  red  have  been 
identified as part of the pneumococcal stress response to vancomycin (Haas et al., 2005). 
 
 
 
 
 